METHODS
IN
MOLECULAR BIOLOGY™
Series Editor John M. Walker School of Life Sciences University of Hertfordshire Hatfield, Hertfordshire, AL10 9AB, UK
For further volumes: http://www.springer.com/series/7651
wwwwwwwwwwww
Bone Research Protocols Second Edition Edited by
Miep H. Helfrich Musculoskeletal Research Programme, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK
Stuart H. Ralston Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK
Editors Miep H. Helfrich, PhD Musculoskeletal Research Programme Division of Applied Medicine Institute of Medical Sciences University of Aberdeen Aberdeen, UK
[email protected]
Stuart H. Ralston, MD Rheumatic Diseases Unit Institute of Genetics and Molecular Medicine University of Edinburgh Western General Hospital Edinburgh, UK
[email protected]
ISSN 1064-3745 e-ISSN 1940-6029 ISBN 978-1-61779-414-8 e-ISBN 978-1-61779-415-5 DOI 10.1007/978-1-61779-415-5 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2011940327 © Springer Science+Business Media, LLC 2012 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. Printed on acid-free paper Humana Press is part of Springer Science+Business Media (www.springer.com)
Preface The last decade has continued to bring tremendous advances in our understanding of bone biology. The genes responsible for the majority of rare inherited bone disorders have been identified and much progress has been made in the identification of genes in polygenic disorders, such as Paget’s disease and osteoporosis. Studies of genetically modified mice have resulted in the identification of other genes with profound effects on bone. These studies have uncovered many new pathways which form the focus of research by bone cell biologists to understand the mechanisms by which these genes and gene products affect bone mass and bone strength. The second edition of Bone Research Protocols contains a catalogue of protocols to assist researchers in the pursuit of mechanistic studies. In the tradition of the Methods in Molecular Medicine series, the chapters are practical laboratory protocols that should enable the reader to carry out the techniques from scratch. We have concentrated on laboratory techniques, rather than clinical methods of assessment and have tried to tailor the methods to the study of bone cells and bone tissue. For example, there are no differences in the analysis of DNA and RNA from bone or other tissues, but special considerations apply to isolation of DNA and RNA from bone and these are described. Equally, histological and histochemical procedures for soft tissues are often easily adapted to bone and are not specifically covered, apart from those included as analysis tools in various chapters. Tissue fixation, embedding and sectioning of bone, however, present unique problems and such methods are described as part of the chapters dealing with electron microscopy and immunostaining. Much progress has been made in digital image analysis recently and several chapters (dealing with confocal microscopy, bone resorption assays, and histomorphometry) include a detailed description on how to make best use of this powerful technology. New chapters have also been included on the analysis of bone tissue by Fourier transform infrared microscopy and Raman Spectroscopy in view of the increasing interest in these techniques as methods of assessing bone quality. The chapters on bone imaging have been updated and extensively revised with new chapters on quantitative analysis of radiographs and real-time bioluminescent imaging. Generally, one method is given for each technique, with the exception of in vitro osteoclast formation studies, for which several protocols are described, illustrating that many methods, often only subtly different, are described in the literature for different species and for different applications. Increasingly, high-throughput methods are used and some of the culture techniques described are suitable for such studies. Those interested in this field are encouraged to read all methods first before deciding which one is most appropriate for their particular application. The section on osteoblast cultures has been updated and new chapters have been included on primary osteocyte cultures, analysis of osteocyte cell lines, and osteogenic differentiation of bone cells from mesenchymal stem cells.
v
vi
Preface
A new section has been added on biochemical and molecular analysis of bone cells to cover topics, such as transfection, analysis of intracellular signaling, promoter reporter assays, gel shift assays, and chromatin immunoprecipitation assays. The section on mechanical loading techniques has been updated from the previous edition and expanded by inclusion of a new chapter on in vivo loading techniques. We hope that Bone Research Protocols will help those entering the bone field to establish new techniques in their laboratories. For those already experienced in bone research, we hope that they will benefit from the detailed description of the methods, in particular the many pointers and pitfalls, which the authors were specifically asked to discuss in the Notes section. We certainly learned a lot! We express our sincere thanks to all authors for their willingness to share their trade secrets and to Prof. John Walker at Humana Press for giving us the opportunity to publish a second edition of Bone Research Protocols; both he and the authors have been most patient during the edits of this volume. Aberdeen, UK Edinburgh, UK
Miep H. Helfrich, PhD Stuart H. Ralston, MD
Contents Preface. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Contributors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
PART I
CULTURE OF OSTEOBLASTS AND OSTEOCYTES
1 Primary Human Osteoblast Cultures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Jane P. Dillon, Victoria J. Waring-Green, Adam M. Taylor, Peter J.M. Wilson, Mark Birch, Alison Gartland, and James A. Gallagher 2 Osteoblast Isolation from Murine Calvaria and Long Bones . . . . . . . . . . . . . . Astrid D. Bakker and Jenneke Klein-Nulend 3 Rat Osteoblast Cultures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Isabel R. Orriss, Sarah E.B. Taylor, and Timothy R. Arnett 4 Isolation of Primary Avian Osteocytes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cor M. Semeins, Astrid D. Bakker, and Jenneke Klein-Nulend 5 Isolation of Mouse Osteocytes Using Cell Fractionation for Gene Expression Analysis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Christine Halleux, Ina Kramer, Cyril Allard, and Michaela Kneissel 6 Studying Osteocyte Function Using the Cell Lines MLO-Y4 and MLO-A5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Jennifer Rosser and Lynda F. Bonewald 7 Isolation, Differentiation, and Characterisation of Skeletal Stem Cells from Human Bone Marrow In Vitro and In Vivo . . . . . . . . . . . . . . . . . . . . . . Rahul S. Tare, Peter D. Mitchell, Janos Kanczler, and Richard O.C. Oreffo
PART II
v xi
3
19 31
43
55
67
83
CULTURE OF OSTEOCLASTS
8 Rodent Osteoclast Cultures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Isabel R. Orriss and Timothy R. Arnett 9 Isolation and Culture of Primary Chicken Osteoclasts . . . . . . . . . . . . . . . . . . . Patricia Collin-Osdoby and Philip Osdoby 10 Isolation and Purification of Rabbit Osteoclasts. . . . . . . . . . . . . . . . . . . . . . . . Fraser P. Coxon, Michael J. Rogers, and Julie C. Crockett
vii
103 119 145
viii
Contents
11 Generation of Human Osteoclasts from Peripheral Blood . . . . . . . . . . . . . . . . Kim Henriksen, Morten A. Karsdal, Adam Taylor, Denise Tosh, and Fraser P. Coxon 12 Osteoclast Formation in Mouse Co-cultures . . . . . . . . . . . . . . . . . . . . . . . . . . Cecile Itzstein and Robert J. van ’t Hof 13 RANKL-Mediated Osteoclast Formation from Murine RAW 264.7 cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Patricia Collin-Osdoby and Philip Osdoby
PART III
177
187
BIOCHEMICAL AND MOLECULAR ANALYSIS OF BONE CELLS
14 Transfection of Osteoclasts and Osteoclast Precursors . . . . . . . . . . . . . . . . . . . Julie C. Crockett, David J. Mellis, and Adam Taylor 15 Analysis of Signalling Pathways by Western Blotting and Immunoprecipitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Aymen I. Idris 16 Analysis of Transcriptional Regulation in Bone Cells . . . . . . . . . . . . . . . . . . . . Huilin Jin and Stuart H. Ralston 17 Extraction of Nucleic Acids from Bone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Alun Hughes, Tracy L. Stewart, and Val Mann 18 Analysis of Gene Expression in Bone by Quantitative RT/PCR . . . . . . . . . . . . Alun Hughes
PART IV
159
205
223 233 249 261
MICROSCOPICAL TECHNIQUES
19 Histomorphometry in Rodents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Reinhold G. Erben and Martin Glösmann 20 Studying Gene Expression in Bone by In Situ Hybridization . . . . . . . . . . . . . . Ina Kramer, Rishard Salie, Mira Susa, and Michaela Kneissel 21 Immunostaining of Skeletal Tissues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Tobias B. Kurth and Cosimo De Bari 22 Techniques for the Study of Apoptosis in Bone . . . . . . . . . . . . . . . . . . . . . . . . Sudeh Riahi and Brendon Noble 23 Transmission Electron Microscopy of Bone . . . . . . . . . . . . . . . . . . . . . . . . . . . Vincent Everts, Anneke Niehof, Wikky Tigchelaar-Gutter, and Wouter Beertsen 24 Scanning Electron Microscopy of Bone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Alan Boyde 25 Fluorescence Imaging of Osteoclasts Using Confocal Microscopy . . . . . . . . . . Fraser P. Coxon 26 Live Imaging of Bone Cell and Organ Cultures. . . . . . . . . . . . . . . . . . . . . . . . Sarah L. Dallas and Patricia A. Veno
279 305
321 335 351
365 401 425
Contents
PART V
IMAGING TECHNIQUES
27 Analysis of Bone Architecture in Rodents Using Microcomputed Tomography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Robert J. van ‘t Hof 28 Bone Measurements by Peripheral Quantitative Computed Tomography in Rodents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Jürg A. Gasser and Johannes Willnecker 29 Quantitative X-ray Imaging of Rodent Bone by Faxitron . . . . . . . . . . . . . . . . . J.H. Duncan Bassett, Anne van der Spek, Apostolos Gogakos, and Graham R. Williams 30 Bioluminescence Imaging of Bone Metastasis in Rodents . . . . . . . . . . . . . . . . Thomas J.A. Snoeks, Ermond van Beek, Ivo Que, Eric L. Kaijzel, and Clemens W.G.M. Löwik 31 Fourier Transform Infrared Imaging of Bone . . . . . . . . . . . . . . . . . . . . . . . . . Eleftherios P. Paschalis 32 Raman Microscopy of Bone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Simon R. Goodyear and Richard M. Aspden
PART VI
461
477 499
507
517 527
IN VIVO TECHNIQUES
33 The Calvarial Injection Assay. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Robert J. van ‘t Hof 34 Ovariectomy/Orchidectomy in Rodents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Aymen I. Idris
PART VII
ix
537 545
MECHANICAL LOADING TECHNIQUES
35 Mechanical Properties of Bone Ex Vivo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Simon R. Goodyear and Richard M. Aspden 36 Mechanical Stimulation of Bone Cells Using Fluid Flow . . . . . . . . . . . . . . . . . Carmen Huesa and Astrid D. Bakker 37 Using Cell and Organ Culture Models to Analyze Responses of Bone Cells to Mechanical Stimulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Andrew A. Pitsillides and Simon C.F. Rawlinson 38 In Vivo Mechanical Loading . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Roberto Lopes de Souza and Leanne Saxon Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
555 573
593 621 637
wwwwwwwwwwww
Contributors CYRIL ALLARD • Transplantation and Inflammation Department, Novartis Institutes for BioMedical Research, Basel, Switzerland TIMOTHY R. ARNETT • Department of Cell and Developmental Biology, University College London, London, UK RICHARD M. ASPDEN • Musculoskeletal Research Programme, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK ASTRID D. BAKKER • Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University Amsterdam, Research Institute MOVE, Amsterdam, The Netherlands J.H. DUNCAN BASSETT • Molecular Endocrinology Group, Department of Medicine and MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK ERMOND VAN BEEK • Department of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands WOUTER BEERTSEN • Department of Oral Cell Biology and Dept. Periodontology Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University Amsterdam, Research Institute MOVE, Amsterdam, The Netherlands MARK BIRCH • Musculoskeletal Research Group, Institute of Cellular Medicine, The Medical School, Newcastle University, Newcastle-upon-Tyne, UK LYNDA F. BONEWALD • Department of Oral Biology, University of Missouri at Kansas City, Kansas City, MO, USA ALAN BOYDE • Biophysics Section, Oral Growth and Development, Dental Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK PATRICIA COLLIN-OSDOBY • Department of Biology, Washington University, St. Louis and Division of Bone and Mineral Metabolism, Washington University Medical School, St. Louis, MO, USA FRASER P. COXON • Musculoskeletal Research Programme, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK JULIE C. CROCKETT • Musculoskeletal Research Programme, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK SARAH L. DALLAS • School of Dentistry/Department of Oral Biology, University of Missouri, Kansas City, MO, USA COSIMO DE BARI • Regenerative Medicine Group, Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK JANE P. DILLON • Bone and Joint Research Group, Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK
xi
xii
Contributors
REINHOLD G. ERBEN • Institute of Physiology, Pathophysiology, and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria VINCENT EVERTS • Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University Amsterdam, Research Institute MOVE, Amsterdam, The Netherlands JAMES A. GALLAGHER • Bone and Joint Research Group, Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK ALISON GARTLAND • Academic Unit of Bone Biology, Department of Human Metabolism, Mellanby Centre for Bone Research, University of Sheffield, Sheffield, UK JÜRG A. GASSER • Department of Musculoskeletal Diseases, Novartis Institutes for BioMedical Research, Basel, Switzerland MARTIN GLÖSMANN • Department of Biomedical Sciences, Institute of Physiology, Pathophysiology, and Biophysics, University of Veterinary Medicine, Vienna, Austria APOSTOLOS GOGAKOS • Molecular Endocrinology Group, Department of Medicine & MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, W12 0NN, UK SIMON R. GOODYEAR • Musculoskeletal Research Programme, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK CHRISTINE HALLEUX • Musculoskeletal Disease Department, Novartis Institutes for BioMedical Research, Basel, Switzerland KIM HENRIKSEN • Nordic Bioscience A/S, Herlev, Denmark ROBERT J. VAN ‘T HOF • Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK CARMEN HUESA • Department of Developmental Biology, The Roslin Institute, University of Edinburgh, Edinburgh, UK ALUN HUGHES • Musculoskeletal Research Programme, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK AYMEN I. IDRIS • Bone and Cancer Group, Edinburgh Cancer Research UK Centre and Rheumatic Disease Unit, the Centre of Molecular Medicine, University of Edinburgh, Edinburgh, UK CECILE ITZSTEIN • Musculoskeletal Research Programme, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK HUILIN JIN • Kennedy Institute of Rheumatology, London, UK ERIC L. KAIJZEL • Department of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands JANOS KANCZLER • Bone and Joint Research Group, Centre for Human Development, Stem Cells and Regeneration, Developmental Origins of Health and Disease, Institute of Developmental Sciences, University of Southampton Medical School, Southampton, UK MORTEN A. KARSDAL • Nordic Bioscience A/S, Herlev, Denmark JENNEKE KLEIN-NULEND • Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University Amsterdam, Research Institute MOVE, Amsterdam, The Netherlands MICHAELA KNEISSEL • Musculoskeletal Disease Department, Novartis Institutes for BioMedical Research, Basel, Switzerland
Contributors
xiii
INA KRAMER • Musculoskeletal Disease Department, Novartis Institutes for BioMedical Research, Basel, Switzerland TOBIAS B. KURTH • Regenerative Medicine Group, Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK ROBERTO LOPES DE SOUZA • Department of Veterinary Basic Sciences, Royal Veterinary College, Royal College Street, London, UK CLEMENS W.G.M. LÖWIK • Department of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands VAL MANN • School of Health, Science and Social Care, University Campus Suffolk, Waterfront Building, Ipswich, UK DAVID J. MELLIS • Musculoskeletal Research Programme, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK PETER D. MITCHELL • Bone and Joint Research Group, Centre for Human Development, Stem Cells and Regeneration, Developmental Origins of Health and Disease, Institute of Developmental Sciences, University of Southampton Medical School, Southampton, UK ANNEKE NIEHOF • Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University Amsterdam, Amsterdam, The Netherlands BRENDON NOBLE • University Campus Suffolk, Ipswich, UK RICHARD O.C. OREFFO • Bone and Joint Research Group, Centre for Human Development, Stem Cells and Regeneration, Developmental Origins of Health and Disease, Institute of Developmental Sciences, University of Southampton Medical School, Southampton, UK ISABEL R. ORRISS • Department of Cell and Developmental Biology, University College London, London, UK PHILIP OSDOBY • Department of Biology, Washington University, St. Louis, and Division of Bone and Mineral Metabolism, Washington University Medical School, St. Louis, MO, USA ELEFTHERIOS P. PASCHALIS • Ludwig Boltzmann Institute for Osteology, Vienna, Austria ANDREW A. PITSILLIDES • Department of Veterinary Basic Sciences, The Royal Veterinary College, Royal College Street, London, UK IVO QUE • Department of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands STUART H. RALSTON • Rheumatic Diseases Unit, Western General Hospital, University of Edinburgh, Edinburgh, UK SIMON C.F. RAWLINSON • Queen Mary University of London, Barts & The London School of Medicine and Dentistry, Institute of Dentistry, Turner Street, London, UK SUDEH RIAHI • University Campus Suffolk, Ipswich, UK MICHAEL J. ROGERS • Musculoskeletal Research Programme, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK JENNIFER ROSSER • Department of Oral Biology, University of Missouri at Kansas City, Kansas City, USA RISHARD SALIE • Musculoskeletal Disease Department, Novartis Institutes for BioMedical Research, Basel, Switzerland
xiv
Contributors
LEANNE SAXON • Department of Veterinary Basic Sciences, Royal Veterinary College, Royal College Street, London, UK COR M. SEMEINS • Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University Amsterdam, Research Institute MOVE, Amsterdam, The Netherlands THOMAS J.A. SNOEKS • Department of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands ANNE VAN DER SPEK • Molecular Endocrinology Group, Department of Medicine & MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK TRACY L. STEWART • Musculoskeletal Research Programme, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK MIRA SUSA • Oncology Department, Novartis Institutes for BioMedical Research, Basel, Switzerland RAHUL S. TARE • Bone and Joint Research Group, Centre for Human Development, Stem Cells and Regeneration, Developmental Origins of Health and Disease, Institute of Developmental Sciences, University of Southampton Medical School, Southampton, UK ADAM TAYLOR • Musculoskeletal Research Programme, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK ADAM M. TAYLOR • Lancaster Medical School, Faculty of Health and Medicine, University of Lancaster, Lancaster, UK SARAH E.B. TAYLOR • Department of Cell and Developmental Biology, University of Lancaster, Lancaster, UK WIKKY TIGCHELAAR-GUTTER • Department of Cell Biology and Histology, Academic Medical Centre (AMC), University of Amsterdam, Amsterdam, The Netherlands DENISE TOSH • Musculoskeletal Research Programme, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK PATRICIA A. VENO • School of Dentistry/Department of Oral Biology, University of Missouri, Kansas City, MO, USA VICTORIA J. WARING-GREEN • Royal Veterinary College, London, UK GRAHAM R. WILLIAMS • Molecular Endocrinology Group, Department of Medicine and MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK JOHANNES WILLNECKER • Stratec Medizintechnik GmbH, Pforzheim, Germany PETER J.M. WILSON • Bone and Joint Research Group, Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK
Part I Culture of Osteoblasts and Osteocytes
Chapter 1 Primary Human Osteoblast Cultures Jane P. Dillon, Victoria J. Waring-Green, Adam M. Taylor, Peter J.M. Wilson, Mark Birch, Alison Gartland, and James A. Gallagher Abstract Osteoblast cultures can be used to investigate the mechanisms of bone formation, to probe the cellular and molecular basis of bone disease, and to screen for potential therapeutic agents that affect bone formation. Here, we describe the methods for establishing and characterising primary human osteoblast cultures. Key words: Osteoblast, HOBs, Osteosarcoma cell, Osteogenesis, Bone formation
1. Introduction Osteoblasts are the cells responsible for the formation of bone; they synthesise almost all of the constituents of the bone matrix and direct its subsequent mineralisation. Once bone formation is complete, osteoblasts differentiate into osteocytes or bone lining cells, both of which play major roles in the regulation of calcium homeostasis and bone remodelling. Osteoblast cultures can be used to study the biochemistry and physiology of bone formation, to investigate the molecular and cellular basis of human bone disease, and to study the mechanisms by which bone resorption is coupled to bone formation. In addition, osteoblast cultures can be used to screen for potential anabolic agents, to develop and test new biomaterials, and to provide a source of cells for tissue engineering. The main focus of the present chapter is to describe the methods for establishing primary cultures of human osteoblast-like cells using the explant technique. We also describe methods for cryopreservation and phenotypic characterisation of these osteoblast cultures. In the following sections, we have also reviewed the
Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_1, © Springer Science+Business Media, LLC 2012
3
4
J.P. Dillon et al.
characteristics of primary osteoblast cultures in relation to other experimental models, such as osteosarcoma cell lines, mesenchymal stem cells (MSCs), and osteoblasts derived from peripheral blood. 1.1. Human Primary Osteoblast Cultures
Bard and co-workers (1) were the first to isolate living cells from adult human bone, but these had low levels of alkaline phosphatase and produced only small amounts of collagen. Although the cells remained viable for up to 2 weeks, they did not proliferate and it was concluded that osteocytes were the predominant cell type present. Subsequently, Mills et al. were successful in culturing cells from explants of human bone from patients with Paget’s disease. These cultures were responsive to parathyroid hormone and expressed alkaline phosphatase positive cells (2). The methods for isolation, culture, and characterisation of primary human osteoblast-like cells on a large scale were established in Graham Russell’s laboratory at the University of Sheffield in the early 1980s (3, 4). The defining characteristics of these studies were the use of an explant culture technique, which avoided the need for digestion of the tissue and the availability of osteocalcin as a phenotypic marker to confirm identity of the cells in vitro. In addition to producing osteocalcin, the cells grown from explants of human bone express other characteristics of osteoblasts, including the fact that they respond to parathyroid hormone (5, 6) and produce high levels of alkaline phosphatase and type I collagen (7). While several modifications of this technique have been published (8–11) (see Note 1), the vast majority of published reports on human osteoblasts rely on the explant technique as depicted in Fig. 1. The nomenclature used by various research groups to describe these cells has also varied including “human bone cells”, “human osteoblasts in vitro”, “human osteoblast-like cells” (HOBs), and human bone-derived cells (HBDCs). In the previous edition of this book, we used the term human bone-derived cells to describe these cultures, but here we refer to the cells as human osteoblast-like cells since the evidence is now overwhelming that these cells express several characteristics of osteoblasts.
1.2. Osteosarcoma Cell Lines
Osteosarcoma cell lines are also widely used as an experimental model of osteoblasts. These cells proliferate more rapidly than primary cells and are immortal which makes them easy to work with. Osteosarcoma cells synthesise bone matrix proteins, respond to various calciotropic hormones, including parathyroid hormone, and express a wide spectrum of osteoblastic marker genes (12, 13). The osteosarcoma cell lines that are most widely used as experimental models are SaOS-2, MG-63, and TE85 cells (sometimes referred as HOS TE85). These cell lines differ with regard to their expression of osteoblastic markers and some researchers feel that
1
Primary Human Osteoblast Cultures
5
Fig. 1. Technique used to isolate cells expressing osteoblastic characteristics (HOBs) from explanted trabecular bone.
this reflects different stages of maturity with MG-63 being least differentiated and SaOS-2 the most differentiated cell line. All three lines are responsive to PTH and are available from ATCC (http://www.atcc.org) or ECACC (http://www.hpacultures.org). The characteristics of these cells are summarised in Table 1. 1.3. Osteoblasts from MSCs
It is possible to generate human osteoblasts from bone marrow by isolating MSCs and culturing these in osteogenic medium. The methods for this is not described here, but can be found in Chapter 7, this volume. Although some researchers distinguish between these cells and cells grown from explants of human bone, it is likely that there is a significant overlap in their origin and phenotype, including their potential for osteogenesis (19, 20). MSCs are usually isolated on the basis of expression of STRO-1, an uncharacterised antigen associated with the stromal lineage (21) which is also expressed in cells derived from explant culture (11).
Reference
Billiau et al. (14)
Mulkins et al. (15)
Rodan et al. (16)
Cell line
MG-63
TE85
SaOS-2
Osteosarcoma of an 11-year-old female Caucasian
Osteosarcoma of a 13-year-old female Caucasian
Osteosarcoma of a 14-year-old male Caucasian
Origin
Table 1 Characteristics of osteosarcoma cell lines
High levels of ALP, low levels of osteocalcin. Highly sensitive to PTH. Easy to transfect
Higher levels of ALP than MG-63, but lower levels of osteocalcin. Responsive to PTH
High growth rate; high production of type VI collagen, low levels of ALP. Responsive to PTH.
Phenotype
Produces mineralised matrix resembling bone in nude mice (16). Has been used to establish stable reporter cell lines, (17, 18)
Have been used for biological evaluation of tissue scaffolds for orthopaedic applications
Recently has been used in biomaterials research to study the effects of substrates on osteogenic differentiation
Comments
6 J.P. Dillon et al.
1
1.4. Human Osteoblasts from Peripheral Blood
Primary Human Osteoblast Cultures
7
Recently, there have been several reports describing the isolation of osteoblastic precursor cells from peripheral blood or cord blood (22–24). These cells have been isolated and enriched for osteoblastic characteristics using antibodies against osteocalcin (22), differential attachment on tissue culture plastic, and Ficoll-Paque density gradient centrifugation. Although there are only a few publications using these techniques, if they can be applied reproducibly, it will open up new opportunities to investigate osteoblastic activity especially in genetic diseases.
2. Materials 2.1. Equipment
1. Bone cutters. 2. Solid stainless steel scalpels with integral handles. 3. Forceps, assorted sizes. 4. Class II tissue culture facilities. 5. Incubator. 6. C-Chip haemocytometer (LabTech International) or Neubauer Haemocytometer (VWR). 7. 70 μm “cell strainer” (Becton Dickinson). 8. Cell freezing container, such as Mr Frosty (Nalgene). 9. Cryoampoules (Nalgene).
2.2. Cell Isolation and Culture
1. Dulbecco’s modification of minimum essential medium (DMEM). 2. Complete Culture medium DMEM with 10% FCS, 2 mM Lglutamine, 50 U/ml penicillin, and 50 μg/ml streptomycin (see Note 2). 3. Phosphate-buffered saline (PBS) without calcium and magnesium. 4. Trypsin/EDTA (0.05% trypsin and 0.02% EDTA in Ca2+- and Mg2+-free Hank’s BSS, pH 7.4). 5. L-ascorbic acid-2- phosphate (see Note 3). 6. Tissue-culture flasks (75 cm2) or Petri dishes (100 mm diameter) (see Note 4). 7. 0.4% trypan blue in 0.85% NaC1. 8. Collagenase type VII (Sigma-Aldrich). 9. DNAse I (Sigma-Aldrich). 10. 1,25(OH)2D3. (Sigma-Aldrich). 11. Dexamethasone (Sigma-Aldrich). 12. 5 mM β-glycerophosphate (Sigma-Aldrich).
8
J.P. Dillon et al.
13. Inorganic phosphate solution (mix 500 mM solutions of Na2HPO4 and NaH2PO4 in a 4:1 (v/v) ratio. Sterile filter and store at 4°C prior to use). 2.3. Phenotypic Characterisation
1. Alkaline phosphatase assay kit (Sigma-Aldrich). 2. Alkaline phosphatase staining kit (Sigma-Aldrich). 3. Osteocalcin radioimmunassay (IDS Ltd., Boldon, UK or other supplier). 4. Alizarin red (Sigma-Aldrich). 5. qPCR primers and reagents for a panel of osteoblastic markers, including osteocalcin (see Note 5).
3. Methods 3.1. Establishing Primary Explant Cultures
This section describes the method for establishing an initial culture (termed explant 1 or E1) from trabecular bone chips that have been freshly obtained from the donor (see Note 6). An overview of the technique is shown in Fig. 1. 1. Transfer the bone tissue removed at surgery or biopsy (see Note 7) into a sterile container with PBS or serum-free medium (SFM) for transport to the laboratory with minimal delay, preferably on the same day (see Note 8). 2. Remove soft connective tissue from the outer surfaces of the bone by scraping with a sterile scalpel blade. 3. Rinse the tissue in sterile PBS and transfer to a sterile Petri dish containing a 5–20 ml PBS, depending on the size of the sample. 4. Isolate the trabecular bone fragments from the tissue using sterile bone cutters or a solid stainless steel scalpel blade as in Fig. 2 (see Note 9). With some bone samples, it may be necessary to gain access to the trabecular bone by breaking through the cortex with the aid of sterile surgical bone cutters. 5. Transfer the trabecular bone fragments to a clean Petri dish containing 2–3 ml of PBS and divide into pieces 3–5 mm in diameter with a scalpel blade and/or scissors. 6. Decant the PBS and transfer the bone chips to a sterile Universal container containing 15–20 ml PBS. 7. Vortex the tube vigorously three times for 10 s and then leave to stand for 30 s to allow the bone fragments to settle. 8. Carefully decant off the supernatant containing haematopoietic tissue and dislodged cells, add an additional 15–20 ml of PBS, and vortex the bone fragments as before.
1
Primary Human Osteoblast Cultures
9
Fig. 2. Equipment required to dissect human trabecular bone prior to the establishment of explant cultures and a sample of bone obtained at surgery.
9. Repeat steps 7 and 8 at least three times, or until no remaining haematopoietic marrow is visible and the bone fragments have assumed a white, ivory-like appearance. 10. Place the washed bone fragments as explants at a density of 0.2–0.6 g of tissue/100-mm diameter Petri dish (Fig. 3). (see Note 10). 11. Add 10 ml of complete medium to each dish and culture at 37°C in humidified atmosphere with 5–7% CO2. 12. Culture the explants undisturbed for 7 days and replace the medium taking care not to dislodge the explants. 13. Check for outgrowth of cells at 7–10 days (Figs. 4 and 5) (see Note 11). 14. Replace the medium after 2 weeks and twice weekly thereafter for 4–6 weeks until the desired density has been attained (see Note 12). 3.2. Secondary Explant Cultures
This section describes the method for culturing HOBs from trabecular bone chips that have already been used to establish an E1 culture. These are termed explant 2 or E2 cultures (see Note 13). 1. Remove bone fragments from the tissue culture plate containing the HOBs using a pair of sterile fine forceps and place in a new Petri dish with fresh medium.
10
J.P. Dillon et al.
Fig. 3. Culture dish containing explanted trabecular bone.
Fig. 4. Migration of cells expressing osteoblastic characteristics (HOBs) from explanted trabecular bone.
2. Chop the fragments using a scalpel to stimulate fresh cell outgrowth. 3. Leave for 7–10 days without changing the medium. 4. Follow steps 13–14 of Subheading 3.1 until the desired cell density has been obtained.
1
Primary Human Osteoblast Cultures
11
Fig. 5. Typical morphology of cells expressing osteoblastic characteristics (HOBs).
3.3. Passaging Explant Cultures
This section describes the method for passaging HOBs which have already reached confluence or near confluence. This is an appropriate stage to confirm that the cells are expressing osteoblastic characteristics by histochemical or biochemical analysis of alkaline phosphatase activity and/or the measurement of osteocalcin in conditioned medium, following incubation with 10−9 M 1,25(OH)2D3 for 48 h (see Note 5). 1. Remove and discard the spent medium. 2. Gently wash the cell layers two times with 10 ml of PBS without Ca2+ and Mg2+ discarding PBS after each wash. 3. Add 5 ml of freshly thawed trypsin–EDTA solution at room temperature to each dish (20°C) and incubate for 5 min at 37°C with gentle rocking every 30 s to ensure that the entire surface area of the flask and explants is exposed to the solution. 4. Remove the dishes from the incubator and examine under the microscope. Look for the presence of rounded, highly refractile cell bodies floating in the trypsin–EDTA solution. If none, or only a few, are visible tap the base of the dish sharply on the bench top in an effort to dislodge the cells. If this is not effective, incubate the cells for a further 5 min at 37°C. 5. When most of the cells have become detached from the culture substratum, transfer to a Universal container containing 5 ml of culture medium. 6. Wash the flask two to three times with 5 ml of serum-free DMEM and pool the washings with the original cell isolate.
12
J.P. Dillon et al.
7. Centrifuge at 250 × g for 5 min at room temperature to pellet the cells. 8. Remove and discard the supernatant, invert the tube, and allow the medium to drain briefly. 9. Resuspend the cells in 2 ml of serum-free DMEM. If the cells are clumping, filter the cell suspension through a 70-μm cell strainer into a 50 ml polypropylene tube (see Note 14). 10. Wash the filter with 2–3 ml serum-free DMEM and add the filtrate to the cells. 11. Take 20 μl of the mixed cell suspension and dilute to 80 μL with serum-free DMEM. Add 5 μl of trypan blue solution, mix, and leave for 1 min before counting viable (round and refractile), and nonviable (blue) cells in a haemocytometer. 12. Plate the harvested cells at a cell density suitable for the intended analysis (see Note 15). 3.4. Ascorbate Containing Cultures
Culturing cells in ascorbate results in the secretion of an abundant collagen-rich extracellular matrix and because of this, difficulty can be encountered in passaging the cells using trypsin/EDTA alone. Here, we describe a method for passage of these cells with collagenase. 1. Rinse the cell layers twice with serum-free DMEM. 2. Incubate the cells for 2 h at 37°C in 10 ml serum-free DMEM containing 25 U/ml purified collagenase type VII and 2 mM CaC12. 3. Gently agitate the flask for 10–15 s every 30 min. 4. Terminate the collagenase digestion by discarding the medium (check that there is no evidence of cell detachment at this stage). 5. Gently rinse the cell layer twice with 10 ml calcium and magnesium-free PBS. 6. Add 5 ml of freshly thawed trypsin–EDTA solution pH 7.4 at room temperature to each flask (20°C). 7. Follow steps 4–12 of Subheading 3.3.
3.5. Mineralising Cultures
Mineralised structures resembling the nodules that form in cultures of foetal or embryonic animal bone-derived cells can be obtained by culturing HOBs in the presence of ascorbate and either β-glycerol phosphate (β-GP) or another source of inorganic phosphate (Fig. 6). These cells can also be shown to make bone in diffusion chambers or on supports following transplantation in vivo (see Note 16). Here, we describe a method for generating mineralised structures from HOBs in vitro.
1
Primary Human Osteoblast Cultures
13
Fig. 6. HOBs cultured under osteogenic conditions for 28 days. Alkaline phophatase positive cells are stained dark grey while alizarin red stained mineralised deposits appear black.
1. Prepare fragments of human trabecular bone as described in Subheading 3.1, steps 1–10. 2. Culture the washed bone fragments in medium supplemented with 100 μM L-ascorbic acid 2-phosphate and 10 nM dexamethasone (see Note 17). 3. Culture the cells for 4–5 weeks until they have attained confluence with medium changes twice weekly. 4. When the cells have synthesised a dense extracellular matrix, subculture using the sequential collagenase/trypsin–EDTA protocol described in Subheading 3.4 and plate the cells in 25-cm2 flasks at a density of 104 viable cells/cm2. 5. After a further 14 days, supplement the medium with 0.01% phosphate solution. 6. After 48–72 h, wash the cell layers two or three times with 10 ml of serum-free DMEM. 7. Aspirate the medium and fix with 95% ethanol at 4°C. 8. To identify mineralised bone nodules, wash the cell layer in PBS and stain with alizarin red (1% solution in water) for 20 min in the dark at room temperature. Rinse with 50% ethanol to remove excess stain, before a final wash in distilled water then air-dry. Cells can be counterstained for alkaline phosphatase activity (see Fig. 6).
14
J.P. Dillon et al.
3.6. Cryopreservation
If required, HOBs can be stored frozen for extended periods in liquid nitrogen or in ultra-low temperature (−135°C) cell freezer banks. Here, we present a protocol for cryopreservation of HOBs. We recommend that this is performed before full confluence is reached. 1. Passage the cells using trypsin/ETDA as described in Subheading 3.3, steps 1–6. 2. Pellet the cells by centrifugation at 250 × g for 5 min and pour off the supernatant. 3. Resuspend the cell pellet in FCS, bring up to a volume of 900 μl and transfer to a cryoampoule. 4. Swirl the ampoule in an ice water bath. 5. Add 100 μl DMSO gradually while holding the ampoule in the iced water. 6. Close ampoules tightly and freeze at 1°C/min to −80°C in a cell freezing container, such as Mr Frosty (Nalgene). 7. Transfer the cells to liquid nitrogen for long-term storage.
3.7. Retrieval of Cryopreserved Cells
1. Remove the cells from liquid nitrogen and place in a water bath set at 37°C. 2. Transfer the cells to a universal containing at least 20 ml of preheated culture medium. 3. Centrifuge at 250 × g for 2 min to pellet the cells and pour off the supernatant. 4. Resuspend the cells in about 10 ml of the medium and place into culture for 24 h. 5. Replace the medium after 24 h and culture for 2–3 weeks.
4. Notes 1. Although most investigators have used the original explant method with only minor modifications, others have developed alternative techniques for the isolation and culture of HOBs. Gehron-Robey and Termine used prior digestion of minced bone with Clostridial collagenase and subsequent culture of explants in medium with reduced calcium concentrations (8). In contrast, Wergedal and Baylink have used collagenase digestion to directly liberate cells (9). Marie and co-workers have used a method in which explants are first cultured on a nylon mesh (10). These alternative methods are described in greater detail in ref. 11 and readers are encouraged to consult the original publications and other references by these authors.
1
Primary Human Osteoblast Cultures
15
2. Batches of serum vary in their ability to support the growth of HOBs. It is advisable to screen batches and reserve a large quantity of serum once a suitable batch has been identified. HOBs will grow in autologous and heterologous human serum, but as yet no comprehensive studies have been performed to identify the effects on the growth and differentiation. 3. Beresford and co-workers introduced the use of this stable analogue of L-ascorbic acid for the generation of mineralising cultures, since it is stable and unlike L-ascorbic acid, does not have to be added to the cultures on a daily basis. 4. The authors have obtained consistent results with plasticware from Sarstedt and Becton Dickinson. Smaller flasks or dishes can be used if the amount of bone available is <0.2 g. 5. In early studies, osteoblastic phenotype was assessed using histochemical staining for alkaline phosphatise and secretion of osteocalcin. However, many researchers now prefer to undertake qPCR for ostoblastic genes (25). 6. We generally perform studies on cells at first passage (P1), but we have previously shown that cells isolated from replated explants cultures (E1P1, E2P1, and E3P1) are phenotypically stable with no reduction in the expression of osteoblastic markers (11). Furthermore, we have not detected any loss of phenotype at P2. Other investigators have studied the effects of repeated subculture on the phenotypic stability of HOBs and found that they eventually lose their osteoblast-like characteristics with successive passages. 7. Bone cells can be cultured from virtually any site, but an excellent source is the upper part of the femur of patients undergoing total hip replacement surgery for osteoarthritis. Trabecular bone is removed from this site prior to the insertion of the femoral prosthesis and would otherwise be discarded. The tissue obtained is remote from the hip joint itself, and thus from the site of pathology, and is free of contaminating soft tissue. 8. Bone can be stored for periods of up to 24 h at 4°C in PBS or serum-free DMEM prior to culture without any obvious deleterious effect on the ability of the tissue to give rise to populations of osteoblast-like cells. 9. Do not use disposable scalpel blades since these often shatter during this process. 10. We prefer Petri dishes to flasks because it is easier to remove the chips from them for subsequent culture and the scoring that is made on the plate surface when chopping the fragments appears to encourage cell spreading. 11. The first evidence of cellular outgrowth from the explants is usually observed within 5–7 days of plating and after 7–10 days
16
J.P. Dillon et al.
cells can be observed migrating from the explants onto the surface of the culture dish (Fig. 4). If care is taken not to dislodge the explants when feeding, and they are left undisturbed between media changes, they rapidly become anchored to the substratum by the cellular outgrowths. Typical morphology of the cells is shown in Fig. 5, but cell shape varies between donors, from fibroblastic to cobblestone-like. 12. Cultures generally attain confluence 4–6 weeks postplating. 13. Using this technique, it is possible to obtain additional cell populations that continue to express osteoblast-like characteristics, including the ability to mineralise extracellular matrix, and maintain their cytokine expression profile (11). Presumably, these cultures are seeded by cells which are situated close to the bone surfaces, and which still retain the capacity for extensive proliferation and differentiation. The continued survival of these cells may be related to the gradual release over time in culture of the cytokines and growth factors that are present in the bone matrix. 14. As an alternative to using the cell filter, cells can be suspended in 2 ml serum-free DMEM containing 1 μg/ml DNAse I for each dish followed by aspiration with a narrow bore 2 ml pipette. However, we find that the act of passaging usually reduces clumping without the use of DNAse 1. 15. The yield of HOBs is typically 1−1.5 × 106 cells per 100 mm Petri dish of which ³75% are viable. In further experiments, we routinely subculture the HOBs at 5 × 103−104 cells/cm2 and achieve plating efficiencies of ³70% after 24 h. 16. The osteogenic potential of these cells can best be demonstrated by culturing the cells in diffusion chambers or on supports and transplanting them in vivo. Researchers wishing to study osteogenesis by transplanted HOBs should read the papers by Gundle et al. (19, 20) and the review by Abdallah et al. (26) and also to consult Chapter 7 in this volume. 17. Mineralising cultures can be generated from E1P1 or E2P1 cultures attesting to the phenotypic stability of E2 cells. Cells cultured in the continuous presence of ascorbate and treated with glucocorticoids at first passage show a patchy pattern of mineralisation, despite possessing similar amounts of extracellular matrix and alkaline phosphatase activity. Cells cultured without ascorbate secrete little extracellular matrix, and do not mineralise. The ability of the cells to mineralise their extracellular matrix is critically dependent on ascorbate being present continuously in primary culture. Moreover, the addition of ascorbate in secondary culture, even for extended periods, cannot compensate for its omission in primary culture. This indicates that maintenance of adequate levels of ascorbate during
1
Primary Human Osteoblast Cultures
17
the early stages of explant culture is of critical importance for the survival of cells that retain the ability to proliferate extensively and give rise to precursors capable of undergoing osteogenic differentiation. Osteoblasts cultured continuously in the presence of ascorbate and glucocorticoids retain the ability to form bone when implanted in vivo within diffusion chambers in athymic mice (19). References 1. Bard, D. R., Dickens, M. J., Smith, A. U., and Zarek, J. M. (1972) Isolation of living cells from mature mammalian bone. Nature 236, 314–315. 2. Mills, B. G., Singer, F. R., Weiner, L. P., and Hoist, P. A. (1979) Long term culture of cells from bone affected with Paget’s disease. Calcif. Tissue Int. 29, 79–87. 3. Gallagher, J. A., Beresford, J. N., McGuire, M. K. B., Ebsworth, N. M., Meats, J. E., Gowen, M., Elford, P., Wright, P., Poser, J., Coulton, L. A., Sharrard, M., Imbimbo, B., Kanis, J. A., and Russell, R. G. G. (1984) Effects of glucocorticoids and anabolic steroids on cells derived from human skeletal and articular tissues in vitro. Adv. Exp. Med. Biol. 171, 279–292. 4. Beresford, J. N., Gallagher, J. A., Poser, J. W., and Russell, R. G. G. (1984a) Production of osteocalcin by human bone cells in vitro. Effects of 1,25(OH)2D3, parathyroid hormone and glucocorticoids. Metab. Bone Dis. Rel. Res. 5, 229–234. 5. MacDonald, B. R., Gallagher, J. A., AhnfeltRonne, I., Beresford, J. N., Gowen, M., and Russell, R. G. G. (1984) Effects of bovine parathyroid hormone and 1,25(OH)2D3 on the production of prostaglandins by cells derived from human bone. FEBS Lett. 169, 49–52. 6. MacDonald, B. R., Gallagher, J. A., and Russell, R. G. G. (1986) Parathyroid hormone stimulates the proliferation of cells derived from human bone. Endocrinology 118, 2245–2449. 7. Beresford, J. N., Gallagher, J. A., and Russell, R. G. G. (1986) 1,25-dihydroxy-vitamin D3 and human bone derived cells in vitro: effects on alkaline phosphatase, type I collagen and proliferation. Endocrinology 119, 1776–1785. 8. Gehron Robey, P., and Termine, J. D. (1985) Human bone cells in vitro. Calcif. Tissue Int. 37, 453–460. 9. Wergedal, J. E., and Baylink, D. J. (1984) Characterisation of cells isolated and cultured from human trabecular bone. Proc. Soc. Exp. Biol. Med. 176, 60–69.
10. Marie, P. J., Sabbagh, A., De Vernejoul, M. C., and Lomri, A. (1988) Osteocalcin and deoxyribonucleic acid synthesis in vitro and histomorphometric indices of bone formation in postmenopausal osteoporosis. J. Clin. Invest. 69, 272–279. 11. Gallagher, J. A., Gundle, R., and Beresford, J. N. (1996) Isolation and culture of bone forming cells (osteoblasts) from human bone, in Human Cell Culture Protocols (Jones, G. E., ed.), Humana Press Totowa, New Jersey. 12. Clover, J. and Gowen, M. (1994) Are MG-63 and HOS TE85 human osteosarcoma cell lines representative models of the osteoblastic phenotype? Bone 15, 585–591. 13. Bilbe, G., Roberts, E., Birch, M., and Evans, D. B. (1996) PCR phenotyping of cytokines, growth factors and their receptors and bone matrix proteins in human osteoblast-like cell lines. Bone 19, 437–445. 14. Billiau, A., Edy, V. G., Heremans, H., Damme, J. V., Desmyter, J., Georgiades, J. A., et al. (1977) Human interferon: mass production in a newly established cell line, MG-63. Antimicrob. Agents Chemother. 12, 11–15. 15. Mulkins, M. A., Manolagas, S. C., Deftos, L. J., and Sussman, H. H. (1983) 1,25-Dihydroxyvitamin D3 increases bone alkaline phosphatase isoenzyme levels in human osteogenic sarcoma cells. J. Biol. Chem. 258, 6219–6225. 16. Rodan, S. B., Imai, Y., Thiede, M. A., Wesolowski, G., Thompson, D., Bar-Shavit, Z., et al. (1987) Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties. Cancer Res. 47, 4961–4966. 17. Bowler, W. B., Buckley, K. A., Gartland, A., Hipskind, R. A., Bilbe, G., and Gallagher, J. A. (2001) Extracellular nucleotide signaling: a mechanism for integrating local and systemic responses in the activation of bone remodelling. Bone 28, 507–512. 18. Buckley, K. A., Wagstaff, S. C., McKay, G., Gaw, A., Hipskind, R. A., Bilbe, G., Gallagher,
18
J.P. Dillon et al.
J. A., and Bowler, W. B. (2001) Parathyroid hormone potentiates nucleotide-induced [Ca2+]i release in rat osteoblasts independently of Gq activation or cyclic monophosphate accumulation. A mechanism for localizing systemic responses in bone. J. Biol. Chem. 276, 9565–9571. 19. Gundle, R. G., Joyner, C. J., and Triffitt, J. T. (1995) Human bone tissue formation in diffusion chamber culture in vivo by bone derived cells and marrow stromal cells. Bone 16, 597. 20. Gundle, R., Joyner, C. J., and Triffitt, J. T. (1997) Interactions of human osteoprogenitors with porous ceramic following diffusion chamber implantation in a xenogeneic host. J. Mater. Sci. Mater. Med. 8, 519–523. 21. Walsh, S., Jefferiss, C., Stewart, K., Jordan, G. R., Screen, J., and Beresford, J. N. (2000) Expression of the developmental markers STRO-1 and alkaline phosphatase in cultures of human marrow stromal cells: regulation by fibroblast growth factor (FGF)-2 and relationship to the expression of FGF receptors 1–4. Bone 27, 185–195.
22. Eghbali-Fatourechi, G. Z., Lamsam, J., Fraser, D., Nagel, D., Riggs, B. L., and Khosla, S. (2005) Circulating osteoblast-lineage cells in humans. N. Engl. J. Med. 352, 1959–1966. 23. Rosada, C., Justesen, J., Melsvik, D., Ebbesen, P., and Kassem, M. (2003) The human umbilical cord blood, a potential source for osteoblast progenitor cells. Calcif. Tissue Int. 72, 135. 24. Liu, G., Li, Y., Sun, J., Zhou, H., Zhang, W., Cui, L., and Cao, Y. (2010) In vitro and in vivo evaluation of osteogenesis of human umbilical cord blood-derived mesenchymal stem cells on partially demineralized bone matrix. Tissue Eng. Part A. 16, 971–982. 25. Gartland, A., Buckley, K. A., Dillon, J. P., Curran, J. M., Hunt, J. A., and Gallagher, J. A. (2005) Isolation and culture of human osteoblasts. Methods Mol. Med. 107, 29–54. 26. Abdallah, B. M., Ditzel, N., and Kassem, M. (2008) Assessment of bone formation capacity using in vivo transplantation assays: procedure and tissue analysis. Methods Mol. Biol. 455, 89–100.
Chapter 2 Osteoblast Isolation from Murine Calvaria and Long Bones Astrid D. Bakker and Jenneke Klein-Nulend Abstract This chapter describes the isolation of primary mouse osteoblasts from adult mouse calvaria and long bones, as well as the process of isolation of bone cells from neonatal mouse calvaria. Osteoblasts from adult mouse bone are obtained as outgrowth from collagenase-treated bone pieces. Isolation of osteoblasts from neonatal calvaria is achieved by sequential enzymatic digestion of the bone matrix. Because of differences in origin and isolation method, each of the primary bone cell cultures described will have their own characteristics. Key words: Osteoblast, Osteocyte, Calvaria, Long bone, Cell culture, Mouse
1. Introduction When conducting in vitro research on bone, often a choice has to be made between the use of bone organ cultures or bone cell cultures. When using cell culture the choice is between primary cells or cell lines. The advantage of cell lines over freshly isolated cells lies in the immediate availability of large numbers of cells, the homogeneity of the cell cultures, and the expected stability of the phenotype. In the long run, however, many cell lines appear unstable to some extent, and subclones of cell lines tend to develop in different laboratories. In addition, the clonal selection generally favors rapidly growing cells, but these might not express all typical features of cells from a certain tissue, and the resulting cell line may thus not be entirely representative. In addition, although silencing RNA techniques are rapidly evolving, enabling the silencing of specific molecular targets in cell lines, transfection efficiency, and duration of silencing are still hard to control. An obvious advantage of using primary cells is that cells can be isolated from genetically
Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_2, © Springer Science+Business Media, LLC 2012
19
20
A.D. Bakker and J. Klein-Nulend
modified animals, expressing a stable phenotype. This means that in certain experiments, the use of primary bone cells is preferred above the use of cell lines. Peck and coworkers initiated the use of primary bone cell cultures in 1964 (1). They isolated cells from frontal and parietal bones of fetal and neonatal rat calvaria by collagenase digestion of the uncalcified bone matrix. The isolated cells were viable, proliferated during culture, and exhibited high activity of the osteoblast marker alkaline phosphatase (ALP). The real nature of the cells, however, especially the amount of contamination with connective tissue fibroblasts, could not be unambiguously defined (1). Wong and Con (1974) tried to isolate a better defined and more homogeneous cell population by removing the outer layers of the periosteum with successive collagenase treatments (2). While this method led to cell cultures that were more osteoblastic in nature, these were still not completely free from other cell types, such as osteoclast precursors (3). Other investigators have tried to improve the osteoblastic character of the isolated bone cell populations by removing the fibroblastic outer periosteum before using enzymatic digestion to isolate the cells from the calvarium (4, 5). This method resulted in two cell populations, one of which was still osteogenic after prolonged culture time (osteoblastic cells), and another one which was not osteogenic after prolonged culture (periosteal fibroblasts) (6). Nowadays, a broad range of methods is available for obtaining well-defined osteoblast-like cells in vitro (also see Chapters 1 and 3), which are widely used as tools in bone biology (7–9). This chapter describes the isolation of primary mouse bone cells from adult mouse calvaria and long bones, as well as the process of isolation of bone cells from neonatal mouse calvaria. Due to their difference in origin and method of isolation, one might expect that each of the primary bone cell cultures described will have their own characteristics. For instance, it is likely that neonatal cell cultures contain more immature rapidly growing cells than cultures from adult bone. Indeed, it has been shown that neonatal cells show a higher basal release of nitric oxide and a higher response to 1,25-dihydroxyvitamin D3 treatment than bone cells obtained from adult bone (10). Thus, for in vitro studies investigating the cellular behavior of adult bone, it seems advisable to use cells from adult bone fragments to best reproduce the inherent cellular properties of the adult tissue. There are also profound differences between bones from the skull and the axial and appendicular skeleton, with regard to matrix composition (11), osteoclast functionality (12), and osteocyte morphology (13). Therefore, one might expect that differences exist between cell cultures derived from calvaria and long bones, and care should be taken which cells are used for in vitro research. We found no difference between cultured osteoblasts from adult mouse calvaria or adult mouse long bones with regard to the nitric
2
Osteoblast Isolation from Murine Calvaria and Long Bones
21
oxide response to mechanical loading (10), suggesting that either cell culture can be used for in vitro mechanotransduction experiments. Interestingly, it has been reported that the differential mechanosensitivity of bones from C57BL/6J and C3H/HeJ mice in vivo is also reflected in the in vitro mechanical loading response of osteoblasts derived from these mouse strains (14). All these factors should be taken into consideration when planning experiments with murine osteoblasts.
2. Materials 2.1. Tissues
Cells are obtained from the long bones and the calvaria of adult (age 9 weeks or older) mice, or from the calvaria from neonatal mouse pups (age 3–4 days).
2.2. Instruments
All of the following materials are supposed to be sterile. 1. Polystyrene plate and needles for fixing the mice. 2. Scalpels (no. 10 and 11), scissors, tweezers, and curved forceps. 3. 5 ml and 10 ml syringes, 27G½ needles and 0.2 μm disposable filter units (Schleicher & Schuell GmbH, Dassel, Germany). 4. 25 and 75 cm2 tissue culture flasks (Nunc, Roskilde, Denmark), 94/16 mm cellstar petri dishes (Greiner), and 145/20 mm cellstar (large) petri dishes. 5. 100 × 16 mm (10 ml) conical base test tubes with screw cap (Bibby Sterilin ltd, Staffordshire, UK) and conical base, 15 and 25 ml polypropylene centrifuge tubes (Greiner).
2.3. Media and Solutions
1. Sterile phosphate-buffered saline (PBS), pH 7.4. 2. Dulbecco’s modified Eagle’s medium, 1 g/l glucose + L-glutamine + pyruvate (DMEM). 3. Complete culture medium (cCM):DMEM supplemented with 100 U/ml penicillin, 50 μg/ml streptomycin sulfate, 50 μg/ ml gentamycin, 1.25 μg/ml fungizone, 100 μg/ml ascorbate, and 10% FBS (e.g., Hyclone, Logan, UT, USA; see Note 1). Make fresh before each medium change and filter sterilize. 4. Collagenase II solution. 2 mg collagenase II (260 U/mg; Worthington, Lakewood, NJ, USA) per ml DMEM. Make fresh and filter sterilize. 5. Trypsin solution. 0.25% trypsin 1:250 (Gibco) plus 0.1% EDTA in PBS, filter sterilize.
22
A.D. Bakker and J. Klein-Nulend
6. Digestion solution: Add 1 ml trypsin solution plus 3.2 mg collagenase II (Worthington) to 4 ml PBS. Make up fresh just before use. 7. Stock solution of collagenase type I: 10 mg/ml collagenase type I in Hank’s balanced salt solution (HBSS). Filter sterilize and freeze aliquots for single use at −20°C. 8. Collagenase I work solution: Dilute stock solution of collagenase type I in HBSS to 1 mg/ml just before use. 9. 4 μM EDTA in PBS. Filter sterilize and store at 4°C.
3. Methods Normal techniques for working under sterile conditions (use of sterile media and instruments and working in a flow cabinet) should be adhered to. 3.1. Isolation and Culture of Primary Bone Cells from Adult Mouse Long Bones
1. Euthanise one or two adult mice. 2. Fixate the mouse in a supine position on a polystyrene plate or in a large petri dish, and rinse the abdomen and extremities using a small amount of 70% ethanol. 3. Make a single incision through the skin, starting at the top of the sternum and ending a few millimeters above the genitals, using a number 10 scalpel. Make a second incision starting from the top of the first incision and ending at the wrist of the upper left extremity. Repeat this procedure with the other paws. Carefully remove the skin from the abdomen with a blade. 4. Change your blade for a sterile number 11 scalpel. Carefully remove all the muscles from one of the long bones (femur, tibia and fibula, or humerus, radius and ulna), and thoroughly scrape the bone with a scalpel until it is clean (see Note 2). Excise the long bone and place it in a petri dish with PBS. Continue until all the bones are excised. 5. When all the long bones have been removed, cut off the epiphyses. 6. Thoroughly flush out the bone marrow with PBS, using a 5 ml syringe and a 27 gauge needle. 7. Cut the clean diaphyses into little pieces of approximately 1–2 mm2 using scissors. 8. The bone pieces are washed several times with PBS, and incubated in 4 ml collagenase II solution at 37°C in a shaking water bath in order to remove all remaining soft tissue and adherent cells.
2
Osteoblast Isolation from Murine Calvaria and Long Bones
23
9. Vigorously shake the collagenase II solution containing the bone pieces, by hand, every 30 min. 10. After 2 h, rinse the bone pieces three times with cCM, shaking the solution containing the pieces for a few seconds during every wash step. 11. Transfer the bone pieces to 25 cm2 flasks, containing 5 ml cCM, at a density of about 20–30 fragments per flask. Replace culture medium three times per week. After each medium replacement, make sure that the bone chips are evenly distributed over the bottom of the culture flask, by gently swirling the culture flask. 12. Adult mouse bone cells will start to migrate from the bone chips after 3–5 days. On average the cells growing from the bone fragments will be ready for use after 11–15 days. Do not allow the cells to become over-confluent around the bone chips. 13. To obtain more cells, cCM is removed from the flask, cells, and bone pieces are gently washed three times with PBS, and incubated in 1 ml trypsin solution at 37°C for 10 min. Swirl and tap the flask on a level surface a few times during the 10 min incubation period. Carefully check whether the cells are released from the tissue culture plastic using a microscope. Remove the trypsin solution containing the cells using a small pipette. Leave the bone pieces in the flask, and discard. 14. The cells are plated at 2.5−5 × 103 cells per cm2 in T25 or T75 flasks in cCM. 15. Medium is changed three times per week, and after approximately 7–10 days cells will reach subconfluency, upon which they can be used for experiments (see Note 3). The average number of cells thus obtained is between 4 × 106 and 6 × 106 cells. 3.2. Isolation and Culture of Primary Bone Cells from Adult Mouse Calvaria
1. Euthanise two adult mice and fixate them on a polystyrene plate, or in a large petri dish. 2. Clean the head using 70% ethanol, and make a cut through the skin at the base of the skull, using scissors. 3. Make an incision starting at the nose bridge, and ending at the base of the skull. Remove the skin from the top of the head. 4. Use scissors to cut through the bone at the base of the neck. Cut the calvaria loose while holding the head with curved forceps placed in the orbita (see Fig. 1). 5. Transfer the calvaria to a petri dish with PBS and remove the soft tissues using tweezers or by scraping with a knife (see Note 2). 6. Remove the sutures using scissors, and chop the remaining bone into small fragments of approximately 1–2 mm2.
24
A.D. Bakker and J. Klein-Nulend
Fig. 1. Mouse calvaria. Make a cut through the skin at the base of the skull, using scissors. For adult tissue, make an incision starting at the nose bridge, ending at the base of the skull, and remove the skin from the top of the head. Use scissors to cut away the skin from the top of the neonatal mouse heads. Dissect calvaria as indicated by the dotted line and remove as much soft tissue as possible. Do not include the area near the neck, since this will result in heavy fibroblast contamination of the cultures. Sf skin flap, C calvaria.
7. Incubate the fragments for 30 min in 4 ml collagenase II solution at 37°C in a shaking waterbath. 8. Discard the collagenase II solution and replace with fresh collagenase II solution. Incubate another 30 min and then replace the collagenase II solution for trypsin solution. 9. Incubate in trypsin for 30 min. Replace by 4 ml collagenase II solution for the fourth and final incubation step of 30 min.
2
Osteoblast Isolation from Murine Calvaria and Long Bones
25
10. Rinse the bone pieces three times with cCM and transfer the bone pieces to 25 cm2 flasks, containing 5 ml cCM, at a density of about 20–30 fragments per flask. 11. Medium is changed three times per week. After each medium replacement, make sure that the bone chips are evenly distributed over the bottom of the culture flask, by gently swirling the culture flask. Adult mouse bone cells will start to migrate from the bone chips after 3–5 days. 12. On average the cells growing from the bone fragments will reach subconfluency after 11–15 days, upon which the cells are incubated with 1 ml trypsin solution at 37°C for 10 min. Swirl and tap the flask on a level surface a few times during the 10 min incubation period. Remove the trypsin solution containing the cells using a small pipet. Leave the bone pieces in the flask and discard. 13. The cells are plated at 2.5 to 5 × 103 cells per cm2 in T25 or T75 flasks in cCM. 14. Medium is changed three times per week, and after approximately 7–10 days cells will reach subconfluency, upon which they can be used for experiments. The average number of cells thus obtained lies between 4 × 106 and 6 × 106 cells. 3.3. Isolation and Culture of Bone Cells from Neonatal Mouse Calvaria
1. Euthanise 20–30 neonatal mice pups (2 nests) by means of decapitation, or inhalation of halothane, and place the heads in a petri dish with PBS (see Note 4). 2. Grab a head in the nape of the neck, and cut the skin away using scissors. 3. Hold the head with curved forceps placed through the orbita, cut the calvaria loose along the edge, and place it in a petri dish with PBS (see Fig. 1). 4. Pin the calvaria down with tweezers and cut away the edges and sutures with a small scalpel. Transfer the calvaria halves to a 25 ml tube with PBS and wash twice with PBS. 5. Incubate the calvaria in 4 ml digestion solution at 37°C in shaking water bath. After 10 min shake the calvaria by hand for a few seconds. 6. Incubate for a total of 20 min, and then transfer the supernatant containing cells to a 10 ml tube. Add 700 μl FBS to the cell suspension to inhibit trypsin activity. 7. Wash the calvaria with 3 ml DMEM (without FBS!), shake well, and add the supernatant to the tube containing the cell suspension. This is population number 1. 8. Add new digestion solution to the calvaria, and repeat the previous three steps to obtain population number 2. During the 20 min that the calvaria have to incubate in the water bath,
26
A.D. Bakker and J. Klein-Nulend
centrifuge cell population number 1 at 300 × g for 5 min. Discard supernatant, resuspend cell pellet in 1 ml cCM, and add to 17 ml cCM. Pipette in a 6-well plate at 3 ml cell suspension per well. 9. Repeat the entire procedure for a total of four times to obtain population 1–4. 10. Culture medium is changed 1 day after isolation of the bone cells. 11. Within approximately 5 days cells will reach subconfluency, upon which they are trypsinized by incubation with 200 μl trypsin solution per well, at 37°C for 10 min. 12. To enhance the number of cells available for experiments, population 1 and 2, resembling osteoblast progenitor cells, are usually pooled, as well as population 3 and 4. This latter pooled cell population is enriched with cells exhibiting biochemical characteristics of differentiated osteoblasts, such as high ALP activity and osteopontin expression. Both pooled and unpooled populations can be directly used for experiments. 13. The number of cells obtained using this method varies between 6 × 106 and 10 × 106 cells. 3.4. Isolation and Culture of Bone Cells from Neonatal Mouse Calvaria (Alternative)
Although we prefer the use of collagenase type II, other groups have reported use of crude collagenase type I, which is cheaper and intrinsically contains trypsin as a contaminant. Therefore, an alternative protocol for isolation of osteoblasts from neonatal mouse calvaria, which uses alternate collagenase I and EDTA incubations to remove as much mineralized matrix as possible, and increases cellular yield, is given below: 1. Dissect calvaria as described in Subheading 3.3 steps 1–3 and collect them in 3 ml HBSS in a 25 ml centrifuge tube in a shaking waterbath at 37°C. 2. Incubate calvaria in 3 ml collagenase I work solution for 10 min in a shaking waterbath at 37°C. 3. Replace the collagenase I work solution (fraction 1) with fresh solution and discard fraction 1. 4. Incubate for 30 min in collagenase I work solution. Collect the solution containing cells (fraction 2) and place in a conical centrifuge tube. Wash calvaria in 7 ml of PBS and add wash to fraction 2. 5. Add EDTA solution to the calvaria and incubate for 10 min at 37°C. Collect EDTA solution (fraction 3). Wash calvaria in 7 ml HBSS and add wash to fraction 3. 6. Add collagenase I work solution to the calvaria and incubate for 30 min at 37°C. Collect the solution containing cells (fraction 4)
2
Osteoblast Isolation from Murine Calvaria and Long Bones
27
and place in a conical centrifuge tube. Wash in HBSS and add wash to fraction 4. 7. Further fractions, presumably containing more mature osteocyte-like cells, can be collected by repeating steps 5 and 6, but cell yields will be increasingly lower. 8. Centrifuge all fractions immediately after collection (250 × g for 5 min) and resuspend pellets in cCM (see Subheading 2.3.3). 9. Plate out pooled or single fractions in 75 cm2 culture flasks using cells derived from 2 to 3 animals/flask. 10. Cultures will be confluent in 3–4 days. To minimize contamination by other adherent cell types, replace medium once cells have adhered (2–3 h after plating). Use the more differentiated fractions (3 and 4) for osteoclast cocultures (see Chapter 12, this volume).
4. Notes 1. Addition of serum to the medium is necessary for the survival and stimulation of proliferation of the primary mouse bone cells. However, “serum” is not a constant and homogeneous product, and the growth rate of primary bone cells can vary considerably between several batches of serum. It is therefore recommended to test several batches of serum on their cell proliferative ability and continue to use the one that produces the best results. 2. Sometimes, the primary bone cultures can contain fibroblasts, which grow faster than the bone cells and can quickly overgrow the primary bone cell cultures. If this problem occurs, care should be taken to remove all soft tissues by scraping the bones with a knife before starting the collagenase treatment. Also make sure the collagenase is not expired, and that the collagenase solution is made fresh every time. 3. Primary bone cell cultures are not 100% pure and may contain some fibroblasts and other cell types that are not from the osteoblast lineage. The osteoblastic phenotype of the primary mouse bone cell cultures can be determined by stimulating the cells with 1,25dihydroxyvitamin D3, which should lead to enhanced ALP activity (11). The exact nature of the bone cells that are isolated from adult long bones and adult calvaria has not been fully determined. Since the cell isolation protocols involve mechanically removing the soft tissues first and then all adhering cells by means of incubation with collagenase, the cells that are isolated from the bones might represent osteocytes that reverted to proliferation after several days of exposure to serum.
28
A.D. Bakker and J. Klein-Nulend
Fig. 2. Phase contrast microscopy of primary mouse bone cell cultures. (a) Adult mouse bone cells growing out of the bone chips, day 6 of culture. (b) Subconfluent layer of adult mouse bone cells, first passage. (c) Neonatal mouse calvarial cells, population number 1 and 2, day 2 of culture. (d) Neonatal mouse calvarial cells, population number 3 and 4, day 2 of culture. Note the oblong trapezoid shaped morphology of the osteoblastsl.
The microscopical appearance of the isolated bone cells is mostly osteoblastic (Fig. 2), but mRNA expression of several markers for (pre)osteocytes, such as MEPE, Phex, and DMP1 can be detected by means of PCR. Absence of staining for von Willebrand factor (factor VIII) shows that the bone cell cultures do not contain endothelial cells. 4. Smaller numbers of calvaria can be used successfully, leading to a proportionately lower yield of osteoblasts. References 1. Peck, W. A., Birge, S. J., and Fedak, S. A. (1964) Bone cells: biochemical and biological studies after enzymatic isolation. Science 146, 1476–1477. 2. Wong, G. L., and Cohn, D. V. (1974) Separation of parathyroid hormone and calcitonin-sensitive cells from non-responsive cells. Nature 252, 713–715. 3. Burger, E. H., Boonekamp, P. M., and Nijweide, P. J. (1986) Osteoblast and osteoclast precursors in primary cultures of calvarial bone cells. Anat. Rec. 214, 32–40. 4. Yagiela, J. A. and Woodbury, D. M. (1977) Enzymatic isolation of osteoblasts from fetal rat calvaria. Anat. Rec. 188, 287–306.
5. Nijweide, P. J., van der Plas, A., and Scherft, P. J. (1981) Biochemical and histological studies on various bone cell preparations. Calcif. Tissue Int. 33, 529–540. 6. Nijweide, P. J., van Iperen-van Gent, A. S., Kawilarang-de Haas, E. W. M., van der Plas, A., and Wassenaar, A. M. (1982) Bone formation and calcification by isolated osteoblast-like cells. J. Cell Biol. 93, 318–323. 7. Klein-Nulend, J., Semeins, C. M., Ajubi, N. E., Nijweide, P. J., and Burger, E. H. (1995) Pulsating fluid flow increases nitric oxide (NO) synthesis by osteocytes but not periosteal fibroblasts: correlation with prostaglandin upregulation. Biochem. Biophys. Res. Commun. 217, 640–648.
2
Osteoblast Isolation from Murine Calvaria and Long Bones
8. Bakker, A. D., Soejima, K., Klein-Nulend, J., and Burger, E. H. (2001) The production of nitric oxide and prostaglandin E2 by primary bone cells is shear stress dependent. J. Biomech. 34, 671–677. 9. Armstrong, V. J., Muzylak, M., Sunters, A., Zaman, G., Saxon, L. K., Price, J. S., and Lanyon, L. E. (2007) Wnt/beta-catenin signaling is a component of osteoblastic bone cell early responses to load-bearing and requires estrogen receptor alpha. J. Biol. Chem. 282, 20715–20727. 10. Soejima, K., Klein-Nulend, J., Semeins, C. M., and Burger, E. H. (2001) Different responsiveness of cells from adult and neonatal mouse bone to mechanical and biochemical challenge. J. Cell Phys. 186, 366–370. 11. van den Bos, T., Speijer, D., Bank, R. A., Brömme, D., and Everts, V. (2008) Differences in matrix composition between calvaria and long bone in mice suggest differences in biomechanical properties and resorption: special emphasis on collagen. Bone 43, 459–468.
29
12. Jansen, I. D., Mardones, P., Lecanda, F., de Vries, T. J., Recalde, S., Hoeben, K. A., Schoenmaker, T., Ravesloot, J. H., van Borren, M. M., van Eijden, T. M., Bronckers, A. L., Kellokumpu, S., Medina, J. F., Everts, V., and Oude Elferink, R. P. (2009) Ae2(a,b)deficient mice exhibit osteopetrosis of long bones but not of calvaria. FASEB J. 23, 3470–3481. 13. Vatsa, A., Breuls, R. G., Semeins, C. M., Salmon, P. L., Smit, T. H., and Klein-Nulend, J. (2008) Osteocyte morphology in fibula and calvaria – is there a role for mechanosensing? Bone 43, 452–458. 14. Lau, K. H., Kapur, S., Kesavan, C., and Baylink, D. J. (2006) Up-regulation of the Wnt, estrogen receptor, insulin-like growth factor-I, and bone morphogenetic protein pathways in C57BL/6J osteoblasts as opposed to C3H/ HeJ osteoblasts in part contributes to the differential anabolic response to fluid shear. J. Biol. Chem. 281, 9576–9588.
sdfsdf
Chapter 3 Rat Osteoblast Cultures Isabel R. Orriss, Sarah E.B. Taylor, and Timothy R. Arnett Abstract This chapter describes the isolation, culture and staining of primary osteoblasts from the calvaria and long bones of neonatal rats. The key advantages of this assay are that it allows direct measurement of bone matrix deposition and mineralisation, as well as yielding good quantities of osteoblasts at defined stages of differentiation for molecular and histological analysis. A special focus of this chapter is on the role of β-glycerophosphate in cell-mediated mineralisation in these cultures. Key words: Osteoblast, Bone formation, Mineralisation, pH
1. Introduction Osteoblasts are derived from mesenchymal stem cells and are responsible for bone formation. A number of different approaches have been developed to study osteoblasts in vitro, including bone organ cultures, primary cell cultures, and immortalised osteoblastlike cell lines. Combined these methods have provided abundant information about the regulation of osteoblast proliferation, differentiation and function. Osteoblastic cell lines are widely used as a convenient source of large numbers of cells with a relatively stable phenotype. However, many of these osteoblast-like cells do not express the whole range of bone-specific genes and/or form bone in vitro. Furthermore, repeated passaging has been shown to cause the loss of the osteoblastic phenotype in some cell lines (1). Primary bone cell cultures were first described in 1964 by Peck and colleagues (2), who isolated cells from the parietal and frontal bones of foetal and neonatal rat calvaria using collagenase digestion.
Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_3, © Springer Science+Business Media, LLC 2012
31
32
I.R. Orriss et al.
The isolated cells proliferated in vitro and exhibited high alkaline phosphatase (ALP) activity, although the cultures were contaminated with other cell types such as fibroblasts. In 1974, Wong and Cohn (3) used sequential collagenase digestion to obtain a more homogenous population of osteoblastic cells. The first description of the formation of bone nodules by differentiating osteoblasts released enzymically from calvarial bones and cultured with β-glycerophosphate (β-GP) ascorbate and dexamethasone was by Bellows and colleagues in 1986 (4). This chapter describes the isolation, culture, and staining of primary osteoblasts from the calvaria and long bones of neonatal rats (see Note 1). The osteoblast bone formation assay has a number of advantages. Firstly, it allows the key function of osteoblasts, namely bone formation, to be studied quantitatively (5). Bone formation in this essentially 2-dimensional culture system appears to recapitulate the intramembranous (woven) bone formation seen in histological sections from developing animals – i.e., large-scale structures resembling trabeculae appear. Secondly, it offers the opportunity to study separately the processes of bone matrix deposition and mineralisation (6). Thirdly, it allows the extracellular environment to be tightly regulated (e.g., pH, pO2) in a manner which is not possible using bone organ cultures or in vivo (7, 8). Fourthly, osteoblast activity can be studied in an environment that is relatively free from the influence of other cell types normally found in bone, such as endothelial cells, nerves, and haematopoietic cells. Lastly, osteoblasts can be studied at clearly identified stages of differentiation from the immature, proliferating cells present early in the cultures through to the mature bone-forming osteoblasts in late stage cultures. Compared to mice of the same age, neonatal rats yield higher numbers of cells per animal. The rat model is therefore more convenient to use, and is appropriate for studies requiring larger numbers of osteoblasts. Two important pitfalls should be highlighted here. The first concerns the use of inappropriately high concentrations of the ALP substrate, β-GP in many published descriptions of osteoblast cultures. At high concentrations, β-GP causes generalised mineral deposition and impaired cell viability (the osteoblasts effectively fossilise), with the result that the cultures fail to progress beyond the formation of small nodules. The second, related pitfall concerns the frequent confusion between mineral deposition (which also occurs on teeth, in caves and in kettles) and true bone formation, which involves selective mineralisation of a collagenous matrix deposited in characteristic patterns. Osteoblast cell lines (and many other cell types) express ALP and can mineralise in the presence of sufficient β-GP – but this is not bone formation.
3
Rat Osteoblast Cultures
33
2. Materials All solutions, instruments, and tissue culture plastics should be sterile. 1. Animals: The cells are obtained from the calvaria and long bones of neonatal (2–3 day old) rats. The number of animals to use depends on the experiments to be performed; typically, one animal will yield 107 and 5 × 106 cells from the calvaria and long bones, respectively (see Notes 1 and 2). 2. Phosphate-buffered saline (PBS): For storing tissues prior to use and washing cells. 3. Supplemented Dulbecco’s modified essential medium (sDMEM): Add 10% foetal calf serum (FCS), 2 mM L-glutamine and 100 U/ml penicillin, 100 μg/ml streptomycin, 0.25 μg/ml amphotericin (mixture is known as antibiotic/ antimitotic or AB/AM). This sDMEM should be stable at 4°C for at least 4 weeks. 4. Osteogenesis DMEM (osDMEM): To the sDMEM described above add 2 mM β-GP (see Note 3), 10 nM dexamethasone, and 50 μg/ml ascorbate. Always make fresh on day of use. 5. Sodium hydroxide (NaOH): 6 M NaOH to alter the pH of the culture medium if required (see Note 4). 6. Trypsin-EDTA: 0.25% (w/v) trypsin with 1 mM EDTA; free of calcium and magnesium, which inhibit trypsin activity (Invitrogen 25200056). 7. Collagenase: 0.2% (w/v) collagenase solution (Type II collagenase from Clostridium histolyticum, Sigma C6885) made up in Hank’s balanced salt solution (HBSS); filter sterilise. Note that HBSS contains calcium, which is required for collagenase activity. 8. Fixative: 2.5% glutaraldehyde in dH2O or 70% ethanol; prepare fresh before use. 9. Alizarin red stain for mineralised bone nodules: 1% (w/v) alizarin red in dH2O; prepare fresh before use. 10. ALP staining: Alkaline phosphatase kit (Sigma kit 86C-1KT). 11. Sirius red stain for deposited collagen: Sircol™ dye reagent (Biocolor kit S1005). 12. Tissue culture plastics: Large petri dishes (100 mm), 5 ml flat bottomed tubes, 15 and 50 ml centrifuge tubes, 75 cm2 tissue culture flasks, and 24-well tissue culture plates. 13. Dissection tools: Scalpels and blades (no. 20), tweezers, and scissors.
34
I.R. Orriss et al.
3. Methods To keep the cell cultures sterile, normal techniques for working under sterile conditions should be employed (working in a flow cabinet, use of sterile media and instruments, etc.). 3.1. Isolation and Culture of Primary Osteoblasts from Neonatal Rat Calvaria
1. Sacrifice two neonatal (2–3 days old) rats and sterilise with 70% ethanol. Place each cadaver in a large petri dish. 2. Remove the head using large scissors; transfer the body to a separate petri dish for long bone isolation (see Subheading 3.2). 3. Grasp the head at the nape of the neck and make a small incision along the base of the skull (small scissors will make the cleanest cut). Carefully remove the skin and the brain tissue from the skull using a scapel and tweezers. 4. Cut away the jaw and scrape off any excess tissue and cartilage from around the edge of the calvaria. 5. Cut the calvaria in half and place in a flat-bottomed 5 ml tube; wash with PBS. 6. Repeat steps 2–5 for the second animal. 7. Incubate the calvariae in 1% trypsin (1 ml/calvarial bone) for 10 min at 37°C. Remove and discard the trypsin solution; wash in sDMEM (serum and calcium will inactivate any residual trypsin). 8. Incubate in 0.2% collagenase solution (800 μl/calvarial bone) for 30 min at 37°C. 9. Remove the collagenase digest, discard, and replace with fresh solution for a further 60 min at 37°C. 10. Keep the final digest and transfer to a 15 ml conical base centrifuge tube. Wash calvaria with sDMEM (5 ml), transfer the solution to the 15 ml tube containing the final digest. 11. Spin the cell solution at 1,500 × g for 5 min at room temperature. Discard the supernatant and resuspend the cell pellet in sDMEM (1 ml/calvarial bone). Pool the cell suspensions. 12. Add 20 ml of sDMEM to 2 × 75 cm2 flasks; add 1 ml of cell suspension to each flask. 13. Incubate the flask at 37°C/5% CO2 until the cells reach confluency (~3 days).
3.2. Isolation and Culture of Primary Osteoblasts from the Long Bones of Neonatal Rats
1. Take the bodies of the animals used for the calvarial osteoblast isolation (see Subheading 3.1). 2. Remove the limbs from the body by cutting with sharp scissors at the point closest to the body, preserving as much of the limb as possible.
3
Rat Osteoblast Cultures
35
3. Using a scalpel cut off the paws and cut the limb in half (at the joint). 4. Remove the skin and scrape away the soft tissue from the limbs. 5. Cut off the epiphyses and place the bone fragments into a flatbottomed 5 ml tube. Wash and vortex in PBS. 6. Incubate the bone fragments in 1% trypsin (1 ml/animal) for 10 min at 37°C. Remove and discard the trypsin solution; wash in sDMEM. 7. Incubate in 0.2% collagenase solution (1 ml) for 30 min at 37°C. 8. Remove the collagenase digest, discard, and replace with fresh solution for a further 60 min at 37°C. 9. Keep the final digest and transfer to a 15 ml conical base centrifuge tube. Wash remaining bone fragments with sDMEM (5 ml) and transfer the solution to the 15 ml tube containing the final digest. 10. Spin the cell solution at 1,500 × g for 5 min at room temperature. Discard the supernatant and resuspend the cell pellet in sDMEM (1 ml). The intitial cell population may be slightly more heterogeneous than a calvarial bone isolate but behaves similarly on subsequent culture in osDMEM. 11. Add 20 ml of sDMEM to a 75 cm2 flasks; add cell suspension. 12. Incubate the flask at 37°C/5% CO2 until the cells reach confluency (~3 days). 3.3. Bone Formation Assay
This protocol is used for osteoblasts from both calvarial and long bone isolations. 1. Once the cells in the 75 cm2 have reached confluency (~3 days), remove the sDMEM and wash with PBS. Add 1% trypsin (2 ml/flask) and incubate for 10 min at 37°C. 2. Inactivate the trypsin by adding 10 ml of sDMEM; transfer the cell suspension to a 15 ml centrifuge tube. 3. Spin the cell solution at 1,500 × g for 5 min at room temperature. Discard the supernatant and resuspend the cell pellet in sDMEM (1 ml/flask). Pool the cell suspensions. 4. Perform a cell count using a haemocytometer; seed the cells in 24-well tissue culture trays at a density of 2.5 × 104 cells/well in osDMEM. 5. Half the medium should be exchanged every 2–3 days. Cultures will typically be fully confluent by day 4; they will begin to form discrete bone nodules from about day 10, with extensive networks of mineralising “trabeculae” developing from day 14 (Figs. 1 and 2).
Fig. 1. Phase contrast microscopy of primary rat osteoblast cultures. Representative images are of unstained cell layers. By day 4 of culture, a confluent monolayer of cells is evident. At day 7, the cells are more compacted and organic matrix is beginning to be deposited (as shown by the arrow ). By day 10, there is abundant deposition of unmineralised collagenous matrix and mineralisation (dark area at lower left of image) is commencing. After 14 days of culture, there is widespread formation of mineralised matrix networks. Scale bar = 250 μm.
Fig. 2. Different staining methods in primary rat osteoblast cultures. Images show 14-day osteoblast cultures either left unstained, or stained with alizarin red (to demonstrate calcium), alkaline phosphatase (ALP) or sirius red (to demonstrate collagen). Bone formed in these cultures exhibits a typical “trabecular” morphology, with discrete mineralisation confined to matrix nodules, as shown in the unstained and alizarin red-stained images. In the unstained image at lower left, unmineralised matrix appears brown and mineralised matrix black. Intense ALP staining (also “trabecular”) is evident in mature, bone forming osteoblasts. Sirius red staining shows the presence of collagen fibres in these cultures. Scale bars = 0.1 cm (cell well scans, upper row) and 250 μm (phase contrast images, lower row ).
3
Rat Osteoblast Cultures
37
6. The pH should be monitored at every medium change and maintained at ~ pH 7.4 by the addition of 6 M NaOH if required (see Notes 4 and 5). 7. ALP activity (ALP assay kit, Biotron) and soluble collagen production (Sircol Red assay, Biocolor) can be assayed throughout the 14-day culture period using commercially available kits. 3.4. Fixation and Staining
1. On termination of the experiment, carefully wash the cell layers with PBS. 2. Transfer to fixative: 2.5% glutaraldehyde for 5 min for alizarin red and ALP staining, 70% ethanol for 1 h for sirius red staining. 3. Wash twice with PBS and leave to air dry (sirius red staining only). 4. For cell layers to be stained with alizarin red or for ALP, wash three times with 70% ethanol and leave to air dry. 5. Stain as required (Fig. 2): (a) Alizarin red for 5 min followed by three washes with 50% ethanol; allow to air dry. (b) ALP for ~30 min in the dark; wash with dH2O and allow to air dry. (c) Sirius red for 1 h; wash with dH2O and allow to air dry.
3.5. Quantification of Mineralised Bone Formation
1. Once fully dry, scan plates at 2,000 dots/cm2 on a highresolution flat-bed scanner. We use an Epson Perfection 4990 photo/slide scanner. Transmitted light scanning of alizarin red-stained plates is commonly used but unstained cell layers also yield excellent high-contrast images in both transmitted and reflected light modes (the latter showing the white bone trabeculae against a dark background) (Fig. 2). 2. Apply a circular mask to the image of each cell well and convert to a binary image (e.g., using “Adobe Photoshop”). 3. Use an image analysis program (e.g., “Image J” – available free from http:www.rsbweb.nih.gov/ij/) to determine the number and surface area of mineralised bone nodules in the binary images of each individual well, using constant threshold and minimum particle size levels.
3.6. Statistics
We routinely use one-way analysis of variance (ANOVA) to analyse experiments. Although often neglected, adjustments for multiple comparisons between treatment groups (e.g., the Bonferroni correction) are frequently needed (see Note 6).
38
I.R. Orriss et al.
4. Notes 1. Calvarial cells vs. long bone cells : Although the flat bones of the skull and the limb bones are formed by different developmental processes, osteoblasts derived from either source appear to behave similarly in culture with regard to proliferation and mineralization. 2. Young cells vs. old cells : An important reason why the rat osteoblast culture system described here is able to form bone is that the initial cell population is obtained from neonates – and thus has considerable growth potential. Cells derived from adult animals (including human donors) may have progressed too far toward their “Hayflick limits” to be capable of the rapid expansion to high cell density required for true osteogenic differentiation. 3. Concentration of β-GP : Bone mineralisation requires a supply of calcium and orthophosphate (Pi), both of which are required for hydroxyapatite crystal formation. A key source of phosphate in bone is alkaline phosphatase, which hydrolyzes a range of phosphate-containing substrates, including adenosine triphosphate (ATP) and inorganic pyrophosphate (6). An additional important mechanism by which ALP promotes mineralisation, however, is by hydrolysing pyrophosphate, a ubiquitous physicochemical inhibitor of calcium phosphate deposition. To form mineralised bone nodules in vitro, an additional source of phosphate is required. The most widely used phosphate source is β-GP, although phosphate itself can also be used. Figure 3 illustrates the critical importance of β-GP concentration in this culture system (see also ref. 6). In osteoblast cultures lacking β-GP, organic matrix is deposited but mineralisation fails to occur. Osteoblasts cultured with 2 mM β-GP reproducibly form abundant bony structures with characteristic “trabecular” morphology; alizarin red staining shows that mineralisation is confined to these matrix structures. In contrast, culture with 5–10 mM β-GP causes a widespread, dystrophic deposition of mineral as soon as the differentiating osteoblasts begin to express significant amounts of ALP, leading to mineralisation of the cells themselves (Fig. 3a). This impairs cell viability (Fig. 3b), with the result that only small mineralised nodules are able to form (rather than the striking trabecular structures evident with lower concentrations of β-GP). Thus, it is critical that a low concentration of β-GP is used in this assay. 4. The importance of pH : Extracellular pH is an important factor in the regulation of bone mineralisation (7). Acidosis causes a selective, inhibitory action on matrix mineralisation by
3
Rat Osteoblast Cultures
39
Fig. 3. The effect of the β-glycerophosphate concentration on bone mineralisation and osteoblast viability in vitro. (a) Rat calvarial osteoblasts were cultured for 14 days before staining with alizarin red to demonstrate mineral deposition. Rat long bone osteoblasts were cultured for 28 days before fixation and transmission electron microscopy (TEM). In the absence of β-glycerophosphate (β-GP), bone mineralisation fails to occur due to insufficient inorganic phosphate; widespread, unmineralised collagenous matrix is evident in the phase contrast and TEM images. Bone formed in the presence of 2 mM β-GP exhibits a typical “trabecular” morphology; mineralisation is confined to these structures. In the presence of 5–10 mM βGP, widespread, nonspecific (dystrophic) deposition of bone mineral occurs across the cell monolayer, with inhibition of normal matrix deposition. Intracellular deposition of mineral that causes damage to cell membranes and organelles is also evident. (b) Increased β-GP concentration is associated with decreased osteoblast viability, assessed as lactate dehydrogenase (LDH) release after 14 days in culture. Values are means ± standard error of the mean (SEM) (n = 6); significantly different from control ***p < 0.001, **p < 0.01. Scale bars = 0.1 cm (cell well scans), 250 μm (phase contrast images), and 1 μm (TEM).
inhibiting ALP expression and activity, while increasing mineral solubility (7). For example, even a reduction in pH from pH 7.43 to pH 7.32 will reduce bone nodule formation in vitro by ~60% (Fig. 4). Due to its high bicarbonate concentration, DMEM is more alkaline than some media (such as minimum essential medium, MEM); in equilibrium with 5% CO2, it is buffered to pH ~7.4. The metabolic activity of osteoblasts will cause progressive acidification, particularly in mature, bone forming cultures when cells numbers are high. To ensure that pH does not affect bone mineralisation in this assay, it may sometimes be necessary to add a small volume of OH− ions (as 6 M NaOH) to the culture medium to ensure an average running pH of 7.4.
40
I.R. Orriss et al.
Fig. 4. Inhibitory effect of acidosis of bone mineralisation by cultured rat osteoblasts. In 14 day cultures, decreasing pH caused progressive reduction in the formation of mineralised nodules stained with alizarin red, with complete inhibition at pH 6.93. Values are means ± standard error of the mean (SEM) (n = 6); significantly different from control (pH 7.43) value, **p < 0.001, *p < 0.05.
5. Measuring the medium pH: Accurate measurement of the operating pH of mammalian osteoblast cultures is important for meaningful comparison of results from different laboratories. For HCO3−/CO2 buffered media, accurate pH measurement can only be achieved by the use of a standardised blood gas analyser. We use a Radiometer ABL 705 blood gas analyser (Radiometer, Crawley, UK), which features a multielectrode system to measure pH, pCO2 and pO2 in a 200 μl injected sample (cyclic time ~ 2 min). The first medium measurement taken immediately after removing the culture plates from the incubator is assumed to provide a pCO2 value that is identical for all wells and that reflects the actual pCO2 during incubation. It should be noted that opening the incubator door during experiments may cause perturbations in CO2 levels that affects the measured pH and pCO2 values. Incubators with individual, separate compartments are unlikely to prevent this problem unless the compartments in question can be sealed. 6. Statistics: Because of interassay variability, statistical comparisons should be performed only within one assay, and not between different assays.
3
Rat Osteoblast Cultures
41
Acknowledgment Grant Funding: The authors gratefully acknowledge the support of Arthritis Research UK, the Biotechnology and Biological Sciences Research Council (UK) and the European Union (Framework 7 programme). References 1. Hausser, H. J., and Brenner, R. E. (2005) Phenotypic instability of SaOS-2 cells in longterm culture. Biochem. Biophys. Res. Commun. 333, 216–222. 2. Peck, W. A., Birge, S. J., Jr., and Fedak, S. A. (1964) Bone cells: biochemical and biological studies after enzymatic isolation. Science 146, 1476–1477. 3. Wong, G., and Cohn, D. V. (1974) Separation of parathyroid hormone and calcitonin-sensitive cells from non-responsive bone cells. Nature 52, 713–715. 4. Bellows, C. G., Aubin, J. E., Heersche, J. N., and Antosz, M. E. (1986) Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif. Tissue Int. 38, 143–154. 5. Hoebertz, A., Mahendran, S., Burnstock, G., and Arnett, T. R. (2002) ATP and UTP at low concentrations strongly inhibit bone formation
by osteoblasts: a novel role for the P2Y2 receptor in bone remodeling. J. Cell Biochem. 86, 413–419. 6. Orriss, I. R., Utting, J. C., Brandao-Burch, A., Colston, K., Grubb, B. R., Burnstock, G., and Arnett, T. R. (2007) Extracellular nucleotides block bone mineralization in vitro: evidence for dual inhibitory mechanisms involving both P2Y2 receptors and pyrophosphate. Endocrinology 148, 4208–4216. 7. Brandao-Burch, A., Utting, J. C., Orriss, I. R., and Arnett, T. R. (2005) Acidosis inhibits bone formation by osteoblasts in vitro by preventing mineralization. Calcif. Tissue Int. 77, 167–174. 8. Utting, J. C., Robins, S. P., Brandao-Burch, A., Orriss, I. R., Behar, J., and Arnett, T. R. (2006) Hypoxia inhibits the growth, differentiation and bone-forming capacity of rat osteoblasts. Exp. Cell Res. 312, 1693–1702.
sdfsdf
Chapter 4 Isolation of Primary Avian Osteocytes Cor M. Semeins, Astrid D. Bakker, and Jenneke Klein-Nulend Abstract Osteocytes can be isolated from chicken calvaria using mild EDTA treatment alternating with collagenase treatment. The cell population obtained contains both osteoblasts and osteocytes. A pure population of osteocytes is obtained following immunomagnetic separation with the osteocyte-specific monoclonal antibody MAb OB7.3. Key words: Osteocyte, Osteoblast, Avian, MAb OB7.3, Phex, Immunomagnetic separation
1. Introduction Osteocytes are the most abundant cells in bone. Although individual osteocytes are buried in an isolated position within the bone matrix, they remain in contact with one another and with cells on the bone surface by long cell processes that run via small channels, the canaliculi. Gap junctions provide intracellular contact, where the cell processes of two osteocytes meet in a shared canaliculus (1). For a long time, osteocytes were outside the main stream of bone research, but this has changed as a result of increasing interest in the mechanoregulation of bone. General consensus exists that osteocytes play a pivotal role as mechanosensors and effectors in bone (2). In addition, there is growing awareness that osteocytes may also play an important role in phosphate homeostasis (3), mineral homeostasis (4), and regulation of matrix mineralization (5, 6). The anatomical location of osteocytes, deep within bone, has proved to be a major obstacle in studying the role of osteocytes in bone metabolism. Osteocytes depend entirely on the diffusion of
Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_4, © Springer Science+Business Media, LLC 2012
43
44
C.M. Semeins et al.
oxygen, hormones, nutrients, and waste via the canaliculi, for their activities and survival. Bone explants have to be very limited in size to allow sufficient transport of nutrients to and from the osteocytes and in fetal bone tissues the osteocyte contribution to the cellular component is very small. Direct isolation of osteocytes is therefore the method of choice to study osteocyte physiology (7). However, three major problems arise. First, how does one isolate live osteocytes from the bone matrix in sufficient numbers for subsequent studies? Second, how can osteocytes be separated from other cells, and how can the population be kept homogeneous? Third, how can osteocytes be recognized in culture, as the cells tend to lose some of their morphological characteristics when they are removed from their three-dimensional tissue structure? This chapter describes the isolation of osteocytes from 18-day-old fetal chicken calvaria. Calvaria of this age are used because at this developmental stage the calvaria are not yet too heavily calcified to allow collagenase to liberate matrix-entrapped cells. The isolation of these cells is facilitated by mild EDTA treatments alternating with collagenase treatments. The choice of fetal chicken calvaria is important because in chicken the periostea from both calvaria surfaces can be relatively easily dissected, which results in a collagenase-released cell population without periosteal cells. Furthermore, fetal chicken calvaria have a much broader layer of osteoid on their surface than mouse or rat calvaria. Finally, the availability of a monoclonal antibody (MAb) that specifically recognizes avian osteocytes allows the purification of osteocytes from mixed cell populations by immunomagnetic separation. The MAb used in the separation procedure (MAb OB7.3) is also used to recognize osteocytes in cell cultures.
2. Materials 2.1. Fertilized Chicken Eggs
2.2. Media and Solutions
Incubate the eggs at 38.5ºC in a humidified air atmosphere for 18 days. The incubator should have a mechanism that turns the eggs regularly through 180°, about ten times per hour. Fertilized eggs can be stored for 2–3 weeks at 14–16°C before development of the embryo is started by incubation in the incubator. 1. Hank’s balanced salt solution (HBSS). 2. Phosphate-buffered salt solution (PBS). 3. Isolation salt solution (ISS): 100 mM NaCl, 30 mM KCl, 1 mM CaCl2, 10 mM NaHCO3, 25 mM Hepes, 5 mg/ml
4
Isolation of Primary Avian Osteocytes
45
glucose, 1 mg/ml bovine serum albumin (BSA), and 7 μM Nα-tosyl-L-lysyl-chloromethane hydrochloride (BDH Biochemicals). Adjust to pH 7.4 at 37°C. The Nα-tosyl-L-lysyl-chloromethane hydrochloride is added to inhibit proteases other than collagenase (8). 4. Collagenase solution: 1 mg/ml ISS. Collagenase Type I. 5. EDTA solution: 4 mM EDTA in PBS. Adjust to pH to 7.4. 6. Wash solution: 10% inactivated chicken serum in HBSS. For inactivation, heat serum for 30 min at 56°C, and centrifuge at 200 × g for 5 min. 7. Culture medium: α-MEM fortified with 2% chicken serum, 0.2 g/l glutamine, 0.05 g/l ascorbic acid, 0.05 g/l gentamycin, and 1 g/l glucose. 8. Trypsin–EDTA (TE) solution: 0.05% trypsin 1:250 and 0.27 mM EDTA in PBS. 9. Coated bead suspension: Mix DNA-conjugated beads (CELLection™ Pan Mouse IgG kit from Dynal), with MAb OB7.3 IgG (see Subheading 2.3) and PBS to a final concentration of 15 μg IgG/8 × 107 beads/ml. 250 μl of this suspension is needed for the isolation of osteocytes from 40 calvaria. Incubate overnight at 4°C gently shaking the suspension and store at 4°C until use. Wash the beads shortly before use two times with 2% inactivated chicken serum in PBS, by placing the bead suspension in a holder next to a magnet (Dynal) that attracts the magnetic beads to one side of the tube, allowing the removal of the suspension fluid. Finally, resuspend the IgGcoated beads in 250 μl 2% inactivated chicken serum in PBS. 10. Cell strainers, 40 μm. 11. Zinc fixative: Dissolve 0.5% zinc chloride and 0.5% zinc acetate in 0.1 M TRIS–acetate buffer, pH 4.5. 2.3. Monoclonal Antibody OB7.3
The antibody MAb OB7.3 was originally raised according standard procedures by injecting bone cells isolated from calvaria of 18-dayold fetal chickens into BALB/c mice (9). In bone sections, it only recognizes osteocytes embedded in osteoid or in calcified matrix (Fig. 1a, b). In cultures of cells enzymatically isolated from fetal chicken calvaria, MAb OB7.3 stains a minority of the isolated cells. The positive cells show an osteocyte-like morphology in culture (Figs. 1c, d and 2). The antibody may be requested from Prof. Dr. J. Klein-Nulend (Dept. Oral Cell Biology, ACTA, University of Amsterdam and VU University Amsterdam, Research Institute MOVE, Amsterdam, The Netherlands; http://www.j.kleinnulend@ acta.nl).
46
C.M. Semeins et al.
Fig. 1. Frozen section of calvaria (a), and air-dried cell cultures (b–d) stained with MAb OB7.3. (a, b and d: Immunofluorescence, c: Phase contrast). (a): Section of 18-day-old fetal chicken calvaria. Note that only the osteocytes inside the bone matrix are stained. (b): OBmix after one day of culture. In the lower left corner, a group of osteocytes with one MAb OB7.3 negative cell is visible; in the upper right corner, an osteoblast colony with two osteocytes is present. (c, d): Purified osteocyte population. Note the contaminating elongated fibroblast-like cell in the upper left corner. Black bar: 100 μm. (Reproduced from see ref. 10 with permission of the American Society for Bone and Mineral Research).
3. Methods 3.1. Tissue Dissection
All of the following steps must be conducted under sterile conditions. 1. Remove the eggs from the incubator after 18 days. Keep one of the eggs with the blunt side upward where the air chamber is located. Crack the top of the shell and peel the shell off to the edge of the air chamber with a pair of sterile tweezers. Stab one leg of a second pair of tweezers underneath the white shell membrane and the chorioallantoic membrane. Close the tweezers and peel both membranes off in one movement.
4
Isolation of Primary Avian Osteocytes
47
Fig. 2. Scanning electron microscopical pictures of isolated osteocytes. (a): Osteocyte 5 min after seeding. The osteocyte is already attached and has formed finger-like projections in all directions. (b): Osteocytes 20 min after seeding. The cell processes in the plane of the support have elongated, whereas the processes perpendicular to the support have disappeared. Note the presence of two magnetic beads. (c): Two osteocytes have made contact with each other via their cell processes after 24 h of culture. (d): Extensive network of flattened osteocytes with many branched cell processes after 48 h of culture. (Reproduced from see ref. 10 with permission of the American Society for Bone and Mineral Research).
2. Grasp the embryo under its head with a curved forceps, lift it a little above the egg, and decapitate underneath the forceps. The body of the embryo will fall back into the egg. Transfer the head to a petri dish with some HBSS placed on ice. Resterilize tweezers and forceps by dipping into ethanol (100%) and burning off the ethanol. 3. Make a cut in the back of the neck with a small pair of scissors. Hold the head by the bill with tweezers and tear the skin off in the direction of the bill. Cut the calvaria loose along the edge and cut it into two parts through the central suture. 4. Put the calvaria halves in a droplet of sterile HBSS and remove the ectocranial and endocranial periostea with small scalpels. Transfer the “bare” calvaria halves into a petri dish with HBSS and keep on ice.
48
C.M. Semeins et al.
5. Repeat these actions for all eggs. Generally, we use 40 eggs in one isolation session. Too many eggs would make the dissection procedure too long, and when the number of eggs is too low, the procedure is inefficient and relatively decreases the number of isolated osteocytes. 3.2. Isolation of OBmix
Perform all incubations in the steps below in a shaking water bath set at 37°C. 1. Transfer all calvaria halves to a small flask containing 2.7 ml ISS and 300 μl collagenase solution (final collagenase concentration: 0.1 mg/ml). Incubate 10 min and discard the supernatant (the discarded supernatants predominantly contain damaged cells and erythrocytes). 2. Repeat step 1. 3. Add 3 ml collagenase solution to the calvaria. Incubate for 15 min and discard the supernatant (this contains predominantly fibroblastic cells and some osteoblasts). Wash calvaria three times with 2.5 ml PBS each time and discard the PBS washes. 4. Add 4 ml EDTA solution to the calvaria. Incubate 10 min and collect the supernatant. 5. Wash the calvaria three times, once with 2 ml PBS, and twice with 1 ml ISS. Add the washes to the supernatant from step 4. 6. Centrifuge at 4°C for 10 min at 600 × g and resuspend the cell pellet in wash solution. This cell suspension is termed Fraction 1. 7. Add 4 ml collagenase work solution to the calvaria, incubate for 45 min, and collect the supernatant. 8. Wash the calvaria three times with 1 ml PBS. Add the washes to the supernatant from step 7. 9. Centrifuge at 4°C for 10 min at 600 × g and resuspend the pellet in wash solution. This cell suspension is termed Fraction 2. 10. Combine Fractions 1 and 2, centrifuge at 4°C for 10 min at 600 × g, and resuspend the sedimented cells in culture medium. This is the OBmix population. It contains osteoblasts, 20–30% osteocytes, and a few fibroblasts (Fig. 1c, d). 11. Determine the cell concentration with a hemocytometer. 12. Seed 1−1.5 × 106 cells into a small (25 cm2) culture flask containing 3.5 ml culture medium. Generally, 40 eggs yield four culture flasks (about 4 × 106 cells in total). 13. Culture the cells for 24 h at 37°C in a humidified atmosphere of 5% CO2 in air (see Note 1).
4
3.3. Isolation of Osteocytes
Isolation of Primary Avian Osteocytes
49
1. After 16–24 h, remove the culture medium from the culture flasks, and rinse three times with PBS. Add 3 ml TE solution per flask and incubate for 5 min at 37°C. Stop the trypsin activity by adding 0.3 ml chicken serum per flask and tap the flask, containing the cells, on the lab table to loosen the OBmix cells from the bottom. 2. Disperse the cells by repeated pipetting over the surface bearing the cell layer. 3. Remove cell clumps by sieving the cell suspension through a 40 μm mesh cell strainer, centrifuge the cells at 600 × g for 10 min, discard the supernatant, and resuspend the cells in 125 μl cold (4°C) 2% inactivated chicken serum in PBS. The sieving procedure is necessary to achieve a single cell suspension. OBmix cells, in particular the osteocytes, tend to form clumps of (probably) gap junction-coupled cells. These clumps however not only contain osteocytes, but also osteoblasts that will later quickly overgrow the nondividing osteocytes (see Note 2). 4. Add 125 μl coated bead suspension and incubate for 30 min in a rotator (60 rpm) at 4°C. Take good care during this step that beads and cells remain in suspension. 5. Separate the bead-bound osteocytes from the osteoblasts with the magnet. Wash the bead-bound osteocytes four times with 2% inactivated chicken serum in PBS (using the magnet to collect the osteocytes) and resuspend the osteocytes finally in 200 μl 2% inactivated chicken serum in PBS. 6. Add a fresh batch of 125 μl coated beads to the osteoblast fraction and repeat the separation procedure. 7. Combine both two bead-bound osteocyte fractions, separate the cells with the magnet and resuspend them in 100 μl culture medium. Count the number of cells per unit volume. Now, the bead-bound osteocytes can either be seeded and cultured, or can be freed from their beads and cultured (see Note 3). 8. For immediate removal of the beads, add 4 μl releasing buffer containing 50 U DNase/μl (CELLection™ Pan Mouse IgG kit) and incubate 15 min at 37°C in a shaking water bath. 9. Separate the beads from the osteocytes with the magnet. Wash the beads two times with PBS containing 2% inactivated chicken serum to remove all osteocytes from the beads and add the washes to the liberated osteocytes. Remove the last contaminating beads with the magnet. 10. Centrifuge the cell suspension, discard the supernatant, and resuspend the osteocyte pellet in culture medium. 11. If it is not necessary to use the isolated osteocytes immediately, it is much easier to seed the bead-bound osteocytes in culture
50
C.M. Semeins et al.
medium in a petri dish. The next day, the beads can simply be removed by washing the cell layer. DNAse treatment is not needed. The osteocyte yield from 40 calvaria is generally about 200,000 osteocytes (Fig. 1c, d). 12. Attached osteocytes can be removed from their support by a short treatment with TE solution. After washing and reseeding, the osteocytes reacquire their typical morphology of stellate cells in secondary culture (see Note 4).
4. Notes 1. Optimizing Isolation of OB mix. The actual procedure one has to use depends heavily on the activity of the collagenase. If you start with a new batch of collagenase, you may have to adapt the procedure. For example, step 3 may have to be shortened if too many osteocytes are isolated in this step. If too many fibroblasts are still present in Fraction 1, then step 3 should be repeated. Steps 4 and 5 have to be repeated if too many cells, in particular osteocytes, are isolated in the repeated steps. The yield of OBmix cells from 40 calvaria following the protocol in Subheading 3.2 is generally 3−4 × 106 cells. About 20–30% of these cells are osteocytes (i.e., about 106 osteocytes). Most of the OBmix cells are however, present in clumps of osteoblasts, osteocytes, or mixtures of osteoblasts and osteocytes. Trying to isolate osteocytes from this population primarily results in the isolation of clumps of osteocytes often containing osteoblastic cells with high proliferative capacity. Sieving the original OBmix population (see Subheading 3.2, step 11) before immunomagnetic separation of osteocytes has been performed results in a very low osteocyte yield. Culturing the OBmix population for 24 h allows the cells of the clumps to separate themselves from each other, thereby increasing the number of single cells after the trypsin/EDTA treatment and thus increasing the osteocyte yield. 2. Reducing numbers of contaminating cells. Generally, we use 2% chicken serum or less in the culture medium. Osteocytes are postmitotic cells. Since serum strongly stimulates cells capable of mitosis to proliferate, isolated osteocytes will quickly be overgrown by contaminating cells in the presence of serum. However, a serum concentration that is too low will lead to deterioration of cell quality. We recommend that osteocyte cultures be used for experimentation as soon as possible after isolation. 3. Purity of the osteocyte population. If the isolation procedure is used routinely, it is advisable to regularly examine the purity of
4
Isolation of Primary Avian Osteocytes
51
the osteocyte populations. Contamination of the osteocyte isolate may be determined by seeding a small sample of the osteocyte suspension in a culture dish. Incubate until the cells are firmly attached (4–6 h) and immunostain the cells for the presence of MAb OB7.3. Note that the removal of the beads will not remove the antibody from the cell surface!! At least 95% of the cells should be positive for the antibody (Fig. 1d). 4. Phenotypic characterization of osteocytes. In bone, osteocytes are fully defined by their location within the bone matrix. For isolated osteocytes, other markers are needed to establish their identity. (a) Stellate morphology. Avian osteocytes reacquire the stellate morphology of osteocytes in situ after isolation and attachment (10) (Fig. 2). This may also be the case for murine osteocytes (11). (b) Antibodies. Three osteocyte-specific MAbs have been described in the literature: MAb OB7.3 (9), MAb OB37.11 (12), and MAb SB5 (13). All three antibodies are specific for avian osteocytes and do not cross-react with mammalian cells. The identity of the antigen involved is only known for MAb OB7.3, the antigen is phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PHEX) (3). MAb OB7.3 is the only antibody used for osteocyte isolation so far. Other antibodies are E11, an MAb that reacts specifically with highly mature osteoblasts and with osteocytes in tissue sections of rat bone (14), and antibodies against fimbrin, an actin-bundling protein that is abundantly present in osteocytes (15). The OB7.3 antigen is easily destroyed by harsh fixation procedures. For immunostaining of osteocytes in bone tissue unfixed, air-dried, frozen sections are recommended (Fig. 1a). Cell cultures can be stained by incubating live cells with MAb OB7.3 in HBSS for 30–60 min at room temperature or by washing the cells with HBSS followed by air drying and incubation with the antibody (Fig. 1b). Also a short (10 min) fixation with 2–4% paraformaldehyde at 4°C will leave enough antigen intact for a reasonable staining. We have also successfully used zinc fixative for the fixation and immunostaining of cell cultures. Zinc fixative does not appear to damage the OB7.3 antigen. A further advantage of this fixative is that cell cultures can be kept in the fixative for a long time (days) without loss of immunoreactivity of the antigen. (c) Protein products. Several proteins, such as osteocalcin and osteopontin, have been demonstrated in or around osteocytes in relatively high amounts (16). Other proteins like matrix extracellular phosphoglycoprotein (MEPE) (17),
52
C.M. Semeins et al.
dentin matrix protein 1 (DMP1) (18), and Phex (19) are highly expressed in osteocytes as compared to osteoblasts. More osteocyte-specific proteins are sclerostin (20) and E11/gp38 (21), which are not expressed in osteoblasts. CD44, a membrane-bound glycoprotein that is involved in cell attachment to matrix proteins, is generally highly expressed in osteocytes (22), but is also expressed by other cells in bone. Alkaline phosphatase, a cell surface-bound enzyme, is generally low in osteocytes, in particular when compared to osteoblasts. The production and presence of some of these proteins may not be specific for osteocytes, but especially when combined with others, they can be used as additional markers for osteocyte identification. References 1. Doty, S. B. (1981) Morphological evidence of gap junctions between bone cells. Calcif. Tissue Int. 33, 509–512. 2. Klein-Nulend, J., and Bonewald, L. F. (2008) The osteocyte, in Principles of Bone Biology (Bilezikian, J. P., Raisz, L. G., and Martin, T. J., eds.), Academic Press, San Diego, California, pp. 153–174. 3. Westbroek, I., De Rooij, K. E., and Nijweide, P. J. (2002) Osteocyte-specific monoclonal antibody MAb OB7.3 is directed against Phex protein. J. Bone Miner. Res. 17, 845–853. 4. Inoue, K., Mikuni-Takagaki, Y., Oikawa, K., Itoh, T., Inada, M., Noguchi, T., Park, J. S., Onodera, T., Krane, S. M., Noda, M., and Itohara, S. (2006) A crucial role for matrix metalloproteinase 2 in osteocytic canalicular formation and bone metabolism. J. Biol. Chem. 281, 33814–33824. 5. David, V., Martin, A., Hedge, A. M., and Rowe, P. S. N. (2009) Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology 150, 4012–4023. 6. Holmbeck, K., Bianco, P., Pidoux, I., Inoue, S., Billinghurst, R. C., Wu, W., Chrysovergis, K., Yamada, S., Birkedal-Hansen, H., and Poole, A. R. (2005) The metalloproteinase MT1-MMP is required for normal development and maintenance of osteocyte processes in bone. J. Cell Sci. 118, 147–156. 7. Van der Plas, A., Aarden, E. M., Feijen, J. H. M., de Boer, A. H., Wiltink, A., Alblas, M. J., de Leij, L., and Nijweide, P. J. (1994) Characteristics and properties of osteocytes in culture. J. Bone Miner. Res. 9, 1697–1704. 8. Hefley, T. J. (1987) Utilization of FPLCpurified bacterial collagenase for the isolation
9.
10.
11.
12.
13.
14.
15.
16.
of cells from bone. J. Bone Miner. Res. 2, 505–516. Nijweide, P. J., and Mulder, R. J. P. (1986) Identification of osteocytes in osteoblast-like cell cultures using a monoclonal antibody specifically directed against osteocytes. Histochemistry 84, 342–347. Van der Plas, A., and Nijweide, P. J. (1992) Isolation and purification of osteocytes. J. Bone Miner. Res. 7, 389–396. Mikuni-Takagaki, Y., Kakai, Y., Satoyoshi, M., Kawano, E., Suxzuki, Y., Kawase, T., and Saito, S. (1995) Matrix mineralization and the differentiation of osteocyte-like cells in culture. J. Bone Miner. Res. 10, 231–242. Nijweide, P. J., van der Plas, A., and Olthof, A. A. (1988) Osteoblastic differentiation, in Cell and Molecular Biology of Vertebrate Hard Tissues. Ciba Foundation Symposium 136 (Evered, D. and Harnett, S., eds.), John Wiley & Sons, Chichester, UK, pp. 61–77. Bruder, S. P., and Caplan, A. I. (1990) Terminal differentiation of osteogenic cells in the embryonic chick tibia is revealed by a monoclonal antibody against osteocytes. Bone 11, 189–198. Wetterwald, A., Hoffstetter, W., Cecchini, M. G., Lanske, B., Wagner, C., Fleisch, H., and Atkinson, M. (1996) Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone 18, 125–132. Tanaka-Kamioka, K., Kamioka, H., Ris, H., and Lim, S. S. (1998) Osteocyte shape is dependent on actin filaments and osteocyte processes are unique actin-rich projections. J. Bone Miner. Res. 13, 1555–1568. Aarden, E. M., Wassenaar, A. M., Alblas, M. J., and Nijweide, P. J. (1996) Immunocytochemical
4 demonstration of extracellular matrix proteins in isolated osteocytes. Histochem. Cell Biol. 106, 495–501. 17. Petersen, D. N., Tkalcevic, G. T., Mansolf, A. L., Rivera-Gonzalez, R., and Brown, T. A. (2000) Identification of osteoblast/osteocyte factor 45 (OF45), a bone-specific cDNA encoding an RGD-containing protein that is highly expressed in osteoblasts and osteocytes. J. Biol. Chem. 17, 36172–36180. 18. Toyosawa, S., Shintani, S., Fujiwara, T., Ooshima, T., Sato, A., Ijuhin, N., and Komori, T. (2001) Dentin matrix protein 1 is predominantly expressed in chicken and rat osteocytes but not in osteoblasts. J. Bone Miner. Res. 16, 2017–2026. 19. Ruchon, A. F., Tenenhouse, H. S., Marcinkiewicz, M., Siegfried, G., Aubin, J. E., DesGroseillers, L., Crine, P., and Boileau, G. (2000) Developmental expression and tissue
Isolation of Primary Avian Osteocytes
53
distribution of Phex protein: effect of the Hyp mutation and relationship to bone markers. J. Bone Miner. Res. 15, 1440–1450. 20. Poole, K. E., van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., and Reeve, J. (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 19, 1842–1844. 21. Zhang, K., Barragan-Adjemian, C., Ye, L., Kotha, S., Dallas, M., Lu, Y., Zhao, S., Harris, M., Harris, S. E., Feng, J. Q., and Bonewald, L. F. (2006) E11/gp38 selective expression in osteocytes: regulation by mechanical strain and role in dendrite elongation. Mol. Cell Biol. 26, 4539–4552. 22. Nakamura, H., and Ozawa, H. (1996) Immunolocalization of CD44 and the ERM family in bone cells of mouse tibiae. J. Bone Miner. Res. 11, 1715–1722.
sdfsdf
Chapter 5 Isolation of Mouse Osteocytes Using Cell Fractionation for Gene Expression Analysis Christine Halleux, Ina Kramer, Cyril Allard, and Michaela Kneissel Abstract Osteocytes are the terminally differentiated cells of the osteoblastic lineage embedded within the mineralized bone matrix. They have been identified as key players in mechanotransduction and in mineral and phosphate homeostasis. In addition, they appear to have a role in mediating bone formation, since they secrete the bone formation inhibitor sclerostin. In contrast to osteoblasts and osteoclasts, which reside on the bone surface, it has been difficult to isolate and analyze cellular and molecular properties of osteocytes due to their specific location inside the “hard” mineralized bone compartment. This chapter describes a method to isolate osteocytes from newborn mouse calvaria and adult mouse long bone, followed by immediate total RNA extraction allowing to selectively study osteocytic versus osteoblastic gene expression by quantitative real-time polymerase chain reaction (qPCR). The osteocyte-enriched cell fraction isolated by this method can further be purified by FACS and selectively expresses osteocytic marker genes, such as Dmp1 and Sost. Key words: Osteocyte isolation, DMP-1, Gene expression, DMP-GFP-sorting, FACS sorting
1. Introduction Osteocytes are the terminally differentiated cells of the osteoblastic lineage embedded within the mineralized bone matrix. They are interconnected with each other and with cells on the bone surface via long cellular protrusions, the so-called dendrites that travel inside small channels, termed canaliculi, thereby forming an extensive canalicular network throughout the mineralized bone matrix. They have been identified as critical regulators of mineral and phosphate homeostasis (1) and are thought to be key players in mechanotransduction (2). Furthermore, they appear to have a role in the mediation of bone formation, since they secrete the potent bone formation inhibitor sclerostin, encoded by the Sost gene (3). Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_5, © Springer Science+Business Media, LLC 2012
55
56
C. Halleux et al.
In contrast to osteoblasts and osteoclasts, which reside on the bone surface, it has been difficult to isolate and analyze cellular and molecular functions of osteocytes due to their specific location inside the “hard” mineralized bone compartment. In addition, even if available, isolated osteocytes cultured on a cell culture dish may not be representative of osteocytes being embedded in the three-dimensional structure of the mineralized bone matrix in vivo. The isolation and culture of osteocytes from chicken calvaria has been described in the past (4–6). More recently, Gu et al. isolated osteocytes from newborn rat long bone (7) and Paic et al. (8) isolated osteocytes from newborn mouse calvaria from DMP1-GFP transgenic mice (9) by fluorescent-activated cell sorting (FACS). Following surgical intervention in human cancer patients, Eisenberger et al. isolated RNA from laser-capture microdissected human osteocytes (10). Here, we describe a method to isolate osteocytes from newborn mouse calvaria and adult mouse long bone, followed by immediate total RNA extraction allowing to study osteocytic versus osteoblastic gene expression by quantitative real-time polymerase chain reaction (qPCR). The osteocyte enriched cell fraction isolated by this method can optionally be further purified by FACS and selectively expresses osteocytic marker genes, such as Dmp1 and Sost.
2. Materials 2.1. Bone Fractionation and Sorting of GFP Positive Osteocytes by FACS 2.1.1. Tissues
2.1.2. Instruments, Material
Fractionation was performed on newborn (i.e., from perinatal mice aged 5 or 6 days) wild-type (C57BL/6 J), DMP1-GFP (9) mouse calvaria expressing green fluorescent protein (GFP) under the control of the dentin matrix acidic phosphoprotein 1 (DMP1) promoter, or adult (aged 4 months) wild-type (C57BL/6J) mouse long bones. In the case of DMP1-GFP mice, FACS sorting followed the fractionation (see Subheading 3.1.4). When isolating osteocytes from newborn calvaria, we determined that calvaria from 5- or 6-day-old mice (P5 or P6) are optimal for the protocol described here (see Note 1). 1. Centrifuge Multifuge 3S-R. 2. Disposable conical polypropylene tubes (15 ml). 3. FACS Aria (Becton Dickinson), BD FACSDiva version 6.0 and higher. 4. FastPrep FP120 Homogeniser (BIO 101, ThermoSavant). 5. Inverted microscope. 6. Needle: 0.6 × 30 mm. 7. Neubauer counting chamber.
5
Isolation of Mouse Osteocytes Using Cell Fractionation…
57
8. Polypropylene tube (1.5 ml). 9. Petri dish (6 and 10 cm diameter). 10. Polypropylene round-bottom tube (14 ml). 11. Screw cap polypropylene tube. 12. Section material (scissors, forceps, curved forceps). 13. Shaker 56EVC (Witec AG). 14. Stainless steel beads 5 mm (Qiagen Cat# 69989). 15. Sterilization filter 0.2 μm, 500 ml. 16. Sterilization filter 0.2 μm, 50 ml. 2.1.3. Media and Solutions
1. BD Accudrop beads (BD Biosciences, Cat# 345249). 2. BD Cytometer Setup and Tracking (CS&T) beads (BD Biosciences, Cat# 641319). 3. Bovine serum albumin, BSA. 4. Dipotassium hydrogen phosphate, K2HPO4. 5. Dentin matrix acidic phosphoprotein 1 (Dmp1) probe (Applied Biosystems, Cat# Mm00803833_g1). 6. Calcium chloride, CaCl2 × 2H2O. 7. Collagenase type IV. 8. Ethylenediaminetetraacetic acid, EDTA 0.5 M solution, pH 8.0. 9. Fetal calf serum, FCS. 10. Glucose. 11. HEPES (Sigma Cat# H7523). 12. HEPES 1 M solution. 13. L-glutamine. 14. MEM alpha medium. 15. Penicillin/streptomycin. 16. Periostin (Postn) probe Mm00450111_m1).
(Applied
Biosystems,
Cat#
17. Phosphate-buffered saline, PBS pH 7.4. 18. Dulbecco’s PBS (Dulbecco’s, 1×), without Ca2+ and Mg2+. 19. Potassium chloride, KCl. 20. Propidium iodide 1 mg/ml. 21. RNeasy MinElute Cleanup Kit (Qiagen Cat# 74204). 22. Sodium chloride, NaCl. 23. Sodium hydrogen carbonate, NaHCO3. 24. Sorbitol. 25. Sclerostin (Sost) probe Mm00470479_m1).
(Applied
Biosystems,
Cat#
58
C. Halleux et al.
26. TRIzol reagent. 27. Water ultrapure. 28. Isolation buffer: 70 mM NaCl, 10 mM NaHCO3, 60 mM sorbitol, 30 mM KCl, 3 mM K2HPO4, 1 mM CaCl2, 0.1% BSA, 0.5% glucose, 25 mM HEPES. 29. Collagenase solution 0.2% in isolation buffer: Make up just before use. Sterilize the solution by filtration through a 0.2 μm filter and store at 4°C until use. 30. EDTA solution: 5 mM EDTA, 0.1% BSA in PBS. Sterilize by filtration through a 0.2 μm filter and store at 4°C until use. 31. MEM medium: 10% FCS, 2 mM L-glutamine, 10 mM HEPES, 100 U/μg/ml penicillin/streptomycin in MEM alpha. Sterilize by filtration through a 0.2 μm filter and store for maximum 1 month at 4°C.
3. Methods 3.1. Bone Fractionation and Sorting of GFP Positive Osteocytes by FACS
1. Decapitate the pups with scissors into 70% ethanol and transfer the heads into PBS.
3.1.1. Isolation of Newborn Mouse Calvaria
4. Dissect the calvaria as indicated by the dashed lines and remove the thin layer of soft tissue (Fig. 1b).
2. Using scissors, incise on both lateral sides of the calvaria (dashed lines) from the eyes until the base of the skull (Fig. 1a). 3. Flip the skin on top of the mouse nose.
Fig. 1. Schematic representation of newborn mouse calvaria isolation. The dashed lines show where to cut the skin (a) and how to remove the calvaria (b).
5
Isolation of Mouse Osteocytes Using Cell Fractionation…
59
Fig. 2. FACS sorting of newborn DMP1-GFP mouse calvaria fractions. Propidium iodide dead cell exclusion (a). Propidium iodide (Pi) is a dye that quantitatively stains cellular DNA and double-stranded RNA. Pi penetrates dead cells but is efficiently excluded from intact cells (i.e., living cells). Pi positive cells are excluded for the gating procedure. DMP1-GFP mouse osteocytes express green fluorescent protein (GFP) (b). On the calvaria fractions, FACS cell sorting was performed according to the GFP expression level [no GFP expression (neg), GFP positive expression (GFP+), and intermediate GFP expression (med)].
5. Before proceeding with the fractionation, store the calvaria in PBS. It is best to start the fractionation as soon as possible (see Fig. 2 and see Note 2). 3.1.2. Fractionation of Newborn Mouse Calvaria
1. Incubate the calvaria (between 4 and 15 calvaria/tube) in 5 ml collagenase solution at 37°C for 20 min in a disposable roundbottom tube under agitation (700 rpm). 2. Collect the digest in a disposable conical tube. 3. Rinse the calvaria once with PBS and collect this rinsing solution into the conical tube containing the initial digest. Centrifuge at 800 × g for 8 min, discard the supernatant, and resuspend the cell pellet in 0.3 ml MEM medium. Determine the number of cells present in the pellet and store it on ice (Fraction 1, see also Note 3). 4. Digest the remains of the calvaria in 5 ml EDTA solution at 37°C for 15 min under agitation (700 rpm). 5. Collect the digest in a new disposable conical tube. 6. Rinse the calvaria remains once with PBS, collect this rinsing solution, and mix it with the digest of step 5. Centrifuge at 800 × g for 8 min, discard the supernatant, and resuspend the cell pellet in 0.2 ml MEM medium. Determine the number of cells present in the pellet and store the pellet on ice (Fraction 2, osteoblast-enriched fraction). 7. Incubate the remains of the calvaria in 5 ml collagenase solution at 37°C for 20 min under agitation (700 rpm). 8. Collect the digest in a new disposable conical tube. 9. Rinse the calvaria remains once with PBS, collect this rinsing solution and mix it with the digest of step 8. Centrifuge at
60
C. Halleux et al.
800 × g for 8 min, discard the supernatant and resuspend the cell pellet in 0.1 ml MEM medium (Fraction 3). 10. Repeat step 7–9 and resuspend the cell pellet in 0.06 ml MEM medium (Fraction 4). 11. Digest the remains of the calvaria in 5 ml EDTA solution at 37°C for 15 min under agitation (700 rpm). 12. Collect the digest in a new disposable conical tube. 13. Rinse the calvaria remains once with PBS, collect this rinsing solution, and mix it with the digest of step 12. Centrifuge at 800 × g for 8 min, discard the supernatant, and resuspend the cell pellet in 0.06 ml MEM medium (Fraction 5, osteocyteenriched fraction). 14. Incubate the remains of the calvaria at 37°C for 20 min in 5 ml collagenase solution under agitation (700 rpm). 15. Collect the digest in a new disposable conical tube. 16. Rinse the calvaria remains once with PBS, collect this rinsing solution, and mix it with the digest of step 15. Centrifuge at 800 × g for 8 min, discard the supernatant, and resuspend the cell pellet in 0.06 ml culture medium (Fraction 6, osteocyteenriched fraction). 17. Repeat last steps 14–16 twice to get Fractions 7 and 8 (see Note 4). 3.1.3. Fractionation of Adult Mouse Long Bone
1. Euthanize the mice with CO2. 2. Decapitate the mice with scissors. 3. Dissect the femur and remove the skin and muscle around the femur as quickly as possible. 4. Cut away both femur ends and flush out the bone marrow with PBS using a needle. 5. Transfer the femora (we recommend 2–12 femora/tube) into 5 ml collagenase solution in a round-bottom tube. Incubate the femora at 37°C for 20 min (30 min is also appropriate) under agitation (700 rpm). 6. Collect the digest in a new disposable conical tube. 7. Rinse the rest of the femora once with PBS, collect this rinsing solution, and mix it with the digest of step 6. 8. Centrifuge at 800 × g for 8 min, discard the supernatant, and resuspend the cell pellet in 1 ml MEM medium if cell number determination is needed (Fraction 1). Store fraction on ice. (If no cell number determination is needed, skip step 8 and proceed directly to step 9, see Note 3). 9. Centrifuge Fraction 1 at 800 × g for 8 min, discard the supernatant, and resuspend the pellet in 1 ml TRIzol. Store it at −80°C until later RNA extraction.
5
Isolation of Mouse Osteocytes Using Cell Fractionation…
61
10. Digest the remainder of the femora in 5 ml EDTA solution in PBS at 37°C for 20 min (30 min is also appropriate) under agitation (700 rpm). 11. Collect the digest in a new disposable conical tube. 12. Rinse the rest of the femora once with PBS, collect this rinsing solution, and mix it with the digest of step 11. Centrifuge at 800 × g for 8 min, discard the supernatant, and resuspend the cell pellet in 1 ml TRIzol (unless cell determination is needed). Store at −80°C for later RNA extraction (Fraction 2). 13. Digest the remains of the femora in 5 ml collagenase solution at 37°C for 1 h under agitation (700 rpm). Repeat steps 11 and 12 to obtain the Fraction 3 (osteoblast-enriched fraction). 14. Repeat step 13 to obtain Fraction 4. 15. Digest the remainder of the femora in 5 ml EDTA solution at 37°C for 45 min under agitation (700 rpm). Repeat steps 11 and 12 to obtain the Fraction 5. 16. Transfer the remainder of each femur into 1 ml TRIzol (per femur) in a 2 ml screw cap polypropylene tube together with one stainless steel bead. Homogenize with a FastPrep Homogenizer under speed Nb. 5 for 30 s. 17. Incubate for 10 min on ice and transfer the homogenate into 1.5 ml polypropylene tube, before storing it at −80°C until RNA extraction (Fraction 6, osteocyte-enriched fraction). 3.1.4. FACS Sorting of Newborn DMP1-GFP Mouse Calvaria Fractions
1. Prepare and set up the FACS Aria cell sorter for four-way high speed sorting (nozzle 70 μm, 70 psi) using the CS&T and Accudrop beads. (BD FACSDiva software version 6.0 and higher). Use sterile filtered Dulbecco’s PBS (1×) for sorting instead of the standard BD sheath fluid. 2. Set the cooling of the injection chamber at +4°C and switch on the cooling device (+4°C) connected to the tube holder for sorted cells. 3. Place four 5 ml collection tubes containing 1 ml cold medium into the cooled holder. 4. Dilute propidium iodide (Pi) in ultrapure water to 80 μg/ml, add the Pi solution to the calvaria fractions to a final concentration of 400 ng/ml (1:200 dilution), and incubate for 20 min at +4°C in the dark to allow cell staining. 5. Dilute the Pi-stained fractions (minimum 1:4) in Dulbecco’s PBS (1×) to reduce the serum concentration when using the FACS, and to adjust cell concentration at approximately 3 × 106 cells/ml. 6. Set up the gating to exclude Pi positive events (dead cells/ dirts, PE-Texas-Red channel, filter 616/23) (Fig. 2a).
62
C. Halleux et al.
7. Duplet exclusion can be done using FSCH/FSCW and SSCH/ SSCW plots to increase sorting purity, but reducing the final yield. 8. Define a negative (neg) intermediate (med) and positive (GFP +) GFP-expressing cell population to be sorted (FITC channel, filter 530/30). Use the four-way purity sorting mode (purity mask 32). 9. After sorting, briefly vortex collection tubes to recover the small droplets on the tube inner side, and then centrifuge each fraction at 500 × g for 5 min and immediately resuspend the cell pellet in 1 mL TRIzol reagent. Freeze the samples immediately at −80°C. 10. GFP positive sorted Fractions 1–8 are pooled as the osteocyteenriched (Ot) fraction before the RNA extraction. Similarly, sorted GFP negative Fractions 2–3 are pooled as well to constitute the osteoblast-enriched (Ob) fraction (Fig. 2b). 3.1.5. RNA Isolation
Total RNA was isolated from each fraction, or pooled fractions, using TRIzol reagent according to the manufacturer’s instructions. Contaminating genomic DNA was removed by digestion with DNaseI and the RNA was cleaned further using the MinElute Cleanup Kit, according to the manufacturer’s instructions. In addition, the eluted RNA was applied a second time to its RNeasy MinElute spin column and centrifuged for 1 min at full speed to increase the total RNA recovery. Reverse transcription and real-time PCR were then performed to quantitatively determine the mRNA levels for selected osteoblastic and osteocytic marker genes.
3.1.6. Comparison of Gene Expression in the Osteocytic and Osteoblastic Fractions
Fractions from newborn wild-type and DMP1-GFP mice as well as from adult mouse femora were analyzed (Fig. 3). Quantitative real-time PCR was essentially done as described by Keller and Kneissel (10), using 5 ng cDNA. As expected, Sost and Dmp1 expression were significantly higher in osteocytic than osteoblastic fractions of all samples tested. Periostin has been described to be differentially expressed in mouse osteoblastic and osteocytic cell lines: Kato et al. showed its expression in primary osteoblasts as well as in several osteoblastic cell lines and early osteocytic clones. In contrast, the more mature MLO-Y4 osteocytic cell line did not express periostin (11). Here, Postn was strongly expressed in both the osteoblastic and osteocytic fractions of newborn calvaria, whereas its expression tended to decrease in adult long bone and be higher in the osteoblastic than the osteocytic fraction. These data confirm the suitability and usefulness of the here described fractionation method. It is interesting to note that the Ct values of all analyzed markers were slightly lower in cell fractions from wild-type compared to those from DMP1-GFP mice, which were isolated by FACS. A possible explanation is that the RNA was
Ot
600 500 400 300 200 100 0 23.8
22.0
Ob
Ot
Ct
P6 wt calvaria
140 120 100 80 60 40 20 0 19.3 Ob
19.5 Ot
6000 4000 2000 0
Ct
12000
32.6
26.9
Ob
Ot
P6 DMP1-GFP calvaria
8000 6000 4000 2000
120
30.7
24.8
Ob
Ot
Ct
P6 DMP1-GFP calvaria
100 80 60 40 20 0 20.7 Ob
22.0 Ot
Ct
63
Adult wt femur
50000 40000 30000 20000 10000 0
Ct
10000
0
Sost expression (%)
8000
Ct
P6 wt calvaria
700
P6 DMP1-GFP calvaria
Dmp1 expression (%)
Ob
10000
Postn expression (%)
24.7
Dmp1 expression (%)
27.2
Sost expression (%)
P6 wt calvaria
900 800 700 600 500 400 300 200 100 0
Isolation of Mouse Osteocytes Using Cell Fractionation…
Postn expression (%)
Postn expression (%)
Dmp1 expression (%)
Sost expression (%)
5
18000
33.3
25.3
Ob
Ot
Ct
Adult wt femur
15000 12000 9000 6000 3000 0 31.6
25.2
Ob
Ot
Ct
Adult wt femur
120 100 80 60 40 20 0
23.1
26.7
Ob
Ot
Ct
Fig. 3. Gene expression in newborn mouse calvaria and adult mouse femur. Gene expression comparison between fractions isolated from 6-day-old wild-type (P6 wt calvaria), 6-day-old DMP1-GFP mouse calvaria (P6 DMP1-GFP calvaria), and 4-month-old wild-type mouse femora (Adult wt femur). Only the fractions isolated from DMP1-GFP mice were FACS sorted. Ob osteoblast-enriched fraction, Ot osteocyte-enriched fraction. Expression values normalized by 18 S are represented as percentage of expression in the Ob fraction and are means ± SD (n = 3 technical replicates) of a representative experiment. Ct values are indicated on the x axis.
partially degraded during the additional handling time of the FACS process. In addition, some osteocytes can be expected to be already extracted with the first EDTA treatment rounds owing to the presence of the cutting edge of the bone, thereby contaminating the osteoblastic fraction in wild-type bone, which was not further purified by an additional FACS step to remove DMP1 positive osteocytes. This interpretation is consistent with the smaller fold change in osteocyte marker gene expression between osteoblast- and osteocyteenriched fractions in wild-type relative to FACS-sorted DMP1GFP calvarial bone. Moreover, using FACS we found that GFP positive osteocytes were indeed present at lower numbers in early fractions (see Note 4). Finally, the higher fold change in osteocyte
64
C. Halleux et al.
marker gene expression between osteoblast- and osteocyte-enriched fractions obtained from adult wild-type mice femur likely reflects spatial and temporal differences in osteocytic marker gene expression indicating higher expression of osteocyte marker genes in adult femora than in postnatal calvaria.
4. Notes 1. We have compared the fractionation of newborn calvaria from 3-, 6-, and 9-day-old mice. Based on our experience with the expression analysis of many different genes, it appears that it is very important to perform the fractionation on mice of exactly the same age. In addition, 6-day-old mice are more suitable for the protocol described here than 3- or 9-day-old mice (Fig. 4). The time of fractionation needs to be carefully adapted for mice at any given age due to changes in bone structure and thickness. 2. Until dissolution of the cell pellet in TRIzol, it is important to carry out the whole fractionation and the following FACS as rapidly as possible to minimize possible gene signature modifications due to the isolation conditions (such as cell stress, apoptosis, etc.). 3. In case no FACS sorting or cell counting is needed, each fraction is resuspended directly in 1 ml TRIzol instead of MEM medium. Direct FACS sorting into TRIzol does not provide good quality RNA.
DMP1 expression (%)
4. Fractionation can usually be stopped after Fraction 7 because very few cells (osteocytes) are still coming off in Fraction 8 (Fig. 5). Given the small amount of cells per fraction obtained from bone of newborn mice, it might be advantageous to pool several fractions after FACS sorting and before RNA isolation.
140 120 100 80 60 40 20 0
700 600 500 400 300 200 100 0
P3
25.6 24.1 23.2 24.5 23.9 23.9 25.4 25.5 F1
F2
F3
F4
F5
F6
F7
F8
140 120 100 80 60 40 20 0
P6
26.4 23.8 23.4 24.0 22.0 23.7 24.8 F1
F2
F3
F4
F5
F6
F7
P9
28.8 24.2 24.9 24.4 24.2 25.2 25.7 25.6 Ct F1
F2
F3
F4
F5
F6
F7
F8
Fractions
Fig. 4. DMP1 gene expression. DMP1 relative expression in fractions isolated from 3-day-old (P3), 6-day-old (P6) or 9-dayold (P9) mouse calvaria. Data were normalized by 18 S and are expressed as percentage of the expression in F2 fraction. Values are means ± SD (n = 3 technical replicates).
Cell number
a
Isolation of Mouse Osteocytes Using Cell Fractionation…
4.0E+06 3.0E+06 2.0E+06 1.0E+06 1.0E+04 F1 F2 F3 F4 F5 F6 F7 F8 Fractions
b
25
Total RNA (ug / Fraction)
5
20
65
15 10 5 0
F1 F2 F3 F4 F5 F6 F7 F8 Fractions
Fig. 5. Cell and RNA recovery per fraction. Cell number (a) and total RNA (b) extracted from various newborn mouse calvaria fractions from a representative experiment.
For example, GFP negative cells from Fraction 2 and 3, representing the osteoblast-enriched fractions, were pooled. Likewise, GFP positive cells from Fractions 1–7, representing osteocytes, were pooled.
Acknowledgments We are most grateful to T. Grabenstaetter and G. Guiglia for excellent technical skills and to Dr. F. Raulf (Novartis Institutes for BioMedical Research, Basel, Switzerland) for giving access to his FACS device and providing valuable advice. We also would like to thank Profs. D. W. Rowe and I. Kalajzic (University of Connecticut Health Center, Farmington, CT, USA) for sharing the DMP1GFP transgenic mouse line. References 1. Feng, J. Q., Ye, L., and Schiavi, S. (2009) Do osteocytes contribute to phosphate homeostasis? Curr. Opin. Nephrol. Hypertens. 18, 285–291. 2. Bonewald, L. F., and Johnson, M. L. (2008) Osteocytes, mechanosensing and Wnt signaling. Bone 42, 606–615. 3. van Bezooijen, R. L., ten Dijke, P., Papapoulos, S. E., and Löwik, C. W. (2005) SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 16, 319–327. 4. van der Plas, A., and Nijweide, P. J. (1992) Isolation and purification of osteocytes. J. Bone Miner. Res. 7, 389–396. 5. Tanaka-Kamioka, K., Kamioka, H., Ris, H., and Lim, S. S. (1998) Osteocyte shape is depen-
dent on actin filaments and osteocyte processes are unique actin-rich projections. J. Bone Miner. Res. 13, 1555–1567. 6. Kamioka, H., Ishihara, Y., Ris, H., Murshid, S. A., Sugawara, Y., Takano-Yamamoto T., and Lim, S. S. (2007) Primary cultures of chick osteocytes retain functional gap junctions between osteocytes and between osteocytes and osteoblasts. Microsc. Microanal. 13, 108–117. 7. Gu, G., Nars, M., Hentunen, T. A., Metsikkö, K., and Väänänen, H. K. (2006) Isolated primary osteocytes express functional gap junctions in vitro. Cell Tissue Res. 323, 263–271. 8. Paic, F., Igwe, J. C., Nori, R. , Kronenberg, M. S., Franceschetti, T., Harrington, P., Kuo, L., Shin, D. G., Rowe, D W., Harris, S. E., and Kalajzic, I. (2009) Identification of differen-
66
C. Halleux et al.
tially expressed genes between osteoblasts and osteocytes. Bone 45, 682–692. 9. Kalajzic, I., Braut, A., Guo, D., Jiang, X. Kronenberg, M. S., Mina, M., Harris, M. A., Harris, S. E., and Rowe, D. W. (2004) Dentin matrix protein 1 expression during osteoblastic differentiation, generation of an osteocyte GFP-transgene. Bone 35, 74–82.
10. Keller, H., and Kneissel, M. (2005) SOST is a target gene for PTH in bone. Bone 37, 148–158. 11. Kato, Y., Boskey, A., Spevak, L., Dallas, M., Hori, M., and Bonewald, L. F. (2001) Establishment of an osteoid preosteocyte-like cell MLO-A5 that spontaneously mineralizes in culture. J. Bone Miner. Res. 16,1622–1633.
Chapter 6 Studying Osteocyte Function Using the Cell Lines MLO-Y4 and MLO-A5 Jennifer Rosser and Lynda F. Bonewald Abstract We describe the culture and use of MLO-Y4 cells in studies of gene expression, response to fluid flow, and dendrite growth. We also describe how to use the MLO-A5 cells as a model of osteoblast to osteocyte differentiation and how to study their mineralization. These studies serve as a beginning point to study osteocyte functions and molecular mechanisms responsible for these functions. Key words: Osteocyte, Mineralization, Dendrites, E11, Fluid flow, MLO-Y4, MLO-A5
1. Introduction Originally, osteocytes were largely defined by their anatomical position within bone and their dendritic morphology. Later, in 1995, molecular markers were identified and they were defined as being low in alkaline phosphatase while high in osteocalcin and casein kinase II (1). Within the past two decades, selective osteocyte markers have been identified including E11/gp38/podoplanin for early, embedding osteocytes, followed by Sost/sclerostin, a marker for the mature osteocyte. In addition, several proteins that play critical roles in phosphate homeostasis, including phosphateregulating gene with homologies to endopeptidases on the X chromosome (PHEX), matrix extracellular phosphoglycoprotein (MEPE), dentin matrix protein 1 (DMP1), and fibroblast growth factor-23 (FGF23) were identified as important and selective osteocyte-expressed genes. Osteocytes are enriched in a number of proteins important in cytoskeletal function, including destrin, CapG, cdc42, E11/gp38, and are also enriched in molecules involved in muscle contractile function, including myosin heavy
Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_6, © Springer Science+Business Media, LLC 2012
67
68
J. Rosser and L.F. Bonewald
and light chains, α-actin, troponins, tropomyosins and α-actinin and the actin binding protein, Capzb (2). Osteocyte selective markers have distinctive functions. E11/ gp38 appears to play a role in dendrite formation, an essential process for osteocytes to generate their network within bone. Sclerostin is a negative regulator of bone formation. Mutation of the SOST gene causes high bone mass in humans, and deletion in mice results in high bone mass. Phex is specific for avian osteocytes but is found in late osteoblasts and osteocytes in mammals. Dmp1 and MEPE are highly expressed in osteocytes compared to osteoblasts or other cell types. Deletion or mutation of either Phex or DMP1 results in hypophosphatemic rickets, which is associated with a dramatic increase in FGF23 expression in osteocytes (2–5). Isolating primary osteocytes is difficult, and yields decrease, with increased mineralization and age of bone, thereby making it difficult to obtain sufficient numbers of cells for many experimental purposes. We, therefore, generated the MLO-Y4 and MLO-A5 cell lines to study osteocyte function (6, 7). Both cell lines were derived from a transgenic mouse in which the immortalizing T-antigen was expressed under control of the osteocalcin promoter. MLO-Y4 cells exhibit properties of osteocytes including high expression of osteocalcin, low expression of alkaline phosphatase, high expression of connexin 43 and the antigen E11, and retain a dendritic morphology, similar to that observed in primary osteocyte cultures. This cell line has proved useful to study effects of fluid flow and substrate stretching on activation of osteocyte-specific signaling pathways and on the release of signaling factors, especially prostaglandin, nitric oxide, ATP, and calcium. Other studies reported have included the role of cilia, gap junctions, and hemichannels, dendrite formation, apoptosis, autophagy, hypoxia, hormonal responses, control of osteoclast formation and activation, and effects on osteoblasts and mesenchymal stem cells. This cell line is exquisitely sensitive to fluid flow shear stress unlike other known fibroblast and osteoblast cell lines (2–5). The MLO-A5 cell line has characteristics of a postosteoblast/ preosteocyte. These cells are very large, over 100 μm, express markers of the late osteoblast such as extremely high alkaline phosphatase, bone sialoprotein, PTH type 1 receptors, and osteocalcin, and rapidly mineralize in sheets, not nodules (7). In culture, these cells start to express markers of mature osteocytes such as E11/ gp38/pdpn as they generate cell processes (8). PTH and mechanical load decreases Sclerostin expression in these cells (9), while BMP increases it (10). MLO-A5 cells have been used to study the osteoblast to osteocyte differentiation process (11), the mineralization process (8), and the effects of mechanical loading on biomineralization (12). As with any cell line, key characteristics are used to monitor the stability of the cell phenotype. For the MLO-Y4 cells, these
6
Studying Osteocyte Function Using the Cell Lines MLO-Y4 and MLO-A5
69
characteristics are generation of dendritic processes, high E11, high osteocalcin, and low alkaline phosphatase. For the MLO-A5, the major characteristic is to form a “honeycomb”-like mineralized matrix within 7–9 days of culture. In this chapter, we describe the culture of the MLO-Y4 and A5 cell lines, their morphology, application of fluid flow shear stress, how to measure dendrite elongation, transfection for siRNA studies, and mineralization assays.
2. Materials 2.1. Tissue Culture Reagents
1. Culture medium: α-MEM with Earle’s salts, L-glutamine, ribonucleosides, and deoxyribonucleosides; supplemented with penicillin/streptomycin at 100 U/ml. 2. Fetal Bovine Serum (FBS) and Bovine Calf Serum (CS) (defined & iron-supplemented); both heat inactivated (Hyclone) (see Note 1). 3. Dulbecco’s Phosphate-Buffered Saline (DPBS) without calcium and magnesium, pH 7.4. 4. 0.05% Trypsin/0.53 mM EDTA solution for passaging cells. 5. Rat tail type I Collagen solution (Becton Dickson Bioscience, Cat.# 354236)for coating plates to maintain cells, or buy precoated plates. 6. 0.02 M Acetic acid for diluting collagen. 7. Dimethyl sulfoxide (DMSO) for freezing cells. 8. Ascorbic acid for mineralizing osteoblast cultures. 9. β-Glycerophosphate for mineralizing osteoblast cultures. 10. Tissue culture treated dishes (100 and 150 mm).
2.2. Fluid Flow Reagents
1. Flexcell® Streamer® Shear Stress Device (Flexcell) includes the following: Pump, Fluid flow chamber with hex bolts and hex wrench, glass bottle, pulse dampeners, latex tubing and quick disconnect fittings. 2. Collagen-coated microscope slides, for example Thermo Scientific Colorfrost* Plus Slides(6776214), which are 25 × 75 × 1 mm, or use Flexcell “Culture slips” (see Note 2). 3. Sterilized forceps for manipulating the slides. 4. Square Petri dishes that can hold three microscope slides. 5. Cell Culture Media for growing cells and performing fluid flow. 6. 70% ethanol and sterile PBS for sterilizing and rinsing the system, respectively. 7. Deionized water and 70% ethanol for cleaning the system.
70
J. Rosser and L.F. Bonewald
2.3. Dendrite Quantitation Reagents
1. 10% buffered formalin.
2.4. siRNA Reagents
1. Opti-MEM® I Reduced Serum Medium without serum (Invitrogen).
2. 0.1% Crystal Violet.
2. Oligofectamine (Invitrogen) (see Note 8). 3. Risc-Free siRNA as a negative control. 4. siRNA to 3 regions of E11 in the form of 21 base nucleotides for transient infection. siRNA “A” and “B” are based on the sequence used for human E11 siRNA (13). siRNA “C” was designed by Ambion (Austin, TX) with the help of the Cenix algorithm. A = +165 ACTGGAGGGCTTAATGAATCT +185 B = +397 AAGATGGCTTGCCAGTAGTCA +417 C = +66 AGGGACTATAGGCGTGAATGA +86 2.5. E11 Western Blotting
1. Primary antibody: Hamster monoclonal antibody 8.1.1 from hybridoma conditioned media- a kind gift of Dr. Andrew Farr at the University of Washington. Dr. Farr has deposited this monoclonal antibody and corresponding hybridoma with the Developmental Studies Hybridoma Bank (http://www.uiowa. edu/~dshbwww/) 8.1.1 (anti-murine GP38; T1alpha; podoplanin) and it is available from there on request. 2. Secondary antibody: Peroxidase-conjugated goat anti-Syrian hamster IgG- (ImmunoResearch Laboratories Inc).
3. Methods 3.1. General Maintenance of MLOY4 OsteocyteLike Cell-Line
All cell culture procedures should be performed in a Tissue Culture hood under aseptic conditions, using sterile supplies. Figure 1 shows the typical appearance of the cells in culture. 1. Maintain stock cultures in α-MEM culture medium containing 2.5% FBS and 2.5% CS at ~60–75% confluence on collagencoated plates (see Subheading 3.2) in a humidified incubator at 37°C and at 5% CO2 (see Note 3). 2. Passage at ~ 1:5 dilution (~1:7maximum), every 3–4 days (see Note 4). 3. Freeze cells in 60% α-MEM, 30% FBS, 10% DMSO, at 1 × 106 cells/ml/cryovial. 4. When defrosting cells, place the frozen vial of cells in a 37°C water bath just long enough to thaw. Transfer the cell suspension into a 15-ml conical tube with 9 ml of media + serum, invert to mix.
6
Studying Osteocyte Function Using the Cell Lines MLO-Y4 and MLO-A5
71
Fig. 1. Appearance of the MLO-Y4 cells at 4 and 12 h after plating. The cells are attached by 4 h and already generate dendritic processes by 12 h.
5. Centrifuge at approx. 1,000 rpm, for 5–10 min. Aspirate media, gently resuspend and plate the cell pellet in media containing 5% FBS and 5% CS. This higher amount of serum, 10% total, is useful to give the cells an extra boost. The next day, check the viability of the cells. If there are a lot of floating “dead” cells, change the medium. You can revert back to medium with 2.5% FBS + 2.5% CS at this point. 3.2. Collagen Coating of Tissue Culture Treated Dishes
Perform this procedure under aseptic conditions and dry plates in a sterile hood. 1. Using a chilled pipette, dilute the concentrated, sterile collagen into previously filter- sterilized 0.02 M acetic acid to a final concentration of 0.15 mg/ml (working dilution). Use 8 and 14 ml of working dilution per 10 and 15 cm dishes, respectively.
72
J. Rosser and L.F. Bonewald
2. Coat the plates for 1 h at room temperature. Then, tilt the plate at an angle for several minutes and remove the solution, which can be reused approximately six times and should be kept in the refrigerator between uses. 3. For immediate use, rinse the plate with PBS to remove residual acid. Alternatively, plates can be stored. To do so, completely dry the plates with the lid off (>1 h). Place lids on dried plates, wrap in plastic, and keep at 4°C for 1–2 months. Before using dried plates, rinse with PBS. 3.3. Fluid Flow using Flexcell ® Streamer ® Shear Stress Device (Flexcell)
1. Plate 2−4 × 105 cells/slide on collagen-coated slides. 2. The next day (day 1), change the medium to include test compounds, or to transfect with siRNA (see Subheading 3.5) if applicable. 3. On day 2, MLO-Y4 cells should be 70–80% confluent and ready for fluid-flow (see Note 5). Wash hands thoroughly before assembling the fluid flow instrumentation. Handle all tubes, parts of the system, and pipette tips carefully making sure they do not come into contact with lab surfaces or skin. When performing the sterilization steps and filling the system with medium, either start the pump from its hardware switch or use the software to choose the manual configuration. The latter is preferable.
3.3.1. To Set Up the Computer System
1. Turn on the computer. 2. Open Stream Gold v1. The Streamer is now under control of the computer and it will read as PO1. 3. Select the “Operate” menu. Add your name as a User by clicking “Add User,” then click “Return.” 4. Select “Operate” menu again, then select “Configure Regimes.” Create procedure by entering values in each step of the new regimen. Click on “Save Step” to save each step, then click “Save Regime” to save the entire procedure. Select the “Visualization” of “Test Profile” tab to verify that the regimen is as expected. Typically we build regimens with a 1 min ramp up to the desired flow intensity, then the entire flow pattern, followed by a 1 min ramp down to zero. This protects cells from undesired shock. 5. On the main screen, select “System 1” tab. Click on “Configure”: this will open a new window. Select the appropriate User, Regime and Hardware (Streamer), and then click “Update.” The regime is now ready to start.
3.3.2. To Set Up the Flow Loop
1. Sterilize the assembled Streamer apparatus with 300 ml of 70% ethanol added to the glass bottle and pumped through the system for 30 min. Check for leaks and if necessary, change rubber seals on the tube connections.
6
Studying Osteocyte Function Using the Cell Lines MLO-Y4 and MLO-A5
73
2. Collect ethanol in the bottle by reverse flow and move it to a used-ethanol container. 3. Rinse the system with 300–400 ml of sterile PBS and pump through the system for at least 5 min and collect in a waste container. 4. Repeat step 3. 5. Place the bottle containing the culture medium (~500 ml) in the FF incubator next to the flow system. Loosen the cap. Take the cap with tube fittings off the empty glass bottle and carefully place the inner tube fittings inside the media bottle without touching anything around it, to maintain optimal sterility. 6. Start pumping the medium through the system to push the remaining PBS out of the flow loop. When the medium reaches the drop off into the bottle and it has pushed most of the PBS out, stop the pump and discard the PBS. 7. Add the rest of the medium. It should be ~500 ml. Cap the bottle again and make sure that it is closed properly. 8. Start pumping the rest of the medium through the system (see Note 6). To create a trap for any excess air that may enter the system, fill each of the pulse dampeners with media by tilting them perpendicular to the flow so that the medium pumping through the system begins to collect there. Start with the pulse dampener closest to the pump and then do the other one. The medium level should be about 1–1.5 inches above the tubing inlets. Check for any bubbles in the tubing and move them out of the system if they are trapped. Also be aware that the Streamer chamber has an air gap spot that will collect bubbles, you need to tilt the chamber on a slant to fill this gap. This is your last chance to check for bubbles and/or leaks. 9. Disconnect the Streamer chamber inlet and outlet tubing and carefully move the system to the tissue culture hood. 10. Remove the screws and open the hinged top. 11. Using sterile forceps and sterile gloves (spray with 70% ethanol), pick up each slide with cells and place it into each one of the slots on the flow device. Make sure the side of the slides with cells is facing the smaller slot, which is the area of flow on the chamber. Gently slide each of them into place and try not to force them in or scratch the sides of the chamber with the glass. All six slots must be filled to ensure proper and consistent flow. If you have less than six slides for an experiment, fill the rest of the slots with empty sterilized slides. 12. Close the chamber, tighten the bolts by hand, and then tighten with the hex wrench. 13. Move the chamber back to the incubator and reconnect the inlet and outlet tubing.
74
J. Rosser and L.F. Bonewald
14. Click start on the software. The profile should already be loaded. A “save as” window will come up, click “cancel.” The flow will start. 15. As the flow is ramping up, tilt the chamber on a slant to help the bubbles in the air gap inside the chamber clear. This should take a few seconds. 16. You will see the shear stress graph building at real time on the software. Periodically monitor the flow system to check for leaks or bubbles. 17. When the program ends, remove the chamber from the incubator and take it to the tissue culture hood. Open the chamber and remove slides for immediate processing, or return to sterile culture conditions for further incubation. Process the cells for example for Western blotting (see Note 7), for RNA isolation, or for analysis of dendrite length (see Subheading 3.4). 18. When you have collected the cells, bring the chamber back to the flow system. Plug in the inlet and outlet tubing and collect all the media into a different container by starting reverse flow. 19. Rinse system with deionized water for 10 min, collect, and discard. 20. Repeat step 18 another two times. 21. Rinse the system with 300 ml of 70% ethanol for 10 min and collect ethanol and discard. 22. Disconnect the tubing, bottle, chamber, and baffles. Open the chamber and clean it with water and ethanol. Make sure that there is no medium residue left on any of the parts, as this will corrode the system. 23. Let the system air-dry until next use. 3.4. Staining and Quantitation of Dendrite Length
Crystal Violet staining is a useful method to enhance the contrast of the dendrites and cell body. See Fig. 2 for an illustration of the method. 1. Fix cell cultures in 10% buffered formalin for 10 min. and wash with H2O. 2. Stain cultures with 0.1% Crystal Violet for 10 min; aspirate and save solution. 3. Gently rinse the cell layer with H2O several times until the solution becomes clear. 4. Drain slides at an angle, or turn plates upside down to air-dry before photographing. Quantitation of dendrite length using the AnalySIS Image Software. 1. Using AnalySIS Image Software (Soft Imaging Systems Corp.), open the photo file to be quantitated.
6
Studying Osteocyte Function Using the Cell Lines MLO-Y4 and MLO-A5
75
Fig. 2. Stained with Crystal Violet, the red line shows the tracing of the cell body, and the green lines, the tracing of the cell extensions. In this manner, the area of the cell body can be quantitated as can the length and number of dendritic processes.
2. Set the “M” magnification at which the original photo was taken. It is very important to make sure that the units are “μm”. Even if there is a “√” next to automated, click on it, then recheck “√” it. This procedure is necessary each time you open a new photo file, so that the dendrite measurements are recorded in “μm” and not pixels. 3. Choose “Measure → Arbitrary area” from the tool bar. Outline the cell body with the cursor (by depressing the left button on the mouse). Double right click the mouse to end the measurement. The software program will automatically generate a data sheet for the cell body area and record the first set of data in column “A.” 4. Outline the dendrites of the same cell (choose “Measure → Polygon length”) using the cursor and using the previously drawn “cell body” as start/stop point. Double right click to end measurement of all dendrites of that cell. The program generates a separate data sheet for the polygon length, and records this first set of data in column “A” also. Double check to make sure that the data measurements are in “μm.” 5. To start measurements on the second cell, click on the appropriate data sheet, and click onto column “B”; otherwise, the program will overwrite or add the new data to the previous measurement. Each individual cell should have a separate column, but this column letter should be the same for both data measurements. (i.e., third cell “C,” fourth cell “D,” etc.).
76
J. Rosser and L.F. Bonewald
6. To erase and redraw, double right click to end the current tracing. Manually delete the numbers from the data sheet. Then click on the picture of the eraser with an “X,” and this will delete the previously drawn layers. 7. To obtain the dendrite Mean for each cell, click on the Polygon length data sheet and choose “Measure → Define Statistics → Mean,” then choose “Measure → Statistics” We combine the dendrite Means from individual cells into any stats program, to get an overall Mean and Std. Error from multiple cells within each sample group. 3.5. E11 siRNA Transfection of MLO-Y4
1. The day before transfection, plate cells at 4 × 104 cells/well in 0.5 ml of growth medium without antibiotics in collagencoated 48 well plates so that they will be 50% confluent at the time of transfection. 2. For each sample, prepare siRNA–Oligofectamine complexes as follows: (a) Dilute 25 nM of each of the 3 siRNA in 40 μl of OptiMEM® I Reduced Serum Medium without serum (or use other medium without serum) (see Note 10). Mix gently. (b) Mix Oligofectamine gently before use, then dilute 1 μl in 9 μl of Opti-MEM® I Medium (or other medium without serum) (see Note 8). Mix gently and incubate for 5 min at room temperature. (c) After the 5 min incubation, combine the diluted siRNA with the diluted Oligofectamine (total volume is 50 μl). Mix gently and incubate for 20 min at room temperature to allow the siRNA–Oligofectamine complexes to form. 3. Add the 50 μl of siRNA–Oligofectamine complexes to each well. Mix gently by rocking the plate back and forth containing 200 μl growth medium without serum. 4. Incubate the cells at 37°C in a CO2 incubator for 24 h until they are ready to assay for gene knockdown. It is generally not necessary to remove the complexes; however, growth medium (1, 2.5, or 5% 50:50 FBS:CS) may be added after 4–6 h without loss of transfection activity, but lower serum may enhance the effect of the siRNA (see Fig. 3). 5. To perform fluid flow on siRNA transfected cells, transfect the cells 24 h after seeding onto collagen-coated slides, then perform fluid flow 24 h later. (a) After 2 h of FF at 16 dynes/cm2, the slides were transferred back to a petri dish with medium containing 2.5% FBS and 2.5% CS. The slides were incubated for another 24 h before assessing dendrite length and/or protein expression.
6
Studying Osteocyte Function Using the Cell Lines MLO-Y4 and MLO-A5
5% serum
2.5% serum
1% serum
100
100
100
80
80
80
60
60
60
40
40
40
20 0
20 0
77
20 0
Fig. 3. Decreasing serum concentration can enhance the effects of siRNA. Concentrations of serum are indicated above the panels. The Y-axis is percent reduction in protein expression. siRNA = siRNA to E11, RF = Risc free control, Vehicle = no RNA, Cells only = no treatment.
Results: Transfection with siRNA to E11 can inhibit the increase in dendrite length induced by application of fluid flow shear stress. Although no effect was observed on dendrite lengthening in those transfected cells which remained under static culture conditions, the protein expression was significantly decreased in subsequent Western analysis for E11 (14). These experiments could be performed to determine if E11 or dendrites play a role in any osteocyte functions such as gap junction or hemichannel function, cell signaling, or osteocyte apoptosis. The same siRNA approach was used to show the role of β-catenin in osteocyte apoptosis and viability (15). 3.6. General Maintenance of MLO-A5 Late Osteoblast/Early Osteocyte-Like Cell-Line
All cell culture procedures should be performed in a Tissue Culture hood under aseptic conditions, and using sterile supplies. 1. Maintain cultures in α-MEM culture medium containing 5% FBS and 5% CS under sub-confluent conditions (85–90%) on collagen-coated plates. Grow in a humidified incubator at 37°C, at 5% CO2. 2. Passage at 1:15–1:20 every 3–4 days. 3. Freeze cells in 60% α-MEM, 30% FBS, 10% DMSO, at 1 × 106 cells/ml/cryovial.
3.7. Mineralization of MLO-A5
Please note that the pattern of mineralization obtained with MLOA5 is different from that described in other chapters (e.g., see Chapter 3, this volume). Here, mineralization is in sheets rather than in nodules. 1. For consistency, perform the experiment within 3–4 passages of defrosting a new batch of cells. 2. Plate cells into collagen-coated wells at ~3.5 × 104 cells/cm2, so the wells are 100% confluent in 2 days. Use α-MEM containing 5% FBS and 5% CS.
78
J. Rosser and L.F. Bonewald
3. At confluence (day 0), change the medium to mineralization medium: α-MEM/10% FBS containing 100 μg/ml ascorbic acid and 4–5 mM β-glycerophosphate (see Note 9). 4. Change the media in the wells every 2–3 days. Aspirate the spent medium using a sterile, beveled needle, taking care not to touch the cell layer. If leaving a small amount of the old medium (~100 μl is acceptable) make sure to be consistent between all wells. Work with four wells at a time so that the wells do not dry out. 5. On day 4–6, collagen fibrils start forming into a swirling, honeycomb pattern, which takes on a “shiny” and refractile appearance as the culture begins to mineralize. 6. Optimal mineralization is usually around day 10–12. 7. To harvest the cultures for Western blotting, you will need to use a 23 gauge needle attached to a syringe to vigorously mix the lysate (10–20 times), to break up the mineralized matrix. See Chapter 15, this volume, for details on Western blotting methods. 8. To harvest the cultures for mineralization, the cells are fixed in 10% buffered formalin for 10 min. and washed with H2O, before proceeding to Von Kossa or Alizarin Red staining. Alternatively the cultures are fixed in 95% ETOH for immunofluoresence staining.
4. Notes 1. Growing the cells in both types of serum is very important, as the CS maintains cell proliferation, while the FBS maintains cell differentiation. Switching to a new batch of serum, especially the FBS, can result in changes in both morphology and phenotypic expression. We suggest testing several new serum lots to make sure that the cells are performing as in the previous serum batch. We suggest you assay cell proliferation, cell morphology, dendrite length, gene and/or protein expression, and if applicable, the ability to mineralize. For heat inactivation, consult the Hyclone Web site. 2. For fluid flow, use positively charged glass slides (Thermo Shandon Colorfrost* Plus Slides cat#6776214) and collagen coat (C.C.) to insure optimal attachment of the cells onto the glass slides. Because the dimensions of the glass slides may be slightly different, you will need to pretest each slide in the Streamer chamber. If you encounter resistance, do not force it in, or it could break and obstruct the chamber. Sterilize the glass slides prior to C.C. by soaking in 70% ethanol or 100%
6
Studying Osteocyte Function Using the Cell Lines MLO-Y4 and MLO-A5
79
isopropanol for at least 30 min. Air-dry or rinse in PBS before proceeding. (You can also sterilize the slides by wrapping and autoclaving.) To C.C., refer to the procedure given in Subheading 3.2. Place the slides in a sterile tissue culture dish, or other sterile container for coating. After coating, transfer the slides to sterile, square petri dishes using sterile forceps. Lean the slides on the side of the dish until they are dry before laying them flat inside the dish, otherwise, they will “stick” to the bottom, and will be difficult to remove later. 3. The MLOY4 osteocyte-like cells, which grow slower than osteoblast-like cell-lines, prefer to only make contact through their dendritic processes, not through their cell bodies. If grown too confluent, this can affect the dendritic characteristics, and the cells will start detaching. Since the cells do not produce their own extracellular matrix, the cells are maintained on collagen-coated plates to help maintain this dendritic morphology. 4. Try to limit the medium changes by providing enough medium at passage to last 3–4 days. Use 12 ml/100 mm dish or 30 ml/150 mm dish. Two reasons we recommend this are that (a) the cells love their own “conditioned media,” and actually become more dendritic, and (b) previously, we observed that frequent medium changes causes morphological changes in the cells. This is particularly important in experiments measuring cell body area or dendrite length. 5. We recommend letting the cells adhere to the glass slide for 48 h (but not longer than that), before performing fluid flow. Depending on the purpose of the experiment, and the endpoint, you may need to change the initial plating density. If the endpoint is to measure dendrite length, you want there to be adequate space between the cells so the dendrites have the space to elongate. 6. It is very important to be careful in filling the flow system. You need to fill the two plastic baffles (pulse dampeners) about 2/3 full. This is crucial to keep vibrations from the pump and bubbles from disturbing the cells. If you fail to adequately fill these baffles, the experiment is likely to fail, as the air bubbles dislodge cells off the slides. 7. For Western blotting, the general procedure given in Chapter 15, this volume, is used. To detect the osteocyte-specific marker E11, we use the hamster monoclonal antibody 8.1.1 from hybridoma conditioned media – a kind gift of Dr. Andrew Farr at the University of Washington. Dr. Farr has deposited 8.1.1 (anti-murine GP38; T1alpha; podoplanin) and the corresponding hybridoma with the Developmental Studies Hybridoma Bank (http://www.uiowa.edu/~dshbwww/) and
80
J. Rosser and L.F. Bonewald
it is available from there on request. This antibody works well in combination with peroxidase-conjugated goat anti-Syrian hamster IgG- (ImmunoResearch Laboratories Inc). 8. Oligofectamine is the preferred solution. Lipofectamine 2000, Lipofectamine Plus (Invitrogen,Carlsbad, CA), and TransITTKO Transfection reagent (Mirus, Madison, WI) affected cell morphology. 9. Ascorbic acid and β-glycerophosphate are added to the culture medium on the day of feeding. Make 100× stock solutions in medium without serum, filter-sterilize using a syringe filter, make small aliquots, wrap in foil, and freeze at −20°C. Aliquots are stable for several months. Since ascorbic acid is light sensitive, we tend to discard the thawed aliquot after use. The thawed aliquot of β-GP can be stored at 4°C and used for a week. 10. In this case, the initial dilution of the siRNA complex should be made as a 5X solution (at 125nM), so after the 50 μl complex is added to the 200 μl of growth medium, the final concentration of siRNA is 25nM. References 1. Mikuni-Takagaki, Y., Kakai, Y., Satoyoshi, M., Kawano, E., Suzuki, Y., Kawase, T., and Saito, S. (1995) Matrix mineralization and the differentiation of osteocyte-like cells in culture. J. Bone Miner. Res. 10, 231–242. 2. Bonewald, L. F. (2007) Osteocytes, In Osteoporosis (R. Marcus, D. Feldman, D. Nelson, C. Rosen, Ed.) 3 rd ed., pp 169–190, Elsevier. 3. Bonewald, L. F., Johnson, M. L. (2008) Osteocytes, Mechanosensing, and Wnt Signaling. Bone 42, 606–615. 4. Dallas, S. L., Bonewald, L. F. (2010) Dynamics of the Transition from Osteoblast to Osteocyte, Ann. N Y Acad. Sci 1192, 434–437. 5. Klein-Nulend, J., Bonewald, L. F. (2008) The Osteocyte, In Principles of Bone Biology (Bilezikian, J. P., Raisz, L.G., Ed.), Academic Press. 6. Kato, Y., Windle, J. J., Koop, B. A., Mundy, G. R., and Bonewald, L. F. (1997) Establishment of an osteocyte-like cell line, MLO-Y4, J. Bone Miner. Res. 12, 2014–2023. 7. Kato, Y., Boskey, A., Spevak, L., Dallas, M., Hori, M., and Bonewald, L. F. (2001) Establishment of an osteoid preosteocyte-like cell MLO-A5 that spontaneously mineralizes in culture. J. Bone Miner. Res. 16, 1622–1633. 8. Barragan-Adjemian, C., Nicolella, D., Dusevich, V., Dallas, M. R., Eick, J. D., and Bonewald, L. F. (2006) Mechanism by
9.
10.
11.
12.
13.
which MLO-A5 late osteoblasts/early osteocytes mineralize in culture: similarities with mineralization of lamellar bone. Calcif. Tissue In. 79, 340–353. Bellido, T., Ali, A. A., Gubrij, I., Plotkin, L. I., Fu, Q., O’Brien, C. A., Manolagas, S. C., and Jilka, R. L. (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146, 4577–4583. Papanicolaou, S. E., Phipps, R. J., Fyhrie, D. P., and Genetos, D. C. (2009) Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells. Biorheology 46, 389–399. Dallas, S. L., Veno, P. A., Rosser, J. L., Barragan-Adjemian, C., Rowe, D. W., Kalajzic, I., and Bonewald, L. F. (2009) Time lapse imaging techniques for comparison of mineralization dynamics in primary murine osteoblasts and the late osteoblast/early osteocyte-like cell line MLO-A5. Cells, tissues, organs 189, 6–11. Sittichockechaiwut, A., Scutt, A. M., Ryan, A. J., Bonewald, L. F., and Reilly, G. C. (2009) Use of rapidly mineralising osteoblasts and short periods of mechanical loading to accelerate matrix maturation in 3D scaffolds. Bone 44, 822–829. Schacht, V., Ramirez, M. I., Hong, Y. K., Hirakawa, S., Feng, D., Harvey, N., Williams, M., Dvorak, A. M., Dvorak, H. F., Oliver, G., and
6
Studying Osteocyte Function Using the Cell Lines MLO-Y4 and MLO-A5
Detmar, M. (2003) T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J. 22, 3546–3556. 14. Zhang, K., Barragan-Adjemian, C., Ye, L., Kotha, K., Dallas, M., Lu, Y., Zhao, S., Harris, M., Harris, S. E., Feng, J. Q., and Bonewald, L. F. (2006) E11/gp38 Selective Expression in osteocytes: regulation by mechanical strain and
81
role in dendrite elongation. Mol. Biol Cell. 26, 4539–4552. 15. Kitase, Y., Barragan, L., Qing, H., Kondoh, S., Jiang, J., Johnson, M. L., Bonewald, L. F. (2010) Mechanical induction of PGE2 in osteocytes blocks glucocorticoid induced apoptosis through both the b-Catenin and PKA pathways. J. Bone Min. Res. 25, 2657–2668.
sdfsdf
Chapter 7 Isolation, Differentiation, and Characterisation of Skeletal Stem Cells from Human Bone Marrow In Vitro and In Vivo Rahul S. Tare, Peter D. Mitchell, Janos Kanczler, and Richard O.C. Oreffo Abstract In this chapter, we describe techniques for the isolation and characterization of skeletal stem cells from human bone marrow. The methods for enrichment of STRO-1 positive cells using magnetic activated cell sorting are described and we also cover techniques for establishing and characterising osteogenic, adipogenic, and chondrogenic cultures from these cells. Finally, we present methods for studying the ability of these cells to produce bone in vivo using diffusion chambers which have been implanted subcutaneously in mice. Key words: Stem cells, Osteoblast, Adipocyte, Chondrocyte, Bone marrow, Diffusion chamber
1. Introduction Adult human bone marrow stromal tissue contains multipotent progenitor cells referred to as skeletal stem cells (or more commonly mesenchymal stem cells), which are capable of differentiating into osteoblasts, chondrocytes, adipocytes, and myocytes. Mesenchymal stem cells can be identified by virtue of the fact that they express various cell surface markers which can be detected by specific antibodies. The most widely used of these is the monoclonal antibody STRO-1, which recognises a cell-surface trypsinresistant antigen expressed by a sub-population of bone marrow stromal cells that essentially includes all adherent high growthpotential clonogenic progenitors or fibroblastic colony-forming units CFU-F (1). This chapter provides an update on the methodologies for the isolation and enrichment of STRO-1 positive skeletal stem cells from bone marrow using immunolabelling followed by Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_7, © Springer Science+Business Media, LLC 2012
83
84
R.S. Tare et al.
magnetic isolation. We also describe the techniques for differentiation of these cells down the osteogenic, chondrogenic and adipogenic lineages in vitro and the techniques that can be used to characterise the differentiated cells. Finally, we describe the methods for the in vivo analysis of stem cells by the use of diffusion chambers in nude mice.
2. Materials 2.1. Equipment for Tissue Culture and Stromal Cell Isolation
1. Class II tissue culture cabinet. 2. Microscope. 3. Incubator. 4. Centrifuge. 5. LS separation columns (Miltenyi Biotec). 6. VarioMACS assembly (Miltenyi Biotec).
2.2. Equipment for In Vivo Diffusion Chamber Experiments
1. Warming pad and sterile cover dressings. 2. Recovery incubator (temperature 28°C). 3. Michel clips & clip stapler. 4. Sterile forceps, scalpel blades No 10, scalpel blade holder, blunt dissection scissors, and artery forceps. 5. Diffusion chamber, outer diameter 14 mm, inner diameter of 10 × 2 mm (Millipore). 6. Mixed cellulose ester membranes, 13 mm diameter with 0.45 μm pore size (Millipore). 7. Cement fixative (Millipore).
2.3. Stromal Cell Isolation and Culture
1. α-MEM. 2. Phosphate-buffered saline (PBS). 3. Lymphoprep. 4. Foetal calf serum (FCS). 5. Trypsin/EDTA 0.05% Trypsin/0.02% EDTA. 6. 2% (w/v) Collagenase Type IV in α-MEM. 7. Normal human AB serum. 8. Hank’s buffered saline solution (HBSS) with 10 mM HEPES, pH 7.4. 9. Blocking buffer (HBSS with 10 mM HEPES, 10% normal human AB serum, 5% FCS, and 1% bovine serum albumin) (see Note 1).
7
Isolation, Differentiation, and Characterisation…
85
10. MACS buffer (2 mM ETDA in PBS with 0.5% (w/v) bovine serum albumin) (see Note 2). 11. Anti-human monoclonal STRO-1 antibody (R&D Systems). 12. Rat anti-mouse IgM-coated Microbeads (Miltenyi Biotec). 2.4. Stromal Cell Differentiation
1. Insulin, Transferrin, & Sodium selenite (ITS) medium supplement (Sigma). 2. 3-Isobutyl-1-1-methylxanthine (IBMX) (Sigma). 3. Human recombinant TGF-β3 (Calbiochem). 4. Osteogenic medium: α-MEM with 10% FCS, 100 μM Ascorbate-2-phosphate, 25 nM 1α, 25-dihydroxy Vitamin D3, and 1.8 mM Potassium dihydrogen phosphate). 5. Chondrogenic medium: α-MEM with 100 μM Ascorbate-2phosphate, 10 nM Dexamethasone, 1% ITS medium supplement, and 10 ng/ml TGF-β3. 6. Adipogenic medium: α-MEM with 3 g/l D+ Glucose, 10% FCS, 1% ITS, 1 μM Dexamethasone, 0.5 mM IBMX, and 100 μM Indomethacin. 7. Adipogenic insulin only medium: α-MEM with 3 g/l Glucose, 10% FCS, and 1% ITS.
D+
2.5. Alkaline Phosphatase Staining
1. 90% Ethanol.
2.6. Alkaline Phosphatase Activity
1. Assay buffer (33% 2-AMP alkaline buffer solution with 0.2% Igepal CA-630.
2. Alkaline Phosphatase staining solution (4% (v/v) Naphthol AS-MX solution with 0.024% (w/v) Fast Violet Salt) (see Note 3).
2. Assay substrate: 3.6 mM 4-Nitrophenyl phosphate disodium salt hexahydrate in 33% 2-AMP alkaline buffer solution. 3. 1 M NaOH. 4. 4-Nitrophenol. 5. Triton X-100 0.05% (v/v) in distilled water. 2.7. DNA Quantification
1. 10 mg/ml DNA stock (BDH laboratories). 2. 1× Tris/EDTA solution. 3. 0.5% PicoGreen® solution in 1× Tris/EDTA.
2.8. Von Kossa Staining
1. 1% (w/v) Silver nitrate in distilled water. 2. 2.5% (w/v) Sodium thiosulphate in distilled water. 3. Van Gieson’s stain: (0.09% (w/v) Acid Fuchsin in 50% (v/v) picric acid).
86
R.S. Tare et al.
2.9. Safranin O Staining
1. Weigert’s Iron Haematoxylin. Solution A: 1% (w/v) Haematoxylin in methanol. Solution B: 1.2% (w/v) Ferric chloride in 1% (v/v) concentrated HCl. Mix equal volumes of solutions A and B just before use. 2. Acid alcohol: 1% (v/v) concentrated HCl in methanol. 3. 0.001% (w/v) Fast green. 4. 1% (v/v) Acetic acid. 5. 0.1% (w/v) Safranin O.
2.10. Immunostaining for Type II Collagen and SOX-9
1. Rabbit anti-human SOX-9 primary antibody (Chemicon AB5535). 2. Rabbit anti-rodent/human Type II collagen primary antibody (Calbiochem 234187). 3. Biotinylated goat anti-rabbit secondary antibody (DakoCytomation E0432). 4. 0.01 M Sodium Citrate buffer, pH 6.0. 5. Hyaluronidase solution: 0.08% (w/v) hyaluronidase in PBS with 1% (w/v) BSA. 6. PBS with 1% (w/v) BSA. 7. 3% Hydrogen peroxide. 8. 30% Hydrogen peroxide. 9. Glacial acetic acid. 10. Histo-Clear. 11. Histology grade Methanol. 12. High salt solution: 400 mM NaCL, 50 mM Tris, 0.05% Tween20 (v/v) in dH2O. Adjust to pH 8.5. 13. Low salt solution: 150 mM NaCL, 50 mM Tris, 0.05% Tween20 (v/v) in dH2O. Adjust to pH 8.5. 14. Tris buffer solution: 100 mM Tris, 0.05% Tween-20 (v/v) in dH2O, pH 8.5. 15. ExtrAvidin Peroxidase solution: ExtrAvidin Peroxidase 2% (v/v) in PBS with 1% (w/v) BSA. 16. Substrate mixture: 50 mM AEC (3 amino-9-ethyl-carbazole) in dimethylformamide. Solution can be kept in fridge for up to 1 week. 17. Working substrate: dilute 0.5 ml substrate mixture in 9.5 ml 50 mM acetate buffer (pH 5.0) and add 5 μl of 30% H2O2. 18. Light Green stain: 2.5 mM Light Green in 2 mM acetic acid. Stir well and filter before use. 19. Alcian blue stain: 4 mM Alcian blue 8GX in 10 mM acetic acid. Stir well and filter before use. Staining solution can be used for approximately 1 week. 20. Crystal mount.
7
2.11. Oil Red O Staining
Isolation, Differentiation, and Characterisation…
87
1. 60% isopropanol. 2. 1% (v/v) Saturated Oil Red O in Isopropanol Stock solution. 3. Oil Red O working solution (see Note 4). 4. Formal Calcium Solution: (11% (v/v) formaldehyde in 1% Calcium Chloride.
2.12. Tissue Implant Models
1. Nude Mice (MF-1 nu/nu strain). 2. Class 1 flow cabinet. 3. Injectable anaesthetic (1:1 mixture of Hypnorm and Midazolam in sterile water).
3. Methods 3.1. Isolation of Bone Marrow Mononuclear Cells
The procedure is based upon immunomagnetic isolation of STRO-1 positive cells from a whole population of bone marrow mononuclear cells using a column that is placed in the magnetic field of a MACS separator as described by Stewart et al. (2). The magnetically labelled STRO-1 positive cells are held in the column under the influence of the magnetic field, while the unlabelled STRO-1 negative cells are eluted by repeated washes of the column. On removal of the column from the magnetic field, the magnetically labelled STRO-1 positive cells are eluted as a STRO1-enriched fraction. These cells can be cultured directly and characterised by immunostaining for stromal cell or stem cell markers (Fig. 1), or differentiated down the osteogenic (Subheading 3.4), chondrogenic (Subheading 3.5) or adipogenic (Subheading 3.6) lineages (Fig. 2). Whatever the researcher chooses to do, these procedures must be performed in a Class II laminar flow hood. 1. Obtain suitable human bone marrow tissue containing pieces of trabecular bone (see Note 5) and transfer into a 50-ml Falcon tube. Add 5 ml α-MEM to the sample and shake the sample vigorously for a couple of minutes. 2. Allow the sample to stand for a minute and pipette out the supernatant cell suspension into another 50-ml Falcon tube (see Note 6). 3. Repeat this process three to four times until most of the cells are released and the debris has been removed from the bone marrow sample. 4. Add α-MEM to make the volume of the cell suspension up to 50 ml and centrifuge at 250 × g for 5 min at 4°C. 5. Discard the supernatant taking care not to dislodge the cell pellet at the bottom of the Falcon tube (see Note 7).
88
R.S. Tare et al.
Fig. 1. Day 6 cultures of adult human bone marrow-derived STRO-1 positive skeletal stem cells in basal medium exhibiting robust immunoreactivity to the STRO-1, anti-Vimentin (primitive mesenchymal cell marker) and anti-SDF-1/Stromal cellDerived Factor-1 (stromal cell marker) antibodies. In addition to the STRO-1 antigen, cells of day 6 cultures co-express the CD105 antigen, a recognised marker of skeletal progenitor cells. Scale bar: 50 μm.
7
Isolation, Differentiation, and Characterisation…
89
Fig. 2. Multipotential ability of adult human bone marrow-derived STRO-1+ skeletal stem cells demonstrated by the expression of alkaline phosphatase in osteogenic culture conditions, formation of 3-D pellets, in chondrogenic medium, cells of which synthesise abundant proteoglycans (stained with Safranin O) and Type II collagen, and generation of adipocytes containing lipid droplets in adipogenic culture medium. Scale bar: 100 μm.
6. Resuspend the cell pellet in 10–15 ml α-MEM and filter the cell suspension into a fresh 50-ml Falcon tube through a 70–75-μm filter (see Note 8). 7. Add α-MEM to the filtered cell suspension to bring the volume to 25 ml and layer gently over 25 ml Lymphoprep which has been pre-warmed to room temperature (see Note 9). 8. Centrifuge at 800 × g for 40 min at 18°C with the centrifuge brake set to off. 9. Carefully remove the mononuclear cells from the interphase using a sterile pastette into another 50 ml Falcon tube and suspend the cells in 25 ml fresh α-MEM. Centrifuge at 250 × g, for 10 min at 4°C to remove any residual Lymphoprep. 10. Resuspend the cell pellet in 25 ml α-MEM and perform a cell count (see Note 10). 11. Pellet the cells by centrifugation at 250 × g for 10 min at 4°C. 3.2. Antibody Labelling of STRO-1 Positive Cells
1. Resuspend the cell pellet derived from Subheading 3.1, step 11 in 10 ml blocking solution. 2. Incubate for 30 min at 4°C, taking care to shake the tube every 10 min to avoid the cells from clumping and settling at the bottom of the tube (see Note 11).
90
R.S. Tare et al.
3. Centrifuge the cell suspension at 250 × g for 5 min at 4°C, and resuspend the cell pellet in 1 ml STRO-1 antibody at a concentration of 10 μg/ml (see Note 12). 4. Incubate the cell suspension/antibody solution for 30 min at 4°C, taking care to shake the tube every 10 min to avoid the cells from clumping and settling to the bottom of the tube (see Note 11). 5. Centrifuge the sample at 250 × g for 5 min at 4°C. 6. Remove the supernatant and resuspend the cell pellet in 50 ml MACS buffer which has been chilled to 4°C and centrifuge at 250 × g for 5 min at 4°C. 7. Repeat step 6. 8. Resuspend the cell pellet in 800 μl fresh MACS buffer and add 200 μl rat anti-mouse IgM Microbeads and mix thoroughly by gentle pipetting. 9. Incubate the cells in the secondary antibody solution for 30 min at 4°C, taking care to shake the tube every 10 min to avoid the cells from clumping and settling to the bottom of the tube (see Note 11). 10. Centrifuge the sample at 250 × g for 5 min at 4°C. 11. Remove the supernatant and wash the cells in chilled MACS buffer as described in step 6. 12. Resuspend the cell pellet in 3 ml MACS buffer and perform cell count. 3.3. Magnetic Separation of STRO-1 Positive Cells
1. Place the LS separation column in the magnetic field of the VarioMACS and place a 15 ml collection tube underneath. 2. Prepare the column by washing it with 3 ml MACS buffer. 3. Add 3 ml of immunolabelled cell suspension to the column and wait until the cell suspension passes through the column into the collection tube. 4. Wash the column three times with 3 ml MACS buffer. 5. Remove the column from the VarioMACS assembly and place in a fresh collection tube. Add 5 ml fresh MACS buffer and firmly flush out the STRO-1 positive cell fraction using the plunger supplied with the column. Suspend the eluted cells in 10 ml fresh MACS buffer. 6. Centrifuge the STRO-1 positive cell suspension at 250 × g for 5 min at 4°C and resuspend the resulting cell pellet in α-MEM supplemented with 10% FCS. 7. Place the cells in culture in α-MEM supplemented with 10% FCS for further characterisation and or differentiation as described in Subheadings 3.4–3.6.
7
3.4. Osteogenic Differentiation of STRO-1 Positive Cells
Isolation, Differentiation, and Characterisation…
91
1. Seed 2 × 106 STRO-1 positive cells derived from Subheading 3.3 into a 25 cm3 tissue culture flask. 2. Maintain the cells in culture in α-MEM with 10% FCS for 9–12 days until they are between 50 and 80% confluent. 3. Aspirate the culture medium and replace with osteogenic medium (Subheading 2.4). 4. Continue the cultures for up to 28 days with changes of medium every 3 days. 5. Terminate the cultures and assay for evidence of osteoblast differentiation (alkaline phosphatase activity, bone nodule formation) as detailed in Subheadings 3.7–3.11.
3.5. Chondrogenic Differentiation of STRO-1 Positive Cells
1. Seed 2 × 106 STRO-1 positive cells derived from Subheading 3.3 into a 25 cm3 flask and culture in α-MEM supplemented with 10% FCS until the cells are about 90% confluent. 2. Remove the medium, wash with PBS, and add Trypsin/EDTA to detach the cell layer (see Note 13). 3. Pellet cells by centrifugation at 250 × g for 5 min at 4°C and resuspend the cell pellet in 5 ml α-MEM. Perform a cell count and adjust the volume so that the cell density is 5 × 105 cells/ml. 4. Add 1 ml of the cell suspension to a sterile 25 ml polycarbonate universal container. 5. Pellet the cells by centrifugation at 250 × g for 10 min at 4°C. 6. Carefully aspirate the supernatant, taking care not to disturb the cell pellet and gently add 1 ml of chondrogenic medium (Subheading 2.4) to each universal container. 7. Place the containers in a humidified CO2 incubator at 37°C with the lids slightly open for 21–28 days, with changes of medium every 2 days. 8. Terminate the experiment and analyse the cultures for evidence of chondrogenic differentiation as described in Subheadings 3.12 and 3.13.
3.6. Adipogenic Differentiation of STRO-1 Positive Cells
This method is used to generate adipocytes from STRO-1 positive cells by alternating periods of culture in adipogenic and insulin only medium. 1. Seed 2 × 106 STRO-1 positive cells derived from Subheading 3.3 into a 25 cm3 flask and culture in α-MEM in supplemented with 10% FCS until the cells are sub confluent. 2. Culture in adipogenic medium (Subheading 2.4) for 3 days and wash the cultures with PBS. 3. Culture in insulin only medium (described in Subheadings 2.4– 2.12) for 1 day and wash the cultures with PBS.
92
R.S. Tare et al.
4. Repeat steps 2 and 3 twice. 5. Continue the cultures in insulin only medium with medium changes every 3 days until adipocytes are observed in the cultures (see Note 14). 6. Terminate the experiment and analyse the cultures for evidence of adipogenic differentiation as described in Subheading 3.14. 3.7. Staining for Alkaline Phosphatase activity
1. Wash the tissue culture plates in PBS and fix in 90% ethanol for 15 min. 2. Remove ethanol and allow the plates to air-dry. 3. Add sufficient ALP staining solution to cover each sample (approximately 3 ml for a 25 cm3 flask). 4. Incubate at 37°C until red staining develops in the cells.
3.8. Analysis of Alkaline Phosphatase activity in cell lysates
1. Wash the tissue culture plates or flask in PBS and fix the cells by adding sufficient 90% ethanol to cover the cell layer and incubate for 15 min. 2. Remove ethanol and allow samples to air-dry. 3. Add sufficient 0.05% Triton-X-100 solution to cover each well in the culture plate. 4. Homogenise the cell layer using a cell scraper. 5. Freeze the plate at −20°C for 30 min and thaw at 37°C for 5 min. 6. Repeat step 5 three times, homogenising the cell layer using a cell scraper after each repeat. 7. Proceed to measure ALP activity and DNA content as described in Subheadings 3.9 and 3.10.
3.9. Measurement of Alkaline Phosphatase Activity
1. Prepare a standard curve by adding 100 μl 4-nitrophenol to the 96 well plate in triplicate over the concentration range 0–200 nmol/ml. 2. Add 10 μl lysate to each well of a 96 well plate in triplicate. 3. Add 90 μl 4-nitrophenol substrate to each well containing cell lysate (do not add to standards). 4. Note the time and incubate the plate at 37°C until the sample wells start to change colour to yellow. 5. Add 100 μl 1 M NaOH to all wells to stop the reaction and record the time elapsed. 6. Transfer the plate to a colorimetric plate reader and read at 410 nm absorbance. 7. Calculate the alkaline phosphatase activity as the amount of substrate converted per minute in relation to the standard curve. 8. Express the alkaline phosphatase activity as a function of DNA content as described in Subheading 3.10.
7
3.10. Measuring DNA Concentration in Cell Lysates
Isolation, Differentiation, and Characterisation…
93
1. Prepare a standard curve of DNA over the concentration range 0–1,000 ng and add 100 μl of each standard to a black 96-well cyto-fluor plate in triplicate. 2. Add 10 μl of cell lysate to each well in triplicate and add 90 μl of Tris/EDTA to each of the wells containing cell lysate. 3. Add 100 μl of 0.5% PicoGreen solution to all wells. 4. Read in a fluorimeter at 485 nm excitation and 530 nm emission. 5. Work out the DNA concentration in each sample well by comparing to the standard curve.
3.11. Von Kossa Staining for Bone Nodules and Osteoid
This method is used to visualise mineralised bone nodules and osteoid. The mineralised bone stains black and the osteoid red. 1. Add 3 ml silver nitrate per 25 cm3 flask. 2. Place under UV light for 20 min. 3. Wash thoroughly using ultra-pure water. 4. Add 3 ml sodium thiosulphate to each flask and leave for 8 min at room temperature. 5. Wash thoroughly using ultra-pure water. 6. Add 3 ml van Gieson stain and leave for 5 min at room temperature. 7. Remove any excess van Gieson stain from the flask by rinsing gently with ultra-pure water.
3.12. Safranin O Staining of Chondrocytes Cultures
This method is used to study production of cartilage glycosaminoglycans in sections of the chondrocyte cultures described in Subheading 3.5. The glycosaminoglycans stain orange whereas the cytoplasm of cells stain green and the nuclei black. 1. Fix the chondrogenic pellets by immersing in 90% ethanol or 4% paraformaldehyde overnight at 4°C. 2. Process the sections through graded methanol and chloroform solutions, embed in paraffin wax and prepare 7 μm sections for analysis using a microtome. 3. Deparaffinise the sections by immersing in Histoclear for 7 min and repeat once. 4. Immerse the sections on 100% methanol for 2 min and repeat once. 5. Repeat step 3 with 90% methanol. 6. Repeat step 4 with 50% methanol. 7. Repeat step 5 with water. 8. Add Weigert’s Iron Haematoxylin to the sections and incubate for 10 min.
94
R.S. Tare et al.
9. Wash the sections in running water for 10 min. 10. Clear the sections by dipping slides three-times in acid alcohol. 11. Wash in running water for 10 min. 12. Stain with Fast green for 5 min. 13. Rinse quickly in 1% acetic acid for no more than 10–15 s. 14. Stain with 0.1% Safranin O for 5 min. 15. Immerse in 100% methanol for 30 s and repeat once. 16. Immerse in 90% methanol for 30 s and repeat once. 17. Immerse in 50% methanol for 30 s and repeat once. 18. Immerse in Histoclear for 30 s and repeat once. 19. Mount by adding a drop of DPX to each section and gently drop a coverslip on top, taking care to avoid introducing any air bubbles. 3.13. Immunolocalisation of SOX-9 and Type II Collagen in Chondrocyte Cultures
This method is used to study production of the chondrocyte specific markers SOX-9 and type II collagen in sections of the chondrocyte cultures described in Subheading 3.5. For immunolocalisation of SOX-9, a microwave step is required for antigen retrieval just before addition of the primary antibody, whereas for type II collagen the sections should instead be incubated with hyaluronidase at this point. 1. Chondrogenic pellets are fixed in 90% ethanol or 4% paraformaldehyde overnight at 4°C, processed through graded methanol and chloroform solutions, embedded in paraffin wax and sequentially sectioned on the microtome at 7 μm. 2. Deparaffinise the sections by immersing in histoclear for 2 × 7 min. 3. Hydrate the sections by immersing in 100% methanol for 2 × 2 min, followed by 90% methanol 50% methanol, then dH2O, each for 2 min. 4. If the sections are to be stained for SOX9, follow step 4.1. If the sections are to be stained for type II collagen, follow step 4.2: 4.1. (Sox9 only) Immerse the slides in 0.01 M sodium citrate buffer in an appropriate container with a lid, put into a microwave and heat for 5 min at full power. Wash the slides in distilled water for 2 min and proceed to step 5. 4.2. (Type 2 collagen only) Add sufficient hyaluronidase solution to cover each section and incubate for 20 min at 37°C. Wash the slides by rinsing in running water and proceed to step 5. 5. Place slides flat on a staining tray, cover sections with 3% H2O2, incubate for 5 min, and wash briefly in running water.
7
Isolation, Differentiation, and Characterisation…
95
6. Add a drop of 1% BSA in PBS to each section and leave for 15 min. 7. Dilute the SOX9 (1:150) and collagen type II (1:500) primary antibody in PBS with 1% BSA and add enough antibody solution to cover each section (see Note 15). 8. Incubate the slides in a lidded staining tray for 1–3 h at room temperature or overnight at 4°C (see Note 16). 9. Rinse gently in running water and immerse slides in High Salt, then Low Salt, then Tris buffer for 5 min each. 10. Drain the slides and add sufficient diluted biotinylated secondary antibody (1:100) to cover each section. Incubate the slides in a lidded staining tray for 1–2 h at room temperature. 11. Repeat step 9. 12. Drain slides and cover the sections with ExtrAvidin Peroxidase solution and incubate for 30 min. 13. Repeat step 9. 14. Add sufficient AEC substrate buffer to cover each section and monitor the slides for the development of a colour change to brown (maximum incubation of 10 min). 15. Place the slides in a staining rack and place into the running water bath to terminate the reaction. 16. Add Light Green to the sections to counterstain and incubate for 1 min. 20 s (see Note 17). 17. Rinse in water bath and gently dab any excess droplets of water from the section using tissue paper. 18. Place a few drops of crystal mount directly onto the section and incubate at 37°C until set (approx. 1–2 h). Do not apply a coverslip. 3.14. Oil Red O Staining
The Oil red O method is used to visualise lipid droplets in adipocytes which stain bright red. 1. Fix cultures by adding sufficient Formal Calcium solution to cover the cell layer. 2. Rinse cells with 60% isopropanol. 3. Add 1 ml Oil Red O working solution per well or enough to cover flask base and leave to stain for 15 min. 4. Rinse three times with excess dH2O to remove lipid droplets released from cells, then add 1 ml dH2O or PBS to wells to visualise under light microscope, taking care not to force water from pipette to prevent damage to the cell monolayer. 5. Photograph within 1 h.
96
R.S. Tare et al.
3.15. Subcutaneous Implant Assay and Diffusion Chamber Assay
This method is used to generate skeletal tissue in vivo by subcutaneous implantation of a diffusion chamber containing skeletal stem cells into a nude mouse or by directly implanting samples of skeletal tissue into a nude mouse (see Note 18) (3, 4). The resulting tissue can then be analysed by various techniques such as imaging, histology and immunohistochemistry (5, 6). The whole procedure is carried out in a sterile operating theatre or in a class I tissue culture cabinet. 1. Sterilise the individual diffusion chamber ring sections overnight using UV exposure. 2. Assemble the diffusion chamber apparatus by attaching the ring to a membrane using the cement fixative (Fig. 3). 3. Add the cells, cell pellets, or bone constructs to the chamber and then add the other side membrane and fix using the cement (Fig. 3). 4. Submerge the constructs in tissue culture media and incubate at 37°C in 5% CO2/balanced air until ready for implantation. 5. Anaesthetise the mice by administering the anaesthetic at a dose of 10 ml/kg intraperitoneally using a 25 G needle and 1-ml syringe. 6. Place the mice on a warming pad, swab the back with an alcohol wipe and make a longitudinal 1–2 cm incision on one side of the vertebral column using a N°10 scalpel blade. 7. Create a subcutaneous pouch lateral to the vertebral column using blunt dissection large enough to contain the bone cell based implants or diffusion chambers required for the experiment. Scaffold Chamber rings
Cells Filter membrane Fig. 3. A schematic diagram of the diffusion chamber set up for in vivo subcutaneous implantation of skeletal scaffold constructs and cells.
7
Isolation, Differentiation, and Characterisation…
97
Fig. 4. A selective laser sintered scaffold (arrows) seeded with human foetal femur derived cells subcutaneously implanted into MF-1nu/nu mice for 28 days (a). The asterisk denotes the skin. Alcian blue (proteoglycans) and Sirius red (collagen) histological staining of a section of a selective laser sintered scaffold seeded with human foetal femur derived cells subcutaneously implanted into MF-1nu/nu mice for 28 days (b). Scale bar = 100 μm.
8. Using sterile forceps, gently insert the bone cell construct or the diffusion chamber (containing cells) into the subcutaneous pocket (see Note 19). 9. Close the incision using Michel staple clips. 10. Transfer mice to the recovery incubator until they recover from the anaesthetic and then place back in appropriate cages (see Note 20). 11. Continue the experiment for up to 28 days. 12. Sacrifice the mice using an approved method and extract the subcutaneous tissue implants or the diffusion chambers. 13. Proceed to molecular, histological, immunohistochemical, or microcomputed tomography analysis of the resulting tissue (Fig. 4).
4. Notes 1. The blocking buffer needs to be made up fresh for each experiment. 2. It is important to de-gas the MACS buffer and to minimise introduction of air bubbles while resuspending cells, since air bubbles in the sample may block the separation columns. 3. Add the fast violet salt to the Naphthol AS-MX solution up just before use. 4. Prepare from saturated Oil Red O solution by passing through filter paper twice. Add 3 ml of the filtered Oil Red O solution
98
R.S. Tare et al.
to 2 ml water and leave for at least 1 h. The working solution should be dark red but clear of sediment; should the solution remain cloudy, pass through a 0.22 μm filter. 5. We use bone tissue that would normally be discarded that is obtained during the course of routine orthopaedic surgical procedures. These samples should be obtained with the patients consent and with the approval of the local ethical committee. If foetal tissue is being used it is advisable to process the femur sample immediately after removal from the foetus. If this is not possible, the sample may be stored in culture media at 37°C, 5% CO2 for up to 48 h. 6. This process assists in releasing cells from the marrow sample and also gets rid of unwanted trabecular bone chips, and tissue debris. 7. The supernatant often contains fat. 8. Filtration is required to remove any residual bone chips and debris. A cell count can be performed at this stage, but is optional. 9. It is important that the Lymphoprep is at room temperature to separate the red cells from the bone marrow mononuclear cells. 10. The cell count should ideally be around 108 cells or higher. The greater the total number of cells, the better is the yield of STRO-1 positive cells. 11. Alternatively, place the tubes containing the cell suspension in the MACSmixTM tube rotator (Miltenyi Biotec). 12. If there are substantially more cells that 1 × 108, then the sample should be split so that 1 ml STRO-1 supernatant or 1 ml antibody is added for each 108 cells processed. 13. The cell layer can also be detached by first incubating with 2% collagenase type IV for 20 min. at 37°C, followed by a 5-min incubation with Trypsin-EDTA. This can help prevent the cell layer from lifting off the tissue culture plastic as a single sheet. 14. Adipocytes can be recognised by the accumulation of lipid droplets in the cytoplasm which appear yellow under phase contrast microscopy. 15. It is important not to let the sections dry out. 16. Each slide will typically require 60–75 μl antibody solution. 17. The sections can also be counterstained with Alcian blue. In this case, the sections should be covered with Alcian blue stain for 45 s before going onto the next step. 18. It can be problematic to differentiate between host and implanted tissue using the subcutaneous implant method, but the diffusion chamber model obviates this problem.
7
Isolation, Differentiation, and Characterisation…
99
19. Bilateral implants can be used to introduce diffusion chambers and tissue explants to either side of the vertebral column, thereby reducing the number of animals required for an individual experiment. 20. The duration of the anaesthesia is typically 30–40 min, and the recovery period is 120–240 min. References 1. Simmons, P., and Torok-Storb, B. (1991) Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 78, 55–62. 2. Stewart, K., Walsh, S., Screen, J., Jefferiss, C. M., Chainey, J., Jordan, G. R., and Beresford, J. N. (1999) Further characterisation of cells expressing STRO-1in cultures of adult human bone marrow stromal cells. J. Bone Miner. Res. 14, 1345–1356. 3. Gundle, R., Joyner, C. J., and Triffitt, J. T. (1995) Human bone tissue formation in diffusion chamber culture in vivo by bone-derived cells and marrow stromal fibroblastic cells. Bone 16, 597–601.
4. Oreffo, R. O., and Triffitt, J. T. (1999) In vitro and in vivo methods to determine the interactions of osteogenic cells with biomaterials. J. Mater. Sci. Mater. Med. 10, 607–611. 5. Bolland, B. J., Kanczler, J. M., Dunlop, D. G., and Oreffo, R. O. (2008) Development of in vivo mCT evaluation of neovascularisation in tissue engineered bone constructs. Bone 43, 195–202. 6. Bolland, B. J., Kanczler, J. M., Ginty, P. J., Howdle, S. M., Shakesheff, K. M., Dunlop, D. G., and Oreffo, R. O. (2008) The application of human bone marrow stromal cells and poly(dl-lactic acid) as a biological bone graft extender in impaction bone grafting. Biomaterials 29, 3221–3227.
sdfsdf
sdfsdf
Part II Culture of Osteoclasts
Chapter 8 Rodent Osteoclast Cultures Isabel R. Orriss and Timothy R. Arnett Abstract This chapter describes quantitative methods for isolating and culturing rodent osteoclasts on dentine, a bone-like, resorbable substrate. These techniques generate relatively large numbers of osteoclasts and allow the key processes of osteoclast formation and activation to be studied independently. A special focus will be on the role of extracellular pH, a critical factor in the control of osteoclast function. Key words: Osteoclast, Resorption, pH, Bone, Dentine
1. Introduction Osteoclasts are the cells responsible for resorbing bone and other mineralised tissues such as enamel, dentine, and cementum. They are derived from mononuclear progenitors of the monocyte/macrophage lineage and are usually large and multinucleated. Osteoclasts are the only cells known to be capable of removing both mineral and organic matrix, creating characteristic scalloped pits and trails with sharply defined edges. Compared to other bone cells, osteoclasts are relatively few in number, particularly in adult bone. The development of two types of in vitro model based on normal cells has helped to transform our understanding of osteoclast biology. Note that there are no immortalised cell lines currently available that can differentiate into authentic osteoclasts capable of forming true resorption pits. The development in 1984 of “disaggregated” osteoclast resorption cultures by Boyde et al. (1) and Chambers et al. (2) was a major step. The method relies on the relative abundance of mature osteoclasts in the bones of neonatal animals (reflecting the requirement for rapid remodelling during growth), which can be released by fragmenting and agitating the bones in a suitable liquid Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_8, © Springer Science+Business Media, LLC 2012
103
104
I.R. Orriss and T.R. Arnett
medium. The suspended osteoclasts, along with other cell types (including osteoblasts, fibroblasts, stromal, and other marrow cells) are then allowed to sediment on to bone or dentine slices, on which they excavate typical resorption pits. Variants of these simple assays were then adopted for quantifying the resorptive function of osteoclasts isolated from neonatal rat bones (3, 4) or chick bones (5). The second key step was the development of long-term osteoclast formation cultures, using haematopoietic precursor cells derived from bone marrow (6). When this assay system was first developed supplementation with factors such as 1α,25-dihydroxyvitamin D3, parathyroid hormone (PTH), and prostaglandin E2 (PGE2) (6, 7) was required. These factors act via the osteoblasts/ stromal cells present in the cultures to stimulate osteoclast differentiation (8). This method was superseded following the identification of macrophage colony stimulating factor (M-CSF) (9) and receptor activator for nuclear factor kB ligand (RANKL) (10, 11) as critical cytokines for osteoclastogenesis. M-CSF and RANKL are now commercially available (see Note 1) and are used to directly stimulate osteoclast formation in cultures from initially non-adherent mononuclear cells derived from marrow, spleen, or peripheral blood. These are now by far the most widely used methods for studying osteoclast function in vitro. There are several important advantages: (1) relatively large numbers of osteoclasts can be obtained (e.g. for biochemical analysis); (2) the key processes of osteoclast formation and activation can be studied independently; (3) osteoclastogenesis occurs in cultures that are relatively free of the confounding influence of stromal cells/pre-osteoblasts. This chapter describes the quantitative methods for studying the function and formation of osteoclasts from rodents. A special focus will be on the role of extracellular pH, a key factor in the control of osteoclast function (see Note 2).
2. Materials All solutions, instruments, and tissue culture plastics should be sterile. 1. Animals: The number of animals to be used depends on the number of treatment groups in the experiment. It should be borne in mind that variation within treatment groups is usually quite high in both the osteoclast formation assay and mature osteoclast resorption assay. Therefore, at least 7–8 replicate dentine discs should ideally be allowed for each treatment group. •
Mouse osteoclast formation assay: Generally, two 6–8-weekold mice will produce approximately nine treatment groups, each containing eight replicates.
8
•
Rodent Osteoclast Cultures
105
Rat mature osteoclast resorption assay: Four, 2–4-day-old rat pups are required for six treatment groups, and five animals for 7–8 groups. It is not recommended that more than five animals are used because the pooled, dissected bones need to be chopped very quickly (see Subheading 3.2).
2. Minimum essential medium (MEM): Add 10% foetal calf serum (FCS), 2 mM L-glutamine and 100 U/ml penicillin, 100 μg/ml streptomycin, 0.25 μg/ml amphotericin (mixture is known as antibiotic/antimycotic or AB/AM). 3. Step 1 MEM (S1MEM): To MEM add 10−7 M prostaglandin E2 (PGE2) and 2.5 ng/ml M-CSF (see Note 1). 4. Step 2 MEM (S2MEM): To MEM add 10−7 M prostaglandin E2 (PGE2), 10 ng/ml M-CSF (R&D Systems, Abingdon, UK; cat. no. 416-ML), and 3 ng/ml mouse RANKL (Escherichia coli expressed; R&D Systems; cat. no. 462-TEC) (see Notes 1 and 2). 5. Acidified MEM: To achieve a basal level of resorption the medium should be acidified by adding approximately 10 mEq/l of hydrogen ions. This can be achieved by adding 85 μl of concentrated hydrochloric acid (HCl) per 100 ml medium (12) (see Note 3). In the mouse osteoclast formation assay, acid is added to S2MEM to produce acidified medium for the final 48 h of the experiment; in the rat mature osteoclast culture basic MEM is used. 6. Phosphate-buffered saline (PBS): For storing tissues prior to use and for removing non-adherent cells from dentine discs. 7. Hydrochloric acid (HCl): Concentrated hydrochloric acid (11.5 M), to alter the pH of the culture medium. 8. Sodium hydroxide (NaOH): 6 M NaOH, to alter the pH of the culture medium. 9. Diamond saw: e.g. Buehler Isomet, to cut dentine slices. 10. Dentine slices: Substrate for osteoclast culture. •
Prepare the dentine slices by cutting 250-μm thick transverse wafers from a block of dentine (see Note 4) using a diamond saw operating at about 60% of maximum speed with a moderate blade weighting.
•
Soak the slices for 2 h in distilled water to reduce brittleness; cut 5 mm diameter discs from the wet wafers using a standard paper punch. These discs fit neatly into the wells of 96-multiwell plates.
•
Wash the discs extensively by sonication in multiple changes of distilled water and store dry at room temperature.
•
Before use, number the discs using a graphite pencil to aid identification and sterilise by immersing for 1 min in 100% ethanol.
106
I.R. Orriss and T.R. Arnett
•
Allow the discs to air dry inside a tissue culture flow cabinet (>30 min) and rinse with sterile PBS.
11. Fixative: 2.5% (v/v) glutaraldehyde in PBS; prepare fresh before use. 12. Tartrate-resistant acid phosphatase (TRAP) staining: Leukocyte acid phosphatase kit (Sigma Kit 387-A). 13. Cell removal solution: 0.25 M ammonium hydroxide. 14. Resorption pit staining solution: 1% (w/v) toluidine blue in 1% (w/v) sodium borate solution. 15. Microscopes: A transmitted light microscope is used to count TRAP-positive osteoclasts and total number of cells. Number and/or area of resorption pits are determined using brightfield reflected light microscopy (13, 14). We use a Nikon Labophot 2A microscope, with 100 W epi-illumination and metallurgical objectives. 16. Tissue culture plastics: Large petri dishes (100 mm), 5 ml flatbottomed tubes, 15 and 50 ml centrifuge tubes, 75 cm2 tissue culture flasks and six-well tissue culture plates. Tissue culture plastics can be obtained from a number of different suppliers (e.g. BD Falcon, Nunc, Corning); we have found that the choice of supplier does not affect the formation of osteoclasts. 17. Dissection tools: Scalpels and blades (no. 20), tweezers, and scissors.
3. Methods To keep the cell cultures free from infection, normal sterile techniques be used (working in a flow cabinet, use of sterile media and instruments). 3.1. Mouse Osteoclast Formation Assay
1. Day 1: Kill two 6–8-week-old mice by cervical dislocation and sterilise with 70% ethanol. Place each cadaver in a large petri dish. 2. Remove the limbs by cutting with sharp scissors at the point closest to the body, preserving as much of the limb as possible. 3. Using a scalpel cut off the paws and cut the limb in half at the joint. 4. Remove the skin and scrape away the soft tissue from the limbs. 5. Cut off the epiphyses and flush the marrow out with PBS using a 25-gauge needle. 6. Collect the marrow in a 50-ml centrifuge tube and pellet the cells by spinning at 300 × g for 5 min at room temperature.
8
Rodent Osteoclast Cultures
107
7. Discard the supernatant and resuspend the cells in 2 ml of S1MEM. Put 14 ml of S1MEM into two 75 cm2 flasks; add 1 ml of cell suspension to each. 8. Incubate cells for 24 h at 37°C in a humidified 5% CO2 atmosphere to allow attachment of stromal cells. 9. Day 2: Place sterile dentine discs into the wells of a 96-well plate, numbered side facing down. Collect the non-adherent cells from each 75 cm2 flask; centrifuge at 300 × g for 5 min at room temperature. 10. Discard the supernatant and resuspend the cells at 5 × 106 cells/ml in S2MEM. 11. Add 200 μl of cell suspension (106 cells/disc) to the dentine slices and incubate overnight at 37°C in a humidified 5% CO2 atmosphere to allow attachment of the osteoclast precursors to discs (see Note 5). 12. Day 3: Transfer the dentine discs to six-well trays (4–5 discs/ well in 3 ml of S2MEM); add test substances as required. 13. Half the medium should be exchanged every 2–3 days. The pH should be monitored at every medium change (see Note 6) and maintained at ~pH 7.3 by the addition of 6 M NaOH (see Note 3). 14. Day 7: Acidify the culture to pH 7.0 by full medium change with S2MEM acidified by the addition of 11.5 M HCl (see Notes 3 and 7). This will “switch on” resorption pit formation. 15. Terminate the cultures 48 h after medium acidification (see Subheading 3.3 below). 3.2. Isolation of Mature Osteoclasts from Neonatal Rat Long Bones
1. Prior to commencing isolation of the cells, place sterile dentine discs into the wells of a 96-well plate, numbered side facing down, and add 50 μl culture medium to each well (MEM acidified to pH 7.0). Incubate for 30 min at 37°C. 2. Prepare 5 ml MEM (acidified to pH 7.0) containing test and control substances for each group and add to individual wells of a six-well plate. Place in a 37°C incubator containing a humidified 5% CO2 atmosphere at 5% CO2 for at least 30 min. 3. Sacrifice neonatal (2–4 days) rat pups by cervical dislocation or decapitation. Cut the limbs off and dissect the long bones dissected free of muscle, connective tissue, and cartilage. 4. Transfer the bones to a 35-mm diameter petri dish containing 3 ml of MEM. Chop the bones finely but rapidly with a scalpel blade, using fine forceps to hold the bones steady. 5. Create a suspension by aspirating the minced bones 10–20 times through a wide mouth polyethylene 3-ml transfer pipette with the tip cut back such that the opening is about 5 mm in diameter.
108
I.R. Orriss and T.R. Arnett
6. Transfer the suspension (including the remaining small bone pieces) to a 15 ml centrifuge tube and vortex for 20–30 s. 7. Allow the mixture to settle for a few seconds and – avoiding the bone fragments – transfer the supernatant to a fresh 15 ml tube, using a 1-ml polyethylene pipette. 8. Wash the dish and remaining bone fragments with 2 ml culture medium, and vortex briefly. Aspirate the supernatant and combine with the cell suspension from step 7. 9. Quickly add 100 μl cell suspension to each well of the 96-well plate and allow to settle for 45 min at 37°C/5% CO2 (see Note 8). 10. Carefully remove the discs (containing adherent cells) from the 96-well plates using fine forceps or a 19-gauge needle and rinse by dipping in two changes of sterile PBS. 11. Transfer to pre-equilibrated MEM containing test substances or vehicle in a six-well plate (5–6 replicate discs in 5 ml/well). 12. Incubate for 24–28 h in a humidified atmosphere of 5% CO2/95% air at 37°C. 13. At the end of the experiment, measure the medium pH and pCO2 using a clinical blood gas analyser, with careful precautions to prevent CO2 loss (see Note 6). 3.3. Fixation and Staining
1. On termination of the experiment, wash the dentine discs twice with PBS. 2. Transfer to 2.5% glutaraldehyde for 5 min; wash twice more with PBS. 3. Perform light TRAP staining by following the directions in the kit. Count osteoclasts/osteoclast nuclei, as required (see Note 9).
3.4. Quantification of Resorption
1. Resorption pits are normally easy to see by reflected light microscopy (following TRAP staining), without the removal of cells. It is recommended that cells are not removed because discs can then be stored indefinitely (at room temperature) to provide a permanent record. Further analysis (e.g., of numbers of nuclei per cell) can be performed at a later date, as needed. We do not routinely stain nuclei; if the TRAP staining is kept light it is possible to clearly see the nuclei in the osteoclasts (see Note 9). 2. If it is necessary to remove cells from the discs, vigorous sonication for 5 min in 0.25 M ammonium hydroxide is reasonably effective (see Note 10). Discs may then need additional staining for 2 min in toluidine blue solution (followed by rinsing in water and air drying) to improve visualisation of pits (see Note 11). 3. Count the pits/measure pit surface area by scanning the entire surface of each disc using reflected light microscopy and a 10× objective (see Note 11).
8
Rodent Osteoclast Cultures
109
4. Express the results as number of pits/osteoclast or area resorbed/osteoclast and as pits/dentine disc or area resorbed/ dentine disc. It is usually preferable to normalise resorption to osteoclast numbers since the latter may vary within and between treatment groups (see Note 12). 3.5. Statistics
Depending on the data, we routinely use one-way analysis of variance (ANOVA) or non-parametric tests (Mann–Whitney) to analyse experiments. Although often neglected, adjustments for multiple comparisons between treatment groups (e.g., the Bonferroni correction) are frequently needed (see Note 13).
4. Notes 1. Batch testing of cytokines: For the murine osteoclast formation assay to work, good quality cytokines must be used. Failure to generate osteoclasts is usually caused by inactive M-CSF and/or RANKL. Both M-CSF and RANKL are commercially available from number of suppliers (such as Invitrogen, R&D systems, Peprotech); however, potency and quality are variable between both companies and batches. The concentrations provided here are optimised for our culture system, using M-CSF and the highly potent E. coli-expressed mouse RANKL from R&D Systems. The E. coli-expressed mouse RANKL from R&D Systems has the highest potency of any RANKL we have tested in both mouse and human osteoclastogenesis systems. When establishing this assay, we recommend that dose–response curves are generated to determine the optimal cytokine concentrations to use. This process should be repeated whenever cytokines are obtained from a new supplier or the batch received changes. 2. Hypoxia: Osteoclast formation is strongly increased in reduced oxygen (15), although permissive concentrations of RANKL and M-CSF are still required. If larger numbers of osteoclasts are required (e.g. for biochemical analyses), cultures may be incubated in an atmosphere of 2–5% O2/5% CO2/balance N2. This approach may also help to reduce cytokine costs. 3. Importance of pH: Extracellular pH is a critical factor in all osteoclast formation and bone resorption experiments. Rat osteoclasts are maximally activated to form resorption pits at pH ~6.9 and resorption is essentially “switched off” above pH ~7.2 (Fig. 1) (3, 14). Similar responses to extracellular acidification have been observed in all bone resorption systems examined to date, using cells or tissues derived from murine, avian, or human sources (Fig. 1) (16, 17). The action of many bone resorbing agents including RANKL (Fig. 2a) (18), parathyroid hormone (Fig. 2b) (3), 1,25-(OH)2-vitamin D3 (19),
110
I.R. Orriss and T.R. Arnett
Fig. 1. Acid activation of osteoclasts cultured on dentine. Culture medium was adjusted by the addition of HCl or NaOH. Rat osteoclasts, isolated directly from the bone of neonates, are essentially “switched off” above pH 7.2; osteoclasts formed from mouse marrow behave similarly (data not shown). Osteoclasts from embryonic chick bones retain some resorptive activity at pH 7.4. Human osteoclasts, formed from human peripheral blood mononuclear cells, were cultured for 14 days at pH 7.4 with M-CSF and RANKL and then maintained for a further 48 h at the indicated pH; these cells also retain some resorptive activity at pH 7.4. Maximal acid-stimulation for all osteoclasts occurs at pH ~6.9. Values are means ± SEM (n = 5).
Fig. 2. Two-step stimulation of osteoclast resorption by low pH in combination with RANKL or PTH. (a) Mature osteoclasts, isolated directly from neonatal rat bones, cultured for 26 h. At “physiological” pH (~7.4), basal resorption was very low and RANKL exerts only a small stimulatory effect. Combined treatment with RANKL and low pH results in large, synergistic increases in resorption (courtesy of N Zanellato, UCL). Significantly different from control in the same pH group: **p < 0.01, ***p < 0.001. Significantly different from the same RANKL concentration at pH 7.4: ##p < 0.01. (b) Osteoclasts formed from human peripheral blood mononuclear cells, cultured for 14 days at pH 7.4 with MCSF and RANKL. Cells were cultured for a further 48 h in the presence or absence of PTH in medium maintained at pH ~7.4 or acidified to pH ~6.9. PTH increases resorption at both pH 7.4 and 6.9, with an additive stumulatory effect evident at the lower pH. Note that human osteoclasts are not completely “switched off” at pH 7.4 (see Fig. 1) (courtesy of A Brandao-Burch, UCL). Significantly different from control in the same pH group: *p < 0.05, **p < 0.01. Values are means ± SEM (n = 5–6).
8
Rodent Osteoclast Cultures
111
and extracellular nucleotides such as adenosine 5¢-triphosphate (ATP) (19) and adenosine 5¢-diphosphate (ADP) (20) is enhanced by acidification. These results indicate that a low pH is an essential requirement for the activation process; once this activation has occurred, further stimulation by a wide range of bone resorbing agents can take place. Most tissue culture media (including MEM) are buffered to pH ~7.20 when fully equilibrated with 5% CO2; this value corresponds to normal interstitial pH and is considerably more acidic than blood pH (7.35–7.40). The metabolic activity of cells cultured in the medium will act to lower the pH further. When cell numbers are high relative to the volume of medium (e.g., when dentine discs are cultured in 96 well plates), this effect can be sufficient to acidify the medium quite rapidly, with resultant activation of resorption pit formation. To activate resorption in a more controlled manner, relatively large volumes (³0.5 ml/dentine disc/24 h) of pre-acidified culture medium should be used. MEM may be acidified by the direct addition of small amounts of concentrated hydrochloric acid, which has the advantage of being self-sterilising (12, 14). This also has the effect of reducing HCO3− concentration (i.e., “metabolic acidosis”) and producing an operating pH close to 6.95 in a 5% CO2 environment (see Fig. 3), which is optimal for resorption pit formation (14). Further acidification in CO2/HCO3−-buffered media does not enhance resorption greatly and may ultimately
Fig. 3. Relationship between pH, pCO2, and HCO3− in tissue culture medium. Data obtained using a blood gas analyser.
112
I.R. Orriss and T.R. Arnett
reduce cell survival. Addition of HCl does also have the effect of increasing medium chloride concentration slightly, but this does not appear to affect bone cell function. For the murine osteoclast formation assay (see Subheading 3.1), the best results are obtained when S2MEM is alkalinised to pH ~7.3 by the addition of ~7.5 mEq/L NaOH for the first 6–7 days; this enables osteoclast formation to occur with little or no resorption pit formation. For the last 2 days of culture, the medium is replaced with S2MEM, acidified to pH ~6.95, to activate resorption. Note, that if the S2MEM is maintained at pH 7.4 during the formation phase of the assay, the osteoclasts which form are very large (>30 nuclei) and sometimes vacuolated (Fig. 4). In contrast, if the culture medium is acidified (e.g. to pH 7.0) during the formation phase, osteoclastogenesis is reduced; however, resorption will still be relatively high because osteoclasts are activated as soon as they are formed. 4. Sources of dentine: Dentine can be obtained in the form of confiscated elephant ivory or sperm whale teeth from customs or fisheries and wildlife agencies (e.g., in the UK or USA). Dentine is a convenient osteoclast substrate because it is uniform, easy to cut, and lacks features such as Haversian systems and osteocytes which make quantification of resorption difficult. If bone slices are being used, they should be prepared from defatted and washed cortical bone from bovine femora; the slices should be transversely cut to reduce the likelihood of confusing in vitro resorption with endogenous features. We find that cortical bone is usually too brittle to permit the fabrication of uniform discs using a hole punch. 5. Other substrates: Mouse marrow cultures grown on plastic will form very large, multinucleate cells with a flat, rounded morphology and less intense TRAP staining than multinucleate osteoclasts formed on dentine or bone (Fig. 4). These cells formed on plastic also tend to exhibit less motile activity than typical mature osteoclasts isolated directly from rodent bones. A number of thin layer synthetic substrates are also available. Commercial preparations consisting of hydroxyapatite sintered at high temperature onto silica discs are available; these have the advantage of being translucent (e.g. for electrophysiology or cell fluorescence work), but in our experience may impair osteoclast survival. Alternatively, mineralised collagen films can be prepared more cheaply using the method of Lees et al. (21). The synthetic mineralised films also suffer from the disadvantage of disintegration and fragility in media acidified to pH 7.1 or below. 6. Measuring pH: Accurate measurement of the operating pH of mammalian osteoclast cultures is necessary for meaningful comparison of results from different laboratories. For
8
Rodent Osteoclast Cultures
113
Fig. 4. Dynamics of osteoclast formation and activation: comparison of dentine and plastic substrates. Osteoclasts formed from mouse marrow mononuclear cells cultured on dentine with RANKL and M-CSF, stained to demonstrate tartrateresistant acid phosphatase and viewed by transmitted light microscopy. (a) Very large, inactive multinucleated cells form in cultures maintained at “physiological” pH (7.4). (b) Acidification for the final 2 days of culture causes dramatic activation of resorption pit formation but tends to prevent further multinucleation of osteoclasts. Note that TRAP staining and transmitted light microscopy visualise osteoclasts (and their mononuclear precursors) as well as resorption pits (tan areas). (c) Osteoclasts cultured on plastic form large, inactive, multinucleate TRAP-positive cells. Scale bars = 10 μm (images on left ) and 50 μm (images on right ).
HCO3−/CO2-buffered media, accurate pH measurements can only be achieved by the use of a properly standardised blood gas analyser. We use a Radiometer ABL 705 blood gas analyser (Radiometer, Crawley, UK). The blood gas analyser uses a multi-electrode system to measure pH, pCO2, and pO2 in a 200-μl injected sample (cycle time ~2 min). The first medium measurement, taken immediately after removing the culture
114
I.R. Orriss and T.R. Arnett
plates from the incubator, is assumed to provide a pCO2 value that is the same for all wells and that reflects the actual pCO2 during the 24-h incubation. (It is worth noting that opening the door of the incubator during experiments may cause perturbations in CO2 levels that affect measured pH and pCO2 values, and possibly osteoclast function.) Measured pCO2 typically drops for each subsequent reading from wells in a multiwell plate, causing pH values to rise accordingly. The pH readings for each well are then back-corrected to the pH value associated with the initially measured pCO2 value, using calibration curves previously measured for culture medium with different bicarbonate concentrations (Fig. 3). 7. Duration of cultures: The rate of osteoclastogenesis in murine cultures is dependent on the quality and potency of the M-CSF and RANKL used. Cytokines with a high biological activity will generate mature osteoclasts in 7 days or less (from the isolation of the bone marrow). To determine the optimum duration for these cultures, we initially recommend that discs are stopped and TRAP stained every other day (Fig. 5). It is important that these cultures are not maintained too long (12 days maximum); otherwise osteoclasts generated may start to die. Note that osteoclasts generated from human peripheral blood can normally survive for longer periods in culture (see Chapter 11, this volume). 8. Technique for plating out cell suspension: An automatic 2.5 ml multidispensing pipette (Gilson) is ideal for plating out the cell suspension. Delays at this stage can cause problems, because
Fig. 5. Time course of mouse osteoclast formation and activation on dentine. Primary osteoclasts were cultured on dentine discs for 9 days; tissue culture medium was acidified to ~pH 6.9 for the final 2 days to activate osteoclast resorption. These light microscopy images are representative of the cells present after 2, 5, 7, and 9 days of culture. At day 2, the cells present were all monocyte/macrophage precursors; by day 5 TRAP positive mononuclear cells were evident. At day 7, there were abundant mature but inactive osteoclasts present. Medium acidification resulted in widespread osteoclast resorption, as seen at day 9. Scale bar = 50 μm.
8
Rodent Osteoclast Cultures
115
the cells sediment rapidly from the suspension unless it is continuously agitated. Care should also be taken to ensure that dentine discs remain seated in the base of the wells and do not float up. To compensate for plating errors, the suspension should be dispensed sequentially across treatment groups, rather than dispensing to each treatment group in turn. 9. Identifying and counting osteoclasts: TRAP staining is a convenient and inexpensive method of visualising osteoclasts; however, it is not entirely specific because other cells of the haematopoetic lineage also express this enzyme (22). Furthermore, since mononuclear osteoclasts are observed in human cultures, osteoclasts are best defined as TRAP-positive cells that have two or more nuclei and/or excavate pits. Osteoclast number should be assessed “blind” to the treatment group using transmitted light microscopy and a 10× objective. During TRAP staining, the dentine discs should be carefully monitored to avoid permanent overstaining (which will obscure detail within the cells such as nuclei) (Figs. 4 and 5). The time needed for optimal, light staining may vary between 25 and 60 min. 10. Removal of cells: Sonication can remove the graphite pencil markings. In view of this, discs should be sonicated in a known sequence, so that identification numbers can be rewritten if necessary. 11. Visualising and quantifying resorption pits: Whilst reflected light microscopy often yields adequate images of resorption pits on unstained specimens, image quality is improved greatly by staining (because this has the effect of increasing reflectivity). Depending on the microscope system used, optimal reflected light images are obtained using either brightfield or darkfield modes. To assess resorption area, we normally use a simple dot counting morphometry system: output from the reflected light microscope via a standard colour video camera is displayed on a monitor, superimposed on which is an acetate sheet bearing a grid of dots. The dot grid is easily created by using a graph paper template that has been photocopied to the required magnification. It is possible to measure the volume of resorption pits using scanning EM or confocal microscopy (23), but this requires specialised and expensive equipment. Pit volume can also be estimated by measuring pit depth, and area, using reflected light microscopy (the fine focus control is usually calibrated in microns) and assuming that pits approximate to hemispheres; this method is not suited to determining the volume of individual pits to very high accuracy, but provides useful comparative data when multiple pits are measured. When very high levels of resorption occur (e.g. >25% of surface area), it may be possible to use automated image analysis of pits viewed by
116
I.R. Orriss and T.R. Arnett
reflected light in a low-power dissecting microscope. For a method for automated quantification using low magnification reflected light microscopy see Chapter 12, this volume. 12. Assay variability: One of the most serious problems with the rat mature osteoclast assay (and to a lesser extent the murine osteoclast formation assay) is the high variability between experiments. First, osteoclast number in some culture preparations can be low, even if the procedure is followed accurately. Secondly, the basal level of resorption can vary from experiment to experiment, perhaps reflecting alterations in ambient concentrations of bone resorbing agents such as growth factors and nucleotides. Thus, culture conditions should be kept as identical as possible (i.e. freshness and pH of the medium; cytokine and serum batches; CO2 concentration of the incubator; origin, washing and sterilising of the discs). 13. Statistics: Because of interassay variability statistical comparisons should only be performed within one assay, and not between different assays. Variability within assays is likely to be high when cell numbers are low. The inherent “noise” in osteoclast resorption assays means that they are best suited for studying large, robust effects.
Acknowledgments The authors gratefully acknowledge the support of Arthritis Research UK and the European Union (Framework 7 Programme). References 1. Boyde, A., Ali, N. N., and Jones, S. J. (1984) Resorption of dentine by isolated osteoclasts in vitro. Br. Dent. J. 156, 216–220. 2. Chambers, T. J., Revell, P. A., Fuller, K., and Athanasou, N. A. (1984) Resorption of bone by isolated rabbit osteoclasts. J. Cell Sci. 66, 383–399. 3. Arnett, T. R., and Dempster, D. W. (1986) Effect of pH on bone resorption by rat osteoclasts in vitro. Endocrinology 119, 119–124. 4. McSheehy, P. M., and Chambers, T. J. (1986) Osteoblast-like cells in the presence of parathyroid hormone release soluble factor that stimulates osteoclastic bone resorption. Endocrinology 119, 1654–1659. 5. Arnett, T. R., and Dempster, D. W. (1987) A comparative study of disaggregated chick and rat osteoclasts in vitro: effects of calcitonin and prostaglandins. Endocrinology 120, 602–608.
6. Takahashi, N., Yamana, H., Yoshiki, S., Roodman, G. D., Mundy, G. R., Jones, S. J., Boyde, A., and Suda, T. (1988) Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 122, 1373–1382. 7. Suda, T., Takahashi, N., and Martin, T. J. (1992) Modulation of osteoclast differentiation. Endocr. Rev. 13, 66–80. 8. Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J., and Suda, T. (1988) Osteoblastic cells are involved in osteoclast formation. Endocrinology 123, 2600–2602. 9. Yoshida, H., Hayashi, S., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., and Nishikawa, S. (1990) The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345, 442–444.
8 10. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J., and Boyle, W. J. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165–176. 11. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N., and Suda, T. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesisinhibitory factor and is identical to TRANCE/ RANKL. Proc. Natl. Acad. Sci. USA 95, 3597–3602. 12. Goldhaber, P. and Rabadjija, L. (1987) H+ stimulation of cell-mediated bone resorption in tissue culture. Am. J. Physiol 253, E90–E98. 13. Walsh, C. A., Beresford, J. N., Birch, M. A., Boothroyd, B., and Gallagher, J. A. (1991) Application of reflected light microscopy to identify and quantitate resorption by isolated osteoclasts. J. Bone Miner. Res. 6, 661–671. 14. Arnett, T. R., and Spowage, M. (1996) Modulation of the resorptive activity of rat osteoclasts by small changes in extracellular pH near the physiological range. Bone 18, 277–279. 15. Arnett, T. R., Gibbons, D. C., Utting, J. C., Orriss, I. R., Hoebertz, A., Rosendaal, M., and Meghji, S. (2003) Hypoxia is a major stimulator of osteoclast formation and bone resorption. J. Cell Physiol. 196, 2–8.
Rodent Osteoclast Cultures
117
16. Meghji, S., Morrison, M. S., Henderson, B., and Arnett, T. R. (2001) pH dependence of bone resorption: mouse calvarial osteoclasts are activated by acidosis. Am. J. Physiol. Endocrinol. Metab. 280, E112–E119. 17. Morrison, M. S. and Arnett, T. R. (1997) Effect of extracellular pH on resorption pit formation by chick osteoclasts. J. Bone Miner. Res. 12, S290–S290. 18. Bushinsky, D. A. (1987) Net calcium influx from live bone during chronic metabolic, but not respiratory, acidosis. Am. J. Physiol. 256, F836–F842. 19. Morrison, M. S., Turin, L., King, B. F., Burnstock, G., and Arnett, T. R. (1998) ATP is a potent stimulator of the activation and formation of rodent osteoclasts. J. Physiol. 511 (Pt 2), 495–500. 20. Hoebertz, A., Meghji, S., Burnstock, G., and Arnett, T. R. (2001) Extracellular ADP is a powerful osteolytic agent: evidence for signaling through the P2Y1 receptor on bone cells. FASEB J. 15, 1139–1148. 21. Lees, R. L., Sabharwal, V. K., and Heersche, J. N. (2001) Resorptive state and cell size influence intracellular pH regulation in rabbit osteoclasts cultured on collagen-hydroxyapatite films. Bone 28, 187–194. 22. Walsh, N. C., Cahill, M., Carninci, P., Kawai, J., Okazaki, Y., Hayashizaki, Y., Hume, D. A., and Cassady, A. I. (2003) Multiple tissue-specific promoters control expression of the murine tartrate-resistant acid phosphatase gene. Gene 307, 111–123. 23. Boyde, A., and Jones, S. J. (1991) Pitfalls in pit measurement. Calcif. Tissue Int. 49, 65–70.
sdfsdf
Chapter 9 Isolation and Culture of Primary Chicken Osteoclasts Patricia Collin-Osdoby and Philip Osdoby Abstract Osteoclasts originate from hematopoietic myeloid progenitors that differentiate into specialized multinucleated cells uniquely capable of resorbing bone in both physiological and pathological conditions. Osteoclast numbers and degradative activities increase in various inflammatory disorders of bone and certain bone oncologies, thereby causing bone loss that may weaken the skeleton, increase fracture incidence, and disturb marrow function. Many valuable insights have been obtained through the use of osteoclasts directly isolated from the bones of chickens fed a low calcium diet to enhance osteoclastogenesis and bone resorption. Particular advantages of this system include the abundance and highly resorptive nature of isolated chicken osteoclasts compared with those directly obtained from other species. After enzymatic release from the harvested bones, osteoclasts may be partially purified by density gradient sedimentation, bone substrate attachment, and/or immunomagnetic capture. Thereafter, osteoclast preparations may be analyzed, either directly or following some period of culture, to investigate their properties (biochemical, immunological, molecular, cell biological), resorptive function, and modulatory responses to various stimuli. Here, we present common procedures for the isolation, culture, and general study of chicken osteoclasts. Key words: Osteoclast isolation, Osteoclast culture, Osteoclast antigens, Bone resorption, Chicken, Avian
1. Introduction Bone is a dynamic tissue that is continually remodeled by the coordinated actions of bone-resorbing osteoclasts (OCs) and bone-forming osteoblasts. Whereas osteoblasts originate from mesenchymal cell precursors, OCs derive from hematopoietic precursors of the myeloid lineage present in the bone marrow and circulation. In response to specific hormonal or local signals, particularly the essential OC differentiation signal receptor activator of NF-κB ligand (RANKL), provided by osteoblasts, stromal cells,
Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_9, © Springer Science+Business Media, LLC 2012
119
120
P. Collin-Osdoby and P. Osdoby
or other cells within the bone marrow, OC precursors fuse and differentiate into large multinucleated cells expressing characteristic morphological features, membrane polarization, adhesion molecules, ion pumps, enzyme activities, and antigenic profiles (1–3). Most importantly, they develop a capacity for bone pit resorption, the unique and defining functional attribute of OCs. Bone resorption and formation are normally carefully balanced processes in adults. However, in various pathologies, an imbalance arises such that the number of OCs, number of resorption sites initiated, and/ or rates of remodeling are altered, thereby resulting in either too much or too little bone turnover. Excessive bone loss occurs in many disorders including postmenopausal osteoporosis, rheumatoid arthritis, periodontal disease, tumor-associated osteolysis, and orthopedic implant loosening (4–7). It is therefore important to decipher the complex signals that control OC bone resorption to further our understanding and provide a rational basis for the design of novel therapeutic or preventative strategies to combat bone loss. In this regard, isolated primary cultures of in vivo formed OCs have proven to be an invaluable tool for investigating the characteristics, function, and regulation of OCs. Many valuable insights have been achieved through the use of avian OCs, cells that are highly active in their resorption of bone and are isolated in abundance from young chickens fed a low calcium diet (8). Following their enzymatic release from harvested bones, OCs can be partially purified by density gradient (Percoll) sedimentation owing to their large size, and further enriched by brief settling onto bone discs or rapid capture with magnetic beads pre-coupled with antibody that specifically recognizes OCs (9). OCs isolated via these procedures can be cultured and analyzed for biochemical, immunological, physiological, and functional properties, as well as modulator responses. Procedures for some of the most commonly used assays are presented.
2. Materials 2.1. Tissue Culture Medium, Solutions, and Supplies
All media and solutions should be prepared with glass distilled water and be sterilized. 1. Culture medium: Sterile α-minimum essential medium (α-MEM) supplemented with 5% fetal bovine serum (FBS, InvitrogenGibco) and 2.5% antibiotic/antimycotic (a/a, InvitrogenGibco); store at 4°C and prewarm to 37°C before use. 2. Hanks’ balanced salt solution, pH 7.2 (HBSS). 3. Moscona’s low bicarbonate (MLB): Add 8 g NaCl, 0.2 g KCl, 50 mg NaH2PO4, 0.2 g NaHCO3, 2 g dextrose, 10 ml a/a, 990 ml water, check pH is 7.2, and sterile-filter.
9
Isolation and Culture of Primary Chicken Osteoclasts
121
4. Moscona’s low bicarbonate–EDTA (MLBE): Dissolve 1 g EDTA in 15 ml 1% KOH, add to 1 l of MLB, check pH is 7.2, and sterile-filter. 5. Phosphate-buffered saline, pH 7.2 (PBS). 6. Collagenase: Prepare 0.5 mg/ml stock solution in HBSS, store aliquots at −20°C, and dilute two parts of thawed stock solution with one part of MLB for use. 7. Trypsin: 1% Stock (1 g/100 ml) solution in MLB, store aliquots at –20°C, and dilute 11.25 ml of stock with 37.5 ml MLBE and 201.5 ml MLB for use. 8. Percoll for 35% Percoll, mix 65 ml of HBSS with 35 ml of Percoll (GE Healthcare Life Sciences); for 6% Percoll, mix 83 ml of the HBSS solution with 17 ml of 35% Percoll/HBSS. Adjust the pH of both solutions to 7.2, sterile-filter, and store at 4°C. 9. Heparin: 1,000 U/ml, GE Healthcare Life Sciences, store at 4°C. 10. Trypan blue: 0.4 g trypan blue dye in 100 ml water. 11. 1% Paraformaldehyde in HBSS (PF-HBSS): Preheat 100 ml HBSS on a hot plate to 60°C in a Pyrex beaker (monitor with a thermometer), move the beaker to a stir plate, add 1 g of PF, cover with foil to contain the vapors (keep the thermometer in place and briefly move the beaker back to the hot plate if the temperature falls below 50°C), slowly stir with a magnetic bar, and add 3–4 drops of 10 N NaOH just to dissolve. Let cool, filter through Whatman #1 paper into a brown glass bottle, and store at 4°C. 12. Protease inhibitor cocktail for cell pellet storage: Prepare an inhibitor stock solution A by dissolving 10 mg each of leupeptin, chymostatin, antipain, and pepstatin A in 1 ml of dimethyl sulfoxide, add 400 trypsin inhibitory units of aprotinin, and store this 1,000× cocktail in 0.1 ml aliquots at −20°C. Mix 10 μl of inhibitor stock solution A with 10 μl of a 1% stock solution of phenylmethylsulfonyl fluoride (PMSF) in ethanol (store at room temperature), 1.25 mg N-ethylmaleimide (NEM), 1.56 mg benzamidine, and 10 ml HBSS to yield inhibitor stock solution B. Store this at −80°C and overlay one drop (~50 μl) on top of each cell pellet to be stored frozen. 13. 350- and 110-μm Nitex filters: Sheets of Nitex (Tetko, Kansas City, MO) mesh are cut into squares larger (~50%) than the opening of a stackable plastic beaker, a filter square is stretched over the beaker, and the filter is tightly secured in place by fitting on a ring (~1-in. deep) made from a second plastic stackable beaker whose lower three-quarter portion has been cut off; filter squares can be washed well and reused.
122
P. Collin-Osdoby and P. Osdoby
2.2. Preparation of Antibody-Conjugated Magnetic Beads
1. Magnetic polystyrene beads: 0.45 μm diameter, covalently conjugated with affinity purified sheep anti-mouse IgG (Invitrogen-Dynal Inc., store at 4°C). 2. Mouse Mab to OC-specific antigen: See Note 1. 3. Rotary mixer: To fit microcentrifuge tubes. 4. Magnet: Invitrogen-Dynal Inc. or other 20-lb pull magnet.
2.3. Fixation and TRAP Staining
Although not fully specific for OC, high tartrate resistant acid phosphatase (TRAP) activity plays a role in bone resorption, and it is upregulated and a convenient measure of OC development (10). 1. 1% Paraformaldehyde in HBSS: See Subheading 2.1, item 11. 2. TRAP staining: Prepare the following stock solutions and mix just before use (or purchase a staining kit from Sigma (cat. no. 386) and follow the manufacturer’s instructions, see Note 2). Solution A: Naphthol AS-BI phosphoric acid (12.5 mg/ml) in dimethyl formamide (store at −20°C). Solution B: 2.5 M acetate buffer, pH 5.2, store at 4°C. Solution C: 0.67 M tartrate solution, pH 5.2, store at 4°C. (a) Mix 0.4 ml of solution A, 0.4 ml of solution B, 0.4 ml of solution C, and 8.8 ml of deionized water (preheated to 37°C) in a 50 ml polypropylene tube, vortex well, and wrap the tube in foil. (b) Add 3 mg Fast Garnet GBC salt, vortex quickly to mix well, and filter the solution through Whatman #1 paper into a new foil-wrapped 50 ml polypropylene tube. Use immediately. 3. General stain: Use Diff-Quik (eosin Y, azure A, and methylene blue, Fisher Scientific) as recommended by the manufacturer.
2.4. Fixation and Immunostaining
For immunostaining, prepare the following solutions: 1. Blocking solution: 1% Bovine serum albumin (BSA) and 10% horse serum in PBS. 2. Monoclonal (MAb) or polyclonal (PAb) antibodies: Directed against OC antigens and appropriately diluted (typically 1:100 to 1:500 of 1 mg/ml stocks) in blocking solution just prior to use. 3. Biotinylated secondary antibodies: Directed against the primary antibody and appropriately diluted (typically 1:200 to 1:500) in blocking solution just prior to use (see Note 3). 4. Glycerol-buffered mounting medium: For example, EM Sciences, 80% glycerol in PBS, store at 4°C.
9
Isolation and Culture of Primary Chicken Osteoclasts
123
For fluorescence immunostaining: 5. Streptavidin conjugated with a fluorescent label [fluorescein isothiocyanate (FITC), Texas Red, or similar]: Appropriately diluted (typically 1:1,000 or more) in PBS (without serum) just prior to use. 6. 4¢,6-Diamidino-2-phenylindole (DAPI): (Molecular Probes), prepare 100 μg/ml of stock solution in water, store dark at 4°C, and dilute stock 1:300 in HBSS for use in fluorescent nuclear staining. For colorimetric immunostaining: 7. Streptavidin conjugated with β-galactosidase: Appropriately diluted (typically 1:100) in buffer A (see item 6). 8. Buffer A: 0.1 M Sodium phosphate, pH 7.2, containing 1.5 mM magnesium chloride, 2 mM β-mercaptoethanol and 0.05% sodium azide; store at 4°C and warm to room temperature before use. 9. Buffer B: 10 mM Sodium phosphate, pH 7.2, containing 150 mM sodium chloride, 3 mM potassium ferricyanide, 3 mM potassium ferrocyanide, and 1 mM magnesium chloride; store at 4°C and warm to room temperature before use. 10. Substrate solution (0.42 mg/ml X-gal in buffer B): Prepare a stock solution of X-gal (21 mg/ml) in dimethyl formamide, store at −20°C (e.g., in a Parafilm sealed, foil wrapped glass tube), and dilute this stock solution 1:50 in buffer B to prepare fresh substrate solution. 2.5. Preparation of Devitalized Bone or Ivory Discs for Bone Pit Resorption Studies
1. Ivory is obtained through donation from a local zoo or the Federal Department of Fish and Wildlife Services (in the USA; or a similar source in another country). Bovine cortical bone is obtained from a local slaughterhouse. Segments of ivory and bovine cortical bone are thoroughly cleaned and washed (multiple HBSS and 70% ethanol rinses), sliced into small chunks, and then reduced to rectangular 0.4-mm thick sheets using a low speed Isomet saw (Buehler, Lake Bluff, IL). 2. The sheets are rinsed three times with 70% ethanol, incubated in 70% ethanol overnight, and then washed for several hours in HBSS before circular discs are cut out using a 5-mm paper punch. 3. Punched discs are soaked repeatedly in 70% ethanol in sterile 50-ml tubes (alcohol changes can be gently poured off because the discs tend to stick to the side of the tube), and stored in 70% ethanol at −20°C. 4. For experimental use, remove the required number of discs from the tube using alcohol presoaked tweezers in a sterile hood, transfer the discs to a new sterile 50-ml polypropylene tube, rinse extensively by inversion and mild shaking at least three
124
P. Collin-Osdoby and P. Osdoby
times with ~40 ml of sterile HBSS per wash, and transfer the discs using sterile tweezers into culture wells or dishes containing sterile HBSS for 3–24 h of pre-incubation in a tissue culture incubator prior to the plating of cells. Remove HBSS only immediately before seeding OC to prevent the discs from drying. 2.6. Preparation of Gold-Coated Glass Coverslips for Phagokinetic Motility Studies (see Note 4)
This procedure is a modification of the gold coverslip motility assay reported by Owens and Chambers (11). Glass coverslips are precoated with a thin layer of gelatin to enhance attachment and homogeneous coverage of the gold coating. All steps are performed in a sterile hood, using sterile reagents and supplies, and more coverslips (10–50%, depending on the skill you develop for this procedure) should be coated than you expect to need in the experiment. 1. Warm a solution of 2% gelatin in deionized water (stored at room temperature) to 37°C in a water bath and two 24-well tissue culture dishes in an incubator. 2. Assemble glass coverslips, sterile tweezers, and one or two 100-mm Petri dishes with fitted Whatman filter paper in a sterile hood. 3. Fill one well of a prewarmed 24-well dish with warm 2% gelatin solution, dip one coverslip at a time into the well using sterile tweezers, briefly drain against the side of the well, and place it gelatin side up on the filter paper in the open 100-mm dish to dry in the hood for at least 2 h. 4. Using tweezers, move each coverslip into one well of a sterile 24-well dish in the hood. 5. Prepare the gold coating solution (19.0 ml) in the hood by adding 11.0 ml of sterile deionized water, 4.44 ml of 0.2% gold chloride (in sterile water), and 3.36 ml of sterile 65.2 nM sodium carbonate into a 100-ml Pyrex beaker (foil covered and presterilized). Heat the solution on a hot plate (this can be performed outside the hood after the foil cover is replaced) just to boiling. 6. Place the covered hot beaker back into the sterile hood, add 1.8 ml of sterile 0.1% paraformaldehyde in water, and allow the gold solution to cool to 60°C. Monitor the temperature (this is critically important to achieve good gold coating) with an alcohol prewiped thermometer. 7. When the solution has cooled to 60°C, pipette 1 ml of the gold solution on top of each gelatin precoated coverslip and refrigerate the 24-well dish for 1 h. 8. Remove the excess solution, gently rinse the coverslips twice with HBSS, and place each coverslip onto filter paper in a 100-mm dish in the sterile hood to dry (several hours to overnight).
9
Isolation and Culture of Primary Chicken Osteoclasts
125
9. Repeat items 5–8 to ensure adequate and even coverage of the gold particles on the coverslips. 10. After the second gold coating, store the coverslips on filter paper in a 100-mm dish in the hood for up to a few days prior to their use. Check one or two coverslips by placing into a 24-well dish with HBSS for at least 1 h to verify that the gold coating does not lift up, is sufficiently dark, and evenly coats the coverslip when viewed under the microscope (otherwise tracks produced by OCs will be hard to evaluate). If the coating lifts up, check a few other coverslips from that batch and discard all if they fail this test. If the gold coating is too sparse, repeat items 5–8 for a third time. 11. Before use, preincubate all coverslips for at least 1 h in HBSS early on the day of cell plating and plan to use only those that exhibit a firm, even, and dark gold coating.
3. Methods 3.1. Isolation of Osteoclasts from Calcium-Deficient Chicks (see Note 5)
After hatching, White Leghorn chicks are fed a normal diet for 4–6 days and then switched to a low calcium diet (0.15–0.25% calcium, analyzed before the feed is shipped from Purina) for at least 28 days (8). Typically, 15 chicks are used for each OC preparation and three people assist in the dissection and initial steps to minimize the time until the cells are isolated and plated (even 1 additional hour can affect the ultimate OC yield and viability, see Note 6). Animals are handled and euthanized in accordance with rules and procedures for the Institutional Animal Care and Use Committee and standards approved by the National Institutes of Health Guidelines for the Care and Use of Experimental Animals (or similar authority for countries other than the USA). 1. Just prior to dissection, multiple forceps, tweezers, and scissors are placed into beakers with 70% alcohol, all buffers are prechilled on ice, and the pH of MLB is readjusted if needed. 2. Fill several ice containers, and place two 100-mm Petri dishes with HBSS on ice. 3. Several people wearing alcohol-rinsed gloves each remove a group of birds immediately following their euthanization (do not delay), alcohol squirt the wings and legs of one bird just prior to its dissection, rapidly remove the tibiae and humeri using the alcohol-soaked scissors and forceps, clean off extraneous soft tissue without removing the bone ends (which are replete with OCs), and place the bones into one of the two HBSS-filled Petri dishes on ice. Repeat for each bird.
126
P. Collin-Osdoby and P. Osdoby
4. When a number of bones have accumulated in the first HBSS dish on ice, this dish is given to one person to extract marrow from the bones in a sterile hood, while the other two people continue to dissect bones from the remaining birds and place them into the second HBSS dish on ice. 5. Marrow is removed from each bone by gripping it with alcohol-soaked tweezers over a 100-mm dish containing MHB, poking several small holes in each end of the bone using a 3-ml syringe with an 18-guage needle, and quickly flushing the marrow out by repeatedly inserting the tip of the syringe filled with MHB (from the dish) into one bone end and squirting fluid (not too hard) through the bone into the dish below. Hold the bone just above the dish, not in contact with the flushed marrow. 6. Carefully flip the bone held with tweezers over, and repeat step 5 to flush MHB several times through the other end of the bone. Place the flushed bone back into the original (non-marrow) dish of HBSS. Repeat for subsequent bones, each time flushing MHB through both ends of the bone before proceeding to the next bone. 7. After all of the marrow has been extruded, remove any bits of extra tissue carefully from the bones and then divide the bones into eight 50-ml tubes filled with 40 ml HBSS each. Shake gently by hand to wash the bones (~30 s). 8. Place the bones into two new dishes of HBSS on ice to split each bone lengthwise using sterile scissors while keeping the bones submersed in HBSS. 9. Transfer the split bones into eight 50-ml polypropylene tubes containing 40 ml of HBSS each, shake vigorously for 30 s, and pass the supernatants sequentially through 350- and 110-μm Nitex filters fitted over plastic beakers set on ice (be sure the filters are tightly fitted so that the cell suspensions do not leak into the bottom beaker unfiltered). 10. Refill each of the eight tubes containing bones with 40 ml MLB, shake, and filter the supernatants through the same 350and 110-μm filters into the beakers containing the first filtrates on ice. 11. Dispense the final filtered solutions into 50-ml centrifuge tubes on ice and centrifuge at 210 × g for 10 min at 4°C. This pellet represents a crude fraction containing the majority of the nonviable OC (which tend to be much larger in size on average than the surviving OC) and a minor proportion of viable OC. Because it provides a valuable source of OC material for enzyme-linked immunoassay (ELISA), SDS-PAGE, Western blotting, and other biochemical assays, it is routinely stored at −80°C as one or two cell pellets overlaid with a drop of protease inhibitor cocktail solution B.
9
Isolation and Culture of Primary Chicken Osteoclasts
127
12. To obtain the viable OC fraction for cell culture, incubate the bones in eight 50-ml tubes, each containing 35 ml of 0.333 mg/ml collagenase in HBSS-MLB, for 30 min at 37°C in a water bath. 13. Gently shake the tubes, discard this solution, add 35 ml of MLB per tube to rinse the bones for 15 min, and then transfer the bones with tweezers to eight tubes containing 35 ml of 0.045% trypsin in MLB-MLBE. Incubate for 30 min at 37°C in a water bath to detach viable OCs from the bone surfaces. 14. Shake the bones vigorously for 3 min, and pass the cell suspensions through a 350-μm Nitex filter into a plastic beaker on ice containing 1 ml of heparin (1,000 U, to reduce clotting) and 5 ml of FBS (to inhibit further trypsin action). 15. Immediately refill the tubes with 20 ml of MLB, shake the bones vigorously for another 3 min, and filter this cell suspension through the same 350-μm Nitex filter into the beaker on ice containing the first shaken suspension from step 14. Repeat once more. 16. Split and pour each half of the combined filtrates through separate 110-μm Nitex filters into beakers on ice (two filters are recommended because they clog easily). Dispense the filtrates into twelve 50-ml centrifuge tubes on ice. 17. Centrifuge the cell suspensions at 300 × g for 10 min at 4°C. Gently pour out the lipid pad and supernatant, and wipe out lipid and matrix material clinging to the side of the tube with a clean tissue before righting each tube. Resuspend each pellet, using a 10-ml wide-bore pipette, in 2–5 ml of chilled MLB (see Note 7). 18. Transfer the OC suspension to six new 50-ml tubes, add 0.1 ml heparin to each, fill the tubes to 50 ml with chilled MLB, and invert to mix. Centrifuge as in step 17 to wash the cells. 19. Discard the supernatants and resuspend the cell pellets (see Subheading 3.1.1). If OCs will be cultured, sterile techniques and solutions should be initiated at this point for Percoll fractionations. 3.1.1. Percoll Purification of Osteoclasts
Use sterile solutions and techniques throughout. 1. Resuspend each of the six OC pellets in 5 ml of ice-cold 35% Percoll, combine into one new tube, add 0.6 ml heparin, vortex briefly at low speed, and divide the cell suspension into four 50-ml tubes. 2. Raise the volume of each tube to 10 ml with additional 35% Percoll, and then slowly overlay each tube with 3.0 ml ice-cold HBSS (do not deform the interface).
128
P. Collin-Osdoby and P. Osdoby
3. Centrifuge the tubes in a swinging bucket rotor at 440 × g for 20 min at 4°C, and then carefully remove the tubes without disturbing the gradients. 4. Slowly withdraw the interface and top 5–8 ml with a pipette (see Note 7), transfer these solutions into four new 50-ml tubes on ice containing 25 ml HBSS, and add ice-cold HBSS up to 50 ml. Discard the residual pellets. 5. Centrifuge at 300 × g for 10 min at 4°C, retain the pellets, and discard the supernatants. 6. The 35% Percoll-fractionated OCs can be used at this point for immunomagnetic purification (see Subheading 3.1.2) or purified further by 6% Percoll fractionation as described in steps 7–12. 7. Set up four tubes containing 10 ml of 6% Percoll on ice. 8. Resuspend each of the four OC pellets from step 5 thoroughly in 3 ml ice-cold HBSS using a 10-ml pipette, combine, and briefly vortex (if clumping is a problem, add 0.12 ml of 1,000 U/ml heparin). 9. Slowly overlay 3–3.5 ml of this suspension on top of each of the four 6% Percoll gradient tubes, and let the tubes stand undisturbed on ice for 1 h to allow OCs to penetrate the Percoll layer. 10. Remove the top 4 ml from each tube and discard. Combine the bottom fractions pairwise and dilute with ice-cold HBSS to 50 ml each. Centrifuge the cell suspensions at 300 × g for 10 min at 4°C. 11. Resuspend each of the two OC pellets in 5 ml α-MEM medium, combine, mix gently, and microscopically evaluate by withdrawing 0.1 ml to mix with 0.1 ml of 0.4% trypan blue and immediately assess OC yield, viability (unstained cells) and purity in a hemocytometer. 12. Meanwhile, centrifuge the OC suspension again at 300 × g for 10 min at 4°C, and resuspend the OC pellet in prewarmed medium to disperse into sterile dishes or multiwell plates for culture. Typically, enrichments of at least 40% on a per cell basis (>80% on a per nucleus basis) are routinely achieved for OCs after 35% Percoll fractionation, and yields of 1–3 million OCs exhibiting >85% viability for OCs are obtained following 6% Percoll fractionation. Further enrichment of the 6% Percoll OC population can be readily accomplished by allowing these cells to settle and attach to bone or ivory in culture for 2.5–3 h, after which the unbound cells are removed and the adherent OCs are gently washed once or twice with fresh medium before further culture.
9 3.1.2. Immunomagnetic Purification of Osteoclasts (see Note 8)
Isolation and Culture of Primary Chicken Osteoclasts
129
OCs can be further enriched after 35 or 6% Percoll fractionation via immunomagnetic sorting (9). However, significantly higher OC yields are obtained if immunomagnetic capture is performed on 35%, rather than 6%, Percoll-separated populations. The last steps of bead preparation (steps 1–4 below) should be timed so that the beads are ready to add as soon as the OCs have been separated on the 35% Percoll gradients. Beads should be handled gently in all steps. 1. Just prior to use, magnetically sort the beads that have been coupled with an anti-OC MAb to remove the MAb coupling solution, wash the beads three times by gentle resuspension in PBS (~1 ml) and magnetic sorting, and incubate them for 30 min with 250 μl sterile 1% FBS in PBS to block nonspecific bead attachment to cells. 2. Wash the beads three times with PBS, and resuspend in 200 μl of PBS in preparation for addition to the 35% Percollfractionated OCs. 3. At this point, the four OC pellets from the 35% Percoll gradient (see Subheading 3.1.1, step 5) are resuspended in a 50-ml polypropylene tube in a total volume of 6 ml of ice-cold HBSS. 4. Add the MAb-coupled magnetic beads from step 2 (200 μl), swirl the tube gently to quickly mix cells and beads (see Note 9), place the tube into a bucket of ice at a ~45° angle (with the bead–cell mixture clearly visible from the top), and set the bucket on a rotary shaker to slowly mix the beads and cells for 30 min (see Note 9). 5. Remove from the shaker, stand the tube upright in the ice, and push a magnet down into the ice and tightly against the lower part of the tube. Let stand ~5 min to draw bead-bound OCs over to the magnet, and use a pipette to slowly remove the unbound (non-bead) cell supernatant for transfer to a new 50-ml tube on ice (this is resorted later to capture any lost beads bound with cells). 6. Move the tube away from the magnet, resuspend the beadbound cells in 40 ml ice-cold sterile HBSS to wash, invert several times to mix gently, and then place the tube back against the magnet in ice. Incubate undisturbed for 5 min to capture bead-bound OCs and transfer the wash using a pipette to another tube (to resort later for lost beads). 7. Repeat step 6 twice more to wash the bead-bound OCs a total of three times. 8. To recover any bead-bound OCs remaining in the original unbound cell supernatant (step 5) or lost during the wash steps (steps 6–7), incubate each of these tubes against the magnet for 5 min on ice, remove and discard the supernatants, and
130
P. Collin-Osdoby and P. Osdoby
resuspend additional bead-bound OCs in a small volume of HBSS and add back to the main sample of bead-bound OCs. 9. Resuspend the final collection of bead-bound cells in 2–5 ml HBSS, mix 0.1 ml with 0.1 ml of 0.4% trypan blue, and immediately assess the sample for OC yield, viability (unstained cells), and purity in a hemocytometer. 10. Sort the remaining 2–5 ml of immunocaptured OCs with a magnet and either resuspend the cells in medium for culture, immediately extract RNA, prepare protein lysates, or use the cells as needed. Typically, five- to tenfold greater OC purity is achieved with MAb 121F immunomagnetic affinity capture in comparison with 6% Percoll density gradient fractionation, with immunomagnetic OC enrichments of up to 90% on a per cell basis and over 98% on a per nuclear basis. 3.2. Osteoclast Culture 3.2.1. Percoll-Purified OCs
1. Resuspend 6% Percoll-purified OCs in 5 ml of culture medium and immediately plate out at: (a) 0.5 ml per well (~100,000 OCs) in 10 wells of a 24-well dish, with or without a glass coverslip in the bottom of the well and/or 2–4 sterile discs of bone or ivory per well (see Subheading 2.5). (b) 0.2 ml per well (~50,000 OCs) in 20 wells of a 48-well dish, with or without one sterile disc of bone or ivory (see Note 10). 2. To enrich further for OCs on bone or ivory, change the medium after 2–3 h to selectively capture OCs onto the bone or ivory substrate. Modulators can be added at this point in fresh medium. Otherwise, change the medium after 16 h of incubation, and add modulators in fresh medium. 3. Culture for the designated period of time, typically 1–2 days (see Note 11).
3.2.2. Immunomagnetically Purified OC (see Note 8)
Because the yield of OCs is lower following immunomagnetic purification than Percoll density gradient separation, highly purified immunomagnetic OC populations are most useful for confirming in a limited fashion that biochemical or functional properties observed with Percoll-fractionated OC can be directly attributed to OCs and not rare contaminating cells. 1. Culture immunomagnetically purified OCs on bone, ivory, glass, or plastic in the presence or absence of modulators for up to several days as described in Subheading 3.2.1 above. 2. Although the temperature is kept at or below 4°C during immunomagnetic capture to prevent OCs from phagocytosing the beads bound to their outer surface, these are internalized within min once the cells are exposed to a higher temperature (see Note 12).
9
3.3. Assay Techniques 3.3.1. Morphology and Ultrastructure
Isolation and Culture of Primary Chicken Osteoclasts
131
Standard protocols are used to evaluate the morphological and ultrastructural characteristics of isolated chick OCs. When viewed by light microscopy, chick OCs appear as large multinucleated cells of varying sizes and shapes, with a grainy cast and often one or more pseudopodial extensions per cell. Immunomagnetically isolated chick OCs are typically decorated with multiple beads per cell and may be so thoroughly coated with MAb-conjugated beads that they resemble a ball of beads (Fig. 1a). On culture of immunomagnetically captured OCs on bone, ivory, glass or plastic, the cells spread out and internalize the beads, rather than shedding them as do nonphagocytic cells.
Fig. 1. Chick OC immunomagnetic purification and bone pit resorption. (a) Chick OCs from 35% Percoll preparations were affinity captured and purified via their binding to MAb 121F-coupled magnetic beads. Phase-contrast microscopy reveals numerous beads avidly attached to and covering OC cell surfaces. (b) SEM appearance of 6% Percoll-purified chick OC preparations cultured on plastic. Scale bar = 50 μm. (c) SEM analysis of MAb 121F immunomagnetically isolated chick OC and an associated resorption pit formed during culture on bone. Scale bar = 10 μm.
132
P. Collin-Osdoby and P. Osdoby
OC morphology and ultrastructure can be analyzed using transmission (TEM) or scanning (SEM) electron microscopy as detailed in other chapters of this volume. Features characteristic of OC and evident by TEM include multiple nuclei often clustered within the cell and varying in number between cells, abundant mitochondria, numerous vesicles, extensive vacuolation, welldeveloped perinuclear Golgi complexes, prominent rough endoplasmic reticulum, free polysomes, and ruffled border membrane and clear zone domains. By SEM, chick OCs cultured on plastic typically appear as large cells having a complex morphology with many fine filopodial projections, microvilli and membrane blebs visible over the cell surface, and a peripheral cytoplasmic skirt (Fig. 1b). When cultured on bone or ivory, chick OCs appear by SEM either as large domed cells actively engaged in excavating a resorption cavity or as stretched inactive cells having a motile phenotype and characteristic leading and trailing membrane domains (Fig. 2f). OCs associated with resorption pits often exhibit membrane projections stretched back over a portion of the wellexcavated lacuna that has exposed collagen fibrils (Fig. 2f). Resorption pits formed by cultured chick OCs are typified by multilobulated excavations or long resorption tracks (which also may be multilobulated) or, less often, as a unilobular cavity adjacent to or underlying an OC actively involved in resorption (Fig. 2f). Immunomagnetically isolated OCs may exhibit less pit resorbing activity (Fig. 1c). The morphology of resorption pits can be examined more thoroughly by SEM following the removal of OCs from the bone or ivory substrate (either initially before a gold coating step or after viewing the sample and then recoating with gold to visualize the pits alone). 3.3.2. Cytochemical Staining
A quick and easy way to discriminate nuclear and cytoplasmic detail in cultured chick OCs is by use of the general differential stain Diff-Quik, which is simply incubated with the fixed chick OCs for several min and then rinsed off. However, by far the most commonly used stain to visualize OCs is based on their high level of TRAP activity which is upregulated early in OC development. Although not specific for OCs alone, this cytochemical stain readily identifies OCs in bone tissue sections and in isolated OC preparations (Fig. 3a, c). TRAP activity also can be quantified in cell extracts using a microplate enzymatic assay (and normalized for cell extract protein) (12). To stain for TRAP activity using freshly prepared solutions (see Subheading 2.3 and Note 2): 1. Remove the culture medium from the cells (and discard or save for other analyses). 2. Rinse the cells quickly three times with warm HBSS (tilt dish to add and remove solutions gently), add 1% PF-HBSS solution
9
Isolation and Culture of Primary Chicken Osteoclasts
133
Fig. 2. Chick OCs form resorption pits on ivory and phagokinetic tracks on gold-coated coverslips. (a–c) 6% Percoll-purified chick OCs were cultured on ivory (2–3 days) and harvested for TRAP staining and resorption pit analysis. As viewed by light microscopy, OCs formed multilobulated resorption tracks that frequently were composed of connecting resorption lacunae. These represent periods of OC attachment and pit formation, followed by OC movement to an adjacent area of ivory for further resorption. (d) Resorption pits viewed by darkfield reflective light microscopy, as performed for quantifying the number and areas of resorption pits within the exact same fields evaluated for OC numbers. (e) 6% Percoll-purified chick OCs cultured on gold-coated coverslips for 16 h and subsequently stained for TRAP activity. OCs phagocytose the gold particles and thereby clear a path during their movement across the gold-coated coverslip. The numbers and areas of such phagokinetic tracks are measured, and expressed relative to the numbers of associated OCs. (f) SEM analysis of 6% Percoll-purified chick OCs engaged in bone pit resorption on ivory. Note the deep, well-excavated lacunae that are typically formed by chick OCs. Scale bar = 50 μm.
134
P. Collin-Osdoby and P. Osdoby
(~300 μl per 48-well, 500 μl per 24-well-plate) to fix the cells for 15 min at room temperature, remove the fixative, rinse three times with HBSS and once with deionized water, and then either air dry the samples overnight or incubate them in −20°C methanol for several minutes followed by a water rinse to permeabilize the cells. 3. Add staining solution to cover the cells in the wells, and incubate the dish or plate at 37°C for 1 h in the dark. 4. Remove the stain, rinse the samples several times with water, and air dry the samples (on the dish or ivory) or mount coverslips by inverting coverslips onto a drop of glycerol-buffered mounting medium spotted on a glass slide (thereafter store at 4°C and rewarm before viewing in a microscope). 5. Alternatively, a commercially available staining kit (Sigma cat. no. 386) can be used as directed by the manufacturer (see Note 2). 3.3.3. Antigenic Profile
Together with specific morphological features and high TRAP activity levels, chick OCs exhibit various characteristic surface markers that are commonly monitored since they are not expressed (or only at lower levels) by related monocytes, macrophages, or macrophage polykaryons. These include expression of αvβ3 integrin (vitronectin receptor), H+-ATPase proton pump, carbonic anhydrase II, calcitonin receptor, galectin-3, and a series of antigens recognized by anti-OC MAbs, including 121F (Fig. 3b, d, f, g). Most or all of these OC markers play important roles in the bone resorption function and/or survival of OCs. Using specific antibodies, these markers can be detected on the surface of chick OCs cultured and fixed on bone, ivory, glass or plastic via immunostaining, alone or in combination with TRAP staining, F-actin cytoskeletal staining (with rhodamine-labeled phalloidin), and/or DAPI nuclear labeling (Fig. 3a–g). The relative surface level expression of these protein markers can also be measured for chick OCs following their fixation (as whole cells) in 96-well microtiter dishes and quantitative analysis by ELISA as detailed elsewhere (12). Alternatively, these markers may be monitored in total cell extracts or membrane lysates of chick OCs by ELISA, gel electrophoresis (with or without immunoprecipitation), or immunoblotting. OCs also express high intracellular levels of pp60c-src, a critical signal molecule required for OC bone resorption. This cytoskeletally associated protein can be detected by immunostaining in permeabilized cells (e.g., incubate fixed OCs in 0.1% Triton X-100 for 30 min prior to blocking) or by immunoblotting of electrophoresed cell extracts, with or without probing for phosphorylation status (see Chapter 15 this volume). Similar methods can be used to detect many other intracellular signaling molecules. A general protocol for OC
9
Isolation and Culture of Primary Chicken Osteoclasts
135
Fig. 3. Cytochemical and immunostaining analysis of 6% Percoll-purified chick OCs. (a, c) Chick OCs cultured on plastic (1–2 days) and stained for TRAP activity. (b, d) Chick OCs cultured on plastic and immunostained using a MAb to the vitronectin receptor, integrin αvβ3 (LM 609), and a biotin-streptavidin β-galactosidase detection system. (e) Chick OCs cultured on plastic, fixed and permeabilized (Triton X-100), and double stained with rhodamine phalloidin to label cytoskeletal F-actin (red ) and DAPI to label multiple nuclei within OCs (blue). Note the peripheral actin ring formation characteristic of mature OCs. (f, g) Chick OCs cultured on plastic and immunostained with MAb 121F using a biotin-streptavidin FITC detection system. Both αvβ3 and the 121F antigen become highly expressed on the OC cell surface during their differentiation into bone-resorptive multinucleated cells, and each of these OC markers plays an important functional role in the resorption of bone by OCs.
136
P. Collin-Osdoby and P. Osdoby
immunostaining is given here (use a minimum of 250 μl of reagent per well of a 24-well plate): 1. After culture of OCs on coverslips, bone or ivory, rinse the tissue culture wells gently and fix as for TRAP staining (see Subheading 3.3.2, steps 1–4). 2. Immediately process the samples for immunostaining and do not allow any part of the sample to dry during the following steps (including the edges of coverslips or bone/ivory slices since this will produce staining artifacts). 3. Block nonspecific binding sites by incubating with blocking solution for 1 h at room temperature. 4. Incubate with appropriate dilutions of anti-OC antibodies for 1 h at room temperature. Include sample(s) incubated in blocking solution alone or an irrelevant antibody to serve as negative controls for nonspecific staining. 5. Rinse three times briefly, and once for 10 min with PBS. 6. Incubate with a secondary biotin-conjugated antibody directed against the primary antibody for 1 h at room temperature. 7. Rinse three times briefly, and once for 10 min with PBS. 8. Incubate 30 min in the dark with streptavidin conjugated with FITC (or Texas Red). 9. Rinse three times briefly and once for 10 min with PBS. 10. Mount specimens onto glass slides with glycerol-buffered mounting medium (see Subheading 3.3.2, step 5), store dark at 4o C, and rewarm slides before viewing in a microscope. 11. If desired, OCs on coverslips can be briefly reacted with a membrane permeable fluorescent dye to label the nuclei (bright blue) by incubation in a 1:300 dilution of DAPI in HBSS for 1 min, followed by two rinses in HBSS before mounting. Immunostained samples can also be stained for TRAP activity (after step 9 above) before being mounted on glass slides. Antigen detection on OCs adherent to bone or ivory is difficult to measure using a fluorescent system unless confocal microscopy is used (see Chapter 25). A histochemical detection method may be better suited for this purpose, and also works well to immunostain OCs cultured on glass or plastic in place of the fluorescent system. We prefer to use antibodies coupled to β-galactosidase (which has negligible background problems and requires no specific blocking), but other enzymes (e.g. horseradish peroxidase) can also be used with good results if endogenous enzyme activities are quenched. For β-galactosidase-based immunostaining, perform steps 1–7 of the protocol given earlier in this subheading, then continue as follows: 1. Incubate for 30 min with streptavidin conjugated with β-galactosidase in buffer A.
9
Isolation and Culture of Primary Chicken Osteoclasts
137
2. Rinse five times with buffer A over 30 min. 3. Incubate for 30 min (or longer, if necessary) in the dark with substrate solution. 4. Rinse five times over 30 min with PBS. 5. Store bone or ivory slices dry before viewing. Mount cells on coverslips onto glass slides as described in step 10 earlier in this subheading. 6. OCs immunostained by this method (on bone, ivory, glass or plastic) also can be double stained for TRAP activity (see Subheading 3.3.2). 3.3.4. Molecular Profile
Both Percoll-fractionated and immunomagnetically purified chick OCs are good RNA sources for analyzing the relative gene expression levels of various OC phenotypic and functional markers, either in freshly isolated cells or following OC culture on plastic, bone or ivory in the presence or absence of modulators. OC preparations provide sufficient RNA for ribonuclease protection assay (RPA), RT-PCR and other applications (13). Typically, one well of a 24-well dish seeded with 200,000 viable chick OCs (in 250 μl medium) yields 2–5 μg of total RNA, of which 100 ng–1 μg may be used per RT-PCR, or up to 5 μg for a single RPA assay. Chicken-specific primers for PCR amplification are available for some chick OC markers, and others can be generated based on interspecies sequence similarities reported for OC genes from human, mouse, or other species. Similarly, species homologous primers may be used to amplify chicken-specific genes and the PCR products cloned into appropriate vectors for the preparation of RPA probes (13). Methods for molecular analyses are given elsewhere in this volume (see Chapters 17 and 18).
3.3.5. Motility (see Note 4)
Because OCs are very large and vary considerably in size (and nuclear number), it is difficult to perform classical chemotaxis/ chemokinesis experiments through porous membranes to measure OC movement in response to various agents. However, OC movement can easily be monitored by culture on gold-coated coverslips, because OCs phagocytose the gold and thereby generate a cleared track in their wake (10). To perform this assay, 6% Percoll-purified OCs are used (see Subheading 3.1.1). 1. Resuspend the cells gently in 6–8 ml of culture medium, plate 0.5 ml (~100,000 OCs) per well of a 24-well dish containing rinsed and prewetted gold-coated coverslips (see Subheading 2.6), and culture for 2–3 h to allow OCs to attach. 2. Remove the nonadherent cells, add fresh medium with or without modulators, and culture the cells for 16–24 h. 3. Rinse gently three times with warm HBSS, fix the cells with 1% PF-HBSS for 15 min at room temperature, and rinse three times with HBSS.
138
P. Collin-Osdoby and P. Osdoby
4. Stain the cells for TRAP activity (see Subheading 3.3.2 and Note 2). 5. Determine the number of TRAP-stained OCs, the number of phagokinetic tracks, and the cleared area of each track within a constant number of random adjacent fields using a microscope fitted with an ocular reticle and computer linked to an image analysis system (Fig. 2e). Calculate the mean track area and the total area of gold cleared, and normalize the data to determine the number of tracks per OC and the mean area cleared per OC. 3.3.6. Bone Resorption
OCs and other phagocytic cells can all resorb (ingest and degrade) very small particles of bone in vitro or secrete acid that dissolves hydroxyapatite [e.g., on calcium phosphate-coated dishes (Osteologic), BD Biosciences]. However, only OCs can create resorption pits on bone. This is, therefore, the key defining attribute and best assay for evaluating the bone resorptive function of fully developed OCs. Because the number of new sites initiated and the rate of resorption by OCs are major parameters controlling bone remodeling in both normal and pathological states, the in vitro bone pit resorption assay has become a very valuable investigational tool. Data obtained from this analysis reveals information about whether a modulator has altered the number of OCs on the bone or ivory (possibly reflecting effects on integrin-mediated attachment, cell survival or development), the number of pits formed (reflecting activation of OCs for initiating pit resorption), and the area of bone or ivory resorbed (overall or per pit, reflecting the amount and rate of resorption by OCs). 1. Culture chick OCs (6% Percoll purified) on bone or ivory in the presence or absence of modulators for 30–40 h (see Note 13). 2. Rinse, fix, and stain for TRAP activity as described in Subheading 3.3.2. 3. Evaluate resorption using a microscope fitted with an ocular reticle and computer-linked image analysis system (see Chapter 12 for description of a system) (Fig. 2a–c). 4. Count the number of TRAP-stained OCs within a constant number of random fields per bone slice, usually measured consecutively from an arbitrary starting location on the edge of the chip that is marked with a dot using a permanent ink marker. The number of fields chosen for analysis should encompass at least 100–300 OCs per bone chip (typically ~20 fields or half of the chip). To ensure that the exact same fields are subsequently analyzed for resorption pits, mark or draw the fields that have been evaluated for each chip on a grid log sheet.
9
Isolation and Culture of Primary Chicken Osteoclasts
139
5. After all the bone chips have been analyzed for OC numbers (to ensure that no category has too few OCs), remove the OCs from the bone surface by soaking the chip for 1 min in 0.2 M NH4OH, rubbing the entire surface with gloved fingers, repeating this treatment a second time, and then rinsing the chip in deionized water. 6. Quantify the number and planar area of each resorption pit contained within the fields evaluated for OC numbers in step 4 using darkfield reflective light microscopy (Fig. 2d). 7. Express resorption measures as the mean number of OCs, number of pits, and total areas resorbed in this constant number of fields for each experimental condition. Also normalize the data to report the mean number of pits per OC, area resorbed per OC, and area (size) per individual pit. 8. In general, several trials, with 4–6 replicates each for control and treated groups, should be performed to achieve statistically significant results.
4. Notes 1. OC-specific antibodies that can be used for this purpose include MAb 121F (available from us upon request), antibodies to integrin αvβ3 (e.g., 23C6 or LM609) and other commercially available antibodies. 2. Cytochemical staining for TRAP activity is routinely performed using either freshly prepared reagents or a commercially available staining kit (Sigma cat. no. 386) as directed. Because TRAP staining intensity tends to be stronger with freshly prepared reagents, this protocol is preferred for tracking changes in OC TRAP activity (during development or in response to modulators), for discriminating OCs in quantitative resorption pit analyses, and for double staining of immunostained OCs. 3. Secondary antibodies may be directly conjugated with an enzymatic or fluorescent probe, but greater sensitivity is achieved if a biotinylated secondary antibody is used to amplify the primary antibody signal. 4. Gelatin pre-coating enables the gold particles to more reliably remain adherent to the glass coverslips. BSA cannot substitute for gelatin, as it interferes with chick OC movement on the gold-coated coverslips. Avoid plating too many OCs on the gold-coated coverslips because overlapping tracks become difficult to analyze. Similarly, incubation times should not exceed 16–24 h because phagokinetic tracks may become too long and convoluted (and overlap), migration differences in
140
P. Collin-Osdoby and P. Osdoby
response to agents may diminish, and OCs may cease moving when overloaded with ingested gold particles. 5. Young posthatch growing chicks represent a highly abundant source of OCs, whose numbers are further increased by maintaining the chicks on a low calcium feed diet. However, the calcium level in this feed should not fall below 0.15% or the bones of the young chicks will become so soft and weak that the birds are unable to stand to walk, eat, or drink. The feed is prepared by special order (Purina) and can be stored at 4°C (kept dry to avoid mold) for up to 12 months. The birds should have free access to tap water (not deionized water which makes them too weak when they are on the low calcium feed). Whereas millions of OCs are obtained from such chicks, more than 1,000-fold fewer OCs are typically isolated from mouse, rat, or rabbit bone preparations, and only negligible OC numbers from most human bone tissue. Besides sharing morphological, phenotypic, and antigenic properties and most or all of the regulatory responses observed with OCs from other species, chick OCs are the most aggressively active species for bone pit resorption. Consequently, chick OCs provide a particularly sensitive assay system to measure the regulatory effects of various agents (many of which suppress, rather than stimulate, OC activity) on OC-mediated bone resorption. With the discovery of the RANKL-RANK-OPG regulatory pathway controlling OC development, resorption, and survival, many of the earlier restrictions on studies with OCs from other species have been alleviated since OCs may now be generated in vitro from precursors present in primary cell preparations (e.g., avian, mouse or human bone marrow or circulating monocytes) or cell lines (murine RAW 264.7 cells). Details of such procedures are given elsewhere in this volume. However, it may still be important in some cases to compare responses obtained with in vitro generated OCs against those of isolated OCs formed in vivo, especially if a particular agent cannot be directly investigated in vivo for its OC-related actions. 6. OC viability is dependent on the total length of time that it takes from the removal and processing of the bones until the 6% Percoll-fractionated or immunomagnetically isolated OC are placed into culture. This time should not exceed 6–7 h, as each additional hour will negatively impact the final OC viability. If the bone marrow is to be used (e.g., for OC precursor studies and RANKL development) from these same chicks, one person should blow out the bone marrow in a sterile hood from a group of bones while other individuals are harvesting or cleaning the remaining bones, and the dishes should be passed back and forth until they are all completed. One person then
9
Isolation and Culture of Primary Chicken Osteoclasts
141
continues with the bone marrow cell preparation independently from those working on isolating OCs from the marrow-stripped bones (12). 7. Use only wide-bore pipettes or tips for any work in isolating or manipulating OC to avoid fragmenting these large multinucleated cells. Also, exercise care in resuspending, mixing, or vortexing OC preparations gently and for as little time as necessary. 8. Immunomagnetic isolation provides a rapid and highly efficient way to purify OCs from mixed cell populations. Magnetic beads coupled with 121F MAb are not species restricted and can effectively purify OCs from rat, rabbit, human and other sources. Other anti-OC MAbs also may be coupled to magnetic beads for use in purifying OCs via this procedure (see also Note 1). The procedure is performed on ice to prevent ingestion of the beads by OCs. However, because MAb 121F (bivalent or Fab fragments) partially inhibits OC bone pit resorption (14), and OC yields are lower in immunomagnetic compared to Percoll purifications, immunomagnetically isolated OCs are considered most useful for (1) obtaining highly purified OC samples for molecular or biochemical analysis and (2) confirming that responses observed in Percoll-purified OC preparations can be attributed to OC-specific effects. 9. For optimum OC immunomagnetic capture, avoid stirring the MAb coupled beads with the cells either too fast (which interferes with attachment) or too slow (which reduces binding due to poor mixing). Best results are achieved with 35% Percollseparated OC preparations used as the starting material as opposed to more crude preparations because the latter yields less pure OC populations and matrix reassembly is more problematic. In addition, 6% Percoll preparations typically yield fewer immunomagnetically isolated OCs than do 35% Percoll preparations. 10. As an alternative to seeding OC onto individual bone slices, OC may be seeded in 2.5 ml of medium onto ~24 bone or ivory discs spread out to fully cover the bottom of a 35-mm dish. After allowing OCs to selectively attach for 2.5–3 h, the nonadherent cells are removed, adherent OCs are gently washed with medium, and the bone or ivory discs are individually removed with sterile tweezers and placed into one well of a 48-well culture dish with fresh medium (250 μl). Modulators are typically administered (in 50 μl of medium, final volume of 300 μl per well) and the cells cultured for 30–40 h before harvest. 11. For resorption, OCs are routinely cultured for 30–40 h before harvest. For histochemical, enzymatic, or immunocytochemical
142
P. Collin-Osdoby and P. Osdoby
analysis, OCs are cultured for 1–2 days before analysis. For molecular studies, RNA may be extracted directly from the Percoll-fractionated or immunomagnetically captured cells. Alternatively, RNA can be harvested from OCs cultured on bone, ivory or plastic for up to 3 days in the presence or absence of modulators. OC survival is enhanced if the cells are cultured on bone or ivory (due to integrin-mediated survival signals) as opposed to glass or plastic, so experiments under the latter conditions should be limited to a few days at most. Although some studies have indicated that OC resorb better under slightly acidic conditions, we find that chick (and human) OC performance is actually better in α-MEM supplemented with 5% FBS. 12. Immunomagnetically purified OCs can be cultured and will form resorption pits on bone or ivory, but because they rapidly ingest the bound beads at 37°C, it is conceivable that antibody and/or bead engagement of the OC cell surface may affect their physiology or resorptive function (Fig. 1a, c). It is possible to remove many, but not all, of the beads from the outer surface by physical (strong vortexing) or biochemical (low pH, protease digestion) methods, performed at 4°C, although some cell damage may occur during these procedures (9). 13. Because ethanol inhibits OC bone resorption, the bone/ivory slices must be well rinsed (and soaked >3 h) in HBSS before having cells plated onto them. Likewise, alcohol-soaked tweezers should be air-dried briefly before being used to move bone or ivory discs. In general, resorption pit analysis on bone is somewhat more complicated than on ivory due to the need to distinguish Haversian and Volkmann canals in the bone apart from the pits made by the cultured OCs. In our replicate studies using bone and ivory, no substrate-dependent differences have been noted to date in either basal or modulator evoked resorption parameters for isolated chicken OCs. Therefore, although ivory can be more difficult to obtain than bovine bone, it is preferable to use for quantitative resorption pit analysis.
Acknowledgments This work was supported by NIH Grants AR32927, AG 15435, and AR42715 to P.O.
9
Isolation and Culture of Primary Chicken Osteoclasts
143
References 1. Hall, T. and Chambers, T. (1996) Molecular aspects of osteoclast function. Inflamm. Res. 45, 1–9. 2. Roodman, G. (1996) Advances in bone biology – the osteoclast. Endocr. Rev. 17, 308–332. 3. Suda, T., Udagawa, N., Nakamura, I., et al. (1995) Modulation of osteoclast differentiation by local factors. Bone 17, S87–S91. 4. Kanis, J. (1995) Bone and cancer: pathophysiology and treatment of metastases. Bone 17, 101S–105S. 5. Mundy, G. (1993) Cytokines and growth factors in the regulation of bone remodeling. J. Bone Miner. Res. 8, S505–S510. 6. Wiebe, S., Hafezi, M., Sandhu, H., et al. (1996) Osteoclast activation in inflammatory periodontal diseases. Oral Dis. 2, 167–180. 7. Manolagas, S., Bellido, T., and Jilka, R. (1995) New insights into the cellular, biochemical, and molecular basis of postmenopausal and senile osteoporosis: roles of IL-6 and gp130. Int. J. Immunopharmacol. 17, 109–116. 8. Oursler, M., Collin-Osdoby, P., Anderson, F., et al. (1991) Isolation of avian osteoclasts: improved techniques to preferentially purify viable cells. J. Bone Miner. Res. 6, 375–385. 9. Collin-Osdoby, P., Oursler, M., Webber, D., et al. (1991) Osteoclast-specific monoclonal antibodies coupled to magnetic beads provide a
10.
11.
12.
13.
14.
rapid and efficient method of purifying avian osteoclasts. J. Bone Miner. Res. 6, 1353–1365. Minkin, C. (1982) Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif. Tissue Int. 34, 285–290. Owens, J. and Chambers, T. (1993) Macrophage colony-stimulating factor (M-CSF) induces migration in osteoclasts in vitro. Biochem. Biophys. Res. Commun. 195, 1401–1407. Collin-Osdoby, P., Oursler, M., Rothe, L., et al. (1995) Osteoclast 121F antigen expression during osteoblast conditioned medium induction of osteoclast-like cells in vitro: relationship to calcitonin responsiveness, tartrate resistant acid phosphatase levels, and bone resorptive activity. J. Bone Miner. Res. 10, 45–58. Sunyer, T., Rothe, L., Kirsch, D., et al. (1997) Ca2+ or phorbol ester but not inflammatory stimuli elevate inducible nitric oxide synthase messenger ribonucleic acid and nitric oxide (NO) release in avian osteoclasts: autocrine NO mediates Ca2+-inhibited bone resorption. Endocrinology 138, 2148–2162. Collin-Osdoby, P., Li, L., Rothe, L., et al. (1998) Inhibition of osteoclast bone resorption by monoclonal antibody 121F: a mechanism involving the osteoclast free radical system. J. Bone Miner. Res. 13, 67–78.
sdfsdf
Chapter 10 Isolation and Purification of Rabbit Osteoclasts Fraser P. Coxon, Michael J. Rogers, and Julie C. Crockett Abstract Newborn rabbits provide a useful and readily available source of authentic mature osteoclasts, which can be easily isolated directly from the long bones in relatively large numbers, compared to other rodents. Primary cultures of authentic rabbit osteoclasts on resorbable substrates in vitro are an ideal model of osteoclast behaviour in vivo, and for some studies may be preferable to osteoclast-like cells generated in vitro from bone marrow cultures or from human peripheral blood, for example in assessing osteoclastmediated bone resorption independently of effects on osteoclast formation. Rabbits also provide a particularly useful model for determining the effects of pharmacological agents on osteoclasts in vivo, by isolating osteoclasts using immunomagnetic bead separation (with an antibody to αVβ3) at the desired time following in vivo administration of the drug. Since osteoclasts are abundant in newborn rabbits, sufficient numbers of osteoclasts can be retrieved using this method for molecular and biochemical analyses. Key words: Rabbit, Osteoclast, Bone resorption, Polarisation, Vitronectin receptor
1. Introduction Osteoclasts are notoriously hard to study because of the difficulty in obtaining pure populations of cells in large numbers for biochemical and molecular analyses. Unlike with other rodents (e.g. mice and rats), mature osteoclasts can be obtained from rabbits in relatively large numbers and can be purified easily. For some studies, such primary cultures of authentic osteoclasts may be preferable to osteoclast-like cells generated in vitro from bone marrow cultures, or from human peripheral blood. Isolated rabbit osteoclasts are capable of resorbing mineralised substrates in vitro and are therefore useful for assessing the effect of pharmacologic agents on osteoclast-mediated bone resorption (1–3), independently of effects on osteoclast formation, which can complicate interpretation of studies using mouse or human osteoclasts. Furthermore, since they are isolated directly, rabbit osteoclasts cultured on a mineralized substrate in vitro are an ideal model of osteoclast Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_10, © Springer Science+Business Media, LLC 2012
145
146
F.P. Coxon et al.
behaviour in vivo (4, 5). We and others have also extracted protein or RNA from purified rabbit osteoclasts for studies on metabolic processes in osteoclasts, or molecular studies on osteoclast biology using western blotting, enzyme assays, or RT-PCR (3, 6–9). We routinely isolate osteoclasts from the long bones of neonatal rabbits using a method adapted from that initially described by Tezuka et al. (10) (see Subheading 3.1). Isolated rabbit osteoclasts can then be cultured on plastic, glass or mineralised substrates (such as cortical bone, elephant ivory, or whale dentine, or hydroxyapatite-coated surfaces). Culturing osteoclasts on glass coverslips (in multiwell plates) is useful for immunocytochemistry, since the coverslips can be mounted onto glass slides, enabling cells to be visualised using an upright microscope. For some applications, such as preparation of osteoclast lysates for western blot analysis, osteoclasts must be further purified from contaminating bone marrow cells. This can be done either by further washing culture dishes with PBS, or by removing contaminating adherent cells using a solution of pronase–EDTA (Subheading 3.2). This provides cultures of >95% pure, tartrate-resistant acid phosphatase (TRAcP)-positive, multinucleated osteoclasts and mononuclear, prefusion osteoclasts (Fig. 1a). When isolating mature osteoclasts we typically achieve a yield of approximately 5 × 104 purified osteoclasts from each rabbit. It is also possible to generate much larger numbers of osteoclast-like cells (up to 16 semi-confluent 10 cm petri dishes of TRAcPpositive, multinucleated cells per rabbit) (Fig. 2), by culturing bone marrow-derived cells in the presence of 1,25 dihydroxyvitamin D3 over a period of 10 days, using a method modified from David et al. (11) (see Subheading 3.3). For in vitro applications, purification of osteoclasts on culture dishes by pronase–EDTA digestion is sufficient to provide pure osteoclasts for biochemical studies. However, a pure population of
Fig. 1. (a) Phase-contrast photograph of multinucleated, rabbit osteoclasts cultured in a plastic petri dish following purification with PBS (bar = 25 μm). (b) A rabbit osteoclast showing vitronectin receptor expression by fluorescence immunostaining.
10
Isolation and Purification of Rabbit Osteoclasts
147
Fig. 2. Phase-contrast photographs of a rabbit bone marrow culture (a) after 7 days, showing a developing multinucleated, osteoclast-like cell (arrow ) beneath the stromal cell layer; (b) following purification of osteoclast-like cells after 10 days (multinucleated cell shown in inset ). Bars = 20 μm.
Fig. 3. Scanning electron micrograph of an immunomagnetically isolated rabbit osteoclast cultured on dentine. The osteoclast is associated with a resorption lacuna and still has magnetic beads attached. Bar = 10 μm.
osteoclasts can also be isolated in relatively large numbers directly from rabbit bones, without prior cell culture in vitro. We have modified a technique (Subheading 3.4) developed by Collin-Osdoby et al. (12) that involves separation of osteoclasts from a mixed cell suspension using immunomagnetic beads and the 23C6 monoclonal antibody (Fig. 3). The latter specifically recognises the αVβ3 integrin (also known as the vitronectin receptor), which is highly expressed on osteoclasts (13) (Fig. 1b). This technique is particularly useful for determining the effects of pharmacological agents on osteoclasts in vivo, since the osteoclasts can be isolated and purified at the desired time following in vivo administration of the drug.
148
F.P. Coxon et al.
The osteoclasts can then be examined by microscopy or lysed for analysis by western blotting or using other molecular and biochemical techniques. This approach has been used to examine the ability of bisphosphonates and phosphonocarboxylates (14–16), and statins (17, 18) to inhibit protein prenylation in osteoclasts in vivo, uptake of bisphosphonates in vivo (16) and to detect the accumulation of a toxic metabolite of clodronate (14) and a metabolite of the mevalonate pathway in osteoclasts in vivo (19). Importantly, the separation of osteoclasts from other cells within the bone marrow is sufficiently effective to determine whether the pharmacological agents under investigation act specifically on the osteoclasts. Rabbit osteoclasts in culture can be identified using markers that are highly abundant in these cells, for example by staining for TRAcP (20) (Subheading 3.5 step 1) and immunological detection of the vitronectin receptor and their (Fig. 1b) (see Subheading 3.5 step 2). Staining for the activity of TRAcP is useful for enabling the number of osteoclasts in culture to be counted (21), particularly when the cells are cultured on a substrate, such as dentine on which cells cannot easily be seen light microscopy. It should be noted, however, that this enzyme is not specific for osteoclasts and is present in other cell types, such as alveolar macrophages. Immunostaining for the vitronectin receptor is particularly useful for single cell studies using fluorescence microscopy, since it delineates the plasma membrane as well as selectively identifies the osteoclasts. When rabbit osteoclasts are cultured on a mineralised substrate such as dentine, actively resorbing osteoclasts can be identified by the presence of a characteristic ring of F-actin (see Subheading 3.5 step 3) and their ability to excavate resorption pits in the substrate (see Subheading 3.5 step 4) (Fig. 4).
Fig. 4. Resorptive activity of rabbit osteoclasts cultured on dentine discs. (a) Scanning electron micrograph showing a cultured rabbit osteoclast (arrow ) adjacent to a resorption pit (asterisk ). Bar = 10 micro m. (b) Rabbit osteoclasts purified through an FCS gradient and cultured on dentine, then stained with TRITC-phalloidin and analysed by fluorescence microscopy. Characteristic F-actin rings are evident, denoted by arrows. (c) Reflected light microscopic image of resorption pits excavated by rabbit osteoclasts (original magnification ×100).
10
Isolation and Purification of Rabbit Osteoclasts
149
2. Materials 2.1. General Reagents
1. α-Minimum essential medium (α-MEM) supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, and 1 mM glutamine. 2. Foetal calf serum (FCS). 3. Phosphate-buffered saline (PBS). 4. 4% Formaldehyde in PBS. 5. Hank’s buffered salt solution (HBSS).
2.2. Isolation and Purification of Rabbit Osteoclasts
1. Sharp scissors. 2. Blunt-ended forceps. 3. Disposable scalpel (for removing tissue). 4. Autoclaved scalpel handle and disposable scalpel blade (for mincing bones). 5. 10 cm diameter glass petri dishes. 6. PBS containing 0.001% (w/v) pronase and 0.002% (w/v) EDTA. Filter-sterilise (0.2 μm filter) before use. Pronase can be prepared as a concentrated stock solution in PBS and stored frozen as aliquots at −20°C, and then be diluted in PBS/EDTA before use. 7. HBSS (for serum gradient enrichment of osteoclasts).
2.3. Generation of Rabbit OsteoclastLike Cells
1. 1,25 Dihydroxyvitamin D3 (Sigma, Poole, UK).
2.4. Isolation of Rabbit Osteoclasts Using Immunomagnetic Beads
1. Anti-αVβ3 mAb (clone 23C6; Serotec, Oxford, UK). 2. 0.1% (w/v) Bovine serum albumin (BSA) in PBS. 3. Magnetic beads conjugated to rat anti-mouse IgG (e.g. Dynabeads from Invitrogen, Oregon, USA). 4. Magnet or magnetic particle concentrator.
2.5. Staining for Tartrate Resistant Acid Phosphatase
1. 10 mg/ml Naphthol-AS-BI-phosphate substrate in dimethylformamide (stable at 4°C for about 2 weeks). 2. 4% (w/v) Sodium nitrite. 3. Pararosanilin: add 1 g of pararosanilin to 20 ml dH2O and then add 5 ml concentrated HCl. In a fume hood, heat the solution carefully with constant stirring in a water bath for 30 min and then filter after cooling (stable at 4°C for several months).
150
F.P. Coxon et al.
4. Veronal buffer: 11.7 g/l anhydrous sodium acetate, 29.4 g/l veronal (barbital) in dH2O (toxic solution) (stable at 4°C for several months). 5. 0.1 N acetate buffer, pH 5.2: dissolve 0.82 g anhydrous sodium acetate in 100 ml dH2O. Adjust the pH of this solution to 5.2 using a solution of 0.6 ml glacial acetic acid made up to 100 ml with dH2O (stable at 4°C for several months). 6. Acetate buffer plus tartrate: add 2.3 g sodium tartrate to 100 ml acetate buffer, to give a stock solution of 100 mM tartrate (stable at 4°C for several months). 2.6. Immunostaining for av b3 Integrin (Vitronectin Receptor)
1. Anti vitronectin receptor mAb (clone 23C6; Serotec, Oxford, UK). 2. Fluorescently conjugated secondary antibody (e.g. Alexa Fluor 555 goat anti-mouse IgG; Invitrogen, Oregon, USA). 3. Nuclear stain, such as 0.5 μg/ml 4,6-diamidino-2-phenylindole (DAPI) or Sytox Green (Invitrogen).
2.7. Detection of F-actin Rings
1. 0.5% (v/v) Triton X-100 in PBS.
2.8. Resorption Pit Assay
1. Dentine discs: cut 200–400 μm sections of 1 cm2 blocks of elephant ivory using a Buehler low speed saw with wafering blade. The surface of the slices can be polished by rubbing vigorously with abrasive tissue paper, then the slices can be punched into discs simply using a paper hole punch. Mark the discs with a non-symmetrical identifier in pencil on one side, to enable the disc to be orientated correctly when handling, which is useful when removing from 96-well plates to mount on slides. Ensure that the mark is on the lower surface when plated so that the cells are seeded onto the unmarked surface. The discs should be sterilised and stored in 70% ethanol prior to use.
2. Tetramethylrhodamine isothiocyanate (TRITC)- or fluorescein isothiocyanate (FITC)-phalloidin (Sigma, Poole, UK).
2. 20% (w/v) Sodium hypochlorite solution.
3. Methods 3.1. Isolation and Culture of Rabbit Osteoclasts
1. Euthanise 2- to 4-day-old rabbits under halothane. 2. Remove all four limbs entirely, skin, and keep in PBS on ice. 3. In a glass petri dish, remove all tissue from the femora, tibiae, ulnae, radii with a disposable scalpel. Transfer the bones to PBS as soon as they are dissected. 4. Create a mixed cell suspension in a glass petri dish by mincing all isolated bones from one rabbit in α-MEM (approx. 20 ml) using a scalpel. At this point, osteoclasts can be partially purified
10
Isolation and Purification of Rabbit Osteoclasts
151
through a serum density gradient (see Subheading 3.2), in which case it is better to mince the cells in HBSS rather than α-MEM. For the larger bones, it is best to first cut longitudinally, then scrape out the marrow and the inside of the bones before mincing the remaining bone. It is important to perform this part of the procedure as quickly as possible, since the osteoclasts settle and adhere to the dish. 5. Transfer the cell suspension and bone fragments to a 50 ml conical tube and vortex vigorously for three 10 s bursts. Allow the bone fragments to settle for 1 min and then decant the cell suspension to a fresh tube. If enriching the osteoclasts through a serum density gradient see Subheading 3.2 below; otherwise, add α-MEM and supplement with FCS to a final concentration of 10% (v/v) in a final volume of 25 or 50 ml (see Table 1). This suspension should contain approximately 1 × 108 total cells. 6. Plate out the mixed cell suspension into petri dishes (see Notes 1 and 2) or multi-well plates using the guidelines in Table 1. 7. For cultures on dentine discs, allow seeded osteoclasts to adhere for 2 h then gently rinse the discs in PBS to remove the non-adherent cells (see Note 3). At this stage, add any agents further agents (e.g. drugs or cytokines) into fresh α-MEM containing 10% (v/v) FCS. 8. Incubate cultures on plastic overnight in 5% CO2 at 37°C, then remove non-adherent cells by washing gently in PBS using a sterile, wide-bore Pasteur pipette. Three washes are usually sufficient to remove most of the non-osteoclastic cells (see Notes 4 and 5). The remaining adherent cells are mainly osteoclasts, prefusion mononuclear cells, and stromal cells.
Table 1 Recommended density of bone marrow cells for preparing cultures of rabbit osteoclasts (see Note 2) Culture vessel
Total volume of cell suspension (ml)
Volume per well, ml (approx. cell number)
10-cm Petri dish
50
16 (3.2 × 107)
6-Well plate
25
2 (8 × 106)
24-Well plate
25
0.5 (2 × 106)
48-Well plate
25
0.3 (1.2 × 106)
96-Well plate
25
0.125 (0.5 × 106)
152
F.P. Coxon et al.
3.2. Enrichment of Osteoclasts Using Foetal Calf Serum Gradients
Osteoclast preparations can be crudely purified prior to seeding by serum density gradient fractionation, using a simplified version of that described by Collin-Osdoby et al. (22). This procedure can improve cultures on resorbing surfaces, by removing the bulk of the contaminating cells that interfere with single cell analysis by fluorescence microscopy, and by increasing the number of resorbing osteoclasts on each disc of dentine. The following volumes are suitable for cells isolated from a maximum of five rabbits. 1. Prepare 30 ml of 70% FCS in HBSS (21 ml FCS plus 9 ml HBSS) and 30 ml 40% FCS in HBSS (12 ml FCS plus 19 ml HBSS) in separate 50-ml tubes. 2. Mix vigorously then transfer 15 ml of 70% FCS/HBSS into a fresh 50-ml tube. 3. Very carefully layer 15 ml of 40% FCS/HBSS on to the 70% FCS/HBSS in each tube, holding the tube at 45° to avoid mixing. 4. Centrifuge isolated bone marrow cells at 100 × g for 5 min at 4°C. 5. Resuspend cells in HBSS, using 15 ml for each gradient to be prepared. 6. Layer the cell suspension extremely carefully on to the FCS gradient, again holding the tube at 45°, then place in a rack and allow cells to settle for 30 min (see Note 4). 7. Remove the upper fraction and discard; this contains primarily red blood cells and mononuclear cells. 8. The middle fraction should contain mainly mononuclear cells plus some multinucleated cells, while the lower fraction should contain a much higher proportion of multinucleated osteoclasts. Therefore, to achieve the highest purity, only the lower fraction should be retained. To achieve the greatest yield, both the middle and lower fractions should be retained. Desired fractions should be transferred to fresh tubes and centrifuge at 100 × g for 5 min. 9. Resuspend pellets in 3 ml supplemented α-MEM and check purity/count in haemocytometer. 10. Seed osteoclasts on to dentine discs at up to 500 per well. Since counting low cell numbers is not particularly reliable, we usually dilute the cell fractions with supplemented α-MEM to approximately 5 ml medium for each rabbit used (up to 10 ml if middle and lower fractions have been combined) then seed into tissue culture plates using the usual volumes (e.g. 100 μl for 96 well plates).
10
3.3. Purification of Rabbit Osteoclasts on Plastic (from Subheading 3.1)
Isolation and Purification of Rabbit Osteoclasts
153
1. If significant numbers of contaminating cells remain even after rinsing with PBS, incubate the adherent cells for 5–10 min (or until the non-osteoclastic cells are released) in pre-warmed 0.001% (w/v) pronase, 0.002% EDTA in PBS, at 37°C. 2. Wash the plates four times in PBS and culture the remaining purified (typically >95% pure) osteoclasts and prefusion mononuclear cells in α-MEM supplemented with 10% (v/v) FCS. The purified osteoclast cultures are typically about 10–20% confluent (higher if purified through an FCS gradient), and each 10 cm petri-dish usually yields 100–200 μg of cellular protein following lysis (see Note 6).
3.4. Generating Large Numbers of Rabbit Osteoclast-Like Cells in Vitro
This simple culture can be set up using whole marrow cell preparations, the non-adherent cells from isolated osteoclast cultures on plastic dishes, or cells from the middle fraction of FCS gradient separations, and is useful for biochemical studies requiring large numbers of osteoclasts, 1. Seed the cells into 10 cm diameter petri dishes at 3 × 107 cells per dish (or other plates at an equivalent density) in α-MEM supplemented with 10% (v/v) FCS and containing 1 × 10−8 M 1,25(OH)2 vitamin D3. 2. Replace half of the medium (containing 1,25(OH)2 vitamin D3) every 2 days. 3. After 10 days, remove the stromal layer by washing extensively with PBS. This usually yields >95% pure multinucleated, TRAcP-positive osteoclast-like cells (capable of resorbing bone mineral when the marrow cells are cultured on dentine discs); therefore, further purification using pronase–EDTA is not usually required.
3.5. Isolation of Rabbit Osteoclasts Using Immunomagnetic Beads
This approach has proved particularly useful for studying the effects of pharmacological agents on osteoclasts in vivo (14–19), since it enables effective purification of the osteoclasts directly from bone cell preparations. 1. Prepare a mixed cell suspension from the long bones of a neonatal rabbit as described in Subheading 3.1. 2. Centrifuge the mixed cell suspension at 300 × g (10 min) and resuspend the cell pellet in 1.0 ml αMEM containing 3.3 μg/ml 23C6 antibody for 30 min at 37°C. 3. Centrifuge the cells at 300 × g (5 min) then wash in 0.1% (w/v) BSA in PBS and resuspend in 0.1% (w/v) BSA in PBS containing 2 × 107 magnetic Dynal beads conjugated to rat anti-mouse IgG. Incubate at 4°C on a rotating mixer for 20 min. 4. Separate the vitronectin receptor-positive from vitronectin receptor-negative cells by placing in a Dynal magnetic particle
154
F.P. Coxon et al.
concentrator for 5 min. Wash the vitronectin receptor-positive cells (osteoclasts) four times in 0.1% (w/v) BSA in PBS, separating the bead-coated cells in the magnet for 1 min after each wash. Finally, place the vitronectin receptor-negative fraction into the magnet to retrieve any lost beads, wash these beads and add to the vitronectin receptor-positive fraction. 5. Count the number of purified osteoclasts using a haemocytometer. This technique typically yields approximately 2 × 104 TRAcP-positive multinucleated cells that are capable of resorption when then cultured on a mineralised substrate (Fig. 3) (see Note 7). 3.6. Characterisation of Rabbit Osteoclasts
1. Rinse cells in PBS then fix in 4% (v/v) formaldehyde for 10 min.
3.6.1. Fluorescence Immunostaining for av b3 Integrin (Vitronectin Receptor)
3. Incubate cells in 2 μg/ml 23C6 monoclonal antibody in PBS/5% FCS for 30 min at room temperature.
2. Incubate cells in 10% (v/v) FCS in PBS for 20 min.
4. Wash four times in PBS containing 0.1% (v/v) FCS. 5. Incubate with fluorescently labelled, secondary antibody according to the manufacturer’s guidelines. We routinely use goat anti-mouse IgG [conjugated to either Alexa Fluor 488 (green emission) or Alexa Fluor 555 (red emission)] from Invitrogen at 1:200 (25 μg/ml) in PBS/5% goat serum, for 30 min. 6. To identify multinucleated cells, nuclei can be fluorescently stained by incubating cells for 10 min with a fluorescent nuclear dye of an appropriate wavelength such as DAPI or Sytox Green. 7. Rinse cells several times with PBS and then visualise using a fluorescence microscope equipped with a ×20 or ×40 objective and appropriate filters (Fig. 1b).
3.6.2. Detection of F-actin Rings in Osteoclasts Cultured on Dentine Discs (see Note 8)
1. Prepare osteoclasts as described in Subheading 3.1 or 3.3, and seed onto dentine discs in 96-well plates. 2. At the end of the culture period (see Note 9), fix the cells on the discs in 4% (v/v) formaldehyde. 3. Rinse cells in PBS then permeabilise with 0.5% (v/v) Triton X-100 in PBS for 15 min. 4. Incubate with 0.5 μg/ml TRITC-phalloidin or FITCphalloidin in PBS for 30 min (see Note 10). 5. Rinse twice in PBS and then store in PBS at 4°C, protected from light. 6. Visualise actin rings using a fluorescence microscope with appropriate filters (Fig. 4b).
3.6.3. Staining for Tartrate Resistant Acid Phosphatase (see Note 11)
1. Osteoclast cultures fixed in 4% (v/v) formaldehyde can be stored at 4°C in PBS for up to 2 weeks before staining for TRAcP.
10
Isolation and Purification of Rabbit Osteoclasts
155
2. Prepare staining solution by mixing solutions A and B described below (see note 12). Once prepared, this staining solution should be used the same day. Solution A: 150 μl naphthol-ASBI-phosphate stock, 750 μl veronal buffer (pH 10.1), 0.45 ml acetate buffer, and 1.35 ml acetate buffer/100 mM tartrate. Solution B: 120 μl pararosanilin and 120 μl sodium nitrite (4% w/v). Filter staining solution through a 0.2-μm filter before use. 3. Incubate osteoclasts in filtered staining solution at 37°C for 30–60 min. TRAcP-positive cells metabolise the substrate to a red-coloured product which appears as granular staining throughout the cytoplasm of osteoclasts. The cells should be rinsed in PBS and can then be stored in 70% (v/v) ethanol at 4°C for several weeks. 4. Count the number of osteoclasts (TRAcP-positive, multinucleated cells with >2 nuclei) under bright field illumination at ×20 magnification. Since mononuclear prefusion osteoclasts are also TRAcP positive, it is important to verify the number of nuclei (easily distinguished by negative contrast as unstained areas) within each cell when counting. 3.6.4. Resorption Pit Assay
1. After analysis of cells (e.g. counting actin ring number and osteoclast number as described above), immerse the discs in 20% (w/v) sodium hypochlorite solution, followed by vigorous rubbing with paper towel to remove cells. 2. Visualise resorption pits using a reflected light microscope. Areas of resorption appear dark since the uneven surface of the disc scatters the light, whereas unresorbed, flat surfaces appear bright since they reflect light (Fig. 4c). Alternatively, pits can be visualised using a conventional light microscope after staining the discs with 0.5% (v/v) toluidine blue, or by fluorescence microscopy following staining with a fluorescent bisphosphonate (see Chapter 25 on confocal microscopy, this volume). 3. The area of resorption pits can be quantitated using image analysis software. We use a Leitz Q500MC image analysis system (Leitz, Milton Keynes, UK) with Aphelion-based software developed in-house. The cultures prepared as described above usually result in 0.5–1 mm2 of resorption pit area per disc.
4. Notes 1. The source of petri dishes appears to influence the yield of osteoclasts. In our hands, tissue-culture grade Falcon 10 cm diameter petri dishes produce the best results.
156
F.P. Coxon et al.
2. It is difficult to obtain confluent monolayers of purified rabbit osteoclasts, since seeding the cells at higher densities than those indicated in Table 1 prevents attachment of the osteoclasts to tissue culture dishes. 3. When seeding osteoclasts onto dentine discs to assess resorptive activity, it is important to gently wash off the non-adherent cells after seeding, since subsequent resorption appears to be greatly reduced in the presence of the non-adherent cells. The non-adherent cells can be removed as little as 1 h after seeding cells onto dentine discs. This will result in a purer population, but lower yield, of osteoclasts. For this reason, partial purification of the osteoclasts using the FCS gradient is often beneficial for resorption assays. 4. Sedimentation time will affect the yield of osteoclasts: shorter sedimentation times will produce purer osteoclast preparations but with lower overall yield, while longer sedimentation will improve yield at the cost of purity. 5. Extensive washing with PBS is often sufficient to remove contaminating stromal cells, which may lift off as a single layer. In these cases digestion with pronase–EDTA is unnecessary. However, cultures should be only gently rinsed with PBS using a wide-bore, plastic Pasteur pipette, to avoid damaging the osteoclasts. 6. Rabbit osteoclasts have a relatively long life-span when cultured in vitro, even following purification. Although cell number gradually declines, some rabbit osteoclasts remain viable after more than 1 week in culture, without the addition of exogenous growth factors or supplements other than FCS. 7. Rabbit osteoclasts are extremely adherent to tissue culture plastic and difficult to remove enzymatically. Therefore, when preparing osteoclast lysates for western blot analysis, we lyse the cells directly in the petri dish. These lysates can be concentrated if necessary by centrifuging through a microconcentrator (we use 12 kDa molecular weight cut-off). 8. We use immunomagnetic separation specifically to isolate osteoclasts for the preparation of cell lysates (e.g. for western blot analysis) or for single cell analysis following in vivo administration of pharmacologic agents (12–17). Although the vitronectin receptor-positive osteoclasts with magnetic beads attached can be cultured on dentine discs, the resorptive function of these cells is typically 20% of that of osteoclasts that have not been separated using magnetic beads; therefore, this is not recommended for routine in vitro cultures. 9. F-actin-rich podosomes can also be observed around the periphery of osteoclasts cultured on plastic or glass following
10
Isolation and Purification of Rabbit Osteoclasts
157
staining with TRITC-phalloidin, but on these surfaces osteoclasts do not polarise and form a genuine “F-actin ring”. 10. Rabbit osteoclasts adhere rapidly to dentine discs but, in our hands, do not begin to resorb until about 12 h after seeding. We routinely incubate cultures of rabbit osteoclasts on dentine discs for 48 h to assess resorptive activity. Only around 25–50% of the TRAcP-positive, multinucleated osteoclasts seeded onto dentine discs are active (i.e. exhibit actin rings) at any one time. 11. Staining for TRITC-phalloidin is useful in combination with staining for the vitronectin receptor, in which case the phalloidin can be added to the secondary antibody solution. We prefer to use TRITC-phalloidin with Alexa Fluor 488-conjugated secondary antibody, when staining in this way. However, it is important to note that staining with phalloidin-conjugates is usually better if the cells have previously been permeabilised. 12. If analysing actin rings as well as the number of TRAcP-positive osteoclasts, staining and analysis of the actin rings must be done first, since this relies on fluorescence microscopy, and will not be able to be seen following histochemical staining for TRAcP. 13. A final tartrate concentration of 50 mM is used when staining for TRAcP in rabbit osteoclast cultures, which is higher than that used for staining for TRAcP in osteoclasts from other species, e.g. mouse (where we use a final tartrate concentration of 30 mM). References 1. Shakespeare, W., Yang, M., Bohacek, R., Cerasoli, F., Stebbins, K., Sundaramoorthi, R., Azimioara, M., Vu, C., Pradeepan, S., Metcalf, C., III, Haraldson, C., Merry, T., Dalgarno, D., Narula, S., Hatada, M., Lu, X., van Schravendijk, M. R., Adams, S., Violette, S., Smith, J., Guan, W., Bartlett, C., Herson, J., Iuliucci, J., Weigele, M., and Sawyer, T. (2000) Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc. Natl. Acad. Sci. USA 97, 9373–9378. 2. Fisher, J. E., Rogers, M. J., Halasy, J. M., Luckman, S. P., Hughes, D. E., Masarachia, P. J., Wesolowski, G., Russell, R. G. G., Rodan, G. A., and Reszka, A. A. (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc. Natl. Acad. Sci. USA 96, 133–138.
3. Coxon, F. P., Helfrich, M. H., van’t Hof, R. J., Sebti, S. M., Ralston, S. H., Hamilton, A. D., and Rogers, M. J. (2000) Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J. Bone Miner. Res. 15, 1467–1476. 4. Stenbeck, G., and Horton, M. A. (2004) Endocytic trafficking in actively resorbing osteoclasts. J. Cell Sci. 117, 827–836. 5. Coxon, F. P., Thompson, K., Roelofs, A. J., Ebetino, F. H., and Rogers, M. J. (2008). Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 42, 848–860. 6. Benford, H. L., McGowan, N. W., Helfrich, M. H., Nuttall, M. E., and Rogers, M. J. (2001) Visualization of bisphosphonateinduced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28, 465–473. 7. Weidema, A. F., Dixon, S. J., and Sims, S. M. (2001) Activation of P2Y but not P2X(4)
158
8.
9.
10.
11.
12.
13.
14.
F.P. Coxon et al. nucleotide receptors causes elevation of [Ca2+]i in mammalian osteoclasts. Am. J. Physiol. Cell Physiol. 280, C1531–C1539. Lees, R. L., Sabharwal, V. K., and Heersche, J. N. (2001) Resorptive state and cell size influence intracellular pH regulation in rabbit osteoclasts cultured on collagen-hydroxyapatite films. Bone 28, 187–194. Chikazu, D., Hakeda, Y., Ogata, N., Nemoto, K., Itabashi, A., Takato, T., Kumegawa, M., Nakamura, K., and Kawaguchi, H. (2000) Fibroblast growth factor (FGF)-2 directly stimulates mature osteoclast function through activation of FGF receptor 1 and p42/p44 MAP kinase. J. Biol. Chem. 275, 31444–31450. Tezuka, K., Sato, T., Kamioka, H., Nijweide, P. J., Tanaka, K., Matsuo, T., Ohta, M., Kurihara, N., Hakeda, Y., and Kumegawa, M. (1992) Identification of osteopontin in isolated rabbit osteoclasts. Biochem. Biophys. Res. Commun. 186, 911–917. David, J. P., Neff, L., Chen, Y., Rincon, M., Horne, W. C., and Baron, R. (1998) A new method to isolate large numbers of rabbit osteoclasts and osteoclast-like cells: application to the characterization of serum response element binding proteins during osteoclast differentiation. J. Bone Miner. Res. 13, 1730–1738. Collin-Osdoby, P., Oursler, M. J., Webber, D., and Osdoby, P. (1991) Osteoclast-specific monoclonal antibodies coupled to magnetic beads provide a rapid and efficient method of purifying avian osteoclasts. J. Bone Miner. Res. 6, 1353–1365. Nesbitt, S., Nesbit, A., Helfrich, M., and Horton, M. (1993) Biochemical characterization of human osteoclast integrins. Osteoclasts express alpha v beta 3, alpha 2 beta 1, and alpha v beta 1 integrins. J. Biol. Chem. 268, 16737–16745. Frith, J. C., Mönkkönen, J., Auriola, S., Mönkkönen, H., and Rogers, M. J. (2001) The molecular mechanism of action of the antiresorptive and anti-inflammatory drug clodronate. Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum. 44, 2201–2210.
15. Coxon, F. P., Ebetino, F. H., Mules, E. H., Seabra, M. C., McKenna, C. E., and Rogers, M. J. (2005) Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone 37, 349–358. 16. Roelofs, A. J., Coxon, F. P., Ebetino, F. H., Lundy, M. W., Henneman, Z. J., Nancollas, G. H., Sun, S., Blazewska, K. M., Lynn, F. B., Kashemirov, B. A., Khalid, A. B., McKenna, C. E., and Rogers, M. J. (2010) Fluorescent risedronate analogs reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J. Bone Miner. Res. 25, 606–616. 17. Staal, A., Frith, J. C., French, M. H., Swartz, J., Gungor, T., Harrity, T. W., Tamasi, J., Rogers, M. J., and Feyen, J. H. M. (2003) The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J. Bone Miner. Res. 18, 88–96. 18. Hughes, A., Idris, A., Rogers, M. J., and Crockett, J. C. (2007) Rosuvastatin inhibits osteoclast function in vitro and prevents in vivo bone loss via an anti-resorptive mechanism. Calcif. Tissue Int. 81, 403–413. 19. Räikkönen, J., Crockett, J. C., Rogers, M. J., Mönkkönen, H., Auriola, S., and Mönkkönen, J. (2009) Zoledronic acid induces the formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br. J. Pharmacol. 157, 427–435. 20. Minkin, C. (1982) Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif. Tissue Int. 34, 285–290. 21. Van’t Hof, R. J., Tuinenburg-Bol, R. A., and Nijweide, P. J. (1995) Induction of osteoclast characteristics in cultured avian blood monocytes; modulation by osteoblasts and 1,25(OH)2 vitamin D3. Int. J. Exp. Pathol. 76, 205–214. 22. Collin-Osdoby, P., Yu, X., Zheng, H., and Osdoby, P. (2003) RANKL-mediated osteoclast formation from murine RAW 264.7 cells. Methods Mol. Med. 80, 153–166.
Chapter 11 Generation of Human Osteoclasts from Peripheral Blood Kim Henriksen, Morten A. Karsdal, Adam Taylor, Denise Tosh, and Fraser P. Coxon Abstract Osteoclasts are multi-nucleated cells that have the unique ability to resorb calcified bone matrix. They derive from haematopoietic precursor cells, and can be generated in vitro by stimulation of peripheral blood mononuclear cells with the cytokines M-CSF and RANKL. In this chapter, we describe the method for generating human osteoclast from peripheral blood or buffy coats, as well as methods for studying both the differentiation and resorbing activity of these cells. Key words: Osteoclast, Resorption, Cytoskeleton, Monocytes, Assays
1. Introduction Osteoclasts are large, multi-nucleated cells, which arise from haematopoietic stem cells found in the bone marrow, spleen, and peripheral blood (1–6). The formation of resorbing osteoclasts is a complex multi-step process involving the commitment of cells from the monocyte lineage to differentiate into osteoclast precursors, the fusion of these cells to form mature multi-nuclear osteoclasts, and finally the activation of the osteoclasts to resorb bone (3, 5, 7–9). Osteoclastogenesis is dependent on a series of molecules with four major functions: (1) the survival and proliferation of the cells (M-CSF, c-fms, c-fos, PU.1); (2) differentiation into osteoclasts (NFATc1, NFkB, DAP12, FcRg, RANK, RANKL); (3) fusion into multi-nuclear osteoclasts (DC-STAMP, d2 subunit of the V-ATPase); and (4) cytoskeletal reorganization (PYK2, c-src, avb3, MitF) (5, 7, 10–12). The cytokines M-CSF and RANKL are both essential and sufficient for differentiation and activation of osteoclasts (4, 5).
Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_11, © Springer Science+Business Media, LLC 2012
159
160
K. Henriksen et al.
Osteoclasts are polarized cells that, through the formation of an actin ring, form a sealing zone, where the osteoclast attaches to the bone surface, effectively isolating the resorption lacuna (5). Within the sealing zone, bone resorption occurs through the activity of hydrochloric acid, which is actively secreted into the resorption lacuna via the V-ATPase protein pump and the ClC-7 chloride antiporter, and the cysteine protease cathepsin K, which is secreted from lysosomal vesicles (13, 14). Cultures of human osteoclasts from osteopetrosis patients with mutations in these proteins have helped to indicate their crucial roles in resorption; osteoclasts form normally, but do not resorb effectively due to failure to acidify the extracellular space (V-ATPase or ClC-7 mutations) or to degrade the collagen matrix of bone (cathepsin K mutations) (15, 16). Hallmarks of osteoclasts are the expression of TRAcP, the calcitonin receptor, αvβ3 (also known as the vitronectin receptor; VNR), and MMP-9, which serve as useful tools for identification of human osteoclasts (5). Many studies have used mature human osteoclasts isolated from human osteoclastomas (giant cell tumours of bone) to obtain basic information about osteoclasts (12). Alternatively, other studies used osteoclasts generated by culture of human peripheral blood mononuclear cells (PBMCs) with an osteoblastic cell line, acting as a feeder layer for the osteoclast precursors (17). However, since recombinant RANKL became commercially available, in vitro methods for human osteoclast formation using peripheral blood as the starting material have become widely accessible. To generate human osteoclasts, PBMCs are first isolated by density centrifugation. Optionally, osteoclast precursors can be purified further by isolating CD14+ cells using magnetic sorting (18). PBMCs or CD14+ cells are cultured in the presence of M-CSF to expand the precursor population, and then with both RANKL and M-CSF to generate osteoclasts (Figs. 1 and 2). The resulting mature, multi-nucleated cells have the ability to degrade dentine and cortical bone (18–25), and display all the classical osteoclast markers, such as CTR, TRAcP, Cathepsin, ClC-7, V-ATPase a3 subunit, and MMP-9 (Fig. 3) (20). Finally, and importantly, they respond to known bone resorption inhibitors, such as bafilomycin, bisphosphonates, calcitonin, and the cysteine protease inhibitor E64 (20). Using human osteoclasts generated in cultures with synthetic growth factors is advantageous in many experimental protocols for the following reasons. 1. It enables human osteoclasts to be studied without the necessity for invasive techniques (unlike osteoclastoma-derived cells). 2. Osteoclast precursors can be obtained readily and in high numbers, enabling cultures to be set up on relatively large scales for biochemical analyses.
11
Generation of Human Osteoclasts from Peripheral Blood
161
Buffy coat/ peripheral blood
CD14+ Isolation (optional)
Separate PBMCs on ficoll gradient
Day 0 M-CSF
M-CSF
Day 3
M-CSF + RANKL
Macrophage expansion
osteoclast formation
M-CSF + RANKL
Fix and stain for analysis
Day 6 M-CSF + RANKL
Day 9 (3d RANKL)
Day 6
Day 9 (3d RANKL)
Day 12 (6d RANKL)
M-CSF + RANKL M-CSF + RANKL
Day 12 (6d RANKL)
Day 12 Re-seed on to resorbable substrate e.g. dentine
osteoclast function Fix and analyse resorbing osteoclasts Day 15 (9d RANKL)
Fig. 1. Schematic showing our general protocol for generating osteoclasts from peripheral blood or buffy coats and culturing these cells for analysis of differentiation or resorptive activity.
3. It enables assessment of osteoclastogenesis, osteoclast function, and osteoclast lifespan in a number of clinical conditions, where osteoclast function is affected, such as in osteoporosis, osteopetrosis, pycnodysostosis, Paget’s disease, and multiple myeloma (16, 19, 23, 26, 27). 4. Osteoclasts generated in vitro are extremely robust and longlived, and are amenable to transfection at an early step in their differentiation (24), as described in Chapter 14, this volume.
162
K. Henriksen et al.
Fig. 2. Phase-contrast images showing human osteoclasts generated from cells isolated from buffy coats and cultured with M-CSF and RANKL for the indicated number of days. After 6 days of treatment with RANKL, the culture contains predominantly multi-nucleated osteoclasts.
Fig. 3. Human osteoclasts generated from buffy coats express αvβ3 integrin (left panel, immunostained using 23C6 antibody), form F-actin rings (middle panel, stained using TRITC-phalloidin), and resorb dentine (right panel, reflected light microscopy).
5. Osteoclast cultures are essentially free from other cells types, unlike co-cultures with osteoblasts or osteoclasts isolated from osteoclastomas.
2. Materials All reagents and materials to be used for collecting the blood sample, performing the cell purification, and culturing the cells should be sterile. General materials: 1. Fresh sample of peripheral blood or buffy coat, collected into an anticoagulent vessel (e.g. EDTA or heparin). 2. Phosphate-buffered saline (PBS). 3. Ficoll-Paque (GE Healthcare) or lymphoprep (Axis-Shield) (see Note 2).
11
Generation of Human Osteoclasts from Peripheral Blood
163
4. 50-ml tubes. 5. Trypsin. 6. Cell culture flasks (T75) and multi-well plates. 7. Cortical bovine bone slices (Nordic Bioscience A/S) or dentine slices. 8. Dynabeads® CD14 (Cat#111-49D, Invitrogen). 9. Magnets compatible with 15-ml tubes (Invitrogen). 2.1. Tissue Culture Reagents
1. Culture medium consisting of alpha minimal essential medium (α-MEM) supplemented with 100 U/ml penicillin–streptomycin and 10% foetal calf serum (FCS). Of importance is the need for testing serum batches, and it is recommended to obtain five different sera from different suppliers and test their ability to support osteoclastogenesis. 2. hM-CSF (R&D Systems , cat#216-MC), use at working concentration of 20 ng/ml. 3. hRANKL (R&D Systems, cat# 390-TN), use at working concentration of 25 ng/ml. 4. mRANKL(R&D Systems, cat#462-TR), use at working concentration of 2 ng/ml. 5. Bone slices: We use cortical bone slices from the femurs of cows/bulls or dentine slices from elephant ivory. The former are prepared from femoral shafts, which are drilled into sticks (diameter fitting into a 96-well plate) along the length of the shaft. These are then cut into slices (0.2-mm thickness) using a slow-speed saw equipped with a diamond blade. The slices are then irradiated in a UV oven for 5 min, and stored in 70% ethanol until further use. Preparation of dentine slices is similar.
2.2. TRAcP Activity Reagents
1. 8.8 mg/ml L-Ascorbic acid (Sigma A0278), in distilled H2O, freshly made. 2. 46 mg/ml Di-sodium tartrate (Merck 106663), in distilled H2O, freshly made. 3. 18 mg/ml 4-Nitrophenylphosphate (Sigma N4645), in distilled H2O, freshly made. 4. Reaction buffer (1 M acetate, 0,5% Triton X-100, 1 M NaCl, 10 mM EDTA, pH 5.5): 59 ml acetic acid 100%, 5 ml Triton X-100, 58 g NaCl, 3.72 g EDTA, 700 ml distilled H2O, adjust pH to 5.5 with 6 M NaOH and add distilled H2O to 1,000 ml. This buffer needs to be cooled down to dissolve completely. 5. STOP buffer (0.3 M NaOH in distilled H2O).
164
K. Henriksen et al.
2.3. Staining
1. Mouse anti-VNR antibody, clone 23C6, Serotec, Oxford, UK. 2. Anti-Mouse IgG-488; Invitrogen. 3. Synergy HT BioTek or similar fluorescence place reader.
3. Methods All steps from obtaining the blood sample to the end point of the culture should be carried out under sterile conditions and using sterile tubes, media, and instrumentation. Be careful when working with human blood and adhere to any local rules pertaining to the use of unscreened blood. Wear gloves and perform the cell isolation and culture procedures in a sterile flow hood. 3.1. Isolation of PBMCs from Peripheral Blood or Buffy Coats
PBMCs for generating human osteoclasts in vitro can be isolated from venous blood samples or from buffy coats, which are usually available from the local blood bank. Ethical approval should be in place for all studies with human tissues. Venous blood samples are a source of fresh cells available on demand and enable the study of osteoclasts from patients with bone diseases (see Note 1). The major advantage of using buffy coats is that a single sample (~50 ml) contains the white cells of 450 ml of whole blood of one donor, and therefore enables isolation of far greater number of osteoclast precursors. The procedure for isolating osteoclast precursors from both samples is very similar (Fig. 1). 1. Dilute the blood sample or buffy coat with an equal volume of PBS. 2. Prepare 50-ml tubes containing 15-ml Ficoll or lymphoprep per tube (see Note 2). 3. Carefully layer 30 ml of the diluted blood/buffy coat on to 15-ml Ficoll/lymphoprep (see Note 3). 4. Centrifuge at 800 × g for 20 min, with brake set to zero. 5. Collect the mononuclear cell layer from each tube and transfer to two new 50-ml tubes. 6. Add PBS to a volume of 45 ml per tube to wash the cells. 7. Centrifuge at 300 × g for 10 min (brake can be used from this stage onwards). 8. Discard the supernatants and resuspend the cell pellet in each tube in 40 ml PBS (second wash) (see Note 4). 9. Centrifuge at 300 × g for 10 min and discard the supernatants from each tube.
11
Generation of Human Osteoclasts from Peripheral Blood
165
10. The cells can then be further purified using magnetic bead separation (see Subheading 3.2), put straight into culture to expand the M-CSF-dependent macrophages (see Subheading 3.3), or frozen down for future use (see Subheading 3.4). 3.2. Purification of CD14+ Osteoclast Precursor Cells
An optional step following the isolation of PBMCs is to purify CD14+ cells, thereby obtaining a pure osteoclast precursor population. Since other cells capable of affecting osteoclastogenesis (such as stromal cells and lymphocytes) are absent, this type of culture is more suitable for studies investigating direct effects of growth factors, cytokines, and glucocorticoids, for example, on osteoclast formation or function. Figure 4 shows that TRAcP-positive osteoclast-like cells are observed in unpurified PBMC cultures even when cultured without RANKL, suggesting the presence of nonosteoclastic cells that express osteoclastogenic factors. Such osteoclast-like cells are not seen in cultures of CD14+ cells without RANKL. The disadvantages of cell selection are the extra time
Fig. 4. Images of TRAcP-stained cells after 10 days of culture. In the PBMC cultures, several multi-nuclear TRAcP-positive cells are seen even after culture in the absence of RANKL (black arrows) while in the CD14+ sorted preparation, multinuclear TRAcP-positive cells are seen only following culture in the presence of RANKL.
166
K. Henriksen et al.
required and the high cost of the CD14+ beads. In addition, the volume of blood needed is increased, as CD14+ cells constitute only ~10% of the PBMCs. Please note that the beads are autofluorescent, especially towards the red end of the visible spectrum, and this may interfere with fluorescent staining at the end of the culture period. 3.2.1. Preparation of the Magnetic Beads
Please note that the numbers and volumes in this protocol are adjusted for the purification of one buffy coat, which corresponds to 450 ml of whole blood. 1. Shake the vial containing the beads vigorously (without vortexing). 2. Add 5 ml cold PBS into 2× 15-ml tubes. 3. Add 125 μl beads (4 × 108 beads/ml) to each tube and mix gently. 4. Place the tubes in the magnetic device for 1 min. 5. Remove the supernatant while the tube is in the magnetic device. 6. Wash three times with 5 ml/tube cold PBS and discard supernatant.
3.2.2. CD14+ Cell Purification
1. Resuspend the cell pellets (from Subheading 3.1, step 10) in cold PBS containing 2% FCS and combine to a final volume of 10 ml. 2. Add 5 ml cell suspension/tube to the beads (in both tubes) (see Note 5). 3. Incubate the cells/beads suspension at 4°C for 20 min with end-over-end rotation. 4. Place the tubes in the magnetic devices for 2 min. 5. Discard the supernatants while the tube is in the magnetic devices. 6. Wash the cells with 5 ml cold PBS + 2% FCS/tube. Pipette gently up and down to resuspend the beads. 7. Place the tubes in the magnetic devices for 2 min. 8. Discard the supernatants while the tubes are in the magnetic devices. 9. Repeat the washing step five times. Resuspend in 20 ml medium and count the cells (see Note 6).
3.3. Expansion of Macrophages/ Osteoclast Precursors
By expanding the macrophages prior to differentiating the osteoclasts, differences between donors can be largely eliminated as identical numbers of osteoclast precursors can be seeded prior to the addition of RANKL. In addition, expansion of precursors in bulk prior to seeding for osteoclast generation also prevents the
11
Generation of Human Osteoclasts from Peripheral Blood
167
variability that arises if the osteoclast precursors are expanded directly in the culture plate to be used for analysis. We normally expand precursors in 75-cm2 flasks. 1. Resuspend cells in supplemented α-MEM containing 20 ng/ ml M-CSF (see Note 7). Seed at a density of 250,000 cells/ cm2 if using non-purified PBMCs or seed at 150,000 cells/cm2 if using CD14+ cells. If using PBMCs from venous blood samples, it is not necessary to count the cells; seed the cells isolated from 15 to 20 ml blood in one 75-cm2 flask (typically, 1.5–2 × 107 cells). 2. Culture the proliferating cells, feeding with fresh media containing 20 ng/ml M-CSF every 3 days, until they reach a suitable confluency. For osteoclast generation in situ (in the same flask), culture until cells are 80% confluent and continue the protocol as under Subheading 3.6. For osteoclast generation in other culture vessels or on glass or dentine, precursors can be cultured until 95% confluent. Typically, the expansion period is 6–7 days, but each culture behaves differently (see Note 8). 3. To harvest the precursors, wash twice in PBS, digest with trypsin for 15–30 min, and remove cells with a cell scraper, see Subheading 3.6. Typical yields are 0.5–2 × 106 cells/flask. 3.4. Cryopreservation of Osteoclast Precursors
PBMCs (isolated as described in Subheading 3.1) can be cryopreserved for future use. An alternative and the preferred option is, however, to cryopreserve the expanded macrophages, which can be cultured directly with RANKL upon thawing, significantly shortening the time required to generate osteoclasts (see Note 9). These approaches are particularly useful for valuable samples, such as patient cells, in which all the necessary analyses may not be able to be carried out immediately. 1. The freezing solution consists of 45% α-MEM, 45% FCS, and 10% DMSO. To prepare, add an equal volume of ice-cold 20% DMSO in FCS to cells at twice the required freezing density, suspended in α-MEM containing 10% FCS. 2. Freeze PBMCs at 60–100 × 106 cells per vial to be able to seed two 75-cm2 flasks with one vial. 3. Freeze macrophages at 0.5–2 × 106 cells/vial.
3.5. Generation of Osteoclasts for Assessment of Osteoclastogenesis
1. Adjust concentration of macrophages to 2 × 105/ml in supplemented α-MEM containing 20 ng/ml MCSF plus RANKL (20 ng/ml human RANKL or 2 ng/ml murine RANKL; see Note 10), and seed 100 μl (i.e. 2 × 104 cells) into wells of a 96-well plate. Use replicates of at least four for each separate treatment, and include cells incubated without RANKL (i.e. medium with M-CSF alone) as a control.
168
K. Henriksen et al.
2. The following day, feed the cells with fresh α-MEM containing M-CSF and RANKL as appropriate, plus the experimental treatments (see Note 11). 3. Feed cells as above every 3 days until osteoclasts are formed. This is typically 4–6 days from first addition of RANKL. 4. Remove the medium, rinse off the non-adherent cells with PBS, and then fix the cells in 4% paraformaldehyde in PBS. 5. Osteoclasts can now be stained as necessary. Staining for VNR and nuclear DNA, described in Subheading 3.7.1 below, is ideal for determining osteoclastogenesis. Furthermore, by counting VNR-positive cells with one to two nuclei and those with three or more nuclei separately, effects on differentiation of osteoclast precursors can be distinguished from effects on precursor fusion. 3.6. Generation of Osteoclasts for Functional Studies
While it is possible to differentiate osteoclasts directly on mineralized surfaces, using the conditions described in Subheading 3.5, the precursors often adhere erratically, leading to large variation even between replicas. Variability is greatly reduced by using mature osteoclasts in resorption assays. In addition, this removes further osteoclast formation as a confounder from resorption studies. To perform functional studies with mature osteoclasts, proceed as below. 1. After expansion of macrophages to ~80% confluency (see Subheading 3.3, step 2), consider how many osteoclasts are required and transfer the appropriate amount of expanded macrophages to an appropriately sized culture vessel. You may also proceed with the T75 flask and generate osteoclasts in situ (see Note 11). 2. Feed the cells with fresh medium containing M-CSF and RANKL to drive osteoclastogenesis. 3. Change the medium every 3 days by removing all medium and replacing it with fresh medium containing M-CSF and RANKL. 4. After app. 6–7 days, multi-nucleated osteoclasts have formed in high numbers and they are ready to be reseeded on a resorbable substrate. 5. Wash cells 3× in PBS. 6. Add 4 ml trypsin per 75 cm2 flask (or equivalent if using different size culture vessel) and incubate for 15 min or until most cells become shrunken in appearance with spiky edges. Note that if the osteoclasts are large and well-spread, this process may take up to 1 h. In our experience, this does no lasting damage to the majority of cells and they are able to adhere as normal even after 1 h in trypsin (see Note 12).
11
Generation of Human Osteoclasts from Peripheral Blood
169
7. Neutralize trypsin by adding α-MEM containing 10% FCS. 8. Detach the remaining adherent cells by scraping very carefully using a cell scraper while keeping the tissue culture vessel flat, and transfer the cells and the medium to a 50-ml tube. 9. Pellet the osteoclasts by centrifuging for 5 min at 200 × g. 10. Resuspend the pellet in α-MEM containing MCSF and RANKL cells. 11. Count osteoclasts and seed on cortical bone, dentine, or other mineralized substrate (see Note 13) at a density of up to 30,000 cells/well of a 96-well plate (see Note 14). 12. Allow osteoclasts to attach for at least 3 h before changing medium and adding treatments. 13. Culture osteoclasts for the desired period. Normally, sufficient resorption has been achieved after 48 h to measure the effect of resorption inhibitors; however, the cultures can be continued for 10–15 days if required, changing the medium and other additives every 3rd day. If quantifying CTX-I or calcium release (see Subheading 3.8), culture supernatants should be collected when changing medium. 14. At the end of the experiment, fix cells in 4% paraformaldehyde in PBS for cellular analysis or alternatively place the slices of bone (or dentine or other mineralized substrate) slices in distilled water to remove the cells for resorption pit analysis (see Subheadings 3.7 and 3.8). 3.7. Analysis of Osteoclast Formation 3.7.1. Assessment of Vitronectin ReceptorPositive Cells
Osteoclast formation on plastic, e.g. in 96-well plates, can be quantified by staining for VNR and a nuclear stain, such as DAPI. Using fluorescent microscopy, the number of multi-nucleated, VNRpositive cells can be manually counted and distinguished from VNR-positive cells containing only one or two nuclei differentiating effects on osteoclast formation from those on osteoclast fusion. Alternatively, the fluorescence intensity in each well can be measured using a fluorescence plate reader to provide an objective measure of osteoclast formation. To do so, proceed from Subheading 3.6, step 13, as follows. 1. Fix cells in 4% paraformaldehyde in PBS for 10 min. 2. Wash cells three times in PBS. 3. Block non-specific antibody binding by incubating in PBS containing 10% FCS for 30 min at room temperature. 4. Incubate with anti-VNR antibody at 1 μg/ml in PBS containing 5% FCS for 1 h at room temperature. Make sure to earmark a couple of wells as “negative control” to assess non-specific staining. These wells are incubated with PBS containing 5% PBS only.
170
K. Henriksen et al.
5. Remove the antibody and wash the cells with three changes of fresh PBS. 6. Incubate the cells with an Alexofluor fluorescent secondary antibody at 1:150 dilution in PBS containing 5% FCS for 1 h at room temperature. 7. Remove the secondary antibody and wash the wells with three changes of fresh PBS. 8. Finally, add 100 μl PBS to each well and count the cells using an inverted fluorescence microscope using an appropriate filterset. 9. Alternatively, read the fluorescence from the bottom of each well (excitation 488 nm; emission 528 nm) using an appropriate plate reader (we currently use a Synergy HT BioTek). To calculate fluorescence intensity per well, deduct the average value obtained from the negative-control wells. 3.7.2. Measurement of TRAcP Activity in the Supernatant
Osteoclast numbers can be assessed by measuring TRAcP activity in supernatants using a colorimetric assay (19). Supernatants from the appropriate matrix, i.e. bone slices incubated without osteoclasts, should be used to provide the background values. Supernatants collected for TRAcP activity measurements can be stored in −20°C until analysis. 1. Use 8 ml of TRAcP solution buffer (see Subheading 2.2) for each 96-well plate. Transfer 20 μl (see Note 15) sample to a 96-well plate in duplicates. 2. Add 80 μl TRAcP solution buffer to each well. 3. Cover the plate with tin foil to protect from light and prevent evaporation. 4. Incubate the plate on a shaker at 3–400 rpm at 37°C for 1 h. 5. Stop the reaction by adding 100 μL 0.3 N NaOH per well. 6. Measure the absorbance at 650 nm while subtracting OD 405 nm as background values. 7. Subtract the background values from each experimental well and plot the mean absorbance of each duplicate sample; the higher the absorbance value, the greater the activity of TRAcP and therefore the greater the number of osteoclasts (18).
3.7.3. Alternative Measurements of Osteoclast Formation
To assess overall human osteoclast formation, western blotting of lysates can be used to analyze the expression of osteoclast-specific proteins, such as cathepsin K, TRAcP, and MMP9, all proteins for which useful reagents are commercially available. In addition, qPCR can be used to analyze osteoclast-specific gene expression at the mRNA level.
11
3.8. Analysis of Osteoclast Activity
3.8.1. Microscopic Analysis of Resorption Pits
Generation of Human Osteoclasts from Peripheral Blood
171
The most common ways to assess osteoclast activity are to measure the area of the resorbed pits on the dentine or to measure the amount of calcium or collagen fragments released into the medium. To allow for possible differences in the number of osteoclasts, it is recommended to express as a function of osteoclast number. We routinely assess osteoclast number by immunostaining for VNR (see Subheading 3.7.1 above) and counting the number of polarized, active cells according to the presence of an F-actin ring after staining with fluorescent phalloidin conjugates. Expressing resorptive activity as a function of osteoclasts containing F-actin rings can help to elucidate mechanistic effects. For example, normal numbers of osteoclasts expressing actin rings, together with decreased resorption, indicate a defect in the effector pathways of resorption, such as vesicular trafficking to the ruffled border. This is seen in osteoclasts from osteopetrosis patients carrying mutations in ClC-7 or Plekhm1 (19, 23, 28) or in osteoclasts treated with phosphonocarboxylate inhibitors of Rab prenylation. 1. Remove the cells from the bone slices using a cotton swab. 2. Wash away cell debris in MilliQ. 3. Incubate the bone slices for 8 min in Mayer’s hematoxylin. 4. Wash the bone slices in MilliQ water. 5. The resorbed area (see Note 16) can be measured under conventional light microscopy using CAST-Grid (Olympus). Alternatively, resorption pit area can be measured using reflected light microscopy, without the need for the staining with hematoxylin (see, for example, Chapter 10, this volume, on rabbit osteoclasts).
3.8.2. Measurement of Calcium or Collagen Fragments in the Supernatant
The concentration of calcium or degraded collagen fragments in the supernatant are other quantitative measures of resorptive activity, which have the potential advantage that they take account of the overall volume of resorption, rather than just the area of the resorption pits. Calcium can be measured in culture supernatants by colorimetric assay using a Hitachi 912 Automatic Analyzer (Roche Diagnostics), using supernatants from bone slices incubated without osteoclasts as background values (29). The release of the c-terminal type I collagen fragments (CTX-I) from bone or dentine slices can be determined using the CrossLaps for Culture kit (IDS Nordic), according to the manufacturer’s instructions. Once again, supernatants from slices incubated without osteoclasts should be used to provide background values.
172
K. Henriksen et al.
4. Notes 1. PBMCs can still be isolated successfully 48 or 72 h after blood collection, provided the samples are stored at 4°C. This allows cultures to be set up for diagnostic assessment from fresh patient samples. If no reliable courier can be found to guarantee shipment within this time, it is safer to isolate PBMCs at the site of sample collection, freeze the cells as per the protocol in Subheading 3.4), and send the cells on dry ice. 2. Ficoll and lymphoprep are equally effective for isolating PBMCs (30). 3. Layering 25-ml diluted buffy coat sample onto 25-ml Ficoll/ lymphoprep (i.e. 1:1 ratio) is also effective. 4. If the pellets contain a lot of red blood cells, they can be resuspended and incubated in Pharm Lyse (BD Biosciences) for 15 min to eliminate this. Centrifuge at 200 × g for 10 min after the incubation and continue with the PBS wash step, but reduce centrifuge steps to 200 × g. This is particularly useful for patient blood samples that may have been in transit for 24–48 h. 5. Titration of Dynabeads® numbers is very important, and this needs to be done for individual types of blood preparations. 6. We always work with a fixed protocol for a fixed blood volume. The yield is usually around 6 × 108 cells from one buffy coat, of which around 6 × 107 are CD14+ cells. 7. M-CSF concentrations used vary widely between different laboratories, and we recommend a titration step if setting up the procedure for continuous use. Otherwise, 20 ng/ml is the recommended concentration. 8. Osteoclast precursors tend to stop proliferating after around 8 days in culture with M-CSF; therefore, there is little benefit to culturing precursors beyond 8 days. Furthermore, the osteoclastogenic potential also appears to be lost with prolonged expansion. 9. We usually allow the thawed macrophages to recover overnight in medium containing M-CSF, before stimulating osteoclastogenesis with RANKL. 10. Although the M-CSF used must be of human origin, either human or mouse RANKL can be used. Mouse RANKL is the more potent of the two, effective at a concentration of 2 ng/ ml. We recommend performing a titration experiment to establish the optimal concentration to give the best osteoclast yield. 11. Osteoclasts can be formed in different sizes of culture vessel. Small-scale cultures may be appropriate, where only relatively
11
Generation of Human Osteoclasts from Peripheral Blood
173
small numbers of cells are required, for example if pretreating with compounds or transducing with a virus prior to analysis of resorptive activity. 12. During trypsinisation and scraping, many of the larger osteoclasts do not survive. It is, therefore, important to transfer osteoclasts before the culture has progressed to the point at which all the osteoclasts are too large; in our experience, they should be no bigger than seven to eight nuclei. 13. Cortical bovine bone slices and dentine slices are the best-characterized substrate for human osteoclasts. 14. Thirty thousand cells is a very high cell density, but is often required if calcium release is used as a measure of resorption. For analysis of pit area or CTX-I evaluation, the number of cells can be reduced. We routinely seed cells derived from one well of a 6-well plate onto 20 dentine slices. 15. The dilution of the supernatant needed for the measurement of TRAcP cannot be pre-specified as it not only depends on the number of osteoclasts, but also on the sensitivity of the plate reader. Therefore, it is recommended to start out with 20 μL, and then test lower volumes if the signal is saturated. 16. Resorption pits generated by human osteoclasts are generally resorption trails as a result of the high motility of the osteoclasts. It is, therefore, difficult to score the number of individual pits. The preferred method is, therefore, to measure the resorption area. References 1. Roodman, G. D. (1999) Cell biology of the osteoclast. Exp. Hematol. 27, 1229–1241. 2. Baron, R., Neff, L., Louvard, D., and Courtoy, P. J. (1985) Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J. Cell Biol. 101, 2210–2222. 3. Osdoby, P., Martini, M. C., and Caplan, A. I. (1982) Isolated osteoclasts and their presumed progenitor cells, the monocyte, in culture. J. Exp. Zool. 224, 331–344. 4. Boyle, W. J., Simonet, W. S., and Lacey, D. L. (2003) Osteoclast differentiation and activation. Nature 423, 337–342. 5. Segovia-Silvestre, T., Neutzsky-Wulff, A. V., Sorensen, M. G., Christiansen, C., Bollerslev, J., Karsdal, M. A., and Henriksen, K. (2009) Advances in osteoclast biology resulting from the study of osteopetrotic mutations. Hum. Genet. 124, 561–577.
6. Fujikawa, Y., Quinn, J. M., Sabokbar, A., McGee, J. O., and Athanasou, N. A. (1996) The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 137, 4058–4060. 7. Vaananen, H. K., and Horton, M. (1995) The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. J. Cell Sci. 108(Pt 8), 2729–2732. 8. Teitelbaum, S. L. (2000) Bone resorption by osteoclasts. Science 289, 1504–1508. 9. Baron, R. (2003) Anatomy and biology of bone matrix and cellular elements, in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, American Society for Bone and Mineral Research, Washington, pp. 1–8. 10. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I.,
174
11.
12.
13.
14.
15.
16.
17.
18.
19.
K. Henriksen et al. Shalhoub, V., Senaldi, G., Guo, J., Delaney, J., and Boyle, W. J. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165–176. Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S. I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., Kanno, T., Murakami, A., Tsuda, E., Morinaga, T., and Higashio, K. (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139, 1329–1337. Horton, M. A., Rimmer, E. F., Lewis, D., Pringle, J. A., Fuller, K., and Chambers, T. J. (1984) Cell surface characterization of the human osteoclast: phenotypic relationship to other bone marrow-derived cell types. J. Pathol. 144, 281–294. Coxon, F. P. and Taylor, A. (2008) Vesicular trafficking in osteoclasts. Semin. Cell Dev. Biol. 19, 424–433. Blair, H. C., Teitelbaum, S. L., Ghiselli, R., and Gluck, S. (1989) Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 245, 855–857. Helfrich, M., Crockett, J. C., Hocking, L. J., and Coxon, F. P. (2007) The Pathogenesis of osteoclast diseases: some knowns, but still many unknowns. BoneKey-Osteovision 4, 61–77. Chavassieux, P., Karsdal, M. A., SegoviaSilvestre, T., Neutzsky-Wulff, A. V., Chapurlat, R., Boivin, G., and Delmas, P. D. (2008) Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis. J. Bone Miner. Res. 23, 1076–1083. Fujikawa, Y., Sabokbar, A., Neale, S., and Athanasou, N. A. (1996) Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis. Ann. Rheum. Dis. 55, 816–822. Karsdal, M. A., Hjorth, P., Henriksen, K., Kirkegaard, T., Nielsen, K. L., Lou, H., Delaisse, J. M., and Foged, N. T. (2003) Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J. Biol. Chem. 278, 44975–44987. Henriksen, K., Gram, J., Schaller, S., Dahl, B. H., Dziegiel, M. H., Bollerslev, J., and Karsdal, M. A. (2004) Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. Am. J. Pathol. 164, 1537–1545.
20. Sorensen, M. G., Henriksen, K., Schaller, S., Henriksen, D. B., Nielsen, F. C., Dziegiel, M. H., and Karsdal, M. A. (2007) Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. J. Bone Miner. Metab. 25, 36–45. 21. Henriksen, K., Sorensen, M. G., Nielsen, R. H., Gram, J., Schaller, S., Dziegiel, M. H., Everts, V., Bollerslev, J., and Karsdal, M. A. (2006) Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification. J. Bone Miner. Res. 21, 58–66. 22. Sorensen, M. G., Henriksen, K., NeutzskyWulff, A. V., Dziegiel, M. H., and Karsdal, M. A. (2007) Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption. J. Bone Miner. Res. 22, 1640–1648. 23. Van Wesenbeeck, L., Odgren, P. R., Coxon, F. P., Frattini, A., Moens, P., Perdu, B., MacKay, C. A., Van Hul, E., Timmermans, J. P., Vanhoenacker, F., Jacobs, R., Peruzzi, B., Teti, A., Helfrich, M. H., Rogers, M. J., Villa, A., and Van Hul, W. (2007) Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J. Clin. Invest. 117, 919–930. 24. Taylor, A., Rogers, M. J., Tosh, D., and Coxon, F. P. (2007) A novel method for efficient generation of transfected human osteoclasts. Calcif. Tissue Int. 80, 132–136. 25. Coxon, F. P., Helfrich, M. H., Larijani, B., Muzylak, M., Dunford, J. E., Marshall, D., McKinnon, A. D., Nesbitt, S. A., Horton, M. A., Seabra, M. C., Ebetino, F. H., and Rogers, M. J. (2001) Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J. Biol. Chem. 276, 48213–48222. 26. Henriksen, K., Gram, J., Hoegh-Andersen, P., Jemtland, R., Ueland, T., Dziegiel, M. H., Schaller, S., Bollerslev, J., and Karsdal, M. A. (2005) Osteoclasts from patients with Autosomal Dominant Osteopetrosis type I (ADOI) caused by a T253I mutation in LRP5 are normal in vitro, but have decreased resorption capacity in vivo. Am. J. Pathol. 167, 1341–1348. 27. Del Fattore, A., Peruzzi, B., Rucci, N., Recchia, I., Cappariello, A., Longo, M., Fortunati, D., Ballanti, P., Iacobini, M., Luciani, M., Devito, R., Pinto, R., Caniglia, M., Lanino, E., Messina, C., Cesaro, S., Letizia, C., Bianchini, G., Fryssira, H., Grabowski, P., Shaw, N., Bishop, N., Hughes, D., Kapur, R. P., Datta, H. K.,
11
Generation of Human Osteoclasts from Peripheral Blood
Taranta, A., Fornari, R., Migliaccio, S., and Teti, A. (2006) Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J. Med. Genet. 43, 315–325. 28. Karsdal, M. A., Henriksen, K., Sorensen, M. G., Gram, J., Schaller, S., Dziegiel, M. H., Heegaard, A. M., Christophersen, P., Martin, T. J., Christiansen, C., and Bollerslev, J. (2005) Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am. J. Pathol. 166, 467–476.
175
29. Henriksen, K., Gram, J., Neutzsky-Wulff, A. V., Jensen, V. K., Dziegiel, M. H., Bollerslev, J., and Karsdal, M. A. (2009) Characterization of acid flux in osteoclasts from patients harboring a G215R mutation in ClC-7. Biochem. Biophys. Res. Commun. 378, 804–809. 30. Yeo, C., Saunders, N., Locca, D., Flett, A., Preston, M., Brookman, P., Davy, B., Mathur, A., and Agrawal, S. (2009) Ficoll-Paque versus Lymphoprep: a comparative study of two density gradient media for therapeutic bone marrow mononuclear cell preparations. Regen. Med. 4, 689–696.
sdfsdf
Chapter 12 Osteoclast Formation in Mouse Co-cultures Cecile Itzstein and Robert J. van ’t Hof Abstract The murine co-culture assay is used to generate mature osteoclasts from bone marrow precursors by culturing them with osteoblasts that are stimulated with 1,25-dihydroxy vitamin D3 and prostaglandin E2. This assay is used particularly to analyse osteoblast–osteoclast interactions and to determine the cell type affected in knock-out or transgenic mice. This chapter describes also the isolation of bone marrow cells from mice and the methods to purify and replate mature osteoclasts. Key words: Co-culture, Osteoclasts, Osteoblasts
1. Introduction The murine co-culture assay originally described by Takahashi et al. (1), was the first culture system developed that generated genuine, bone-resorbing osteoclasts. In this assay, osteoblasts are stimulated with 1,25-dihydroxy vitamin D3 (1,25-(OH)2D3) and prostaglandin E2 (PGE2) to promote RANKL and M-CSF expression. These factors then stimulate early osteoclast precursors present in the spleen or bone marrow cell populations to differentiate into mature osteoclasts. At the end of the culture, osteoclasts can be identified by TRAcP staining, and, when the cultures are performed on dentine slices, resorption activity can be measured as well. Even though nowadays it is possible to generate osteoclasts from bone marrow cells alone by treating the cultures with RANKL and M-CSF, the co-culture system is still a useful model for studying osteoblast–osteoclast interactions and to determine the cell type affected in knock-out or transgenic mice. It has been widely used to study the origin of the osteoclast (2) and the effects of growth factors and drugs on osteoclast formation (3, 4). In studies with osteopetrotic mice, the co-culture assay has been used to Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_12, © Springer Science+Business Media, LLC 2012
177
178
C. Itzstein and R.J. van ’t Hof
determine whether the underlying mechanism was due to a defect in the osteoblasts or a defect in the osteoclast precursors (5). We also describe here the methods for detaching and replating mature osteoclasts using collagen gel-coated plates and for purifying osteoclasts formed in co-culture.
2. Materials 2.1. General Reagents/ Materials
1. Sterile instruments (scissors, forceps, scalpels). 2. Sterile syringes and needles (19 and 25 G). 3. Ficoll or Lymphoprep (Axis-Shield). 4. Sterile Petri dishes. 5. Conical polypropylene centrifuge tubes. 6. Falcon tissue culture plates (see Note 1).
2.2. Tissue Culture Reagents
1. Culture medium: α-MEM supplemented with 10% FCS and antibiotics. 2. Hank’s balanced salt solution (HBSS). 3. HBSS supplemented with 10% FCS. 4. Collagen gel (cellmatrix type 1A) from Nitta Gelatin Inc. (Japan) (available from Wako Chemicals in Europe and USA). To the 100-ml bottle of collagen gel, add 20 ml of 1 mM HCl pH 3.0 and store the bottle at 4°C. 5. 5× concentrarted α-MEM. 6. 200 mM hydroxyethylpiperazine-N¢-2-ethanesulfonic acid (HEPES) buffer, pH 7.4 containing 2.2% NaHCO3. 7. 1,000× concentrated stock of 1,25(OH)2D3 (10−5 M in ethanol, Sigma), further referred to as D3. 8. 1,000× concentrated stock of Prostaglandin E2 (10−3 M in ethanol, Sigma), further referred to as PGE2. 9. Collagenase solution: α-MEM containing 0.1% collagenase type IA (Sigma) and sterilised using a 0.22-μm filter. Make fresh before use. 10. Pronase-EDTA solution: PBS containing 0.001% pronase (Sigma) and 0.02% EDTA (Sigma). Make fresh before use. 11. Dentine slices: we use elephant ivory, cut into slices of approximately 200 μm thickness using a Buehler Isomet low-speed saw with a diamond wafering blade (series 15 HC). Out of these slices we punch discs that fit the wells of a 96-well plate, using a paper puncher (see Notes 2 and 3).
12
2.3. TRAcP Stain Reagents
Osteoclast Formation in Mouse Co-cultures
179
1. Naphtol-AS-BI-phosphate stock: 10 mg/ml Naphtol-AS-BIphosphate in dimethylformamide (Sigma). Stable ±1 week at 4°C. 2. Veronal buffer: 1.17 g sodium acetate anhydrous, 2.94 g veronal (sodium barbiturate). Dissolve in 100 ml distilled water. 3. Acetate buffer 0.1 N, pH 5.2: (a) Dissolve 0.82 g sodium acetate anhydrous in 100 ml distilled water. (b) 0.6 ml Glacial acetic acid, make up to 100 ml with distilled water. (c) Adjust the pH of solution (a) to pH 5.2 with solution (b). 4. 100 mM Tartrate: Dissolve 2.3 g of sodium tartrate in 100 ml of acetate buffer. 5. Pararosanilin, acridinfrei: add 1 g Pararosanilin to 20 ml distilled water and add 5 ml concentrated hydrochloric acid, heat carefully for 15 min in a 95°C water bath while stirring, and filter once the solution has cooled down. Solutions 2–5 are stable for months if kept protected from light in a refrigerator.
3. Methods 3.1. Osteoblasts
The assay starts with the isolation of the cell populations needed. Although some groups have reported good results with osteoblastlike cell lines, such as ST2 cells (6), we have not been very successful with these and use primary osteoblasts isolated from the calvaria of 2–3 day old neonatal mice (see Chapter 2, this volume). The osteoblasts are plated on plastic, collagen gel or dentine 1 day before the addition of the bone marrow cells.
3.2. Isolation of Bone Marrow Cells
Although the assay was originally described using spleen cells ((1), see Note 4), we generally use bone marrow cells as the source of osteoclast progenitors. Furthermore, others have successfully used certain haemopoietic stem cell lines, such as C2GM cells (7). 1. Dissect the femurs and tibia out of a mouse (3–8 weeks old). 2. Flush out the marrow using a 25 G needle and HBSS + 10% FBS. 3. The cells are collected by centrifugation at 300 × g for 3 min and resuspended in 1 ml of culture medium. Alternatively: ●
Get a single cell suspension by squeezing the cell suspension through needles of decreasing size (start with 19 G, end with 25 G).
180
C. Itzstein and R.J. van ’t Hof ●
Remove red blood cells by Ficoll density centrifugation (600 × g, 25 min, brake off).
●
Harvest the bone marrow cells from interface and wash once in HBSS.
●
Resuspend in 1 ml of culture medium.
4. Keep the cells on ice until use (but try and get the cells in culture as soon as possible). To perform mix-match experiments using osteoblasts and bone marrow cells from mice of different genotypes, it is necessary to isolate the haematopoietic precursors from the total population of bone marrow cells. It is possible to use Ficoll gradients or to simply culture the cells overnight in culture medium allowing the mesenchymal stromal cells to adhere to the tissue culture plate. Harvest the non-adherent bone marrow cells by centrifuging the medium the next day and proceed as described in Subheading 3.3 using similar cell numbers. 3.3. Setting Up the Co-culture
The optimal number of bone marrow cells and osteoblasts per well may vary and is dependent on the mouse strain used. For the C57Bl/6 mouse strain, we use routinely the following seeding densities give optimal numbers of osteoclasts. In a 6-well plate: 1. On day 0, plate 1 × 105 osteoblasts in 2 ml medium per well. 2. On day 1, remove the medium and add 2 × 106 freshly isolated bone marrow cells or non-adherent bone marrow cells in 2 ml medium/well. The medium should contain 10 nM D3 + 1 μM PGE2. 3. On day 3, gently remove 1.5–1.7 ml medium from each well and add 2 ml of fresh medium containing 10 nM D3 + 1 μM PGE2 (see Note 5). 4. Proceed with the co-culture for up to 4–6 more days by changing the media every other day or until multinucleated osteoclasts are observed. The medium changes need to be done very carefully because the confluent layer of osteoblasts can be quite easily disturbed, and come off (see Note 5). This would result in a total absence of osteoclasts. Usually, the first osteoclasts appear on day 4 or 5 (see Note 6). Reasonable numbers of osteoclasts (see Note 7) are present between day 7 and 9.
3.4. Collagen Gel Culture
Detaching mouse osteoclasts formed on plastic is very difficult even when using trypsin-EDTA or collagenase treatment. Therefore performing the co-culture assay on collagen gel-coated plates allows us to easily obtain mature functioning mouse osteoclasts (8) that can then be replated on various substrates such as dentine, plastic culture plates, or glass coverslips.
12
Osteoclast Formation in Mouse Co-cultures
181
1. To coat a 6-well plate, prepare the collagen gel-coating solution in a 50-ml tube by mixing: ●
7 parts of collagen gel.
●
2 parts of 5× concentrated αMEM.
●
1 part of 200 mM Hepes pH 7.4, 2.2% NaHCO3 buffer.
2. Mix without creating air bubbles by inverting gently the tube several times. 3. Add 1.5 ml of this solution to each well. 4. Incubate 30 min at 37°C until polymerisation. 5. Plate osteoblasts and bone marrow cells as described in Subheading 3.3. 6. Once osteoclasts are formed, wash the cells with α-MEM without serum. 7. Add 1 ml of 0.1% collagenase solution per well. 8. Incubate 15–20 min at 37°C with gentle shaking (30 cycles/ min in a shaking incubator or give a gentle swirl every 5 min). 9. The cells are collected by centrifugation at 300 × g for 3 min and resuspended in 5–8 ml of culture medium. 10. Plate 100 μl onto dentine slices to quantify the bone resorbing activity or on 96-well plate to evaluate osteoclast numbers. 3.5. Purification of Osteoclasts Obtained by Co-culture
In a co-culture, osteoclasts represent only 2–5% of the cells and further purification is essential for biochemical studies (9, 10). Osteoblasts and stromal cells can easily be removed either by peeling away the osteoblast monolayer or by treatment with pronaseEDTA solution. ●
If osteoblasts and stromal cells are forming a monolayer, rinse with PBS and gently squirt PBS on the wall of the well using a plastic Pasteur pipette to detach a corner of the layer. Once detached, rinse the cells with PBS.
●
If the cells are not confluent, rinse once with PBS and add 1 ml/well of pronase-EDTA solution. Incubate 5–10 min at 37°C and gently wash three times with PBS.
Using these techniques, the purity of osteoclasts is increased to more than 80% (9, 10). Purified osteoclasts need to be used rapidly because no growth factors, cytokines, or osteoblasts are present to maintain them alive. 3.6. Tartrate Resistant Acid Phosphatase Staining
Osteoclasts express very high levels of the enzyme tartrate resistant acid phosphatase (TRAcP) and can therefore be easily visualised by staining for this enzyme as follows ((11), see Notes 8–11). As an alternative to the protocol described here, a staining kit from Sigma (387-A, Leukocyte Acid Phosphatase staining kit) can be used.
182
C. Itzstein and R.J. van ’t Hof
This kit uses fast Garnet as the dye, and this leads to a very dark purple stain (see Chapter 8, this volume). 1. Rinse the culture with PBS. 2. Fix the cells for 5 min with 4% formaldehyde. 3. Rinse with PBS. 4. Prepare staining solution: Solution 1 In a glass container, add 150 μl Naphtol-AS-BI-phosphate stock to 750 μl Veronal buffer (pH 10.1). Then, add 0.9 ml Acetate buffer. Add 0.9 ml Acetate buffer with 100 mM Tartrate. Solution 2 120 μl Pararosanilin. 120 μl 4% NaNO2. Mix solutions 1 and 2, filter through a 0.45-μm filter and use immediately. 5. Incubate the cells for 30–60 min at 37°C with staining solution (50–100 μl/well of a 96-well plate). 6. Rinse with distilled water. 7. Store in 70% ethanol. Osteoclasts and mononuclear osteoclast precursors should be visible as bright red stained cells (see Fig. 1a). 3.7. Quantification of the Resorption Area
After the osteoclasts have been stained and counted, the slices are cleaned and the resorption pits can be visualised either by staining with dyes such as Toluidine blue or Coomassie blue, by scanning electron microscopy or by reflected light microscopy. We routinely use reflected light microscopy because it is easy to perform, the slices only need thorough cleaning and no staining, and the image obtained can be fairly easily quantified using image analysis. We use a Zeiss Axiolab reflected light microscope, fitted with a 2.5× lens, wide field c-mount adapter, and Diagnostics Instruments Insight B/W large chip digital camera. This set-up allows us to capture an entire bone slice in one image at sufficient resolution to identify and measure the resorption pits (see Fig. 1b). We developed our own image analysis software package using the Aphelion ActiveX image analysis toolkit from ADCIS (ADCIS SA, Hérouville-SaintClair, France). The program prompts the user to focus the slice to be measured (see Fig. 2a), captures the image, and identifies the dentine slice (see Fig. 2b) so that any dark objects outside the dentine slice can be automatically removed. Next, the resorption pits are identified using grey level thresholding and selection by shape (see Fig. 2c), and the resorption area is calculated. The entire process takes 2–3 min per slice. A non-automated system for quantification that works well is described in Chapter 8, this volume.
Fig. 1. End result of a co-culture. (a) Multinucleated osteoclast identified by TRAcP staining. (b) Resorption pits visualised by reflected light microscopy. The resorption pits stand out as dark objects. (c) Actin rings in the osteoclasts, visualised by phalloidin staining.
Fig. 2. Measurement of resorption pits. Clockwise from the top left: An image of the dentine slice is captured using a digital camera; The dentine slice is identified by the software; The resorption pits are detected using grey level thresholding.
184
C. Itzstein and R.J. van ’t Hof
4. Notes 1. Osteoblasts and bone marrow cells appeared to adhere better on Falcon tissue culture plates leading to better osteoclast differentiation. 2. Ivory is the preferred to cortical bone for this assay, since it is very even and does not contain osteocyte lacunae, which interfere with the identification of the resorption pits. 3. As we use reflected light microscopy and automated image capture to visualise the resorption pits at the end of the culture, it is important that the surface of the slices is as smooth and shiny as possible without compromising the cell adhesion to the dentine. Therefore, the slices are polished using a paper towel until the surface of the disc appears even under light reflected microscopy. Any remaining polish particles are removed by sonicating the dentine slices for ±15 min in 70% ethanol. The slices are stored in 70% ethanol until use. 4. Spleen cells can be used as an alternative to bone marrow cells in the co-culture. The advantage is, that they are easier to isolate than bone marrow cells. However, we generally get more consistent results using bone marrow. To use spleen cells, dissect the spleens out of two young adult mice. Use a bent 19 G needle to press the cells out of the spleen. Thoroughly resuspend the cells, load onto Ficoll, and proceed as described in the alternative method in Subheading 3.2, step 3 using similar cell numbers. 5. The most common problem with the co-culture is the osteoblast layer contracting and coming off the slice. This is usually due either to the plating density of the osteoblasts being too high or an uncareful medium refresh. Because of the last point, we do not remove completely the medium when changing it and we leave around 250–300 μl in each well. Make sure that the tip of the pipette does not touch the osteoblast layer. 6. Any drugs or factors to be tested can be present during different parts of the co-culture. To test effects on mature osteoclasts, drugs can be added during the last 2–3 days of the culture, whereas having the drugs present during the first 3–4 days gives an indication of effects on osteoclast precursors. 7. The usual yield of osteoclasts should be between 150 and 300 osteoclasts per slice. If the numbers are substantially lower, this may be due to non-optimal seeding densities. Although the seeding densities mentioned above work well for cells from C57Bl/6 mice, other mouse strains may need different densities. It should be noted that numbers of osteoblasts and bone marrow cells that are either too high or too low will both lead
12
Osteoclast Formation in Mouse Co-cultures
185
to a reduction of osteoclast numbers and a series of densities should be tested. 8. In this murine assay, the most convenient procedure is the TRAcP stain. However, it should be noted that in long term cultures, macrophage polykaryons become TRAcP positive as well (12). These macrophage polykaryons can be distinguished from osteoclasts by their staining for the macrophage antigen F4/80. Furthermore, the TRAcP stain as described here works fine for murine osteoclasts. However, when staining osteoclasts from different species, the concentration of tartrate may need to be changed. For human osteoclasts for example, we use a final concentration of 100 mM tartrate. 9. In some species, osteoclasts can easily be identified by immunohistochemical or immunofluorescent staining for the vitronectin receptor (13). However, reagents for detection of vitronectin receptor in the mouse are not easily available. 10. Osteoclasts can also be identified by the presence of calcitonin receptors (14). However, this procedure is too involved and time consuming for routine analysis as it involves using radiolabeled calcitonin and autoradiography. 11. Osteoclasts that are actively resorbing display an actin ring, and this can be visualised by staining the actin with phalloidin, coupled to rhodamine (Molecular Probes, or Sigma). Comparing total number of TRAcP positive osteoclasts with the number of cells displaying the actin ring gives an indication of the fraction of osteoclasts actively resorbing bone. References 1. Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J., and Suda, T. (1988) Osteoblastic cells are involved in osteoclast formation. Endocrinology 123, 2600–2602. 2. Hagenaars, C. E., Kawilarang-De Haas, E. W., van der Kraan, A. A., Spooncer, E., Dexter, T. M., and Nijweide, P. J. (1991) Interleukin-3dependent hematopoietic stem cell lines capable of osteoclast formation in vitro. J. Bone. Min. Res. 6, 947–954. 3. van ’t Hof, R. J. and Ralston, S. H. (1997) Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity. J. Bone. Min. Res 12, 1797–1804. 4. van ’t Hof, R. J., Armour, K. J., Smith, L. M., Armour, K. E., Wei, X., Liew, F. Y., and Ralston, S. H. (2000) Requirement of the inducible nitric oxide synthase pathway for IL-1- induced osteoclastic bone resorption. Proc. Natl. Acad. Sci. USA. 97, 7993–7998.
5. Lowe, C., Yoneda, T., Boyce, B. F., Chen, H., Mundy, G. R., and Soriano, P. (1993) Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc. Natl. Acad. Sci. USA 90, 4485–4489. 6. Udagawa, N., Takahashi, N., Akatsu, T., Tanaka, H., Sasaki, T., Nishihara, T., Koga, T, Martin, T. J., and Suda, T. (1990) Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc. Natl. Acad. Sci. USA 87, 7260–7264. 7. De Grooth, R., Mieremet, R. H., Kawilarang-De Haas, E. W., and Nijweide, P. J. (1994) Murine macrophage precursor cell lines are unable to differentiate into osteoclasts: a possible implication for osteoclast ontogeny. Int. J. Exp. Pathol. 75, 265–275. 8. Akatsu, T., Tamura, T., Takahashi, N., Udagawa, N., Tanaka, S., Sasaki, T., Yamaguchi, A., Nagata, N., and Suda, T. (1992) Preparation
186
C. Itzstein and R.J. van ’t Hof
and characterization of a mouse osteoclast-like multinucleated cell population. J. Bone Miner. Res. 7, 1297–1306. 9. Nakamura, I., Takahashi, N., Sasaki, T., Tanaka, S., Udagawa, N., Murakami, H., Kimura, K., Kabuyama, Y., Kurokawa, T., Suda, T., and Fukui, Y. (1995) Wortmannin, a specific inhibitor of phosphatidylinositol-3 kinase, blocks osteoclastic bone resorption. FEBS Lett. 361, 79–84. 10. Jimi, E., Ikebe, T., Takahashi, N., Hirata, M., Suda, T., and Koga, T. (1996) Interleukin-1 alpha activates an NF-kappaB-like factor in osteoclast-like cells. J. Biol. Chem. 271, 4605–4608. 11. Barka, T. and Anderson, P. J. (1962) Histochemical method for acid phosphatase
using hexazonium pararosanilin as coupler. J. Histochem. Cytochem. 10, 741–753. 12. Modderman, W. E., Tuinenburg-Bol Raap, A. C., and Nijweide, P. J. (1991) Tartrate-resistant acid phosphatase is not an exclusive marker for mouse osteoclasts in cell culture. Bone 12, 81–87. 13. Horton, M. A., Taylor, M. L., Arnett, T. R., and Helfrich, M. H. (1991) Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23 C6 inhibit dentine resorption and cell spreading by osteoclasts. Exp. Cell Res. 195, 368–375. 14. Nicholson, G. C., Horton, M. A., Sexton, P. M., D’Santos, C. S., Moseley, J. M., Kemp, B. E., Pringle, J. A., and Martin, T. J. (1987) Calcitonin receptors of human osteoclastoma. Horm. Metab Res. 19, 585–589.
Chapter 13 RANKL-Mediated Osteoclast Formation from Murine RAW 264.7 cells Patricia Collin-Osdoby and Philip Osdoby Abstract Extensive research efforts over the years have provided us with great insights into how bone-resorbing osteoclasts (OCs) develop and function and, based on such work, valuable antiresorptive therapies have been developed to help combat the excessive bone loss that occurs in numerous skeletal disorders. The RAW 264.7 murine cell line has proven to be an important tool for in vitro studies of OC formation and function, having particular advantages over the use of OCs generated from primary bone marrow cell populations or directly isolated from murine bones. These include their ready access and availability, simple culture for this pure macrophage/pre-OC population, sensitive and rapid development into highly boneresorptive OCs expressing hallmark OC characteristics following their RANKL stimulation, abundance of RAW cell-derived OCs that can be generated to provide large amounts of study material, relative ease of transfection for genetic and regulatory manipulation, and close correlation in characteristics, gene expression, signaling, and developmental or functional processes between RAW cell-derived OCs and OCs either directly isolated from murine bones or formed in vitro from primary bone marrow precursor cells. Here, we describe methods for the culture and RANKL-mediated differentiation of RAW cells into boneresorptive OCs as well as procedures for their enrichment, characterization, and general use in diverse analytical assays. Key words: Osteoclast, Osteoclast development, Bone resorption, RANKL, Mouse macrophage, RAW 264.7 cells
1. Introduction Osteoclasts (OCs) are cells uniquely responsible for dissolving the organic and inorganic components of bone during bone development and remodeling throughout life. They originate from hematopoietic precursors of the monocyte/macrophage lineage present in the bone marrow and peripheral circulation, and their numbers and/or activity frequently increase in a wide array of
Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_13, © Springer Science+Business Media, LLC 2012
187
188
P. Collin-Osdoby and P. Osdoby
clinical disorders associated with excessive bone loss (1). For many years, investigations into how OCs develop and function were hampered by considerable difficulties associated with isolating and culturing these normally rare cells. Whereas cell lines have frequently provided an invaluable research tool and are widely used to decipher mechanisms involved in osteoblast (OB) differentiation and bone formation, no immortalized cell lines for mature OCs exist and the few pre-OC cell lines that were reported either did not undergo full OC differentiation (2, 3) or involved coculture systems and cells that were not readily available to all researchers (4–6). To further compound the problem, it was difficult to reliably generate bone-resorptive OCs expressing mature OC characteristics from primary bone marrow or circulating precursor cells in vitro. This all changed with the breakthrough discovery of the key OC differentiation signal, receptor activator of nuclear factor κB ligand (RANKL), that triggers the full development and activation of OCs both in vitro and in vivo (7–9). During OB development or in response to specific hormonal or local signals, RANKL becomes highly expressed on the surface of OB/stromal cells and interacts with a receptor, RANK, upregulated by macrophage colony-stimulating factor (M-CSF) on the surface of pre-OCs to stimulate their fusion, differentiation, and resorptive function. Many researchers now routinely form OCs in vitro through the exogenous addition of soluble recombinant RANKL (in combination with M-CSF to stimulate pre-OC proliferation, survival, and RANK expression) to cultures of primary bone marrow cells or peripheral blood monocytes derived from various species (e.g., human, mouse, rat, rabbit, or chicken, as discussed in other chapters in this volume). However, such procedures still require the isolation of primary precursor populations, and in sufficient numbers, to provide enough in vitro generated OCs for experimentation or characterization. In addition to primary cells, at least one pre-OC cell line, murine macrophage RAW 264.7 cells, responds to RANKL stimulation in vitro to generate bone resorbing multinucleated OCs (RAW-OCs) with the hallmark characteristics expected for fully differentiated OCs (10–12). RAW cells have been extensively employed in macrophage studies for >30 years and were originally established from the ascites of a tumor induced in a male mouse by intraperitoneal injection of Abelson leukemia virus (although RAW cells do not secrete detectable virus particles) (13). RAW cells express the c-fms receptor for M-CSF (14) as well as M-CSF, perhaps explaining why they also express high levels of RANK (10) and do not require M-CSF as a permissive factor in their RANKL-induced formation into RAW-OCs. RAW cells are often used in studies of OC differentiation and function, in parallel or as a prelude to studies with OCs formed from primary cells. There are many advantages of this system over the
13
RANKL-Mediated Osteoclast Formation from Murine…
189
generation of OCs from primary cell populations, including the following: (1) ready access (making it unnecessary to schedule experiments around when primary cells may become available) and widespread availability of this cell line to most researchers, (2) easy culture and homogeneous nature of the pre-OC population (devoid of OBs, stromal, lymphocytes, or other cell types), (3) sensitive and very rapid RANKL-mediated formation of RAWOCs (within days), (4) very large number of RAW-OCs that can be generated (and, thus, RNA or protein for study), (5) high bone pit resorptive capability and expression of OC characteristics exhibited by RAW-OCs, (6) relative ease of transfection for genetic and regulatory manipulation, and (7) close correlation in characteristics, gene expression, signaling, and developmental or functional processes between RAW-OCs, OCs formed from primary precursor cells in vitro, and isolated in vivo formed OCs. In this chapter, we describe methods for the culture and RANKLmediated differentiation of RAW cells into bone-resorptive RAWOCs, the preparation of RAW-OC enriched populations by serum density gradient fractionation, and the culture and characterization of RAW-OCs. Such in vitro generated OCs can be analyzed using biochemical, immunological, physiological, molecular, functional, or other assays according to commonly employed procedures; see also various other chapters on osteoclasts in this volume.
2. Materials 2.1. Tissue Culture Medium, Solutions, and Supplies
All media and solutions are prepared with glass distilled water. 1. Culture medium: mix 90 ml of sterile Dulbecco’s modified Eagle medium (DMEM) supplemented with 4 mM L-glutamine, 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, and 1.0 mM sodium pyruvate with 10 ml of fetal bovine serum (FBS, Invitrogen-Gibco) and 1 ml of a 100× stock of antibiotic/antimycotic (a/a, Invitrogen-Gibco); store at 4°C and prewarm to 37°C for use with cells. 2. Phosphate buffered saline, pH 7.2 (PBS). 3. RANKL (Enzo Life Sciences, PeproTech, EMD4Biosciences, R&D Systems, or homemade): reconstitute and store as a concentrated stock solution (typically 100 μg/ml in PBS) in aliquots (~10–50 μl) at −80°C as recommended by the manufacturer, briefly thaw and dilute into culture medium (to 35 ng/ml final concentration for murine recombinant soluble RANKL) immediately before use with RAW cells, and refreeze remaining RANKL (and aim to thaw individual vials no more than three times to retain optimal bioactivity).
190
P. Collin-Osdoby and P. Osdoby
4. Moscona’s high bicarbonate (MHB): add 8 g of NaCl, 0.2 g of KCl, 50 mg of NaH2PO4, 1.0 g of NaHCO3, 2 g of dextrose, 10 ml of a/a, and 990 ml of water; check pH is 7.2 and sterilefilter. 5. Hanks’ balanced salt solution (HBSS, Invitrogen-Gibco), pH 7.2. 6. Collagenase (Type 3): prepare a 3% stock (3 g in 100 ml) solution in HBSS; store in aliquots (0.5–1.0 ml) at −20°C. 7. Trypsin: 1% stock (1 g in 100 ml) solution in HBSS; store in aliquots (1.0 ml) at −20°C. 8. Collagenase–trypsin digestion solution: briefly thaw and add 71 μl of 3% collagenase solution and 141 μl of 1% trypsin solution to 3 ml of MHB (per dish) immediately before use with cells. 9. Protease (EC 3.4.24.31, Sigma P-8811): 0.1% (100 mg in 100 ml) stock solution in PBS; store at 4°C for up to several months or in aliquots (0.5 ml) at −20°C for long-term storage. 10. EDTA: 2% (2 g in 100 ml) stock solution (using EDTA sodium salt) in PBS; store at 4°C. 11. Protease–EDTA digestion solution: briefly thaw and add 50 μl of 0.1% protease solution and 50 μl of 2% EDTA solution to 5 ml of PBS (per dish) immediately before use with cells. 12. Supplies: sterile bottles, flasks, and tissue culture dishes; rubber cell scrapers (Fisher); hemocytometer. 13. Devitalised bone or dentine slices, prepared as described (see Section 3.1). Ivory is obtained through donation from a local zoo or, in the USA, the Federal Department of Fish and Wildlife Services (or similar Department in other countries). Bovine cortical bone is obtained from a local slaughterhouse.
3. Methods 3.1. Preparation of Devitalized Bone or Dentine Slices
1. Segments of ivory and bovine cortical bone are thoroughly cleaned and washed (multiple HBSS and 70% ethanol rinses), sliced into small chunks and then reduced to rectangular 0.4mm thick sheets using a low-speed Isomet saw (Buehler, Lake Bluff, IL). 2. The sheets are rinsed three times with 70% ethanol, incubated in 70% ethanol overnight, and then washed for several hours in HBSS before circular disks are cut using a 5-mm paper punch.
13
RANKL-Mediated Osteoclast Formation from Murine…
191
3. The disks are soaked repeatedly in 70% ethanol in sterile 50-ml tubes (alcohol changes can be gently poured off because the disks tend to stick to the side of the tube), and stored in 70% ethanol at −20°C. 4. For experimental use, the required number of disks are removed from the tube using alcohol-presoaked tweezers (to maintain sterility) in a tissue culture hood, transferred to a new sterile 50-ml polypropylene tube, rinsed extensively by inversion and mild shaking at least three times with ~40 ml sterile HBSS per wash, and the disks transferred using sterile tweezers into culture wells or dishes containing sterile HBSS for 3–24 h of preincubation in a tissue culture incubator prior to the plating of cells. HBSS is removed only immediately before the disks are used so that they do not dry prior to RAW cell or RAW-OC seeding. 3.2. RAW 264.7 Cell Culture
RAW 264.7 cells are obtained from the ATCC or similar cell repository. They represent a murine macrophage cell line that has the capability to be grown indefinitely as an OC precursor population or can be differentiated by treatment with RANKL into multinucleated bone resorptive OCs expressing the hallmark characteristics of in vivo formed OCs (see Subheading 3.3). All work should be performed in a sterile hood using sterile solutions and supplies. 1. If starting from a frozen (liquid nitrogen) vial of RAW cells, quickly (<1 min) thaw the vial (e.g., in a 37°C water bath or by rapidly rubbing between palms), resuspend the cells in a small amount (~0.5 ml) of culture medium, and add the cell suspension to a T25 tissue culture flask. Increase the volume in the flask to 10 ml with additional culture medium and place into a tissue culture incubator (day 0). 2. On day 3, withdraw the spent medium and refeed the cells with 10 ml of fresh medium (see Note 1). 3. Culture the cells until confluent (typically 4–5 days). 4. To subculture the confluent RAW cells, withdraw the spent medium, add 10 ml of fresh medium to the flask, and scrape the cell layer into this fresh medium using a rubber scraper (see Note 2). 5. Immediately add 0.01 ml of the cell suspension to 0.09 ml of fresh medium in a microfuge tube, mix gently, and count the cells using a hemocytometer. 6. Calculate the cell concentration. Plate the RAW cells at 1.5 × 105 cells/cm2 into tissue culture dishes of the desired size. Typically, one confluent T25 flask will provide a sufficient number of RAW cells to seed two 100-mm dishes or 24-well dishes (see Notes 3 and 4). Increase these volumes
192
P. Collin-Osdoby and P. Osdoby
with additional medium as needed to yield 8 ml per 100-mm dish or 0.5 ml (or 1.0) per well of a 24-well dish, and then place the cells into a tissue culture incubator. 7. To grow the RAW cells for an extended period of time, refeed the cultures every 2–3 days and subculture when they reach confluency as in steps 4–6. 3.3. RAW-OC Formation (See Note 4)
This method is based on the published procedure of Hsu et al. (10). 1. Culture RAW cells to confluency (see Subheading 3.2, steps 1–3). 2. Subculture confluent RAW cells into 24-well dishes as described in Subheading 3.1, steps 4–6 (see Notes 3–6). If the cells are to be used for cytochemical or immunological staining, replate the RAW cell suspension into 24-well dishes that contain a sterile glass coverslip in each well. If bone resorption is to be evaluated in parallel with OC development in the RAW cell cultures, replate the RAW cell suspension into 24-well dishes that contain 2–4 small disks of bone or ivory (see Subheading 3.1) per well (with or without a glass coverslip under the disks). 3. Immediately add soluble recombinant RANKL to the dishes at a final concentration of 35 ng/ml to initiate OC development (day 0) and increase the volume in the wells to 0.5 ml (or 1.0) with additional culture medium (see Note 7). 4. Culture to day 3. Briefly examine the cells under a microscope for evidence that RAW cells are beginning to fuse into multinucleated RAW-OCs. Refeed the developing RAW-OC cell cultures with 0.5 ml (or 1.0) of fresh medium containing 35 ng/ml RANKL. 5. Culture until day 5 or 6 when many multinucleated RAW-OCs have formed but have not completely covered the dish (see Note 8). The day 5 or 6 RAW-OC populations may be immediately fixed and used for cytochemical or immunological staining, harvested for biochemical or molecular studies, or analyzed for bone resorption (see other Chapters in this volume). For greater bone resorption, such cultures may be incubated until days 7–9. Alternatively, RAW-OCs can be purified further by serum gradient density fractionation (see Subheading 3.4).
3.4. Serum Gradient Purification of RAW-OC
Because not all RAW cells fuse into multinucleated RAW-OCs by day 5 or 6, those that have can be purified from the remaining mononuclear cells using serum density gradient fractionation (see Note 9). This procedure is a modification of the one we routinely use to purify in vitro formed OCs or OC-like cells from chick or human origin (15). Directions are provided for RAW-OCs formed on 100-mm tissue culture dishes. All steps are conducted at room
13
RANKL-Mediated Osteoclast Formation from Murine…
193
temperature, unless otherwise noted, and are performed in a sterile hood using sterile solutions and supplies. 1. Remove the spent culture medium from two 100-mm dishes of day 5 or 6 RANKL-generated RAW-OCs. 2. Gently add 10 ml of MHB to each 100-mm dish to wash the cells. Remove and discard the washes. 3. Repeat step 2 to wash the RAW-OCs twice more with MHB. 4. Add 10 ml of MHB to each dish and place them into a tissue culture incubator at 37°C for 15 min. 5. Remove and discard the MHB solution from each dish. 6. Add 5 ml of freshly prepared collagenase–trypsin digestion solution to each dish and incubate at 37°C for 5 min. 7. Remove the dishes from the incubator and shake the plates gently by hand back and forth (e.g., slide the dish on a flat surface) for ~30 s to detach and loosen the interaction of cells with extracellular matrix produced by the cells. 8. Completely remove the collagenase–trypsin solution containing the released matrix material from each dish and discard (see Note 10). 9. Gently wash the adherent cells on each dish by releasing 10 ml of PBS slowly against the side wall of the dish. Completely remove and discard the washes. 10. Repeat step 9 to wash the cells on each dish with PBS twice more. 11. Add 5 ml of protease–EDTA digestion solution to each dish. Incubate at 37°C for 10–15 min (see Note 11). 12. Loosen the adherent cells on each dish by flushing the protease– EDTA incubation solution with a pipette gently over the surface of the cell layer to free the cells (see Note 12). 13. Transfer the cell suspensions from two 100-mm dishes into one 50-ml sterile centrifuge tube containing 1.0 ml FBS (to inhibit further protease action). 14. Centrifuge the cells at 100 × g for 5 min. 15. Remove and discard the supernatant. Gently resuspend the cell pellet in 15 ml of MHB by repeatedly drawing up and releasing from a pipette (not too vigorously, see Note 12). 16. Prepare 16 ml of 70% FBS in MHB (11.2 ml FBS plus 4.8 ml of MHB) in a 50-ml centrifuge tube, and 16 ml of 40% FBS in MHB (6.4 ml FBS plus 9.6 ml MHB) in another 50-ml tube. 17. Prepare an FBS gradient in a 50-ml round-bottom centrifuge tube. To do this, carefully dispense 15 ml of the 70% FBS-MHB solution (from step 16) into the bottom of the tube. Very slowly overlay this with 15 ml of the 40% FBS-MHB solution (from
194
P. Collin-Osdoby and P. Osdoby
step 16), using a pipette held at a 45° angle against the side of the tube just above the 70% FBS layer and slowly releasing the 40% FBS solution in a thin stream so as not to deform the surface of the 70% FBS layer. 18. Let the tube stand undisturbed for 30 min (at room temperature) to allow the larger multinucleated RAW-OCs to settle under normal gravity and penetrate the FBS layers (see Note 13). 19. Carefully take off the top 17 ml which contains mononuclear cells, and transfer it into a 50-ml tube. 20. Then, remove the 16 ml middle layer, which contains primarily mononuclear cells and some small multinucleated RAW-OCs, and transfer this into another 50-ml tube. 21. The bottom 12 ml fraction contains predominantly large multinucleated RAW-OCs. 22. Centrifuge the purified RAW-OC bottom fraction (and the other fractions if they are also to be cultured and/or analyzed) at 100 × g for 5 min. 23. Gently resuspend the RAW-OC pellet in culture medium, count an aliquot in a hemocytometer, and plate 1,000–4,000 cells per well of a 24-well dish. Typically, the purified RAWOCs from two 100-mm dishes can be cultured in 2–10 wells of a 24-well dish (with 0.5–1.0 ml medium per well) for 6–24 h (see Note 14). The top and middle fractions from the serum gradient fractionation are typically cultured in 20–40 wells and 15–30 wells of a 24-well dish, respectively. Alternatively, RAWOCs (and the top and middle fractions, if desired) may be used immediately for analysis (see Subheading 3.2, step 5). Serum gradient fractionation routinely provides 4,000–10,000 purified RAW-OCs from one 100-mm dish (this depends on the efficiency of one’s technique and, more importantly, on the exact stage of RAW-OC used to purify the cells; see Notes 6, 8, 13, and 14). In unfractionated RANKL-generated RAW-OC cultures, multinucleated (more than three nuclei) RAW-OCs typically represent ~1% on a per cell basis and 25% on a per nuclear basis of the total cell population (Fig. 1, left panel). By contrast, serum gradient purified RAW-OCs (with more than three nuclei) typically comprise 60–90% on a per cell basis and 96% on a per nuclear basis of the total cell population in the bottom serum fraction (Fig. 1, lower right panel). On average, RAW-OCs in this bottom serum fraction contain 15–30 nuclei per cell. 3.5. Phenotypic and Functional Characterization of RAW-OCs
Standard protocols can be used to evaluate the morphological (light, scanning electron microscopy), ultrastructural (transmission electron microscopy), histochemical (general or enzymatic activity stains), or immunocytochemical staining (e.g., for OC developmental markers) characteristics of RAW cells representing pre-OCs and
13
RANKL-Mediated Osteoclast Formation from Murine…
195
Fig. 1. RANKL-mediated RAW-OC formation and serum gradient purification. (Left ) RAW cells were cultured with 35 ng/ml murine recombinant RANKL for 6 days and then subjected to serum gradient fractionation. A well cultured in parallel was fixed and stained for TRAP activity to show the proportion of mononuclear and multinucleated TRAP+ cells that arise by day 6 in RANKL-differentiated RAW cell cultures. The cells were viewed using a light microscope and images were captured with a computer-linked digital camera. (Reduced from original magnification, ×100.) (Right ) The top, middle, and bottom fractions from the serum gradient fractionation were replated and cultured on plastic for several hours, after which the cells were fixed and stained for TRAP activity. (Upper right ) The top fraction consists entirely of mononuclear cells, some of which are TRAP+ (in contrast to untreated RAW cells which are all TRAP-, not shown). (Reduced from original magnification, ×200.) (Middle right ) The middle fraction primarily contains mononuclear cells, a portion of which are TRAP+, and some small multinucleated RAW-OC. (Reduced from original magnification, ×200.) (Lower right ) The bottom fraction consists primarily of large multinucleated RAW-OC, although a few mononuclear cells may still be present. (Reduced from original magnification, ×100).
in vitro RANKL-formed RAW-OCs (see Chapter 9, this volume). Whereas untreated RAW cells do not stain for tartrate resistant acid phosphatase (TRAP) activity, a key marker and enzyme involved in OC bone resorption, RANKL-differentiated RAW cell cultures develop both TRAP+ mononuclear and multinucleated cells (Fig. 2a, c). The RAW-OCs formed by cell fusion contain multiple nuclei clustered together, and the cells may appear either spread out or partially elongated when cultured on plastic (Fig. 2a). RAW-OCs cultured on bone or ivory (either during RANKL development or following replating of the differentiated cells) frequently display a more compact and highly motile elongated shape with numerous pseudopodial extensions (Fig. 2c). Resorption pits formed by RAWOCs are typified by clusters of multilobulated excavation cavities or long resorption tracks (which may also be multilobulated) adjacent to or underlying RAW-OCs actively engaged in bone resorption (Fig. 2c). Molecular, immunological, and/or biochemical analyses have shown that RAW-OCs express the key hallmark properties of OCs including TRAP, calcitonin receptor, cathepsin K, matrix
196
P. Collin-Osdoby and P. Osdoby
Fig. 2. RANKL-mediated RAW-OC or MA-OC formation and bone pit resorption. (a, c) RAW cells were cultured with 35 ng/ ml murine recombinant RANKL for 6 days on plastic (a) or ivory (c), and then fixed and stained for TRAP activity. Note the well spread morphology of RAW-OCs on plastic (a) compared with the more compact and motile phenotype of such cells actively engaged in bone resorption on ivory (c). Abundant resorption pits and tracks were evident that were frequently composed of connecting excavation cavities. These represent periods of RAW-OC attachment and pit formation, followed by RAW-OC movement to an adjacent area of ivory for further resorption. (a) and (b) reduced from original magnification, ×200). (b, d) Murine bone marrow cells were isolated and cultured at 5.6 × 105 cells per well of a 24-well dish (1.9 cm2 per well) with 25 ng/ml of murine M-CSF and 35 ng/ml of murine RANKL for 6 days on plastic (c) or ivory (d), after which the cells (MA-OCs) were fixed and stained for TRAP activity. Like RAW-OCs, the TRAP+ MA-OCs were well spread on plastic (b) and more compact on ivory (d). Resorption pits and tracks formed by MA-OCs (d) were indistinguishable from those formed by RAW-OCs (b). (b) and (d) reduced from original magnification, ×100 and ×200, respectively).
metalloproteinase-9, integrin αvβ3, and c-src (refs. 10, 16, our unpublished data). Both the phenotypic and functional characteristics of RANKL-differentiated RAW-OCs resemble those of in vivo formed isolated murine OCs or RANKL-differentiated OCs (MAOC) formed from murine bone marrow cells in the presence of M-CSF (Fig. 2b, d). Thus, like RAW-OCs, TRAP+ MA-OCs exhibit a well-spread morphology on plastic (Fig. 2b) and a more compact, motile phenotype on bone or ivory (Fig. 2d). Multilobulated resorption pits and tracks formed by MA-OCs (Fig. 2c) also resemble those formed by RAW-OCs, with well defined margins and deep resorption lacunae (Fig. 2d). Resorption pit formation by RAW-
13
RANKL-Mediated Osteoclast Formation from Murine…
197
OCs, in the presence or absence of modulators, can be quantified as for other OCs (see Chapters 8 – 12, this volume). In addition to these phenotypic and functional analyses, RAW-OCs provide abundant material (protein, RNA, etc.) for investigations of gene or protein expression or microarray profiling, receptors and signal transduction pathways, production of various factors (cytokines, chemokines, growth factors, and arachidonic acid metabolites), release of other substances (free radicals and enzymatic activities), cell and matrix interactions, and diverse regulatory mechanisms (particularly since RAW cells are more easily transfected than primary bone marrow cells) (see Note 15).
4. Notes 1. Some DMEM formulations may produce a visible dark precipitate that causes rapid cell death of RAW cells during culture. In such cases, we find it best to obtain new DMEM lacking Fe(NO3)3 along with a separate stock (1,000×) of Fe(NO3)3 that is stored in aliquots (1 ml) at −20 C. This iron stock is only thawed and added to DMEM at the time that complete medium is prepared (containing FBS and a/a) for current use. Typically, this complete medium is usable for 10 days to 2 weeks for cell refeeding before evidence of precipitation occurs, at which time any remaining medium should be discarded. Some investigators have reported that RAW cells also grow and form OCs well in α-MEM medium, so this may be an alternative to DMEM if problems are encountered with the latter. 2. We find that a rubber-tipped cell scraper works best because it completely contacts the surface of the tissue culture flask (or dish) and causes the least cell damage. 3. In general, RAW cells should be subcultured at a ratio of 1:3–1:6. 4. If more cells will be needed than are provided by a reasonable number of T25 flasks, the confluent RAW cells can be subcultured into T75 flasks (at a 1:3–1:6 ratio) and then grown to confluency. 5. The number of RAW cell passages affects RANKL-mediated OC formation. In our hands, RAW-OCs seem to better form after passage 4 and will no longer form in response to RANKL stimulation once they have undergone 18–20 passages from the time that they were received from the ATCC repository. The reason for this is not fully clear, although other researchers have similarly noted that not all RAW 264.7 cell lines (or passages?) will form OCs after RANKL treatment, and subclones of RAW 264.7 cells can be derived that are more or less efficient at
198
P. Collin-Osdoby and P. Osdoby
RANKL-mediated OC formation (17, 18). It is also possible that particular lots of FBS may differentially influence RANKLmediated RAW-OC formation. Therefore, different lots and sources of FBS may be tested if there are difficulties encountered in trying to form RAW-OCs, although RAW-OCs have been formed even in serum-deprived conditions (19). 6. The density of RAW cells plated affects the rate and yield of RAW-OC development, as well as the subsequent analysis of RAW-OCs formed. Too low a cell density (100–500 cells/ cm2) delays RAW-OC formation and decreases the final yield. For most purposes (e.g., testing the effects of various agents on RAW-OC development), the plating density for RAW cells should be in the range of 103–3 × 104/cm2 to facilitate counting or characterization of the RAW-OCs formed and still generate a sufficient number for analysis. If RAW-OCs are to be purified by serum density gradient fractionation, the initial plating density of RAW cells should be considerably higher (1.5 × 105/cm2) so that enough RAW-OCs are obtained following their purification (see Subheadings 3.1 and 3.2). However, too high a density of RAW cells (4.5–7.5 × 105/cm2) inhibits RAW-OC formation. 7. In our experience, the potency of recombinant soluble RANKL for inducing OC formation is dependent upon its source (not only for RAW cells, but also for human monocyte, mouse bone marrow, or chicken bone marrow preparations). Thus, different commercial RANKL preparations vary significantly in the dose required, kinetics of OC formation, and final yield of bone pit resorptive OCs obtained. This is not strictly due to species compatibility issues because human or murine recombinant RANKL are similarly efficient for inducing OCs from murine RAW or bone marrow-derived cells, chicken bone marrow cells, or human peripheral blood monocytes (although all but RAW cells require M-CSF costimulation). Although we have successfully used various commercial RANKL preparations, we typically prepare soluble recombinant mouse RANKL in our own lab that exhibits high osteoclastogenic activity with murine RAW or bone marrow cells, chicken bone marrow cells, or human monocytes. At 35 ng/ml, this mouse RANKL induces multinucleated TRAP+ cell formation that is first apparent on days 3–4 of RAW cell culture. Lower RANKL concentrations delay the kinetics and final yield (and size) of RAW-OC formation. Others have used recombinant RANKL preparations in the range of 20–100 ng/ml (depending upon its source and bioactivity) to form multinucleated TRAP+ cells that usually first appear on days 3–4 of RAW cell culture (11, 18, 20, 21). However, certain recombinant mouse RANKL preparations appear to require an additional anti-RANKL antibody
13
RANKL-Mediated Osteoclast Formation from Murine…
199
cross-linking step to induce osteoclastogenesis (16). Therefore, it is recommended that pilot studies be performed with each new source and preparation of recombinant RANKL to ascertain an appropriate dose to achieve the level of RAW-OC formation needed (see also the discussion in Chapter 7, this volume). 8. In our model of RANKL-mediated RAW-OC development, TRAP+ cells first become apparent on day 2 of culture, and multinucleated TRAP+ cells appear on days 3–4 and nearly reach a peak on days 5–6 of culture. It is important to either use the cells or subject them to serum gradient purification at this point (and not wait another day until the full peak of RAW-OC formation has occurred) because if the cells become overconfluent and overfused, they die very rapidly (<24 h) thereafter. 9. The mononuclear cells that remain in the RANKL-treated RAW cell cultures by days 5–6 can still fuse to form more RAW-OCs upon further culture, even in the absence of any additional RANKL stimulation. Therefore, such cells represent an early stage in OC differentiation and are not equivalent to the original non-RANKL treated RAW cells (in a number of characteristics). It is not advisable to simply culture the RANKL-treated RAW cell populations for any longer period of time than days 5–6 to encourage more of the mononuclear cells to fuse into multinucleated RAW-OCs because continuing cell fusion (even 1 extra day) produces cells that are too large and fragile, and which undergo rapid and massive apoptosis in the cultures once such RAW-OCs have formed. 10. It is important to completely remove this released extracellular matrix, here and in the subsequent washes, or the cells will reattach to it and become extremely difficult to detach. At this point, the cells can be seen to have begun to pull up from the dish. 11. A rounding up from the dish becomes more obvious at this point for the RAW-OCs. The cells may appear somewhat shrunken, but should still appear bright and viable. 12. Use only wide-bore pipettes or tips for any work in isolating or manipulating OCs to avoid fragmenting these large multinucleated cells. Also, care should be taken to resuspend, mix, or vortex OC preparations gently and for as little time as necessary. 13. The extent of RANKL-mediated RAW-OC formation impacts on this step as well. Therefore, if the RAW-OCs formed are relatively small (<10 nuclei per cell), they will be unable to effectively settle into the 70% portion of the serum gradient. However, if the RAW-OCs are too large (>30 nuclei per cell), they will be too fragile, prone to break, and die too quickly so
200
P. Collin-Osdoby and P. Osdoby
that few viable RAW-OCs will be recovered following the serum gradient purification. 14. Even under controlled conditions of RANKL-mediated RAW-OC formation as discussed in this chapter, once such cells have formed they tend to apoptose very rapidly and the cells can be lost within 24 h if allowed to develop too long (see also discussion in Chapter 8, this volume). Short survival after formation in culture is specifically a problem with mouse osteoclasts and not seen with for example human osteoclasts. Addition of 10 ng/ml IL-1α to promote RAW-OC survival on plastic only slows the apoptotic process slightly, and a recent report indicates that it preferentially activates larger over smaller RAW-OCs (22). Therefore, we typically use RAW-OCs formed in tissue culture dishes by days 5–6 for analysis within 6–24 h (e.g., staining, RNA or protein extraction, etc.). If RAW-OCs have been formed on bone or ivory, resorption pits are usually evident by day 4 and maximal by day 6 or 7; modulators can be added at appropriate times to observe stimulatory or inhibitory effects on resorption. When RAW-OCs are purified by serum gradient fractionation and replated onto tissue culture dishes, their viability is usually extended for an additional 24 h. Alternatively, purified RAW-OCs can be replated onto bone or ivory (~800 cells per well of a 48-well dish containing one piece of ivory or bone) and cultured with 35 ng/ml RANKL and 10 ng/ml IL-1α, in the presence or absence of other modulators, for 5–6 days to ascertain effects primarily on preformed RAW-OCs (although some additional RAW-OC development also occurs during this time period since the 70% serum purified fraction still contains some mononuclear cells). Purified RAW-OCs typically do not exhibit pit formation within the first 24 h after replating onto bone or ivory. 15. Although many of the phenotypic and functional characteristics of RAW-OCs match those of RANKL-differentiated primary murine bone marrow-derived OCs or isolated in vivo formed murine OCs, this cannot automatically be assumed to be true for any particular property being evaluated. The most obvious difference is the requirement for M-CSF in RANKLstimulated OC formation from bone marrow cells (which have relatively low RANK prior to M-CSF exposure) but not for transformed RAW cells (which already make M-CSF and express high RANK levels). In addition, apoptosis/survival pathways (including ERK) may differ between primary bone marrow cells and transformed RAW cells, and various other differences have been noted. Therefore, it is important to consider that the specific attribute under study in the RAW-OC cell system may not necessarily reflect that of normal murine OC formation or function. However, because RAW cells are
13
RANKL-Mediated Osteoclast Formation from Murine…
201
easier to obtain and culture than primary bone marrow cells, represent a pure population of pre-OCs (deficient in osteoblasts, stromal cells, lymphocytes, etc.), are more readily transfected, and provide abundant material for study, they provide a highly valuable resource for rapidly and efficiently screening and determining mechanisms underlying OC-related processes. Therefore, we recommend that RAW cell studies are subsequently followed by at least a limited number of experiments using primary murine OCs (directly isolated and/or RANKLgenerated in vitro) to confirm that these processes are likewise observed in normal murine OCs and are not unique to transformed RAW cells or RAW-OCs.
Acknowledgments We are greatly indebted to the Drs. Xuefeng Yu and Hong Zheng for their advice and many valuable contributions to an earlier version of this chapter. This work was supported by NIH Grants AR32927, AG15435, and AR32087 to P.O. References 1. Roodman, G. (1996) Advances in bone biology – the osteoclast. Endocrine Rev. 17, 308–332. 2. Mancini, L., Moradi-Bidhendi, N., Brandi, M., Perretti, M., and McIntyre, I. (2000) Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. Biochem. Biophys. Res. Commun. 279, 391–397. 3. Nagai, M., Kyakumoto, S., and Sato, N. (2000) Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem. Biophys. Res. Commun. 269, 532–536. 4. Hentunen, T., Reddy, S., Boyce B. et al.,(1998) Immortalization of osteoclast precursors by targeting Bcl-XL and Simian virus 40 large T antigen to the osteoclast lineage in transgenic mice. J. Clin. Invest. 102, 88–97. 5. Chen, W., and Li Y. (1998) Generation of mouse osteoclastogenic cell lines immortalized with SV40 large T antigen. J. Bone. Miner. Res. 13, 1112–1123. 6. Takeshita, S., Kaji, K., and Kudo, A. (2000) Identification and characterization of the new osteoclast progenitor with macrophage pheno-
types being able to differentiate into mature osteoclasts. J. Bone Miner. Res. 15, 1477–1488. 7. Takahashi, N., Udagawa, N., and Suda, T. (1999) A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/ RANKL, regulates osteoclast differentiation and function. Biochem. Biophys. Res. Commun. 256, 449–455. 8. Chambers, T. (2000) Regulation of the differentiation and function of osteoclasts. J. Pathol. 192, 4–13. 9. Schoppet, M., Preissner, K., and Hofbauer, L. (2002) RANK ligand and osteoprotegerin. Paracrine regulators of bone metabolism and vascular function. Arterioscler. Thromb. Vasc. Biol. 22, 549–553. 10. Hsu, H., Lacey, D., Dunstan, C., et al (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96, 3540–3545. 11. Yamamoto, A., Miyazaki, T., Kadono, Y., et al (2002) Possible involvement of IkappaB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor kappaB ligand. J. Bone Miner. Res. 17, 612–621.
202
P. Collin-Osdoby and P. Osdoby
12. Mizukami, J., Takaesu, G., Akatsuka, H., et al (2002) Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol. Cell Biol. 22, 992–1000. 13. Raschke, W., Baird, S., Ralph, P., and Nakoinz, I. (1978) Functional macrophage cell lines transformed by Abelson leukemia virus. Cell 15, 261–267. 14. Shadduck, R., Waheed, A., Mangan, K., and Rosenfeld, C. (1993) Preparation of a monoclonal antibody directed against the receptor for murine colony-stimulating factor-1. Exp. Hematol. 21, 515–520. 15. Sells-Galvin, R., Cullison, J., Avioli, L., and Osdoby, P. (1994) Influence of osteoclasts and osteoclast-like cells on osteoblast alkaline phosphatase activity and collagen synthesis. J. Bone Miner. Res. 9, 1167–1178. 16. Cappellen, D., Luong-Nguyen, N., Bongiovanni, S., Grenet, O., Wanke, C., and Susa, M. (2002) Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NF-kappa B. J. Biol. Chem. 277, 21971–21982.
17. Cassady, A., Luchin, A., Ostrowski, M., et al (2003) Regulation of the murine TRAP gene promoter. J. Bone Miner. Res. 18, 1901–1904. 18. Watanabe T, Kukita T, Kukita A, et al. (2004) Direct stimulation of osteoclastogenesis by MIP-1a: evidence obtained from studies using RAW264 cell clone highly responsive to RANKL. J. Endocr. 180, 193–201. 19. Vincent, C., Kogawa, M., Findlay, D., et al (2009) The generation of osteoclasts from RAW 264.7 precursors in defined, serum-free conditions. J. Bone Miner. Metab. 27, 114–119. 20. Koseki, T., Gao, Y., Okahashi, N., et al (2002) Role of TGF-beta family in osteoclastogenesis induced by RANKL. Cell Signal 14, 31–36. 21. Shin, J., Kim, I., Lee, J., Koh, G., Lee, Z., and Kim, H. (2002) A novel zinc finger protein that inhibits osteoclastogenesis and the function of tumor necrosis factor receptor-associated factor 6. J. Biol. Chem. 277, 8346–8353. 22. Trebec-Reynolds, D., Voronov, I., Heersche, J., et al (2010) IL-1alpha and IL-1beta have different effects on formation and activity of large osteoclasts. J. Cell Biochem. 109, 975–982.
Part III Biochemical and Molecular Analysis of Bone Cells
sdfsdf
Chapter 14 Transfection of Osteoclasts and Osteoclast Precursors Julie C. Crockett, David J. Mellis, and Adam Taylor Abstract Osteoclasts and their precursors have traditionally been considered difficult cells to transfect using standard approaches. Here, we describe several methods for transfection of mature osteoclasts and their precursors using the Amaxa™ Nucleofector system, lentiviruses, and adenoviruses. Key words: Osteoclast, Transfection, Adenovirus, Lentivirus
1. Introduction It is often necessary to evaluate the role that specific proteins play in the formation, function, or survival of osteoclasts in vitro. This can be achieved by expressing proteins of interest in the target cells using plasmid or viral vectors or by reducing expression of an endogenously produced protein by introducing small interfering RNA molecules (siRNA) into the target cell. Retroviral vectors have been extensively used by some research groups to transfect osteoclast precursors (1–3) but mature osteoclasts cannot be transfected with this technique since mitosis is required for integration of the retrovirus into the genome of the target cell. In this chapter, we describe methods for transfection of osteoclast precursors using lentiviral vectors (4–6) and the Amaxa™ Nucleofector (7) and also describe methods for transduction of mature osteoclasts using adenoviral vectors (8), Fig. 1 illustrates the stages of osteoclast differentiation at which each technique is best employed. 1.1. Amaxa ™ Nucleofector
This instrument uses electroporation in combination with specialised buffers supplied by the manufacturer to transfect target cells. We have used the Amaxa™ system to transfect osteoclast precursors with GFP and have shown that these cells can be differentiated into multinucleated osteoclasts that expressed the transgene for
Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_14, © Springer Science+Business Media, LLC 2012
205
206
J.C. Crockett et al.
MCSF & RANKL
MCSF
Haematopoietic stem cell
Macrophage /monocyte
MCSF & RANKL
MCSF & RANKL
Committed osteoclast progenitor
• Electroporation • Lentiviral transduction • Lentiviral transduction
• Adenoviral transduction • Lentiviral transduction
• Adenoviral transduction • Lentiviral transduction
Fig. 1. A schematic representation of the stages of osteoclast differentiation, highlighting when Amaxa™ nucleofection, lentiviral transduction, or adenoviral transduction is an effective method.
Fig. 2. Gene overexpression in human osteoclasts following transfection of precursor cells using the Amaxa™ Nucleofector. Human osteoclast precursors were transfected with EGFP-Rab6 after 2 days’ culture in M-CSF and RANKL and osteoclast formation was induced by culturing the cells with M-CSF and RANKL for a further 3 days. The cells were fixed in 4% (v/v ) paraformaldehyde, stained with wheatgerm agglutinin (WGA) and analysed by confocal microscopy. E-GFP-Rab6 (righthand panel ) co-localised with WGA (lefthand panel), suggesting that EGFP-Rab6 is localised to the Golgi apparatus, in agreement with the localisation of endogenous Rab6 in osteoclasts (7) (bar = 50 μm).
more than 7 days, whilst retaining the ability to polarise and resorb dentine. We have also used the Amaxa™ Nucleofector to generate human osteoclast-like cells over-expressing EGFP-Rab6, although this approach appears to be construct specific since we have been unable to generate osteoclasts that express Rab18, RANK, or PLEKhm1 using the same technique (7). We have, however, successfully used the Amaxa™ technique to introduce siRNA into osteoclasts and knockdown various Rab proteins including Rab 18 (Figs. 2 and 3).
14
Transfection of Osteoclasts and Osteoclast Precursors
207
mRNA level by qPCR
a 100
0
-ve Ctl
siRNA1
siRNA3 Rab18
siRNA4
GAPDH
Protein level by western blot
b
GAPDH
Rab18 -ve Ctl
siRNA1
siRNA3
siRNA4
GAPDH
Rab18 Fig. 3. siRNA knock-down in human osteoclast precursors using the Amaxa™ Nucleofector. Human osteoclast precursors were transfected with 1 μg of three different siRNAs against Rab18 or siRNA against GAPDH as a positive control. The cells were incubated for 72 h in MCSF and RANKL. (a) mRNA levels were assessed by quantitative RTPCR and (b) protein abundance was determined by western blot analysis using primers and antibodies against Rab18 and GAPDH. Both qPCR and western blot confirm the knockdown of GAPDH expression and the effectiveness of siRNA #1 against Rab18.
1.2. Lentiviral Vectors
Lentiviruses are a type of retrovirus which can incorporate into the genome of the host cell but do not require mitosis and can therefore be used to transduce both dividing and non-dividing cells. Recombinant lentiviral vectors have been engineered in which the genes necessary for incorporation of the virus into the host DNA have been retained but in which the genes required for viral replication have been deleted (9). These viruses can be used to insert foreign DNA sequences into the genome of the target cell with minimal viral sequence. Although these recombinant lentiviruses are replication incompetent, it is possible to transfect these vectors into a “packaging” cell line which expresses other components that are required for DNA replication and generation of intact lentiviruses containing the foreign DNA of interest, which are released
208
J.C. Crockett et al.
into the culture supernatant. The viral particles can then be harvested from the supernatant and used to transduce host cells. A number of commercially available kits are available to generate lentiviral vectors. It is important to select a three or four plasmid system whereby the structural and coat proteins required for the production of lentiviral particles are encoded on separate plasmids to reduce the amount of lentiviral sequence within the expression vector and prevent homologous recombination events between the vector and wild-type HIV. All commercial systems involve a series of cloning steps to generate the lentiviral expression vector and these steps will depend on the availability of compatible restriction sites within the expression vectors and flanking your gene of interest. The Invitrogen ViraPower™ kit utilises Gateway™ cloning to transfer genes of interest from Gateway™ cloning vectors into the lentiviral vectors. We have found the Cell Biolabs promoterless lentiviral vector useful for incorporating entire expression cassettes into lentiviral vector (e.g. expression cassettes containing a cDNA driven by a cell-specific promoter or a bidirectional expression cassette). Whichever lentiviral system is used, the process of producing, purifying, and titreing the lentiviral particles is similar. 1.3. Adenoviral Vectors
Adenoviral vectors are useful for introducing foreign DNA into mature osteoclasts since they have the capacity to transduce terminally differentiated cells and express an RGD sequence on the penton base which allows them to attach to the αvβ3 integrin which is highly expressed by osteoclasts (10). Adenoviruses reside within the cytoplasm and are not incorporated into the host genome which means that they are of less value for transducing early osteoclast precursors which need to undergo cell division and fusion to form mature osteoclasts. Recombinant adenoviral vectors containing the construct of interest can be generated using various techniques including homologous recombination and in vitro ligation (11–13). The recombinant adenoviruses used in these experiments are replication deficient since the gene of interest replaces elements E1 and E3 which are essential for viral replication. However, the HEK293 cell line endogenously expresses the genes required for adenoviral replication and can therefore be used to produce recombinant infectious adenoviral particles when transfected with a recombinant adenoviral vector. We have employed the AdenoX™ expression system 1 (Takara Clontech) to generate recombinant adenoviral vectors. This involves ligating the construct of interest into the pshuttle2 vector and then ligating the entire expression cassette into pre-linearised adenoviral DNA. Adenoviral vectors can also be generated by homologous recombination. Whichever method is employed to generate the recombinant adenoviruses, assessment of the viral titre is required before experiments can commence so that the target cells can be transduced
14
Transfection of Osteoclasts and Osteoclast Precursors
209
Fig. 4. Adenoviral transduction of human osteoclast-like cells. Human osteoclast-like cells were generated in the presence of rh-MCSF and rmRANKL for 6 days and transduced with (a) no virus, (b) 200 pfu/cell wildtype RANK. The cells were incubated for 48 h, fixed in 4% (v/v ) paraformaldehyde and (i) immunostained with an anti-RANK antibody and (ii) counterstained with TO-PRO 3 (bar = 100 μm).
with a known multiplicity of infection (MOI). This can either be assessed by a bioassay in which the researcher looks for evidence of a cytopathic effect in cells exposed to the virus [described as plaqueforming units (PFU)/ml] or by commercially available kits in which viral proteins are detected by immunostaining of infected cells. We have successfully used recombinant adenoviruses to study the effects of mutations in TNFRSF11A on the subcellular localisation of the RANK protein within mature osteoclast-like cells in vitro (Fig. 4).
2. Materials 2.1. Primary Cells
1. Human peripheral blood mononuclear cells. 2. Mouse bone marrow macrophages.
210
J.C. Crockett et al.
2.2. Cell Lines for Virus Production
1. HEK293 cells (ECACC).
2.3. Reagents
1. Recombinant mouse and human M-CSF (R&D Systems).
2. 293 LTV cells (Cell Biolabs) or 293 FT cells (Invitrogen).
2. Recombinant mouse RANKL (R&D Systems) (see Note 1). 3. Mouse Macrophage Nucleofector™ Solution for electroporation (Amaxa™). 4. AdenoX Expression System 1™ (Takara Clontech). 5. Lentiviral Expression System e.g. ViraPower™ (Invitrogen) or ViraSafe™ (Cell Biolabs). 6. Polybrene for lentiviral transduction. 7. Lentiviral purification kit, ViraBind™ (Cell Biolabs). 8. Lentiviral titration kit, QuickTitre™ Lentivirus Titre kit (Cell Biolabs). 9. Pac 1 restriction enzyme (New England Biolabs). 10. Tris–EDTA (TE) buffer (10 mM Tris–HCl (pH 8.0) and 1 mM EDTA). 11. 3 M sodium acetate, pH 5.2 (NaOAc). 12. Phenol–Chloroform–isoamyl alcohol (25:24:1; Sigma). 13. Glycogen (20 mg/ml; Roche). 14. 100% Analytical grade ethanol. 15. 4% (v/v) Paraformaldehyde in PBS. 16. Cell lysis buffer [1% (v/v) triton-X-100, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS in dH2O] supplemented with 1% protease inhibitor cocktail (Sigma), 1% phosphatase inhibitor cocktail (Sigma), 1 mM EDTA, 1 mM sodium orthovanadate, 10 mM sodium fluoride. 2.4. Culture Media and Buffers
1. Complete medium #1 [α-MEM containing 10% (v/v) FCS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 2 mM L-glutamine]. 2. Complete medium #2 [α-MEM containing 20% (v/v) FCS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 2 mM L-glutamine]. 3. Complete medium #3 [D-MEM containing 10% (v/v) FCS, 2 mM L-glutamine, 0.1 mM MEM non-essential amino acids]. 4. SF medium #4 (D-MEM containing 2 mM 0.1 mM MEM non-essential amino acids).
L-glutamine,
5. Serum-free α-MEM for viral transductions. 6. Phosphate buffered saline (PBS). 7. Trypsin-EDTA [0.05% (w/v) trypsin in 0.5 mM EDTA].
14
2.5. Equipment
Transfection of Osteoclasts and Osteoclast Precursors
211
1. Amaxa™ Nucleofector II™ machine. 2. Amaxa™ cuvettes and Pasteur pipettes. 3. Centrifuges. 4. Selection of pipettes and tips. 5. Tissue culture flasks and plates (Falcon). 6. Sterile Eppendorf tubes, bijoux, 15 ml conical tubes and 50 ml conical tubes. 7. Vacuum flask for liquid nitrogen. 8. Water bath set to 37°C.
3. Methods 3.1. Transfecting Human Osteoclast Precursors Using the Amaxa™ Nucleofector
This technique can be used to transfect human osteoclast precursors and requires at least 1 × 106 cells per transfection. If cell numbers are limited, the lentiviral system can be used as an alternative (Subheading 3.3). 1. Isolate peripheral blood mononuclear cells from 30 ml of venous blood sample by ficoll-hypaque gradient density centrifugation (see Note 2). 2. Wash the cells in PBS, divide into two Falcon 75 cm2 tissue culture flasks and culture in complete medium #1 supplemented with human M-CSF (20 ng/ml) until they reach 80–90% confluence (6–7 days). 3. Add mouse RANKL (10 ng/ml) to the cultures and maintain in culture for a further 48 h. 4. Aspirate the medium and wash the cell layer in PBS which has been pre-warmed to 37°C. 5. Add about 5 ml trypsin/EDTA to the flask and incubate for 30 min at 37°C. 6. Add 10 ml complete medium #1 and gently scrape the cells and transfer into a sterile Universal Container. 7. Pellet the cells by centrifugation at 300 × g for 5 min. 8. Resuspend the cells in 5 ml complete medium #1 and incubate on ice. 9. Count the cells using a haemocytometer and prepare aliquots of 1 × 106 cells for each transfection you wish to perform. Include two extra aliquots of cells as controls (see Note 3). 10. Pellet each aliquot by centrifugation at 300 × g for 3 min and carefully remove the supernatant.
212
J.C. Crockett et al.
11. Suspend the cell pellet in 100 μl Mouse Macrophage Nucleofector™ Solution (see Note 4) and transfer to an Eppendorf tube containing 2 μg of endotoxin-free plasmid DNA or 1 μg of siRNA. 12. Transfer the cell suspension–DNA mixture to Amaxa™ electrode cuvettes and electroporate in an Amaxa™ Nucleofector II™ using program Y-010. 13. Immediately after the program has finished, transfer the cells to a bijou tube using the Amaxa™ Pasteur pipette and add 2.5 ml complete medium #1 containing 20 ng/ml M-CSF and 10 ng/ ml RANKL, which has been pre-heated to room temperature. 14. Cool the cell suspension on ice for 5–10 min. 15. Seed the transfected cells into 96-well plates at 4 × 104 cells/ well and/or onto 9 mm glass coverslips in 48-well plates at 1 × 105 cells/well and/or in 6-well plates at 4 × 105 cells/well (see Notes 5 and 6). 16. Seed the sham-transfected and control cells at half of this density. 17. Replace the medium after 48 h with complete medium #1 containing 20 ng/ml human M-CSF and 10 ng/ml mouse RANKL. 18. Replace with complete medium #1 containing 20 ng/ml human M-CSF and 10 ng/ml mouse RANKL every 3 days until multinucleated osteoclast-like cells have formed (a further 4–5 days). 3.2. Generating Lentivirus
Here, the lentiviral expression vector containing your gene of interest (that will have been generated through a series of cloning steps as broadly explained in Subheading 1.2) will be transfected, together with a cocktail of plasmids that encode the replication and structural proteins for lentivirus generation, into a 293-based packaging cell line. The exact conditions for transfection and production of lentiviral particles will depend on the system; here transfection using the Invitrogen Virapower™ lentiviral packaging mix is described. 1. Seed 293 FT cells (see Note 7) in a 10-cm culture dish and culture until the cells are 70–80% confluent. 2. To 1.5 ml SF medium #4 add 36 μl Lipofectamine 2000 in a bijou tube. Incubate for 5 min at room temperature. 3. In a separate bijou tube, add 1.5 ml SF medium #4 to 9 μg Virapower™ lentiviral packaging and 3 μg lentiviral expression vector. Mix by gently flicking the tube. 4. Combine the DNA and Lipofectamine solutions, mix gently and incubate for 20 min at room temperature. 5. Add DNA/Lipofectamine to 293 FT cells in a dropwise manner and rock plate gently to distribute evenly across plate.
14
Transfection of Osteoclasts and Osteoclast Precursors
213
6. Incubate overnight and then replace medium with complete medium #3. 7. Maintain the cells in culture at 37°C for a further 72 h. 8. Aspirate the culture supernatant containing the infectious lentiviral particles using a syringe and pass through a 0.45 μm filter. 9. Purify the viral particles using the ViraBind™ kit by adding the filtrate from step 8 onto the LTV filter and allow it to flow through the filter under gravity (see Note 8). 10. Wash the filter twice with LTV wash buffer. 11. Elute the virus into a collection tube with 2 ml of LTV elution buffer. 12. Measure the amount of lentivirus present using the Quicktitre™ lentivirus kit and follow manufacturer’s instructions (see Note 9). 13. Add glycerol to a final concentration of 10%. Aliquot the viral preparation and freeze at −80°C. 3.3. Transduction of Human Osteoclast Precursors with Lentiviral Vectors
The lentivirus based technique is useful for experiments where cell numbers are limited since the Amaxa™ Nucleofector protocol described in Subheading 3.1 requires a minimum of 1 × 106 cells per transfection. 1. Generate M-CSF-dependent human macrophages from peripheral blood as described in Subheading 3.1 steps 1–2. 2. Seed the macrophages into a 96-well plate at a density of 3 × 104 cells/well in complete medium #1 supplemented with 20 ng/ml human M-CSF and 10 ng/ml mouse RANKL and culture overnight. 3. Aspirate the medium and wash the cells in PBS. 4. Add between 1.5 × 106 and 3 × 106 TU of the lentiviral vector (see Note 10) to each well in 50 μl serum free α-MEM containing human M-CSF (20 ng/ml) and mouse RANKL (10 ng/ml) and 8 μg/ml Polybrene. 5. Culture the cells for 3 h, remove the medium and replace with complete medium #1 containing human M-CSF (20 ng/ml) and mouse RANKL (10 ng/ml). 6. Culture the cells for up to 7 days, replacing the culture medium every 2 days. 7. When multinucleated osteoclasts have formed (typically 6–7 days) terminate the experiment by aspirating the medium and adding 50 μl of 4% paraformaldehyde to each well to fix the cells.
3.4. Generating Recombinant Adenoviruses
1. Linearise the recombinant adenoviral DNA containing the gene of interest by PacI digestion for 2 h at 37°C in Eppendorf tubes. Add 60 μl 1× TE buffer and 100 μl phenol–chloroform– isoamyl alcohol and vortex gently.
214
J.C. Crockett et al.
2. Centrifuge at 13,000 × g for 5 min to separate the phases. Transfer the top, aqueous layer to a clean 1.5-ml Eppendorf tube. 3. Add 100 μl 95% (v/v) ethanol, 50 μl 3 M NaOAc (pH 5.2), and 1 μl glycogen (20 mg/ml). Vortex gently. 4. Remove supernatant and wash pellets in 70% (v/v) ethanol. Centrifuge at 13,000 × g for 2 min. Remove supernatant and air-dry pellets at room temperature. Re-dissolve DNA in 10.5 μl TE buffer. Check restriction digest has been successful by analysis of 0.5 μl of the DNA on a 0.8% agarose gel. Store remaining DNA at −20°C. 5. Seed 2 × 106 HEK293 cells into each well of a 60-mm tissue culture plate and culture overnight at 37°C in complete medium #1. 6. Change the medium on the HEK293 cells at least 90 min (up to 3 h) prior to transfection. Transfect the 10 μl of linearised DNA (from step 4) into the HEK293 cells using CalPhos™ transfection kit (BD Biosciences) according to the manufacturer’s instructions (see Note 11). Include a mock transfected control. 7. After 3 h replace the medium with complete medium #1. 8. Culture the cells for between 8 and 12 days, and check the cultures each day on an inverted, phase contrast microscope to determine the proportion of cells that have detached from the plate. Do not replace the medium during this time. If necessary, add 2–3 ml more medium to the plate if the colour of the medium becomes very yellow. 9. When the majority (60–80%) of the cells have detached aspirate the contents of the dish into a 15-ml conical tube and pellet the cells by centrifugation at 300 × g for 5 min. Dislodge the cells by gentle agitation; do not use trypsin. 10. In the 15 ml conical tube, resuspend the cell pellet in 500 μl PBS and lyse the cells using a freeze–thaw technique. Using forceps, immerse the bottom of the tube (and hence the cell suspension) for approximately 2 min in liquid nitrogen held in an open vacuum flask. 11. When cell suspension is frozen, thaw by transferring to a waterbath set at 37°C for periods of 10 s at a time, interspersed with bursts of vortexing for 30 s at a time until the lysate has just melted (see Note 12). 12. Repeat the freeze–thaw cycles described in steps 10 and 11 two more times. 13. Centrifuge the lysate at 1,500 × g for 10 min, aspirate the supernatant, and store this adenovirus stock at −80°C until required.
14
Transfection of Osteoclasts and Osteoclast Precursors
215
14. For amplification of this stock, seed a 60-mm tissue culture dish with 2 × 106 HEK293 cells. 15. The following day, defrost the adenoviral stock and add the total volume (~500 μl) to the HEK293 cells in the 60-mm plate. 16. Incubate for 3–5 days. Check the cells on an inverted microscope to check for cells lifting off. When 60–80% cells have lifted off follow steps 9–12 (see Note 13). Freeze this primary amplification stock at −80°C in 50 μl aliquots. 3.5. Determining the Titre of Adenovirus
This subheading describes the end-point dilution method for estimating the number of viral particles present in the supernatant from step 16 of Subheading 3.4. By convention adenoviral titres are expressed in plaque forming colony units (pfu)/ml (see Note 14). 1. Seed HEK293 cells into 96-well plates at a density of 1 × 104/ well in 100 μl complete medium #1 and culture overnight. 2. Thaw the adenoviral stock (Subheading 3.4, step 16) on ice and make a 1:100 (10−2) dilution by adding 10 μl virus to 990 μl complete medium #1. 3. Prepare eight serial 1:10 dilutions from step 2 by transferring 100 μl of diluted virus into 900 μl of complete medium #1 to give a “standard curve” ranging from a dilution of 10−3–10−10 as compared with the original adenoviral stock. This gives sufficient volume of each dilution for eight replicates. 4. Add 100 μl of the diluted adenovirus stock to each well of the first eight columns of the 96-well plate set up in step 1 and add 100 μl of culture medium to the remaining rows. 5. Culture the cells for a further 10 days without changing the medium. 6. Score each well for the presence of cytopathic effect (CPE) and express the results as the fraction of CPE positive wells per column. 7. Calculate the viral titre (pfu/ml) using the following equation: viral titre (pfu/ml) = 10(x+0.8) where x is the sum of the fractions of all the virus infected columns (see Note 15).
3.6. Amplification of Adenoviral Stocks (See Note 16)
1. Seed HEK293 cells into 75-cm2 tissue culture flasks and culture overnight at 5 × 106 cells. 2. Add adenovirus stock to the flask with a multiplicity of infection (MOI) of 1–5 pfu/cell. 3. Maintain the cells in culture for up to 12 days and monitor daily by microscopy until the majority (60–80%) of the cells have detached from the flask. 4. Aspirate the contents of the flask into a 50-ml conical tube and pellet the cells by centrifugation at 300 × g for 5 min.
216
J.C. Crockett et al.
5. In the 50-ml conical tube, resuspend the cell pellet in 1 ml PBS and lyse the cells using a freeze–thaw technique. Using forceps, immerse the bottom of the tube (and hence the cell suspension) for approximately 1 min in liquid nitrogen held in an open vacuum flask. 6. When cell suspension is frozen, thaw by transferring to a waterbath set at 37°C for periods of 10 s at a time, interspersed with bursts of vortexing for 30 s at a time until the lysate has just melted (see Note 12). 7. Repeat the freeze–thaw cycles described in steps 5 and 6 two more times. 8. Centrifuge the lysate at 1,500 × g for 10 min, aspirate the supernatant, and store this adenovirus stock in 50 μl aliquots at −80°C until required. 9. Determine the titre (following Subheading 3.5) of these adenoviral stocks prior to moving on to Subheading 3.7. 3.7. Adenovirus Transduction of Mature Human Osteoclasts
This technique works well for transfecting mature human osteoclastlike cells that have been generated from peripheral blood using M-CSF and RANKL. 1. Generate osteoclast-like cells from human M-CSF dependent macrophages in complete medium #1 supplemented with human M-CSF (20 ng/ml) and mouse RANKL (10 ng/ml) and seed into 96-well plates at 1.5 × 104 cells/well, 48-well plates containing 9 mm glass coverslips at 3 × 104 cells/well, or 6-well plates at 2 × 106 cells/well (see Note 6) until multinucleated osteoclast-like cells have formed (approximately day 6). 2. Remove the medium and replace with between 50 and 750 μl (see Note 17) of serum free α-MEM supplemented with human M-CSF (20 ng/ml) and mouse RANKL (10 ng/ml) containing the equivalent of 200 pfu adenovirus per cell, based on the initial seeding density, and incubate at 37°C for 3 h. 3. Add an equal volume of complete medium #2 to each well supplemented with human M-CSF (20 ng/ml) and mouse RANKL (10 ng/ml) and culture the cells for a further 48 h. 4. If you want to study the effect of the gene of interest on bone resorption, follow steps 6–10. If you want to study the effect on signalling pathways in osteoclasts follow steps 11–13. 5. Wash the cells from step 5 in PBS which has been pre-warmed to 37°C. 6. Incubate the cells in trypsin/EDTA solution for 30 min. 7. Gently scrape the cells into complete medium #1 and pellet the cells by centrifugation at 300 × g for 5 min.
14
Transfection of Osteoclasts and Osteoclast Precursors
217
8. Resuspend the cells in complete medium #1 supplemented with human M-CSF (20 ng/ml) and mouse RANKL (10 ng/ml). 9. Seed the cells into a 96-well plate containing sterile dentine slices at a density of 2 × 104 cells/well and culture the cells for up to 72 h. 10. Terminate the experiment by aspirating the medium and fixing the cells in 4% paraformaldehyde in PBS. 11. To prepare protein lysates for western blot analysis (see Note 18), wash cells in 2 ml ice cold PBS and then add 100 μl cell lysis buffer to each well, keeping the plate on ice. 12. Scrape the cells into the lysis buffer using a rubber policeman and transfer the lysate to 1.5 ml Eppendorf tube. Incubate on ice for 20 min and then centrifuge at 13,000 × g for 15 min. 13. Transfer the supernatant to a clean Eppendorf tube and snap-freeze the lysate in liquid nitrogen before transferring to a −80°C freezer for storage. 3.8. Adenovirus Transduction of Mature Mouse Osteoclasts
This technique works well for transfection of mouse osteoclasts but since these cells have a very short life span, the transfection must be performed just before the osteoclast precursors fuse to form mature osteoclasts (see Note 19). 1. Prepare M-CSF dependent mouse macrophages according to standard techniques. 2. Suspend in complete medium #1 supplemented with mouse M-CSF (100 ng/ml) and mouse RANKL (100 ng/ml) and seed into 96-well plates at 1.5 × 104 cells/well, 48-well plates containing 9 mm glass coverslips at 3 × 104 cells/well, or 6-well plates at 2 × 106 cells/well (see Note 6). 3. Continue the cells in culture for a further 3–4 days. 4. Remove the culture medium from each well and replace with 50−750 μl (see Note 17) serum free α-MEM supplemented with mouse M-CSF (100 ng/ml) and mouse RANKL (100 ng/ml) and 200 pfu/cell of adenoviral vector stock. 5. After 3 h, remove the medium and replace with complete medium #1 supplemented with M-CSF (100 ng/ml) and mouse RANKL (100 ng/ml). 6. Culture the cells for a further 48 h and fix or lyse the cells, depending on the analysis that you wish to perform (see Note 18).
3.9. Assessment of Cell Viability
Cell viability can be assessed using the Alamar blue technique and we recommend that you perform this routinely the first few times the experiments are carried out as part of optimisation. If you are using the Amaxa™ system, cell viability can be assessed in parallel with the experiment by seeding transfected cells at 4 × 104 cells/well
218
J.C. Crockett et al.
(or sham-transfected and control cells at 2 × 104 cells/well) in a separate 96-well plate. For lentiviral and adenoviral transductions, it is necessary to prepare additional wells at the start of the experiment that will be specifically used to assess viability. 1. Add 10 μl Alamar blue reagent to test wells in 96-well plates either 24 h and/or 48 h after the transfection procedure. 2. Culture the cells for 3–4 h. 3. Read the fluorescence on a plate reader with the emission spectrum set to 530 nm and the excitation spectrum set to 590 nm. 4. The effect of the transfection procedure on viability can be assessed by comparing values for the transfected cells with those in the control wells (untransfected and sham transfected). 3.10. Assessment of Transfection Efficiency
Transfection efficiency can be assessed in cells that have been transfected with a GFP containing construct or where the gene of interest has been epitope tagged (see Note 20). The procedure for assessing transfection efficiency is as follows: 1. At the end of the experiment, remove the medium and fix the cells in 4% paraformaldehyde for 15 min and wash with PBS. 2. For GFP-transfected cells, obtain digital fluorescent and phase contrast images of the wells and merge these to assess the numbers of cells which are positive for GFP. Since GFP is a fluorescent protein, this can be carried out on both unfixed (i.e. throughout the culture) or fixed cells. 3. Repeat the procedure for untransfected and sham transfected cells to assess background fluorescence. 4. Work out the proportion of positive versus negative cells in the transfected versus non transfected or sham transfected controls. 5. If the gene of interest has been epitope tagged, perform immunostaining using a suitable antibody and count the number of cells that stain positive. 6. Repeat the procedure for untransfected and sham transfected cells to determine background staining. 7. Work out the proportion of positive versus negative cells in the transfected versus non transfected or sham transfected controls.
4. Notes 1. We use mouse RANKL for both human and mouse osteoclast cultures. It would also be possible to use human RANKL for human cultures, but this cannot be used to generate mouse osteoclasts.
14
Transfection of Osteoclasts and Osteoclast Precursors
219
2. 30 ml of venous blood will generate approximately 4 × 106 M-CSF dependent macrophages over the culture expansion period. 3. Two controls should be included; untransfected control cells and sham transfected cells – which should be processed as for the cells undergoing transfection with the exception that electroporation is carried out in the absence of plasmid DNA. 4. We have also tested human macrophage Nucleofector™ solution, but found that this was associated with higher levels of cytotoxicity than the mouse solution. 5. The transfected cells are seeded at a high density (double that is normally used for these cultures) to take account of the fact that the electroporation procedure is associated with approximately 50% toxicity. 6. Mouse and human osteoclasts are generated in 96-well plates to assess osteoclast formation, 48-well plates (containing 9 mm glass coverslips) for downstream confocal microscopic analysis of fixed cells, or 6-well plates for analysis of cellular proteins by western blot analysis. 7. The 293FT cell line, stably expresses the SV40 large T antigen and must normally be maintained in medium containing Geneticin™ as per suppliers instructions. For transfection of lentiviral expression construct with the packaging mix, all antibiotics including Geneticin should be omitted from the culture medium (complete medium #3). 8. It is possible to snap-freeze the filtrate in liquid nitrogen at this point, store at −80°C and proceed with the purification steps at a later date. 9. The number of viral particles within a given volume of supernatant (termed transforming units; TU) can be estimated by transducing HeLa cells with the supernatant and determining the number of antibiotic resistant clones that develop over 2–3 weeks. For a much faster and more objective assay, this commercially available ELISA kit that detects the HIVassociated p24 protein that is associated with the virus gives absolute values for the amount of p24 present in each sample which can then be worked back to calculate TU/ml. 10. The amount of lentivirus must be optimised for each experiment, but we find that a MOI of between 50 and 100 TU/cell gives good results. 11. We have tried numerous methods to transfect the recombinant adenoviral DNA into 293 cells (including Fugene-6 and Clonfectin) and the only method that resulted in production of adenoviral particles was the CalPhos transfection kit. 12. It is important that the suspension does not warm up, hence the need to assist the thawing process by 30 s bursts of vortexing
220
J.C. Crockett et al.
between the periods of submersion in the waterbath (which should be for no more than 10 s at a time). 13. The adenovirus obtained as the result of this procedure is referred to as “Primary Amplification Stock”. 14. The titre of your adenoviral stocks can be determined by various methods which should be selected based on time and budget considerations. When adenovirus is applied to HEK293 cells, the cells undergo lysis and this can be visualised as a cytopathic effect (CPE) in the cell cultures as regions of dead or absent cells. Any evidence of CPE within a culture demonstrates that there was a least one infectious unit of virus present. This can be exploited in the end-point dilution assay that is described here. In addition a plaque formation assay can be performed in which cells are grown under a layer of medium enriched agarose and areas or plaques of dead cells identified and counted, or immunohistochemistry based kits are quick but expensive. We have occasionally used the Adeno-X™ Rapid-Titre kit (Clontech), which employs an anti-hexon primary antibody and horse-radish peroxidase secondary antibody to stain infected cells. 15. The equation for calculating viral titre is a modification of the Spearman-Karber method (as described in pAdenoX User Manual, Takara Clontech). The values for 10−1 and 10−2 dilutions must be included in the calculation (which will be 1 and 1 if 10−3 dilution is 1) for the equation to be valid. This method relies on the data representing a total response curve, i.e. 100% effect at the lowest dilution and no CPE at the highest dilution. Therefore, an accurate estimation of titre will only be achieved if at the lowest virus dilution (10−3) all wells show CPE (ratio = 1) and at the highest dilution (10−10), zero wells show CPE (ratio = 0). If there is not CPE in all wells for 10−3 then the viral titre is not sufficiently high for transduction experiments. If, in this case, the end-point dilution assay was on a Primary Amplification Stock then start again with adenoviral transfection into HEK293 cells (Subheading 3.4). If the end-point dilution assay was on a later stock of virus, repeat Subheading 3.6 and use 5 pfu/cell to transduce your HEK293 cells and freeze–thaw the cells in a smaller volume of PBS (e.g. 500 μl). In all cases, ensure that CPE has occurred in 60–80% of cells before harvesting the adenovirus from the cells. If, on the otherhand, CPE is observed in the cells containing the 10−10 dilution then the adenoviral stock should be diluted (e.g. 1:10) and this diluted stock taken as 100 (i.e. undiluted) for the purposes of the end-point dilution assay – it is important to correct your calculated titre for this dilution at the end of the assay. The expected viral titres for the primary amplification stocks should be around 109 pfu/ml.
14
Transfection of Osteoclasts and Osteoclast Precursors
221
16. The risk of generating replication competent adenoviruses increases with the number of amplification steps performed. Therefore, it is important to return to early amplification stocks when you are generating large volumes of high titre adenovirus. 17. Use the minimum volume of virus-containing medium possible to cover the bottom of your culture plate to maximise efficiency of transfection. We recommend the following: 50 μl/well for 96-well plates, 150 μl/well for 48-well plates, 750 μl/ well for 6-well plates. 18. For studying the effects on cell signalling pathways then the cells should be stimulated with an appropriate cytokine, lysed and cytoplasmic extracts prepared. In the case of experiments investigating the effects of siRNA knockdown RNA can be extracted in preparation for cDNA synthesis and quantitative RT-PCR. 19. Since mouse osteoclast-like cells have a very short life span, it is necessary to transduce the cells about 24–48 h before they fuse to form multinucleated osteoclasts. This is usually between 3 and 4 days after the cultures are initiated but the most appropriate stage of the culture should be determined prior to commencing these experiments. 20. It is possible to tag the cDNA by cloning GFP downstream to generate a fusion protein but if you are conducting functional experiments, it is important to confirm that the GFP does not interfere with the properties of your protein. Alternatively, the cDNA can be tagged with an epitope tag (e.g. FLAG tag) that can be detected with commercially available antibodies. In all cases, it is important to consider the position of the tag (N- or C-terminus) and whether it might interfere with protein processing or function. References 1. Xu, D., Wang, S., Liu W, et al. (2006) A novel receptor activator of NF-KappaB (RANK) cytoplasmic motif plays an essential role in osteoclastogenesis by committing macrophages to the osteoclast lineage. J. Biol. Chem. 281, 4678–4690. 2. Kapur, R. P., Yao Z., Iida, M. H., et al. (2004) Malignant autosomal recessive osteopetrosis caused by spontaneous mutation of murine Rank. J. Bone Miner. Res. 19, 1689–1697. 3. Maruyama, T., Fukushima, H., Nakao, K., et al. (2010) Processing of the NF-KappaB2 precursor, p100, to p52 is critical for RANKL-induced osteoclast differentiation. J. Bone Miner. Res. 25, 1058–1067.
4. Teschemacher, A. G., Wang, S., Lonergan, T., et al. (2005) Targeting specific neuronal populations using adeno- and lentiviral vectors: applications for imaging and studies of cell function. Exp. Physiol. 90, 61–69. 5. Chu, K., Cornetta, K. G., and Econs, M. J. (2008) Efficient and stable gene expression into human osteoclasts using an HIV-1-based lentiviral vector. DNA Cell Biol. 27, 315–320. 6. Zhao, H., Ross, F. P., and Teitelbaum S. L. (2005) Unoccupied alpha(v)beta3 integrin regulates osteoclast apoptosis by transmitting a positive death signal. Mol. Endocrinol. 19, 771–780.
222
J.C. Crockett et al.
7. Taylor, A., Rogers, M. J., Tosh, D., et al. (2007) A novel method for efficient generation of transfected human osteoclasts. Calcif. Tissue Int. 80, 132–136. 8. Crockett, J. C., Mellis, D. J., Duthie, A., et al. (2011) Signal peptide mutations in RANK prevent downstream activation of NF-κB. J. Bone Miner. Res. 26, 1926–1938. 9. Naldini, L. (1998) Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr. Opin. Biotechnol. 9, 457–463. 10. Tanaka, S., Takahashi, T., Takayanagi, H., et al. (1998) Modulation of osteoclast function by adenovirus vector-induced epidermal growth factor receptor. J. Bone Miner. Res. 13, 1714–1720.
11. Miyake, S., Makimura, M., Kanegae, Y., et al. (1996) Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the fulllength virus genome. Proc. Natl. Acad. Sci. USA 93, 1320–1324. 12. Mizuguchi, H., and Kay, M. A. (1998) Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum. Gene Ther. 9, 2577–2583. 13. Mizuguchi, H., and Kay, M. A. (1999) A simple method for constructing E1- and E1/ E4-deleted recombinant adenoviral vectors. Hum. Gene Ther. 10, 2013–2017.
Chapter 15 Analysis of Signalling Pathways by Western Blotting and Immunoprecipitation Aymen I. Idris Abstract This chapter describes the analysis of signalling pathways in bone cells by the use of western blotting and immunoprecipitation, including a step by step guide to cell culture techniques, protein isolation, purification, measurement, electrophoretic transfer, and detection. Key words: Signalling, Western blotting, Immunoprecipitation, Protein, Phosphorylation, Prenylation
1. Introduction Signal transduction is the process by which extracellular information is received, relayed, and translated into a cellular response (1). Systemic hormones and local cytokines regulate bone cell differentiation and activity by activating signalling transmission systems that originate at the cell surface or cytoplasm and terminate in the nucleus (Fig. 1). At the molecular level, bone-selective ligands such as receptor activator of NFκB (RANK) ligand and parathyroid hormone (PTH) bind to their respective membrane receptors and activate a complex network of receptor associated factors (RAF) to relay the initial signal across cell membrane (2, 3). The strength and duration of the signal is regulated by the action of a number of highly specialised intracellular enzymes which form signalling cascades that operate as “biological switches” (Fig. 1). Specialised enzymes such as protein kinases phosphorylate specific amino acids in the target protein, most commonly at specific tyrosine or serine residues (1, 4). This causes a change in
Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_15, © Springer Science+Business Media, LLC 2012
223
224
A.I. Idris
Fig. 1. Schematic diagrams showing a hypothetical model of post-translational modification of signalling proteins and methods that routinely used to study these changes. Signalling proteins are normally present in the cytoplasm. Upon cell stimulation, receptor associated factors (RAF) are recruited by membrane receptors. This results in structural modification of cytoplasmic signalling proteins (CSP) that in turn alter protein mobility, level, and/or activity. Some cytoplasmic signalling proteins function as transcription factors (TF) by translocating to the nucleus where they bind to DNA and induce the transcription of various genes needed for cell survival, differentiation, and activity.
configuration and a change in function. For example, studies showed that pharmacological inhibition of RANK ligand-induced phosphorylation of cytoplasmic proteins such as IκB kinase (IKK) in osteoclast is sufficient to suppress osteoclast formation in vitro and in vivo, and as a result prevent osteoclastic bone destruction in animal models of osteoporosis and breast cancer (5–7). Conversely, signalling is often de-activated by protein phosphatases which dephosphorylate the target protein rendering it inactive (4). Reflecting this fact, phosphorylation is the most common post-translational modification to occur in mammalian cells (1, 4, 8). Over the last decade, there has been a tremendous increase in understanding of the signal transduction pathways that systemic hormones, local regulatory factors, and drug treatments
15
Analysis of Signalling Pathways by Western Blotting…
225
use to regulate bone cell differentiation, survival, and function. Protein prenylation is another extensively studied mode of protein post-translation modification in bone cells (9, 10). Treatment with nitrogen-containing bisphosphonates inhibits prenylation of small GTPases and leads to the accumulation of unprenylated GTPases in osteoclasts (10). Following cytoplasmic events, the propagation of the signal to the nucleus involves nuclear translocation and DNA binding of transcription factors (Fig. 1). Changes in the levels, phosphorylation status and binding partners of intracellular signalling proteins are most commonly assessed by Western blotting and immunoprecipitation and I shall describe these techniques in this chapter (Fig. 2). Electrophoretic mobility shift assay (EMSA) or mobility shift electrophoresis (Fig. 2) frequently used to study the activation and DNA binding of transcription factors in bone cells is described in Chapter 16, this volume. For the description of “kit-based” methods such as enzyme-linked immunosorbent assay (ELISA) and immunosorbent assays refer to Fig. 2 and follow instruction by suppliers of kits.
resolved protein
Immunoprecipitation
Cytoplasmic protein Transcription factor
pull down protein and run on SDS page gel add primary and purify protein secondary antibody
visualise protein
DNA Primary Antibody
resolved protein
Western blot
lyse cell
run on SDS page gel
add primary and secondary antibody
HRP conjugated secondary antibody Chemiluminescent substrate EMSA labelled probe*
visualise protein
EMSA competitive probe
Enzyme-linked immunosorbent assay treat cells
permeabilise cells add primary antibody
add secondary add fluorescent substrate and visualise protein antibody
supershift shift
Electrophoretic gel mobility shift assay
probes
lyse cell and add EMSA labelled run on SDS page gel nuclear and competitive probes
visualise transcription factor
Enzyme-linked immunosorbent assay lyse cell
add cell lysate to add primary antibody add secondary antibody followed DNA-coated plate by chemiluminescent substrate
Fig. 2. Overview of the principles of protocols routinely used to study signalling transduction mechanisms in bone cells.
226
A.I. Idris
2. Materials Trade names and commercially products are occasionally stated for identification purposes only and do not imply endorsement. 2.1. Immunoprecipitation
1. Standard lysis buffer: 0.1% (w/v) sodium dodecyl sulphate (SDS), 0.5% (w/v) sodium deoxycholate, 2% (v/v) protease inhibitor cocktail (see Note 1) in sterile PBS. 2. Modified lysis buffer: Standard lysis buffer containing 1 mM EDTA, 1 mM sodium orthovanadate, and 10 mM sodium fluoride in sterile PBS.
2.2. Western Blotting
1. Resolving gel: 40% bisacrylamide:acrylamide (1:29), 25% Tris (1.5 M, pH 8.8), 0.1% SDS (10%), 0.1% ammonium persulfate (10%), and 0.04 μl of TEMED, 34.8% distilled water; added in this order. 2. Stacking gel: 12.5% bisacrylamide:acrylamide (1:29), 25% Tris (0.5 M, pH 6.8), 1% SDS (10%), 0.5% ammonium persulfate (10%), and 0.1% TEMED, 60.9% distilled water; added in this order. Pre-cast SDS PAGE gels provide an alternative to making the resolving and stacking gels and can be purchased from a number of manufacturers. 3. Sample loading buffer: 12.5% Tris–hydrochloric acid (Tris– HCl) (0.5 M; pH 6.8), 10% glycerol, 20% SDS (10%), 5% β-mercaptoethanol, 2.5% bromophenol blue (0.05%), 50% distilled water. 4. Electrophoresis running buffer: dissolve 3% Tris base, 1% SDS, 1.1% glycine dissolved in distilled water. 5. Transfer buffer: 48 mM Tris base, 39 mM glycine, 0.04% (w/v) SDS, 20% methanol in distilled water. 6. 100% Methanol. 7. Pads or standard chromatography papers. 8. Nitrocellulose or polyvinylidene fluoride (PVDF) membrane. 9. Tris–HCl: dissolve 10% (w/v) Tris base in 60 ml of dH2O, adjust pH by adding HCl (1 M), make up volume to 150 ml in distilled water, and store at 4°C. 10. Tris-buffered SDS with Tween (TBST): 50 mM Tris and 150 mM sodium chloride in distilled water. 11. Blocking solution: 5% w/v dried non-fat milk in TBST. 12. Stripping buffer: 1 mM dithiothreitol (DDT), 2% SDS, and 6.35 mM Tris–HCl (pH 6.7).
15
Analysis of Signalling Pathways by Western Blotting…
227
3. Methods 3.1. Immunoprecipitation
3.1.1. Preparation of Cell Lysate
Immunoprecipitation (IP) is a technique carried out to probe for the presence of proteins of interest in a cell lysate and to determine if it forms part of a protein complex (Fig. 2). The technique involves incubating an antibody directed against the protein of interest with a cell lysate and precipitating the complex of antibody bound to the target protein by agarose or magnetic beads (see Note 2). The antibody/protein complex can then be separated by SDS-PAGE and subjected to Western blotting. This allows the investigator to determine if the protein of interest is present within the cell lysate and to determine (by probing with antibodies to other proteins) if the protein of interest is part of a protein complex. 1. Culture bone cells to confluence in standard tissue culture plates in the presence or absence of test stimuli for the desired period of time. 2. Aspirate and rinse monolayer three times with ice-cold PBS. 3. Incubate adherent cells in standard lysis buffer for 10 min. Use modified lysis buffer for studies involving extraction of phosphorylated proteins (see Notes 3 and 5). 4. Vortex cell suspension for 10 s, pass supernatant through a 21-gauge needle, and incubate on ice for 10 min. 5. Centrifuge cell lysate at 14,000 × g at 4°C for 10 min and transfer the supernatant to a clean Eppendorf (at this point it is possible to proceed with the IP or store the samples frozen at −80°C for up to a year). 6. Determine protein concentration using a standard commercially available protein assay such as bicinchoninic acid (BCA) Pierce® protein assay (Pierce, UK).
3.1.2. Immunoprecipitation
1. Incubate 490 μl of cell lysate containing 250–500 μg of total protein concentration with 5 μg of polyclonal or monoclonal antibody specific for protein of interest at 4°C for 24 h (see Note 4 and Fig. 2). 2. Add 10 μl of bead of choice to the immunoprecipitation cell lysate mix and then incubate with agitation at 4°C for 6–16 h (see Note 2). 3. Briefly centrifuge sample, carefully aspirate, discard the supernatant, and recover the pelleted bead/protein(s) complex. 4. Wash pellet three to five times in ice-cold standard lysis buffer by inverting Eppendorf several times. 5. Boil sample mixture at 90°C for 5 min to dissociate protein of interest from bead/protein(s) complex.
228
A.I. Idris
6. Briefly centrifuge sample, carefully aspirate, and transfer the supernatant to a fresh Eppendorf. 7. Repeat steps 1–5 to further purify or dissociate desired protein from other proteins if part of a complex. 8. Mix cell lysate with the appropriate volume of sample loading buffer and boil at 90°C for 5 min to denature protein. 9. Resolve samples on polyacrylamide-SDS gel and blot to nitrocellulose or PVDF membrane (see below). 3.2. Western Blotting
Western blotting is used to determine if a protein of interest is present within a specific cell type, to assess protein abundance and to assess phosphorylation status or other post-translational modifications such as prenylation (11). The technique uses denaturing gel electrophoresis to separate proteins present in cell extracts according to their molecular weight (Fig. 2). Once separated, proteins are transferred to nitrocellulose or PVDF membrane and incubated with a primary antibody directed against the proteins of interest. If the protein of interest is present within the lysate the primary antibody will bind to the membrane-bound protein and this can be detected by incubating the membrane with a secondary antibody linked to an amplification system such as HRP that uses HRPconjugated secondary antibody that can be visualised using enhanced chemiluminescence imager or transferred on a film (Fig. 3).
Fig. 3. Schematic of gel assembly and transfer assembly for western blotting. (a) Gel assembly; (b) transfer assembly.
15 3.2.1. Preparation of Cell Lysate
Analysis of Signalling Pathways by Western Blotting…
229
1. Culture bone cells to confluence in standard tissue culture plates in the presence or absence of test stimuli for the desired period of time. 2. Aspirate and rinse monolayer three times with ice-cold PBS. 3. Incubate adherent cells in standard lysis buffer for 10 min. Use modified lysis buffer for studies involving extraction of phosphorylated proteins (see Note 5). 4. Vortex cell suspension for 10 s, pass supernatant through a 21-gauge needle, and incubate on ice for 10 min. 5. Centrifuge cell lysate at 14,000 × g at 4°C for 10 min and transfer the supernatant to a clean Eppendorf (at this point it is possible to proceed with the WB or store the samples frozen at −20°C for up to a year). 6. Determine the protein concentration using a standard commercially available protein assay such as BCA Pierce® protein assay (Pierce, UK).
3.2.2. Preparation of SDS Polyacrylamide Gel
1. To prepare SDS polyacrylamide gels in the laboratory, assemble a glass-plate gel assembly using in-house components or those supplied by commercially available kits (see Fig. 3a). 2. Once the glass-plate assembly is in place, carefully pour resolving gel allowing about 3 cm from the top. Add a layer of distilled water on top of the resolving gel to ensure an even surface. 3. Once the resolving gel is polymerised, aspirate water and replace with a layer of stacking gel. Insert a plastic comb between the two glass-plates to create wells (see Fig. 3a). 4. Alternatively pre-cast SDS polyacrylamide gels can be used. These can be obtained in a wide range of sizes and thicknesses from a number of suppliers (see Note 6).
3.2.3. Electrophoresis
The procedure separates the denatured proteins according to their molecular weight. 1. Mix cell lysate with the appropriate volume of sample loading buffer. 2. Boil sample mixture at 95°C for 5 min to denature protein. 3. Place pre-cast gel into a vertical electrophoresis tank filled with electrophoresis running buffer. 4. Load carefully into the designated well on the pre-cast gel (see Note 7). 5. Place gel-plates assembly into electrophoresis tank filled with electrophoresis running buffer and run at constant volume of 200 V for 30–40 min (see Note 8).
230
A.I. Idris
3.2.4. Electrophoretic Transfer from Gel to Membrane
The procedure transfers proteins from the SDS polyacrylamide gel to a nitrocellulose or PVDF membrane, prior to incubation with the primary and secondary antibodies and detection step. 1. Remove gel from the glass-plate assembly and immerse gel into transfer buffer for 3–5 min. 2. Meanwhile, cut nitrocellulose or PVDF membrane to size, immerse in 100% methanol, and then allow it to equilibrate in transfer buffer for 5 min. 3. Prepare a blotting sandwich by arranging successive layers of three pads pre-soaked in transfer buffer, nitrocellulose or PVDF membrane, SDS polyacrylamide gel, three pre-soaked pads (see Fig. 3b). 4. Run transfer at a constant current for 1–3 h (see Note 8).
3.2.5. Protein Detection
1. Incubate nitrocellulose or PVDF membrane at room temperature for 1 h in blocking solution containing 5% dried non-fat milk in TBST (see Note 9). 2. Rinse nitrocellulose or PVDF membrane in TBST buffer for at least 15 min while changing the buffer every 5 min. 3. Incubate membranes with the appropriate amount of primary polyclonal or monoclonal antibody at 4°C for 16–24 h with continuous gentle agitation (see Note 4). 4. Rinse nitrocellulose or PVDF membrane as described in step 2 and then incubate with the appropriate amount of the HRPconjugated secondary antibody for 1 h at room temperature or overnight at 4°C with continuous gentle agitation (see Note 4). 5. Repeat step 2 and visualise protein of interest using a standard chemiluminescence imager. The intensities of the bands can be quantified using software supplied with most commercially available imagers. 6. To probe the membrane for a different protein, remove primary and secondary antibodies by incubating the membrane in stripping buffer at 56°C for 5–10 min depending on the strength of the signal obtained with previous antibody. Revisualise blot using a chemiluminescence imager to ensure that the antibody has been completely removed. 7. Proceed with detection from step 1 above using a different antibody at step 3. Membrane can be stripped and reprobed with a different primary and secondary antibodies many times (see Note 10).
15
Analysis of Signalling Pathways by Western Blotting…
231
4. Notes 1. We routinely use protease inhibitor cocktail at concentration that 1 ml of the protease inhibitor cocktail is sufficient for the inhibition of proteases extracted from 20 g of bovine liver. 2. There are numerous types of protein beads available on the market, therefore, consult the literature and manufacturer’s websites. Use the most suitable commercially available protein bead at the right pH to ensure optimum elution of desired protein from the beads. 3. Incubate cells for shorter periods (1–3 min) if working with fragile cells such as osteoclasts. 4. Prepare antibody in blocking buffer (3% bovine serum albumin or 5% low fat milk) to reduce non-specific binding during the incubation period. Avoid using large quantities of an antibody or a cocktail of two or more primary antibodies to minimise non-specific binding and antibody to antibody cross reaction. 5. Use fresh protease and phosphatase inhibitors to avoid antigen degradation during immunoprecipitation. 6. Pre-cast SDS polyacrylamide gels are convenient but expensive and most have a short shelf life. 7. Standard marker with known apparent molecular weights should be loaded alongside the sample to aid with the identification of molecular weight of protein under investigation. Load multicoloured kaleidoscope pre-stained standard marker to check the quality of transfer. 8. Consult manufacturers of gel and transfer equipment on deciding the current at which the electrophoresis and/or electrophoretic transfer can be carried out. The duration of transfer depends on the size of protein under investigation – larger proteins require more time to transfer across. 9. This step is essential to ensure blocking of non-specific binding sites. 10. When stripping primary and secondary antibodies, membrane bound proteins – in particular phosphorylated proteins – may be damaged or affected resulting in reduced sensitivity in subsequent detections. This can be avoided by using fluorescent imagers, which allow detection of multiple proteins simultaneously.
232
A.I. Idris
References 1. Gomperts, B. D., Kramer, I. M., and Tatnell, M. A. (2004) Signal transduction. Elsevier. 2. Feng, X. RANKing intracellular signaling in osteoclasts. (2005) IUBMB. Life 57, 389–395. 3. Swarthout, J. T., D’Alonzo, R. C., Selvamurugan, N., and Partridge, N. C. (2002) Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. Gene 282, 1–17. 4. Hubbard, M. J., and Cohen, P. (1993) On target with a new mechanism for the regulation of protein phosphorylation. Trends Biochem. Sci. 18, 172–177. 5. Idris, A.I, Mrak. E, Greig. I, Guidobono, F., Ralston, S. H., van ’t Hof, R. (2008) ABD56 causes osteoclast apoptosis by inhibiting the NFkappaB and ERK pathways. Biochem. Biophys. Res. Commun. 371, 94–98. 6. Idris, A. I., Libouban, H., Nyangoga, H., Landao-Bassonga, E., Chappard, D., and Ralston, S. H. (2009) Pharmacologic inhibitors of IkappaB kinase suppress growth and
7.
8.
9.
10.
11.
migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol. Cancer Ther. 8, 2339–2347. Idris, A. I., Krishnan, M., Simic, P., LandaoBassonga, E., Mollat, P., Vukicevic, S., and Ralston, S. H. (2010) Small molecule inhibitors of I{kappa}B kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy-induced bone loss in vivo. FASEB J. 24, 4545–4555. Cohen, P. Protein kinases--the major drug targets of the twenty-first century? (2002) Nat. Rev. Drug Discov. 1, 309–315. Zhang, F. L., and Casey, P. J. (1996) Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65, 241–269. Rogers, M. J. (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 9, 2643–2658. Kurien, B. T., Scofield, R. H. (2006) Western blotting. Methods. 38, 283–293.
Chapter 16 Analysis of Transcriptional Regulation in Bone Cells Huilin Jin and Stuart H. Ralston Abstract Transcription is the process by which the rate of RNA synthesis is regulated. Here, we describe the techniques for carrying out promoter-reporter assays, electrophoretic mobility shift assays, and chromatin immunoprecipitation assays, three commonly used methods for studying gene transcription. Key words: Transcription, Chromatin, Immunoprecipitation, ChIP, EMSA, Promoter, Gene
1. Introduction Gene expression is regulated by the process of transcription which governs the rate at which ribonucleic acid (RNA) is produced. Transcription is carried out by RNA polymerase enzymes but they cannot initiate transcription in isolation. Instead, the activity of RNA polymerase is regulated by other proteins called transcription factors, which bind to regulatory elements in DNA, either in the gene promoter or at other regulatory sites within or around the gene. In this chapter, we describe three commonly used methods for the study of gene transcription. These are promoter-reporter assays (1), electrophoretic mobility shift assays (1), and chromatin immunoprecipitation assays (2); all of these techniques have previously been used to investigate the functional effects of polymorphisms and mutations that have been associated with osteoporosis (3–6) and other bone diseases (7). In promoter-reporter assays, DNA sequences containing putative regulatory elements are cloned upstream of a reporter gene such as Firefly luciferase and transfected into cultured cells. In order to control for transfection efficiency the cells are usually cotransfected with another vector such as β-galactosidase or Renilla luciferase. The activity of the promoter or enhancer of interest is then assessed by measuring activity
Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_16, © Springer Science+Business Media, LLC 2012
233
234
H. Jin and S.H. Ralston
of the luciferase reporter in cell lysates with correction for activity of the control vector. Electrophoretic mobility shift assays (EMSA) are used to study the binding of transcription factors to recognition sites in DNA and/or their binding affinity for the recognition site. They involve incubating labeled double-stranded oligonucleotides containing the recognition site of interest with nuclear protein extracts. Then, the reaction mixture is subject to gel electrophoresis to assess if proteins within the extracts bind the DNA and slow migration of the oligonucleotides through the gel. Chromatin immunoprecipitation (ChIP) assays are used to study interaction of transcription factors with DNA in chromosomal fragments. These assays involve the use of specific antibodies to immunoprecipitate fragments of DNA bound to the transcription factor of interest followed by PCR amplification of the DNA sequences flanking the recognition sites in the gene of interest. The advantage of ChIP assays over EMSA assays is that they examine transcription factor binding in a chromosomal context. They can also be used to identify cis-acting sequences in the genome when combined with DNA sequencing (ChIP-Seq) and can also be used to quantify allele-specific transcription when combined with quantitative PCR.
2. Materials 2.1. Promoter-Reporter Assay
1. Endofree MaxiPrep Kit (Qiagen). 2. Spectrophotometer. 3. Dual-luciferase® Reporter Assay System, including pGL3 & pRL-TK Luciferase Reporter Vectors and associated buffers and reagents (Promega). 4. Magnetic assisted transfection kit and magnetic plate (MATra, IBA BioTAGnology). 5. Luminometer. 6. Tissue culture facilities. 7. Culture medium (aMEM medium with 10% fetal calf serum, 50 IU/ml penicillin, and 2 mM glutamine).
2.2. Nonradioactive Electrophoretic Mobility Shift Assay
1. Oligonucleotides flanking target DNA–protein binding site with or without biotin-labeling. 2. 10× Annealing buffer: 1 M Tris, pH 8.0, 5 M NaCl, and 0.5 M EDTA. 3. 5× TBE Buffer: 445 mM Tris Base, 445 mM Boric Acid, and 10 mM EDTA, pH 8.0. Dilute 1 in 10 with distilled water before use.
16
Analysis of Transcriptional Regulation in Bone Cells
235
4. Lightshift® Chemiluminescent EMSA Kit (Pierce, UK). 5. Positively charged nylon membrane (Pierce). 6. UV lamp or transilluminator equipped with 312 nm bulb. 7. Electrophoresis apparatus. 8. Electroblotter or capillary transfer apparatus. 9. Blotting paper and pad. 10. Polyacrylamide gel. 2.3. Chromatin Immunoprecipitation Assay
1. Nuclear extract kit (Active Motif ®). 2. 37% formaldehyde. 3. 1 M glycine in PBS. 4. PBS with protease inhibitor cocktail: One Roche protease inhibitor cocktail tablet dissolved in 10 ml PBS (keep on ice until use). 5. Lysis buffer: 50 mM Tris, pH 8.1, 10 mM EDTA and 1% (w/v) SDS. 6. Protease inhibitor cocktail in lysis buffer: One Roche protease inhibitor cocktail tablet in 10 ml lysis buffer from step 5. 7. IP Dilution buffer: 16.7 mM Tris pH 8.1, 1.2 mM EDTA, 167 mM NaCl, 1.1% Triton X 100 (v/v), and 0.01% (w/v) SDS. 8. TSE I Buffer: 20 mM Tris pH 8.1, 2 mM EDTA, 150 mM NaCl, 1% (v/v) Triton X-100, and 0.1% (w/v) SDS. 9. TSE II buffer: 20 mM Tris pH 8.1, 2 mM EDTA, 500 mM NaCl, 1% (v/v) Triton X-100, and 0.1% (w/v) SDS. 10. Elution buffer: 0.1 M NaHCO3 and 1% (w/v) SDS (make up fresh before use). 11. Buffer III: 10 mM Tris pH 8.1, 0.25 M LiCl, 1 mM EDTA, 1% (v/v) NP40, and 1% (w/v) sodium deoxycholate. 12. TE buffer: 50 mM Tris pH 8.1 and 1 mM EDTA. 13. Phenol–Chloroform–Isoamyl alcohol (25:24:1) or Quiaquick PCR purification kit. 14. Sonicator.
3. Methods 3.1. Dual Luciferase Reporter Assay
This technique involves cloning the target promoter region to upstream of the reporter gene and measuring Firefly luciferase activity in cell lysates. In the example given, a second Renilla luciferase vector is cotransfected to provide an internal control.
236
H. Jin and S.H. Ralston
The advantage of using Firefly luciferase and Renilla luciferase together is that the activities of both vectors can be measured sequentially in the same cell lysate by using different substrates for each enzyme. Here, we describe the use of the MATra magnetic transfection system to introduce a PGL-3 reporter vector and a PRL-TK control vector into human osteosarcoma TE85 cells. 1. Purify the vectors using an EndoFree Plasmid Maxi Kit according to the manufacturer’s recommendations (see Note 1). 2. Determine the DNA concentrations by UV spectrophotometry (see Note 2) and store the vectors at −20°C until required. 3. Culture the TE85 cells in medium using 75-cm2 tissue culture flasks at 37°C in a humidified atmosphere of 5% CO2. Replace the medium every 3 days until the cells are nearly confluent. 4. Twenty-four hours prior to carrying out the transfection, passage the cells and seed into 24-well plates at a density of 4 × 104 cells per well. 5. For each well to be transfected, combine 0.6 mg of PGL-3 reporter vector with 0.1 mg of PRL-TK control vector and 50 ml aMEM without serum, glutamine, or antibiotics. 6. For each well to be transfected, add 0.6 ml MATra-A reagent, to the diluted reporter vector mix in step 5 and mix thoroughly. Incubate at room temperature for 20 min. 7. Remove the culture medium from each well of the 24-well plate and replace with 500 ml fresh culture medium. 8. Add 50 ml of the vector/MATra-A reagent mix from step 6 to each well of the plate and gently mix by swirling the medium around the plate. 9. Place the 24-well plate on the Magnetic Plate and incubate for 15 min at 37°C in a tissue culture incubator set at 37°C in a humidified atmosphere of 5% CO2. 10. Remove the Magnetic Plate and continue to culture cells. Check the cells after 6 h for evidence of toxicity (e.g., detachment of cells or rounding up of cells) and if present replace the transfection mixture with normal culture medium. 11. Incubate the cells for 24 h after transfection in the presence or absence of test agents. 12. Terminate the experiment by aspirating the culture medium. 13. Wash each well of the plate three times with PBS. 14. Add 80–100 ml lysis buffer provided with the Dual-luciferase® Reporter Assay System, to completely cover each well of the tissue culture plate. 15. Wrap the plate in foil paper and store it at −80°C for at least 24 h.
16
Analysis of Transcriptional Regulation in Bone Cells
237
16. Thaw the plates at room temperature and transfer 40 ml of the lysate from each sample into a 96-well clear bottom plate, ensuring that there are no bubbles in the sample (see Note 3). 17. Measure Firefly luciferase activity and Renilla luciferase activity sequentially by auto-injection of 40 ml of luciferase assay reagent and 40 ml Stop & Glo® reagent (provided with the Dual Luciferase reporter assay system) into the lysate from each well using a luminometer fitted with two injectors (see Note 4). 18. Assess the activity of the promoter of interest by correcting the Firefly luciferase activity to that of Renilla activity for each sample. 19. Calculate values for each of the replicates and assess between group differences using an appropriate statistical test such as t-Test (for paired samples) or ANOVA. This technique is based on the fact that protein–DNA complexes migrate through a nondenaturing polyacrylamide or agarose gel more slowly than free DNA molecules. The EMSA technique involves mixing a crude nuclear extract or sample of purified protein with a labeled oligonucleotide probe containing the putative transcription factor binding site. The samples are then analyzed by electrophoresis through a nondenaturing polyacrylamide. Oligonucleotides that are bound to transcription factors migrate more slowly through the gel than free oligonucleotides and can be detected as a “gel shift” (see Fig. 1). Furthermore specificity of the DNA–protein binding is established by addition of
3.2. Electrophoretic Mobility Shift Assay
a
b
Probe Protein Antibody Specific competitor non-specific competitor
+ -
+ + -
+ + + -
+ + + -
+ + +
Probe (Allele 1)
+
+
+
+
+
+
+
+
Protein
-
+
+
+
+
+
+
+
Competitor(Allele 1) -
-
+
+
+
-
-
-
Competitor(Allele 2) -
-
-
-
-
+
+
+
supershift shift
shift
Free DNA probe
Free DNA probe
Fig. 1. In the EMSA, DNA–protein binding complex migrates more slowly than free DNA probe on the gel, called a shift. (a) Testing the specificity of a DNA–protein binding reaction. Addition of a protein specific antibody further shifts the band called a supershift. The DNA–protein shift is completely (or partly) eliminated by addition of an unlabeled specific competitor which contains known DNA–protein binding sequence. However, a nonspecific competitor will not alter the shift. (b). Testing the DNA–protein binding affinity between alleles. Unlabeled competitor at higher concentrations competitively binds to the protein and blocks the labeled DNA probe–protein binding, which causes a reduction in intensity of the shift. For example, unlabeled competitor with allele 2 eliminates the labeled DNA–protein shift at a lower concentration than the one with allele 1. Therefore allele 2 has higher binding affinity to this protein than allele 1.
238
H. Jin and S.H. Ralston
the specific antibody or competition experiments using oligonucleotides containing a binding site for the protein of interest or other unrelated DNA sequences. The technique described here uses a nonradioactive method of detecting the DNA–protein complexes (5–9) instead of the radioactive methods of detection that have been used previously by ourselves and other investigators (4–6). 3.2.1. Probe Design
1. Obtain a pair of complementary oligonucleotides (probes) flanking the putative DNA–protein binding site of interest with HPLC purification. 2. End-label the forward strand sequence with biotin (see Note 5). 3. Combine 2 mM of biotin-labeled forward probe with 3 mM reverse probe, 5 ml 10× annealing buffer and make up to 50 ml with distilled water. 4. Mix well and incubate at 90°C for 1 min. 5. Allow it to cool slowly to room temperature on the bench (approximately 1 h). 6. Store the resulting double-stranded probes at −20°C until required. 7. To make double-stranded competitor probe, follow the above steps 3–6 but replace the biotin-labeled forward probe with unlabeled forward probe.
3.2.2. Preparation of Nuclear Extracts
1. Culture the cells of interest in a 75-cm2 tissue culture flask until near confluent. 2. Remove the medium and wash the cells three times with icecold PBS. 3. Extract nuclear proteins from cells using the Active Motif® nuclear extract kit according to the manufacturer’s instructions. 4. Determine the protein concentration in the extract using a standard commercially available protein assay. Store the extracts frozen in 10 ml aliquots at −80°C until further use (see Note 6).
3.2.3. Setting up the EMSA Binding Reaction
1. Prepare the binding reactions according to the schedule shown in Table 1a if you wish to test the specificity of a putative DNA–protein binding, and Table 1b if you wish to test the DNA–protein binding affinity of different probes. 2. Incubate binding reactions at room temperature for 20 min.
3.2.4. Electrophoresis and Transfer from Gel to Membrane
1. Place a precast 4–6% native polyacrylamide minigel (8 × 8 × 0.1 cm), into a vertical electrophoresis tank filed with 0.5× TBE buffer (see Note 7). 2. Prerun the gel at a 100 V for 60–90 min.
16
Analysis of Transcriptional Regulation in Bone Cells
239
Table 1 Typical setup for EMSA binding reactions a. Binding reactions to test the specificity of putative DNA–protein binding Component
#1
#2
#3
#4
#5
Ultrapure Water (ml)
15
14
13
13
13
10× Binding Buffer (ml)
2
2
2
2
2
BSA (10 mg/ml) (ml)
2
2
2
2
2
Unlabeled specific competitor probe (4 mM) (ml)
–
–
–
Unlabeled nonspecific competitor probe (4 mM) (ml)
–
–
–
Hos TE85 protein extract (8–10 mg/ml) (ml)
–
Antibody (ml)
–
Biotin-labeled probe (0.04 mM) (ml) Total volume (ml)
1
1 –
1
–
– 1
1
1
1
1
1
1
1
1
20
20
20
20
20
b. Binding reactions to test binding affinity between different probes Component
#1
#2
#3
#4
#5
#6
#7
#8
Ultrapure Water (ml)
15
14
13
12
10
13
12
10
Binding Buffer (10×) (ml)
2
2
2
2
2
2
2
2
BSA (10 mg/ml) (ml)
2
2
2
2
2
2
2
2
1
2
4
Unlabeled specific competitor probe 1 (1 mM) (ml)
–
–
Unlabeled specific competitor probe 2 (1 mM) (ml)
–
–
Hos TE85 protein extract (8–10 mg/ml) (ml)
–
Biotin-labeled probe 1 (0.04 mM) (ml) Total volume (ml)
–
–
–
–
–
–
1
2
4
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
20
20
20
20
20
20
20
20
®
Binding buffer (10×) is supplied in the LightShift Chemiluminescent EMSA Kit (Pierce). Other components are also supplied in the kit for optimization of the binding reaction such as glycerol, Poly (dI·dC), NP-40. Always add the components in descending order as listed in the table. To reduce nonspecific binding, a short preincubation (~2 min) may be required before adding the biotin-labeled probe
3. Mix the binding reaction with 5 ml 5× loading buffer (provided with the chemiluminescent EMSA kit) by pipetting up and down several times. 4. Flush each well with 0.5× TBE buffer and load carefully 20 ml of each sample. 5. Run the gel at a 100 V until the bromophenol blue dye migrates approximately three quarters of the way down the gel.
240
H. Jin and S.H. Ralston a
Well Glass plates
Stacking gel
Resolving gel
Spacer
Clip polyacrylamide stacking gel
b
SDS polyacrylamide gel
pad pad PVDF membrane
+
Fig. 2. (a) Gel assembly; (b) transfer assembly.
6. Remove gel from the cassette and immerse it in 0.5× TBE buffer for a few minutes. 7. Meanwhile, soak a PVDF membrane, filter paper, and pad in 0.5× TBE buffer for 10 min. 8. Make a blotting sandwich by arranging successive layers of one presoaked filter pad, two filter papers, PVDF membrane, gel, presoaked filter paper, and pad (see Fig. 2). 9. Remove any air bubbles by using a pencil or a glass tube to flatten the filter papers and pads during the layering process. 10. Close the cassette firmly and place it in a clean electrophoretic transfer unit. 11. Add the cooling unit and fill the tank with 0.5× TBE buffer. 12. Place the whole tank in a cold room or a container filled with plenty of ice. 13. Run the blot at 380 mA for 60 min. When the transfer is complete cross-linked the membrane for 15 min by placing face down on a transilluminator equipped with 312 nm bulb.
16 3.2.5. Detection of Biotin-Labeled DNA–Protein Complex by Chemiluminescence
Analysis of Transcriptional Regulation in Bone Cells
241
The buffers referred to in this section are not listed individually in the materials section but are included in the Lightshift® Chemiluminescent EMSA kit. 1. Immerse the membrane in 10 ml blocking buffer for 15 min at room temperature with gentle shaking. 2. Prepare Conjugate/Blocking buffer by adding 66.7 ml Stabilized Streptavidin–Horseradish Peroxidase Conjugate to 20 ml Blocking Buffer. 3. Discard the Blocking buffer and add 10 ml Conjugate/ Blocking buffer. Incubate for 15 min at room temperature with gentle shaking. 4. Discard and rinse the membrane five times for 5 min each in 10 ml 1× Washing buffer with gentle shaking. 5. Transfer the membrane to a new container and incubate with 10 ml Equilibrium Buffer for 5 min with gentle shaking. 6. Remove the membrane and excess buffer. Place the membrane in a clean sheet of plastic wrap. Pour 600 ml Substrate Working buffer over the membrane and incubate for 5 min without shaking. 7. Visualize DNA–protein binding complex using a standard chemiluminescence imager. The intensity of the band can be quantified using image analysis software.
3.3. Chromatin Immunoprecipitation Assay
3.3.1. Cross-Link Chromatin
The Chromatin Immunoprecipitation Assay (ChIP) involves crosslinking cell extracts to bind chromatin-associated proteins to the DNA, shearing the DNA into fragments of between 300 and 1,000 bp by sonication, and immunoprecipitating the DNA– protein complexes using specific antibodies directed against the protein of interest. The immunoprecipitated DNA fragments are then purified and analyzed by PCR or DNA sequencing (see Fig. 3). In this example we described an adaptation of the ChIP technique developed by Naughton (9) using MG63 human osteosarcoma cells as the source of chromatin (5). 1. Culture the MG63 cells in culture medium in two 10 cm tissue culture dishes until nearly confluent. 2. Cross-link the chromatin to the protein by adding 37% formaldehyde directly to the culture medium to a final concentration of 1% (v/v) and incubate for 10 min at 37°C. 3. Add glycine to a final concentration of 0.125 M to the culture medium and incubate for 10 min at room temperature with gentle rocking. 4. Aspirate the medium and wash the cells twice with ice-cold PBS. 5. Scrape the cells from each plate into separate tubes and add 1 ml of PBS with protease inhibitor cocktail solution to each and mix by pipetting up and down.
242
H. Jin and S.H. Ralston
Fig. 3. Overview of Chromatin precipitation (ChIP).
6. Pellet the cell lysate by centrifugation at 450 × g for 4 min at 4°C (see Note 8). 7. Resuspend the cell pellets from each plate in 200 ml lysis buffer with protease inhibitor cocktail and mix by gently pipetting up and down taking care to avoid forming air bubbles. Incubate for 10 min on ice. 8. Combine the lysates (400 ml) from both culture plates into a single tube. 9. Sonicate the lysates to shear the DNA into lengths of between 300 and 1,000 bp with 12 sets of 20 s pulses at 2 Am. Keep samples on ice at all times to avoid overheating and sonicating at intervals of not less than 1 min (see Note 9). 10. Centrifuge samples at 20,000 × g for 10 min at 4°C. 11. Aliquot 100 ml of the sheared chromatin extract to a fresh 1.5 ml microcentrifuge tube and store frozen at −80°C until further use. 3.3.2. Examination of the Sheared Chromatin
This step can be used to ensure that the chromatin has been sheared into fragments of the desired size by the sonication procedure. 1. Add 5 ml 4 M NaCl to a 100 ml sample from step 11 in Subheading 3.3.1 and incubate for 4 h at 65°C. 2. Purify the DNA by adding 100 ml Phenol–Chloroform– Isoamyl alcohol (25:24:1) to each 100 ml sample. Vortex for 10 s and centrifuge at 20,000 × g for 5 min at 4°C. 3. Carefully aspirate 100 ml of the supernatant and transfer to a fresh 1.5 ml microcentrifuge tube.
16
Analysis of Transcriptional Regulation in Bone Cells
243
Fig. 4. MG63 cells were fixed with 1% formaldehyde and 0.125 M glycine, and then chromatin was prepared using PBS and lysis buffer as described. Chromatin was fragmented with 12 pulses at 2 Am using a sonicator in a volume of 400 mL. Each pulse consists of a 20 s sonication followed by a 60 s rest on ice. 100 mL of the sheared chromatin were extracted and precipitated as described. Sample (lane 2 ) was separated by electrophoresis through a 1% agarose gel along with a 100-bp DNA ladder (NEB, lane 1 ).
4. Add 10 ml 3 M Acetate and 220 ml ice-cold 100% ethanol to each sample and vortex. 5. Place the solution in a −80°C freezer for 15 min or a −20°C for 30 min to allow the DNA to precipitate. 6. Centrifuge the sample at 20,000 × g for 5 min at 4°C. 7. Aspirate the supernatant and wash the DNA pellet by adding 1 ml 70% ethanol and inverting the tube a few times. 8. Collect the DNA pellet at the bottom of the tube by centrifuging the sample at 20,000 × g for 5 min at 4°C. 9. Briefly air-dry the pellet for no more than 5 min at room temperature. 10. Suspend the DNA pellet in 30–50 ml TE buffer. 11. Run aliquots of sample (e.g., 5, 10, 15, and 20 ml) and a 100bp DNA ladder on a 1.5% agarose gel to visualize the size of the sheared chromatin fragments (see Fig. 4). 3.3.3. Immunoprecipitation of Chromatin Bound to Protein
1. Prepare fresh IP dilution buffer by adding one protease inhibitor tablet to 10 ml IP dilution buffer. 2. Add 800 ml IP dilution buffer to 100 ml of chromatin extract from Subheading 3.3.1, step 11 (see Note 10). 3. Remove 30 ml of the above sample and save as an input/starting control for the subsequent PCR.
244
H. Jin and S.H. Ralston
4. Add 1 ml IP dilution buffer to 50 ml Protein G-Agarose beads and mix well, preparing additional tubes for each sample of chromatin extract that you wish to analyze. Pellet the beads by centrifugation at 450 × g for 1 min at 4°C and aspirate the supernatant. 5. Wash the beads with IP dilution buffer by repeating step 4 on a further two occasions. 6. Add 1 mg mouse IgG, and 2 mg salmon sperm DNA to the washed beads and make up to a final volume of 100 ml with IP dilution buffer (see Note 11). 7. Add 900 ml of the chromatin mixture from step 2, to the washed beads containing mouse IgG and salmon sperm DNA from step 6. Incubate for at least 3 h at 4°C in a rotary mixer set at 15 rpm. 8. Centrifuge at 450 × g for 1 min at 4°C and aspirate the supernatant using a syringe and fine needle. Transfer the supernatant to a fresh Eppendorf tube for the immunoprecipitation (step 12). 9. Add 50 ml fresh Protein G-Agarose beads to a new tube and wash with IP dilution buffer as described in steps 4–5 above, preparing separate tubes for each sample that you wish to analyze and include an additional tube as a negative control. 10. Add 5 mg of the antibody specific for the protein of interest (see Note 12) and 2 mg salmon sperm DNA to the washed beads from step 9 and make up to a final volume of 100 ml in each tube with IP dilution buffer. 11. Prepare the negative control tube as described in step 10, in which mouse IgG is added in place of the specific antibody. 12. Add the samples of chromatin containing supernatant from step 8 to the mix of Protein G agarose beads, salmon sperm DNA, and antibody from step 10 and 11. 13. Incubate the samples overnight at 4°C in rotary mixer set at 15 rpm. 14. Centrifuge at 450 × g for 1 min at 4°C. Aspirate the supernatant using a syringe and fine needle and discard. 15. Wash the pellet by adding 1 ml TSE I buffer and mix by incubating in a rotary mixer at 4°C set at 20 rpm for 5 min. 16. Centrifuge at 450 × g for 1 min at 4°C. Aspirate the supernatant using a syringe and fine needle and discard. 17. Wash the pellet by adding 1 ml TSE II buffer and mix by incubating in a rotary mixer at 4°C set at 20 rpm for 5 min. 18. Centrifuge at 450 × g for 1 min at 4°C. Aspirate the supernatant using a syringe and fine needle and discard.
16
Analysis of Transcriptional Regulation in Bone Cells
245
19. Wash the agarose pellet by adding 1 ml buffer III and mix by incubating in a rotary mixer at 4°C set at 20 rpm for 5 min. 20. Centrifuge at 450 × g for 1 min at 4°C. Aspirate the supernatant using a syringe and fine needle and discard. 21. Wash the agarose pellet by adding 1 ml TE buffer and incubate on a rotary mixer set at 20 rpm for 5 min at 4°C. 22. Centrifuge at 450 × g for 1 min at 4°C. Aspirate the supernatant using a syringe and needle and discard. 23. Repeat steps 21 and 22 once more and proceed to recover the immunoprecipitated DNA as described in Subheading 3.3.4. 3.3.4. Recover DNA Bound to Protein of Interest
1. Add 250 ml freshly made elution buffer to each sample from Subheading 3.3.3, step 23 and incubate on a rotary mixer set at 15 rpm for 30 min at room temperature. 2. Centrifuge at 450 × g for 1 min at 4°C. Aspirate the supernatant carefully using a syringe and needle and transfer to a fresh tube. 3. Add 200 ml elution buffer to the agarose pellet remaining in the tube from step 2 and incubate on a rotary mixer set at 15 rpm for 15 min at room temperature. 4. Centrifuge at 450 × g for 1 min at 4°C. Aspirate the supernatant carefully using a syringe and needle and transfer to a fresh tube. 5. Combine both elution products together from steps 2 and 4 for each sample (450 ml). 6. Add 25 ml 4 M NaCl to each 450 ml sample from step 5 and 1.7 ml 4 M NaCl to 30 ml input control (from Subheading 3.3.3, step 3). Incubate all samples at 65°C for 6 h. (At this point samples can be stored at −20°C overnight). 7. Prepare fresh recovery buffer by mixing 10 ml 0.5 M EDTA, 20 ml 1 M Tris–HCl (pH 6.5), and 2 ml 10 mg/ml proteinase K for each sample. Add 32 ml of the recovery buffer into each test sample from step 6 and 2.12 ml into the input control. 8. Incubate all samples at 45°C for 1 h. 9. Clean the DNA using a QIAquick PCR purification kit according to the manufacturer’s instructions or perform a phenol– chloroform extraction followed by ethanol precipitation. 10. Recover the DNA from step 9 and suspend in 30 ml dH2O. Store samples at −20°C for use in subsequent PCR or DNA sequencing reactions (see Note 13).
246
H. Jin and S.H. Ralston
4. Notes 1. The following vectors are required for a transfection experiment: a Firefly luciferase reporter vector (PGL3 basic) containing the promoter sequence of interest, a negative control vector which does not contain the promoter sequence (PGL3 basic), a positive control vector which contains a promoter sequence such as SV40 that is constitutively active in Eukaryotic cells (e.g., PGL3 promoter) and a Renilla luciferase vector which constitutively expresses Renilla luciferase as an internal control (e.g., PRL-TK). 2. High quality DNA is required for the subsequent transfection. That is evaluated by the A260/280 reading from a spectrophotometry. Ensure the values are close to 1.8. 3. The exact amount of lysate used in the detection of luciferase expression depends on the activity of target promoter sequence and should be determined empirically for each experiment. 4. If using a luminometer without two injectors, predispense 40 ml of LAR II reagent into a luminometer tube. Add lysate to the luminometer tube and mix. Place the tube in the luminometer and measure the Firefly luciferase activity. Then add 40 ml Stop & Glo Reagent to the same tube either manually or using a reagent injector. Mix briefly and measure the Renilla luciferase activity from the same sample. 5. This can be carried out in house by using a commercially available Biotin 3¢end DNA labeling kit (e.g., Pierce) or ordering 5¢ end labeling when the probe is synthesized by a manufacturer (e.g., Invitrogen). 6. The yield of protein varies between cell types but for HOS TE85 cells growing in a 75 cm2 culture flask the total protein yield should be in the range of 8–15 mg/ml. Note that the frozen aliquots are best for single use and freeze/thaw cycles should be avoided. 7. Commercially available mini gels work very well for reactions with small to medium size probes (<300 bp). The percentage of the gel depends on the size of the probe and the size, number, and the charge of the proteins that bind. 8. The lysates can be stored frozen at −80°C at this point until further use. 9. You might need to vary the number of the 20-s pulse to break DNA into different sizes. The shearing fragment sizes should be 100–1,000 bp smear with an average length of 400–500 bp. Once the conditions have been optimized, keep cell number and the all above steps consistent for subsequent experiments.
16
Analysis of Transcriptional Regulation in Bone Cells
247
If samples from different experiments are being used ensure that the sonicator probe is cleaned with 75% ethanol between samples. 10. Depending on the abundance of the DNA–protein binding you might need to add less IP dilution buffer to the chromatin extract so that the extract is more concentrated. 11. This step is required to reduce nonspecific binding. 12. The amount of antibody used needs to be determined empirically for each experiment, depending on the abundance of the protein and the antibody’s affinity for the protein. One tube should also be prepared in which the antibody has been omitted to act as a negative control. 13. Several options are possible at this stage. For example, to verify the binding of a transcriptional factor to the gene promoter of interest in cells, a PCR reaction could be performed to amplify the target promoter region using the DNA which was enriched in above IP using antibody to the transcriptional factor. Quantitative real-time PCR assay could be used to further quantify the binding. References 1. Strachan, T., and Read, A. P. (2011) Human Molecular Genetics. Garland Science, New York. 2. Das, P. M., Ramachandran, K., vanWert, J., and Singal, R. (2004) Chromatin immunoprecipitation assay. Biotechniques 37, 961–969. 3. Morrison, N. A., Yeoman, R., Kelly, P.J., and Eisman, J.A. (1992) Contribution of trans-acting factor alleles to normal physiological variability: Vitamin D receptor gene polymorphisms and circulating osteocalcin. Proc.Natl.Acad.Sci. USA. 89, 6665–6669. 4. Mann, V., Hobson, .E. E., Li, B., Stewart, T. L., Grant, S .F., Robins, S. P., Aspden, R. M., and Ralston, S. H. (2001) A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. J. Clin. Invest. 107, 899–907. 5. Jin, H., van’t Hof, R. J., Albagha, O. M., and Ralston, S. H. (2009) Promoter and intron 1 polymorphisms of COL1A1 interact to regulate transcription and susceptibility to osteoporosis. Hum. Mol. Genet. 18, 2729–2738.
6. Arai, H., Miyamoto, K. I., Yoshida, M., Yamamoto, H., Taketani, Y., Morita, K., Kubota, M., Yoshida, S., Ikeda, M., Watabe, F., Kanemasa, Y., and Takeda, E. (2001) The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J. Bone Miner. Res. 16, 1256–1264. 7. Leupin, O., Kramer, I., Collette, N. M., Loots, G. G., Natt, F., Kneissel, M., and Keller, H. (2007) Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J. Bone Miner. Res. 22,1957–1967. 8. Garcia-Giralt, N., Enjuanes, A., Bustamante, M., Mellibovsky, L., Nogues, X., Carreras, R., ez-Perez, A., Grinberg, D., and Balcells, S. (2005) In vitro functional assay of alleles and haplotypes of two COL1A1-promoter SNPs. Bone 36, 902–908. 9. Naughton, C., MacLeod, K., Kuske, B., Clarke, R., Cameron, D. A., and Langdon, S. P. (2007) Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine resistance. Mol.Endocrinol. 21, 2615–2626.
sdfsdf
Chapter 17 Extraction of Nucleic Acids from Bone Alun Hughes, Tracy L. Stewart, and Val Mann Abstract Here, we present methods for extracting DNA and RNA from samples of whole bone tissue and culture bone cells and describe methods quantitative and qualitative measurement of the extracted nucleic acids. These protocols described provide high-quality nucleic acids suitable for downstream applications such as quantitative PCR and microarrays. Key words: RNA extraction, DNA extraction, RNA quantification, DNA quantification, RNA integrity
1. Introduction Nucleic acids can be extracted from bone for analysis of gene expression, to look for somatic mutations in the analysis of tumors or other pathological tissue, or for genotyping archive material when other sources of DNA are not available. Extraction of nucleic acids of sufficient purity, abundance, and quality from bone presents many problems, especially in maintaining the integrity of RNA that is essential for the accurate measurement of gene expression. Factors such as the speed of isolation and how samples are stored prior to isolation can greatly affect the quality of the extracts prepared. For example, if delays occur in transportation of samples from clinic to the laboratory this can cause degradation of RNA leading to inconsistent and unreliable results in gene expression analysis. Animal bone tissues must likewise be handled and stored appropriately to prevent nucleic acid degradation. High-purity nucleic acid is also essential for the success of many downstream applications. For both DNA and RNA this involves preparing samples devoid of protein or solvent contamination, as both can adversely affect the success of post-purification processing. For gene expression work, it is also important to ensure that the extracted Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_17, © Springer Science+Business Media, LLC 2012
249
250
A. Hughes et al.
RNA is free from DNA contamination, to avoid false-positive results in subsequent PCR-based assays which do not differentiate between cDNA and genomic DNA. Several methods have been published for the extraction of DNA and RNA from cultured cells and nonmineralized tissues (1–4). Here, we describe methods for isolating DNA and RNA from whole bone and bone cell cultures in a form suitable for many downstream applications such as PCR, DNA sequencing, quantitative RT/PCR, and microarray analysis
2. Materials 1. Cryogenic Mill to pulverise bone samples (e.g., SPEX 6770 Freezer/Mill, Wolf Laboratories, York, UK).
2.1. Equipment
2. Sterile scalpels, scissors and bone cutters. 3. Sterile 35-mm tissue culture plates. 4. 19–20 G needles and 2-ml syringes. 5. Mortar and pestle. 6. Spectrophotometer for measuring nucleic acid yield. 7. Horizontal electrophoresis tank for measuring RNA integrity. 1. Tris-saturated phenol (pH 7.8–8.0) (Sigma).
2.2. For DNA Extraction
2. 3 M Sodium acetate, pH 5.2. 3. Tris–EDTA: 1 mM Tris/100 μM EDTA. 4. DNA extraction buffer: 40 mM sodium citrate, pH 7.0, 25 mM sodium lauryl sarcosinate, 6 M guanidinium isothiocyanate. Add 7.2 μl β-mercaptoethanol per ml of Lysis Buffer on the day of use (see Note 1). 5. Fumed Silica: Required for DNA extraction from dried or embedded bone (Subheading 3.3). ●
Suspend 50 g of unfumed silica (Sigma) in 100 ml double distilled water. Stir for 1 h and allow to settle under gravity for 1 h.
●
Aspirate the supernatant and centrifuge at 6,000 × g for 10 min to pellet the glass. Resuspend the pellet in 25–30 ml doubledistilled H2O.
●
Add concentrated nitric acid to 50%. Bring to boil in a fume hood and allow to cool.
●
Pellet the silica by centrifugation at 6,000 × g for 10 min.
●
Wash the pellet with double-distilled water until the pH of the supernatant is 7.0.
●
Store the pellet as 50% slurry in double-distilled H2O (see Note 2).
17
Extraction of Nucleic Acids from Bone
251
6. Silica Wash buffer: 10 M Tris–HCl, 6 M guanidinium isothiocyanate. 7. Hoechst 33258 (see Note 3). 2.3. For RNA Extraction
1. TRIzol® reagent (InVitrogen, Paisley, UK). 2. Agarose. 3. TBE buffer (50 mM Tris–HCl pH 7.8, 50 mM orthoboric acid, 2 mM Na2EDTA). 4. 6× Orange G loading buffer (0.2% (w/v) Orange G, 30% glycerol, 0.1% SDS in distilled water). 5. Ethidium bromide (5 μg/ml) (see Note 4). 6. RiboRulerTM High Range RNA Ladder (Fermentas).
2.4.General Reagents
1. DEPC-treated water (0.1% diethylpyrocarbonate in water, incubated for 12 h at 37°C then inactivated by autoclaving) (see Note 5). 2. Chloroform. 3. Isopropanol. 4. 75 and 100% Ethanol.
3. Methods 3.1. DNA Extraction from Fresh Bone
This method is suitable for extraction of genomic DNA fragments (up to 80 Kb) from fresh or freshly frozen bone. It should be noted that the resulting DNA will be derived from primary bone cells such as osteoblasts and osteocytes as well as other cells in the bone marrow space. 1. Collect the bone sample in a sterile container containing PBS and transport to the laboratory within 1–2 h (see Note 6). 2. Place the bone tissue in a clean glass petri dish. Using bone cutters dissect out a piece of bone measuring about 1 cm3 and transfer to a sterile 35-mm cell culture plate. 3. Add 1 ml DNA extraction buffer and mince the tissue with the bone cutters finely until a slurry is obtained. 4. Transfer 500 μl of the homogenised tissue into two screwtopped conical-bottomed 1.5-ml eppendorf tubes. 5. Add one volume of Tris-saturated phenol, followed by one volume of chloroform to each tube. Mix well by inverting the tube a few times or by shaking. Do not vortex (see Note 7). 6. Centrifuge the tubes at 10,000 × g for 20 min to separate the phases.
252
A. Hughes et al.
7. Transfer the supernatant to a fresh centrifuge tube being careful not to disturb the white layer at the interface. Make a note of the volume you transfer. 8. Add 1 volume of ice-cold isopropanol and 0.1 volumes of 3 M sodium acetate to the supernatant. Mix well and place on ice for 15 min. 9. Centrifuge the tubes for at 10,000 × g for 20 min to pellet the DNA (see Note 8). 10. Aspirate and discard the supernatant, taking care not to disturb the pellet. Wash the sample with 1.75 ml ice-cold 70% ethanol and centrifuge at 10,000 × g for 5 min. 11. Repeat step 10. 12. Carefully aspirate the supernatant and allow the DNA pellet to air-dry for 5 min. Dissolve the DNA pellet in 10–50 μl water or Tris–EDTA buffer and quantitate by spectrophotometry (see Note 9). 13. Store the sample frozen at −20°C or below until further use. 3.2. DNA Extraction from Cultured Cells
1. Remove the medium from the cultured cells and discard. 2. Wash the cell layer twice with sterile PBS. 3. Aspirate the PBS and add 1 ml DNA extraction buffer per 75 cm3 flask of cells. Swirl the Lysis Buffer around the flask so that all cells are coated. Leave for 1 min, and detach the cells using a cell scraper. 4. Transfer the extracted cell layer into screw-capped conical-bottomed 1.5-ml eppendorf tubes in 500 μl aliquots. Pipette the mixture up and down to lyse the cells. 5. Follow steps 5–12 Subheading 3.1.
3.3. DNA Extraction from Dried or Embedded Bone
of
the
extraction
procedure
in
Dried bones contain little cellular material and the following method is more suitable for these specimens. The technique relies on the propensity of nucleic acids to adsorb to silica (5). Kits based upon this methodology are available (e.g., High Pure kit, Roche, Burgess Hill, UK). 1. Homogenise the bone sample using a liquid nitrogen-cooled powder mill or manually by cooling the specimen with liquid nitrogen and then grinding to a fine powder in a mortar and pestle or an electric food grinder. 2. Add 500 μl DNA extraction Buffer to a clean eppendorf and place on ice. Carefully add 100–500 mg of bone powder to the extraction buffer, ensuring that it moistens all the powder. 3. Place the sample on an end-over-end rotator in a cold room for 24 h.
17
Extraction of Nucleic Acids from Bone
253
4. Centrifuge the sample at 10,000 × g for 5 min in a microcentrifuge to pellet the bone powder. 5. Aspirate the supernatant (which contains the DNA) and transfer to a fresh eppendorf tube. 6. Add 50 μl fumed silica to the supernatant. Place on an endover-end rotator in a cold room for 1 h. 7. Pellet the silica (which contains the adsorbed DNA), by centrifugation at 6,000 × g for 5 min and discard the supernatant (see Note 10). 8. Add 1 ml of silica wash buffer to the pellet and invert a couple of times to resuspend the silica. Centrifuge at 6,000 × g for 5 min and discard the supernatant. 9. Resuspend the pellet in 95% ethanol to remove salt contamination and mix by inverting 2–3 times (see Note 11). 10. Centrifuge at 6,000 × g for 5 min, aspirate the supernatant and discard. 11. Repeat steps 9 and 10 once. 12. Elute the DNA from the silica by resuspending the pellet in up to 100 μl of either 10 mM Tris–HCl (pH 8.0) or distilled deionized water (pH >7.5) (see Note 12). 13. Incubate the sample at 56°C for 10 min. 14. Centrifuge at 6,000 × g for 5 min to pellet the silica and aspirate the supernatant (which contains the DNA) into a fresh tube and store frozen at −70°C or below. 3.4. RNA Extraction from Fresh Bone
This method uses TRIzol® reagent to isolate RNA from fresh bone. The method described focuses on the isolation of RNA from bone, but TRIzol can be used to isolate DNA, RNA and protein from a single bone sample. The procedure should be performed under RNAse free conditions (see Note 13). 1. Collect the bone sample in a sterile container containing PBS and transport to the laboratory within 30 min (see Note 14). 2. Place a ~200 mg sample of bone tissue (see Note 15) into a 35-mm sterile petri dish using sterile forceps. 3. Add 1 ml TRIzol® solution and chop the tissue up into a coarse slurry using bone cutters or scissors, followed by a sterile scalpel until the tissue is homogenised (see Note 16). 4. Carefully transfer the homogenate into a 2-ml screw-cap eppendorf tube and place on ice for 5 min. 5. Centrifuge samples for 12,000 × g for 10 min at 4°C and transfer the supernatant to a clean 2-ml screw-cap eppendorf tube (see Note 17).
254
A. Hughes et al.
6. Pass lysate slowly through a 19–20 G needle 4–6 times to shear genomic DNA and reduce viscosity of the sample. 7. Add 0.1 volume of chloroform and shake vigorously for 15 s. 8. Centrifuge at 10,000 × g for 15 min at 4°C. 9. Carefully aspirate the supernatant (taking note of the volume) into a fresh 1.5-ml conical bottom screw-top eppendorf, taking care not to disturb the interface (see Note 18). 10. Add 1 volume of isopropanol to the supernatant and mix gently by inverting the tube 5–6 times. 11. Incubate the sample at room temperature for 10 min to precipitate the RNA (see Note 19). 12. Centrifuge at 10,000 g for 10 min at 4°C to pellet the RNA (see Note 20). Aspirate the supernatant and discard. 13. Wash the pellet with 1 ml ice-cold 75% ethanol and centrifuge at 10,000 × g for 5 min at 4°C. Aspirate the supernatant and discard. Briefly centrifuge the tubes again for about 15 s and aspirate the remaining traces of ethanol from the RNA pellet. 14. Allow the pellet to air-dry for 3–5 min. Do not over-dry the pellet. 15. Dissolve the RNA pellet in 10–30 μl of water (see Note 21). 16. Quantitate and assess purity of the eluted RNA by spectrophotometry (Subheading 3.8) and integrity by gel electrophoresis (see Note 22). 17. Store the RNA frozen in aliquots of 5–10 μl at −70°C or below until further use. 3.5. Extraction of RNA from Frozen Bone
If the sample has been stored at −70°C it can be ground to a fine powder prior to the extraction protocol, either in a cryogenic mill (Glen Creston, Middlesex, UK) or by mortar and pestle. 1. Pulverise the sample to a fine powder using a cryogenic mill or mortar and pestle (see Note 23). 2. Transfer the powder into a clean 2-ml screw-cap eppendorf tube, add 1 ml of TRIzol® (see Note 24), mix well by shaking the tube vigorously, and place on ice. 3. Proceed through steps 5–17 of the RNA extraction procedure described in Subheading 3.4.
3.6. Extraction of RNA from Adherent Cultured Cells
1. Aspirate the medium from the cell culture and discard. 2. Wash the cells with sterile PBS and discard. 3. Add 1 ml TRIzol® per 75 cm3 flask of cells and allow it to spread over the cell layer. 4. Detach the cell layer using a cell scraper and transfer the resulting slurry into a clean 2-ml screw-cap eppendorf tube. 5. Proceed through steps 6–17 of the RNA extraction procedure described in Subheading 3.4.
17
3.7. Extraction of RNA from Nonadherent Cultured Cells
Extraction of Nucleic Acids from Bone
255
1. Pellet the cells by centrifugation at 400 g for 10 min. 2. Aspirate the culture medium and discard. 3. Suspend the cell pellet in 1 ml TRIzol®. 4. Proceed through steps 6–17 of the RNA extraction procedure described in Subheading 3.4.
3.8. Quantification of Nucleic Acids by Spectrophotometry
a
DNA and RNA can be quantified by spectrophotometry, which is also useful for determining if any protein or solvent contamination is present in the prepared samples. However, spectrophotometry cannot assess whether or not the nucleic acid is degraded (see Note 22). Here, we present a method that should be applicable to most spectrophotometers, but specialized spectrophotometers such as the NanoDrop (Thermo Scientific), permit rapid quantification of undiluted RNA and DNA samples using a very low sample volumes (~1 μl). The NanoDrop also provides a spectral scan that can be used to detect protein or solvent contamination. Example spectrophotometer results from samples obtained using the methods described above are presented in Fig. 1, which also highlights the importance of checking not only yield and purity, but also RNA integrity (see Note 22 and Subheading 3.9).
Agilent Bioanalyser traces Sample 1
b
Sample 2
Spectrophotometer results Sample
260/280 ratio
260/230 ratio
Total RNA conc (ng/µl)
1
1.99
2.02
255.0
2
2.06
1.94
247.8
Fig. 1. Agilent Bioanalyser and spectrophotometer readings for total RNA extracted from bone. RNA was extracted as per the protocol in Subheading 3.5 from a 10 mm (H) × 5 mm (D) core of human trabecular bone, including the optional column-based clean-up and DNase I treatment discussed in Note 22. Aliquots of the isolated RNA were assayed by (a) Agilent Bioanalyser (see Note 23 ) and (b) Nanodrop spectrophotometer. Note the similar lack of protein or solvent contamination in both samples, as indicated by the 260/280 and 260/230 ratios respectively, and the similar yield in both samples despite the degraded profile of Sample 2 on the Agilent Bioanalyser trace.
256
A. Hughes et al.
1. Dilute RNA 1/100 or DNA 1/200 in water. 2. Using a quartz cuvette, blank the spectrophotometer using water. 3. Read the absorbance for each sample at 230, 260, and 280 nm. 4. Calculate the amount of nucleic acid present in each sample by multiplying the A260 value by 40 ng/μl for RNA or 50 ng/μl for dsDNA, then by the dilution factor used, e.g., ×100 for RNA, ×200 for dsDNA (see Note 25). 5. Calculate the A260/A280 and A260/A230 ratios to determine the levels of protein or solvent contamination respectively (see Note 26). 3.9. Evaluation of RNA Integrity by Agarose Gel Electrophoresis
It is important to evaluate the integrity of isolated RNA to validate the extraction has been successful in not only isolating an abundance of solvent- and protein-free RNA (as measured by spectrophotometry), but also in maintaining the integrity of the RNA. A quick way of achieving this is by analysing the degradation of the 18 s and 28 s ribosomal RNA on an agarose gel. Figure 1 illustrates the importance of checking RNA integrity to ensure, whilst Fig. 2 shows what undegraded high-quality RNA looks like when analysed on an agarose gel, as described below.
Fig. 2. Agarose gel electrophoresis of total RNA extracted from cultured mouse calvarial osteoblasts. RNA was extracted from one, two or three wells of a six-well tissue culture plate into 1 ml of TRIzol® reagent as per Subheading 3.6. After quantification, 1 μg of total RNA was loaded onto an agarose gel as per Subheading 3.9. The integrity of RNA can be assessed by the absence of “smearing” of the 28S and 18S ribosomal RNA bands, assuming that mRNA will be degraded if the rRNA is affected.
17
Extraction of Nucleic Acids from Bone
257
1. Prepare a 1% agarose gel in TBE buffer plus 0.5 μg/ml ethidium bromide (see Note 4). 2. Mix 1–2 μg of RNA with 6× Orange G loading buffer and heat to 65°C for 5 min. 3. Mix RNA ladder (e.g., RiboRulerTM High Range RNA Ladder, Fermentas) with 6× Orange G loading buffer. 4. Load and run gel in TBE at 10 V per cm between electrodes in electrophoresis tank. 5. Image gel and visualise bands on a UV transilluminator with a digital camera.
4. Notes 1. All chemicals should be of molecular biology grade. The solutions can be stored at 4°C for up to 3 months. 2. Working solutions can be stored for up to 1 week at 4°C. Stock solutions should be stored frozen at –70°C. 3. Hoechst 33258 is a DNA specific dye that can be used to quantitate DNA. Quantification is achieved by setting up a standard curve of DNA at known concentrations and analysing the test samples in a fluorimeter at an excitation wavelength of 350– 363 nm and a detection wavelength of 410–480 nm. 4. Alternatives to the use of Ethidium Bromide in laboratories are available, such as SYBR® safe DNA gel stain (Invitrogen) and SYBR® green II which binds RNA. These dyes have reduced mutagenicity and also lower waste management costs than Ethidium Bromide. While these products can be viewed using UV illumination better results can be obtained with a Safe Imager™ Blue-Light Transilluminator system (Invitrogen). 5. There is some debate whether DEPC-treated water is required as it can inhibit subsequent enzyme-mediated reactions. Sterile distilled water filtered through 0.2 μm filter would suffice if this is a concern. 6. If the DNA extraction is not initiated immediately, freeze the sample at −20°C or below for later use. 7. Vortexing causes long strands of DNA to shear. 8. Orientate the eppendorf tube so that you can identify where the DNA pellet lies. A pellet should be visible the bottom of the tube. 9. Dilute the sample 1/200 for DNA in distilled water and read the absorbance at 260 nm and 280 nm using a quartz cuvette in a UV spectrophotometer (Subheading 3.8). Hoechst 33258 dye can also be used to quantify DNA.
258
A. Hughes et al.
10. You may wish to keep the supernatant in a fresh tube until you are confident that the extraction has been successful. 11. Do not simply add the ethanol and immediately decant it off again; the pellet needs to be well mixed so that the ethanol can penetrate the sample and dissolve the salt. 12. The pH must be above 7.5 to elute the DNA from the silica. 13. Gloves should be worn at all times when handling samples and all solutions should be prepared to ensure that they are free of RNAses. This involves making up the solutions for RNA use with DEPC treated water using glassware, stirrers and spatulas which have been oven baked for 2 h to inactivate RNAses. Further details can be found in Sambrook’s text (6). 14. A major challenge in extracting RNA from any tissue is to isolate the nucleic acid in an intact state before it is degraded. If it is impractical to begin the extraction within 30 min, the bone should be snap-frozen in liquid nitrogen immediately and stored at −70°C or below until use. Reagents such as RNAlater® (Invitrogen) can be useful for preserving soft tissues or cell pellets for weeks, but may not permeate bone samples fully enough to inactivate all RNases. In our experience, it is best to homogenise the bone as soon as possible into the extraction buffer and then snap-freeze the homogenate for storage as above, rather than using RNA preservation buffers. 15. Too much starting material can result in a high degree of DNA and protein contamination, so you may need to scale up TRIzol® volumes if you exceed 200 mg sample weight. 16. Samples can also be homogenized using a Precellys homogeniser and MK28 tubes with large diameter metal bearings. Homogenisation at 6,500 for 2 × 45 s cycles yielded RNA of high integrity from whole bones isolated from mouse. A mortar and pestle can also be used for fresh bone, as per Subheading 3.5, by snap-freezing the fresh sample in liquid nitrogen and grinding it to a fine powder in the mortar. 17. Samples with a high fat content, such as trabecular bone samples obtained from osteoporotic femoral heads, may yield a layer of fat that floats on top of the clear phase containing the nucleic acid. This should be discarded. 18. The upper (clear) aqueous layer contains the RNA and is separated from lower (pink/purple) phase containing debris and DNA by a white layer containing protein and lipids. Do not attempt to completely remove the aqueous layer, to minimise the risk of protein or DNA contamination. 19. The samples can be stored overnight at −20°C at this point. 20. It is a good idea to mark the side of the eppendorf so you can identify where the RNA pellet lies. Small pellets can be “bulked
17
Extraction of Nucleic Acids from Bone
259
up” for easier detection by adding 10–100 μg/ml glycogen to the isopropanol precipitation stage. 21. For some subsequent applications it may be necessary to perform further purification or DNA digest. If so, the RNA can be further purified on a Qiagen RNeasy Minikit with an on-column DNase digest using a Qiagen RNase Free DNase Set (Qiagen, West Sussex, UK). These additional steps are highly recommended for preparation of RNA suitable for microarray or quantitative PCR analysis. 22. Spectrophotometry cannot measure the integrity of RNA, which is an important consideration for further downstream applications; quantity and purity should be reinforced by a measure of integrity, such as gel electrophoresis (see Subheading 3.9) or by Agilent Bioanalyser. The Bioanalyser is a microfluidics, laser-detection based system that can sensitively assay fragment size and calculate the RNA Integrity Number (RIN) for quality control of RNA samples destined for quantitative techniques such as qPCR or microarrays (see Fig. 1). 23. A small amount of liquid nitrogen can be poured into the pestle to maintain low temperature. 24. Too much starting material can result in a high degree of DNA and protein contamination, so you may need to scale up TRIzol® volumes if you exceed 200 mg sample weight. 25. Nucleic acids have an absorbance maximum at 260 nM, so spectrophotometry can not determine if RNA samples are free of DNA contamination. 26. If the separation is free of protein contamination, the optical density reading at A260/A280 should be 1.8 or greater, although this is based on RNA solubilized in TE buffer (10 mM Tris–HCl pH 8.0, 1 mM EDTA). Ratios generated in water will tend to be lower on most spectrometers. The A260/A230 ratio should be >2.0 and gives an indication of solvent contamination; Solvent contamination can inhibit subsequent enzyme-based reactions. References 1. Chomczynski, P., and Sacchi, N. (1987) Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156–159. 2. Blin, N., and Stafford, D. W. (1976) A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acid Res. 3, 2303–2308. 3. Kupiec, J. J., Giron, M. L., Vilette, D., Jeltsch, J. M., and Emanoil-Ravier, R. (1987) Isolation of high molecular weight DNA from eukaryotic cells by formamide treatment and dialysis. Anal. Biochem. 164, 53–59.
4. Bowtell, D. D. L. (1987) Rapid isolation of eukaryotic DNA. Anal. Biochem. 162, 463–465. 5. Vogelstein, B., and Gillespie, D. (1979) Preparative and analytical purification of DNA from agarose. Proc. Natl. Acad. Sci. USA. 76, 615–619. 6. Sambrook, J., Fritsch, E.F., and Maniatis, T. (2000) Molecular Cloning. A laboratory Manual. 3rd Edition, Cold Spring Harbour Laboratory Press.
sdfsdf
Chapter 18 Analysis of Gene Expression in Bone by Quantitative RT/PCR Alun Hughes Abstract This chapter describes methods for quantitation of gene expression in bone cells and bone tissues using the technique of quantitative reverse transcription-polymerase chain reaction. Key words: PCR, Quantitative PCR, Gene expression, RNA, Bone disease, Osteoporosis
1. Introduction The polymerase chain reaction (PCR) is a technique that can amplify small amounts of target DNA in an exponential manner by using sequence-specific oligonucleotide primers (1). In this chapter, I describe the methodology for performing quantitative PCR, linked to a reverse-transcription step, thereby allowing one to analyse levels of gene expression in cells or tissues of interest. 1.1. Assay Choice for Quantitative PCR
Like conventional PCR, qPCR relies upon the specificity of two primers for amplification. A surrogate for actual copy number is generated by use of either a fluorophore that intercalates with the double-stranded amplicon generated during extension (e.g. SYBR Green; see Fig. 1a), or by using the principles of FRET (Förster resonance energy transfer) to generate labelled probes (sequencespecific, modified primers) that emit the expected wavelength either when they are bound in the correct position (hybridisation probes) or when they are hydrolysed by the exonuclease activity of the DNA polymerase (hydrolysis probes; see Fig. 1b). The addition of a third modified primer with hybridisation or hydrolysis probes provides extra specificity, although the sensitivity of intercalating dyes is higher due to the binding of multiple fluorophore molecules.
Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_18, © Springer Science+Business Media, LLC 2012
261
262
A. Hughes
Sample extraction
RNA Extraction Exogenous Control
(Sections 1.3 & 3.4)
Sample preparation
cDNA Synthesis
(Sections 2.2 & 3.1)
Assay design
Analysis method
Hydrolysis Probes
(Sections 1.1 & 3.2)
SYBR Green
(Sections 1.1 & 3.3)
Absolute Quantification
Relative Quantification
(Section 1.2)
(Section 1.2)
Standard Curve (Section 1.2)
Efficiency Corrected
(Section 1.2)
Purified PCR product
Plasmid DNA
cDNA Template
(Section 3.5)
(Section 3.5)
(Section 3.6)
Delta-delta Ct (Sections 1.2 & 3.9)
Fig. 1. Quantitative assay design considerations flow chart. For discussion on the most appropriate pathway for your application, refer to Subheadings 1.1–1.3.
The choice of assay system for qPCR depends to an extent on the funding available with which to conduct your experiment. Assays with SYBR green are cheaper than those that use fluorescently labelled probes and can be useful where a single target is being assayed repeatedly in a series of experiments. Although fluorescently labelled probes are more expensive to synthesise they offer greater specificity than SYBR green and can be more cost effective for some targets. Another advantage of hydrolysis probes is that they can be multiplexed, and allow one to analyse expression of several genes in a single well using different fluorophores. Several companies provide “off-the-shelf” probe kits (e.g. TaqMan® assays from Applied Biosystems) or “do-it-yourself” hydrolysis probe style assays (e.g. the Universal ProbeLibrary system from Roche), allowing researchers to quickly and conveniently measure gene expression.
18
Analysis of Gene Expression in Bone by Quantitative RT/PCR
263
1.2. Methods for Quantification of Transcripts
Quantitative PCR can be performed in terms of “absolute” or “relative” quantification. The majority of applications require just relative quantification, where the investigator wants to determine if there has been a change in expression of a specific target gene, relative to an internal control or “housekeeping” gene. Absolute quantification, involves measuring the exact number of transcripts of the gene of interest in relation a standard curve constructed from a reversed transcribed “decoy” mRNA, a plasmid, a purified PCR product or, less commonly, a synthetic oligonucleotide sequence (see Note 1). Relative quantification can be calculated at a basic level using the delta-delta Ct method (2), which compares two samples based on expression of a gene of interest and a reference gene, returning a fold increase or decrease value that describes their relationship. While quick and convenient, this method makes the assumption that all qPCR assays work with perfect efficiency. Modifications to the delta-delta Ct calculation have been made by to include values for the efficiencies of both the reference and gene of interest, allowing for more accurate values to be calculated (3).
1.3. Relating Expression of Target Genes to an Internal Control
Levels of expression for the gene(s) of interest can also be related to those of an endogenous reference (or “housekeeping”) RNA. The reference RNA has to be chosen carefully since expression of many housekeeping genes can vary substantially as the result of changes in cell proliferation and differentiation (4, 5). To compensate for this, multiple reference genes can be used and an average taken which is then used as a control with which to relate levels of expression of the gene(s) of interest (6). Alternatively, an exogenous target can be spiked in to samples prior to reverse transcription and used as a reference (7). The accuracy of quantification using exogenous controls is dependent upon both the accurate quantification of RNA transcript and the use of identical starting amounts or RNA for cDNA synthesis between samples. Absolute quantification is commonly normalised to the input amount of RNA prior to cDNA synthesis, or by the amount of cDNA used per reaction, resulting in data of the form copies/μg RNA or cDNA. However, this relies on accurate quantification of the RNA or cDNA and assumes identical integrity or impurities across all samples to be compared. As a result this strategy is often unsatisfactory, so it is common to use additional forms of normalisation to help improve confidence in absolute quantification results, such as the endogenous or exogenous controls used for correcting relative quantification experiments described above.
1.4. Preparation of Input RNA
The quality and purity of the starting RNA template is of critical importance to qPCR. A degraded sample can severely impair the quality of the results obtained and decrease the confidence associated in observations, while protein or solvent contamination can negatively affect the enzymatic steps involved in procuring the final
264
A. Hughes
a
SYBR Green
b
Hydrolysis probes
Q
5’
3’
5’
5’
3’
5’
3’
R
Annealing
R
3’
Q
3’
5’
3’
5’
5’
3’
5’
3’
Extension
R
Q
3’
5’
3’
5’
5’
3’
5’
3’
Fig. 2. Commonly used qPCR assays for gene quantification. Primers anneal to each strand of the template DNA, allowing binding of the DNA polymerase (indicated by the open arrow ) and subsequent elongation and synthesis of two new strands in the 5¢ to 3¢ direction. During elongation, SYBR Green binds to the minor groove of double stranded where it emits fluorescence of the expected wavelength when excited, see panel (a). Hydrolysis probes (b) require the use of a specialised primer that is labelled at the 5¢ end with a reporter (R) dye in proximity to a 3¢ quencher (Q) that inhibits the production of the expected fluorescence. The exonuclease activity of the DNA polymerases used in hydrolysis probe reaction mixes cleaves the probe during elongation, liberating the reporter from the quencher and allowing fluorescence to be detected.
data and lead to artefacts (8). The utmost care and attention must therefore be made to standardise sample preparation to generate robust and reliable data. The protocols within this chapter assumes pure, high-integrity RNA has been generated. The flow chart in Fig. 2 indicates which sections within this chapter will be appropriate for your particular application.
2. Materials 2.1. Reverse Transcription
1. High-quality RNA. 2. Diethylpyrocarbonate (DEPC)-treated water: Incubate water containing 0.1% v/v DEPC water at 37°C for 1 h and then autoclave to inactivate DEPC (see Note 2). 3. RNase-free PCR tubes and filter pipette tips.
18
Analysis of Gene Expression in Bone by Quantitative RT/PCR
265
4. 2 μg/ml Random oligonucleotide hexamer primers. 5. 10 mM Deoxyribonucleotides in water (dNTP). 6. Reverse transcriptase (e.g. SuperScriptTM, Invitrogen, Paisley, Scotland). 7. A thermocycler compatible with use of FAM dyes, such as the Roche LightCycler®480 (see Note 3). 8. Custom oligonucleotide primers and labelled hydrolysis probes. 9. Mastermix compatible with hydrolysis probe (e.g. LightCycler®480 Probes Master Mix) or with SYBR Green (e.g. LightCycler®480 SYBR Green I Master Mix).
3. Methods 3.1. Reverse Transcription
A reverse transcription step is required to convert the RNA into complementary DNA (cDNA) prior to PCR. Some “one-step” kits exist for performing the RT reaction in the same tube as the qPCR reaction, but the method presented here is for a separate RT reaction that yields sufficient cDNA for the measurement of multiple transcripts. 1. Aliquot 2 μg of RNA into duplicate RNase-free PCR tubes and adjust total volume to 11 μl with DEPC-treated water. Store on ice. 2. Add 1 μl of 2 μg/ml random hexamer primers to each sample, flick tube to mix and pulse on a centrifuge to collect the reaction mix at the bottom of the tube (see Note 4). 3. Heat to 70°C for 10 min on a thermocycler and then immediately cool on ice for 2–3 min. 4. Add 4 μl of 5× Reaction Buffer, 2 μl of 0.1 M DTT and 1 μl of 10 mM dNTPs mix to each tube. Add 200 U of SuperScriptII M-MLV reverse transcriptase to half of the tubes or an equivalent volume of DEPC-treated water to the other to generate no-RT controls (see Note 5). 5. Mix tubes by flicking and collect the reaction mix at the bottom of the tube by pulsing briefly on a centrifuge. 6. Incubate the reaction mix at room temperature for 10 min. 7. Heat the tube to 42°C for 50 min in a thermal cycler then at 95°C for 5 min before cooling on ice for 2–3 min. 8. Adjust reaction volume to 100 μl with DEPC-treated water and store at −20°C or short-term at 4°C (see Note 6).
266
A. Hughes
3.2. Designing Primers and Probes for Hydrolysis qPCR Assays
Many companies provide off-the-shelf hydrolysis probe assay probes and primers, but it can be more economical to design your own especially if it is an assay you intend to use frequently. This method uses the online version of the open source Primer3 program by Rozen and Skaletsky (9). 1. Download mRNA sequence from Ensembl database (http:// www.ensembl.org/) or GenBank database (http://www.ncbi. nlm.nih.gov/nuccore/), making sure to note the position of the exon–exon boundaries. 2. Paste sequence in to Primer3 (http://frodo.wi.mit.edu/ primer3/). 3. Chose a “Mispriming Library (repeat library)” if a suitable species library is available. 4. Mark the two bases at the interface of adjacent exons using the “[”and “]” characters. 5. Check the tick box to design an internal oligo. 6. Set the product size range to 70–150. 7. Keep “General Primer Picking Conditions” to pick primers with an optimal Tm of 60°C. 8. Change “Hyb Oligo (Internal Oligo) General Conditions” to return a hybridisation oligo with a minimum, optimum, and maximum Tm of 65, 68, and 70°C, respectively. 9. Select a “Hyb Oligo Mishyb Library” if a suitable species library is available. 10. Click “Pick primers” and select primer and probe combinations that give short product sizes and have at least one base gap between the left primer and the hybridisation oligo. Reject assays which have a 5¢ “G” on the hybridisation oligo. 11. BLAST search primers and hybridisation oligo to insure specificity (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 12. If no suitable assays can be found, repeat the process selecting a different exon–exon boundary using the “[”and “]” characters (see Note 7). 13. Order primers from a reputable supplier with HPLC purification. Order the hybridisation probe with a 5¢ FAM and 3¢ TAMRA, Dabcyl or Black Hole Quencher (e.g. BlackBerry®). 14. Proceed to perform PCR as described in Subheading 3.7.
3.3. Design of Primers for SYBR Green qPCR Assays
Quantitative PCR assays using SYBR green are more sensitive than those that employ hydrolysis probes, and can work out cheaper to perform. However, since any double-stranded product will contribute to the fluorescent signal generated, care must be taken to design very specific primers that don’t generate non-specific products or primer-dimers. The design strategy outlined below uses the
18
Analysis of Gene Expression in Bone by Quantitative RT/PCR
267
National Center for Biotechnology Information’s Primer-BLAST tool using the Primer3 primer design programme (9): 1. Obtain the RefSeq ID for your gene via the Entrez Gene web site (http://www.ncbi.nlm.nih.gov/gene/) (see Note 8). 2. Insert the RefSeqID in to the “PCR Template” box on NCBI Primer-BLAST tool (http://www.ncbi.nlm.nih.gov/tools/ primer-blast/). 3. Set the product size range to 80–200 in the “Primer Parameters” section (see Note 9). 4. Keep “Primer melting temperatures” to pick primers with an optimal Tm of 60°C. 5. Select “Primers must span an exon–exon junction” from the “Exon junction span” drop-down menu. 6. Enter organism species in to the “Specificity check” box to allow automatic BLAST searching of your primers for specificity. 7. Click “Get Primers”. 8. Order primers from a reputable supplier with HPLC purification (see Note 10). 9. Proceed to perform PCR as described in Subheading 3.8. 3.4. Preparation of an Exogenous Control
Exogenous controls are completely foreign transcripts (e.g. from a different kingdom or synthetically generated) spiked into all samples to produce a target that can be used as an alternative to native, endogenous reference genes for normalisation. Purified sample RNA is accurately quantified and mixed with a known amount of exogenous controls (e.g. 5 × 104 copies of exogenous control per μg of sample RNA), creating a “constant” that can be used between samples for normalisation or to measure inhibition of cDNA synthesis caused by solvent or protein contamination of RNA samples. Exogenous spikes are useful when commonly used endogenous genes such as beta-actin might give erroneous results due to the effects of drug treatment, cell differentiation or tissue variation. Exogenous controls can be prepared in-house according to established techniques (10) or obtained commercially (e.g. Alien Reference RNA QRT-PCR Detection Kit by Agilent Technologies). 1. Add 105 copies/reaction of the exogenous RNA transcript to the cDNA synthesis components described in Subheading 3.1, step 1. Reduce the volume of water accordingly. 2. Design an assay that will amplify your exogenous transcript using the principles outlined in Subheadings 3.2 or 3.3. 3. Following qPCR analysis, normalise all your candidate reference genes to the exogenous control as per Subheading 3.9. Suitable endogenous controls should maintain a constant ratio across all samples.
268
A. Hughes
3.5. Preparation of an External Reference Curve for Absolute Quantification
Various methods can be used to generate a standard curve for qPCR including the generation of recombinant RNA (recRNA) molecules (see Note 11), but here I describe the method for generating a standard curve from plasmid DNA since this is considered to be a more stable and reliable method for generating standard curves (11) (see Note 12). 1. Purify the plasmid that contains the target of interest using a commercially available cDNA clean-up kits (e.g. QIAquick PCR Purification Kit, Qiagen). 2. Quantify the abundance of purified PCR product or linearised plasmid by spectrophotometry or by PicoGreen® (see Note 13). If using spectrophotometry, please note that an absorbance value of 1 at 260 nm is equal to 50 μg/ml of dsDNA. Whatever method is being used, take repeated measurements at two or three dilutions to increase accuracy. 3. Calculate the number of copies/μl of sample by the following formula: Copies/ml=
6.022 ´ 10
23
(molecules/mol) ´ DNA concentration (g/ml)
Length of plasmid or product (basepairs) ´ 660 daltons
.
4. Prepare serial dilutions of the plasmid to give a suitable range of copies for use as a standard curve in Subheadings 3.7 or 3.8 (see Note 14). 3.6. Preparation of cDNA Reference Curve for Relative Quantification
Relative quantification, unlike absolute quantification, does not require the use of standard curves generated from plasmid or recRNA sources to calculate copy number. However, to obtain the most accurate results using relative quantification it is essential to calculate the efficiency of each gene-specific assay used. The efficiency of each assay can be obtained from the slope of a series of serially diluted samples, creating a “standard curve” but using arbitrary values to define the relationship between each dilution (see Note 15). Using this method, an individual cDNA sample or pool of cDNA can be used to correct relative quantification data from errors associated with assuming a default efficiency value of 2. 1. Select a cDNA sample that you know or suspect will express your gene(s) of interest, or create a pool of cDNA to use as a reference curve. 2. Serially dilute cDNA across a range of at least four dilutions suitable to the suspected abundance of your transcript (e.g. a highly expressed gene will be detectable across a dilution range of neat, 1/10, 1/100, 1/1,000, etc. dilutions, or neat, 1/3, 1/9, 1/27, etc. can be used for genes with lower abundance).
18
3.7. Performing Quantitative RT-PCR Using Hydrolysis Probes
Analysis of Gene Expression in Bone by Quantitative RT/PCR
269
1. Pipette 3 μl of each cDNA sample (RT and no-RT controls) in triplicate technical reactions per gene (see Note 16) to be measured on to a white-walled plastic plate suitable for your qPCR machine (see Note 17). 2. Pipette 3 μl of each standard into the plate in triplicate, plus triplicate blank wells each containing 3 μl of water. 3. Prepare sufficient master mix for each assay plus 10% to account for losses on tips, allowing for a total reaction volume of 20 μl per well (17 μl master mix + 3 μl standard, sample or blank). An example master mix per reaction is displayed in Table 1. 4. Add 17 μl of master mix to the relevant standard, sample, and blank wells on the plate 5. Run on a qPCR machine for 40 cycles, using thermal cycling conditions of: 95°C, 10 min; 40 cycles of (95°C, 10 s; 60°C, 30 s) (see Note 18). 6. Analyse the data as outlined in Subheading 3.9.
3.8. Performing Quantitative RT-PCR Using SYBR Green Assays
These assays can be adversely affected by the formation of primerdimers or by mispriming events. Because of this SYBR Green assays should always be evaluated using a melting curve profile (i.e. a post-amplification monitoring of the fluorescence as the temperature is increased incrementally from 65 to 95°C) to ensure only a single product is generated during amplification. If multiple peaks are present in the melting curve analysis, then the specificity of the assay can be improved by increasing the annealing temperature or, especially in the case of primer-dimer, decreasing the primer concentrations.
Table 1 Example reaction components for SYBR Green and hydrolysis probe qPCR
LightCycler®480 SYBR Green l Master (2×) ®
LightCycler 480 Probes Master (2×)
SYBR Green Volume per well (ml)
Hydrolysis probes Volume per well (ml)
10
–
–
10
Forward primer (10 μM)
1
1
Reverse primer (10 μM)
1
1
Hydrolysis probe (2 μM) PCR grade water
– 5
1 4
N.B.: These are example reaction mixes assuming a 20 μl total volume and are presented as an illustration of the general primer/probe concentrations utilised in SYBR Green and hydrolysis probe assays. Other assay mixes are available and can be optimised to work with most qPCR machines, but please refer to your specific reagent supplier’s guidelines. When creating “master mixes”, remember to include 10% extra volume to account for loss of mixture in pipette tips
270
A. Hughes
Table 2 Example thermal cycling conditions for SYBR Green qPCR Cycles
Step
Temperature (°C)
Hold time
1×
Enzyme activation
95
5 min
40×
Denaturation Annealing Extension
95 Avg. primer Tm minus 2–5°C 72
10 s 15 s (amplicon length [b.p.]/25) s
1×
Denaturation Strand annealing Melting curve
95 65 65–97
10 s 1 min –
These conditions work well for SYBR Green assays using Roche’s LightCycler®480 SYBR Green I Master enzyme mix on a Roche LightCycler®480 qPCR machine and are presented for illustrative purposes. Please refer to your reagent supplier’s guidelines for appropriate conditions for your enzyme and system as recommendations can vary
1. Pipette 3 μl of each cDNA sample (RT and no-RT controls) in triplicate per gene to be measured on to a white-walled plastic plate suitable for your qPCR machine. 2. Pipette 3 μl of each standard into the plate in triplicate, plus triplicate blank wells each containing 3 μl of water. 3. Prepare sufficient master mix for each assay plus 10% to account for losses on tips, allowing for a total reaction volume of 20 μl per well (17 μl master mix + 3 μl standard, sample, or blank). An example master mix per reaction is displayed in Table 1. 4. Add 17 μl of master mix to the relevant standard, sample, and blank wells on the plate. 5. Run on a qPCR machine for 40 cycles, using the thermal cycling conditions in Table 2 (see Note 18). 6. Perform melting curve analysis to validate amplification is specific and not due to primer-dimer or mispriming events. Plot the first derivative (dF/dT) of the melting curve data generated against temperature. Specific primers will generate a single, strong peak, while non-specific primers will generate multiple peaks. Primer dimerisation will cause a “hump” evident at lower temperatures (see Note 19). 7. Analyse data as outlined in Subheading 3.9. 3.9. Analysis of q-RT-PCR Data
The analysis method below can be used with arbitrary units or with quantified standards to generate normalised data based on the use of either an endogenous or exogenous reference gene. Alternatively, the data generated from a reference curve of cDNA template can be used to calculate the efficiency of each assay as per step 1 and 2, allowing changes in gene expression to be calculated using Pfaffl’s
18
Analysis of Gene Expression in Bone by Quantitative RT/PCR
271
modification of the delta-delta Ct method (3), or inserted in to the freely available REST© spreadsheet (available at www.gene-quantification.de/download.html) (12). In the absence of a standard curve, changes in gene expression can be roughly calculated out via the delta-delta Ct method, as per Livak and Schmittgen (2). Karlen et al. (13) provide an in-depth discussion of the number of independent biological repeats required to provide confidence in the changes observed (see Note 16), while a discussion of several appropriate ways to perform statistical analysis of qPCR data can be found in Yuan et al. (14). 1. Calculate the cycle threshold (Ct) values for each amplification curve (see Note 20). 2. Analyse the standard curve for each gene-specific assay. Calculate the Ct value of each standard curve point generated from cDNA (Subheading 3.6), plasmid or PCR product (Subheading 3.5) and plot against log copy number or arbitrary units. The efficiency of each assay can be determined by the slope of the standard curve using the formula E = 10−1/slope. 3. Calculate the mean and standard deviation (SD) for each sample based on the triplicate reactions performed. 4. Calculate the coefficient of variation (CV) for each sample: CV = SD/mean. 5. Normalise your “gene of interest” (GOI) data to your reference gene or exogenous control (Ref) by dividing the value for each sample’s GOI by the value for the corresponding Ref (see Note 21). 6. Calculate the quotient CV value: CVQ = (CVGOI2 + CVRef2)1/2. 7. Calculate the SD of the quotient: SDQ = CVQ⋅X (where X = the ratio of your GOI/Ref ). 8. Results can be displayed as GOI/Ref ± SDQ or calculated as fold change from a calibrator control as required (see Note 22).
4. Notes 1. It is technically difficult to accurately measure transcript numbers by qPCR for various reasons. First, reverse transcription is not 100% efficient and the ease with which different mRNA targets are reverse transcribed can vary greatly (15). Although PCR products, plasmid and synthesised oligonucleotides can be used to estimate target abundance, they are likely to provide an overestimate, since they do not have to undergo the RT stage.
272
A. Hughes
2. There is some debate whether DEPC-treated water is required as it can inhibit subsequent enzyme-mediated reactions. Sterile distilled water filtered through 0.2-μm filter would suffice if this is a concern. 3. Fluorescein (FAM) has a similar excitation and emission maxima as SYBR Green, which all qPCR machines currently on the market are capable of detecting. 4. Random primers provide good 3¢/5¢ coverage of most mRNA transcripts but will initiate reverse transcription of all RNA to cDNA including ribosomal RNA. Oligo-dT primers will only initiate reverse transcription of mRNA, but may not provide complete 3¢/5¢ coverage. RNA that is partially degraded is better analysed by using random primers. Gene-specific primers can also be used to ensure reverse transcription of troublesome transcripts. Nolan et al. (8) provide practical advice on how to evaluate the best priming strategy for reverse transcription. 5. The efficiency of reverse transcription varies between enzymes, so ensure that the same priming strategy and enzyme choice is used between any samples that are to be compared (15). 6. Contaminants from the reverse transcription process can negatively effect PCR reactions, so sometimes diluted samples give more accurate and reliable results. Always perform a dilution series of your cDNA in advance of quantification experiments to titrate out any PCR inhibitors. 7. The unfortunate situation may arise that no suitable intronspanning assays can be designed, in which case RNA samples will need to be treated with DNAse and no-RT controls must be included for every sample to exclude false-positive results due to amplification of contaminating genomic DNA. 8. RefSeq IDs follow the format of “NM_xxxxxx”. FASTA format sequence information can be used instead. 9. The optimal SYBR green assay length is 150 bp. Amplicon lengths of longer than 300 bp are not recommended, but can be used if essential. 10. Desalted primers also work well in most qPCR assays. 11. Plasmids or purified PCR products are not subject to the inefficiencies of reverse transcription; hence, give a value for the amount of transcript successfully reverse transcribed rather than the actual copy number in the original sample. One way of overcoming this disparity in measurement is to generate standard curves from recombinant RNA (recRNA) for each gene of interest, then subjecting each recRNA to the same reverse transcription methods as the RNA samples of interest. Methods for generating standard curves for absolute transcript quantification using recombinant RNA can be found in the papers by Fronhoffs et al. (16) or Bustin (17).
18
Analysis of Gene Expression in Bone by Quantitative RT/PCR
273
12. Plasmids can be more reliably quantified than purified PCR products, and are more stable for long term storage. A quick and convenient method for cloning a purified PCR product into a pBAD-TOPO plasmid can be found in the paper by Whelan et al. (18), although any expression plasmid containing your transcript of interest is perfectly acceptable. There is no need to linearise plasmids prior to use as standard curve in a qPCR assay. Whelan et al. (18) compared intact via linearised plasmids and observed no significant difference in the resulting quantification. 13. Substantially more accurate quantification of plasmid or purified PCR product can be obtained by using PicoGreen®. Kits for quantification using this dye are available from many suppliers. Plasmid dilutions can be stored at −20°C. Diluted purified PCR products may be less stable and are best made fresh from concentrated stocks for each qPCR assay. 14. For example, a tenfold dilution series from 1 × 105 copies/μl to 10 copies/μl should be appropriate for must genes. 15. For relative quantification it is best to generate a reference curve using material as close to that you are assaying as possible: cDNA template generated using the same protocols for reverse transcription is ideal and will give the best estimation of reaction efficiency. 16. Technical replicates should not be confused for biological replicates. Four independent biological replicates will give sufficient confidence to detect changes or around twofold. This will vary by the relative “tightness” of your biological system and the size of changes in gene expression expected between treatments or conditions. 17. White-walled plates give substantially better fluorescent signals than clear wells, offering an improvement in data quality that far outweighs the inconvenience associated with effectively “blind” loading in white wells. 18. Conditions may vary depending on your qPCR machine and choice of enzyme, probes and primers. Use these conditions as a guideline, but always refer to manufacturer’s instructions to obtain the best results. 19. The effects of primer dimerisation on melting curves can be diminished by either increasing the annealing temperature used or by decreasing the concentration of primers used, but it is important to remember that both of these options could affect the efficiency of the PCR reaction. Primer dimerisation is not necessarily a problem if it only affects your blank wells. Melting curves displaying multiple peaks can be run on an agarose gel, imaged by ethidium bromide or similar, and evaluated for multiple bands. Some “humps” on the side of melting
274
A. Hughes
curves can look like two products, but may in fact be breathing in A/T-rich regions of the amplicon. It is often prudent to design new primers if the melting curve profiles are exceptionally noisy. 20. CP (crossing point) values obtained using Roche instruments are equivalent to Ct values. Ct values can be calculated by whatever method is available on your system: Roche systems use the Second Derivative Max which works well with sigmoidal amplification curves, while most other systems predominately use the setting of arbitrary threshold lines. No matter which method you use, the important thing is to be consistent. 21. Exogenous spikes (i.e. those described in Subheading 3.2) can be used as a “reference” gene to treat potential endogenous housekeeping genes as “genes of interest”. If the ratio between endogenous and exogenous is consistent across samples and treatments then the endogenous gene can be used as a housekeeping (or reference) gene. 22. If using this method to calculate relative expression using a reference curve of diluted sample cDNA, then units are arbitrary. Care should be taken not to infer differences between different genes if you have used this approach: The only really appropriate comparisons that can be made are of the differences of expression within individual genes. References 1. Saiki, R., Scharf, S., Faloona, F., Mullis, K., Hom, G., and Erlich, H. (1985) Enzymatic amplification of β-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230, 1350–1354. 2. Livak, K. J., and Schmittgen, T. D. (2001) Analysis of relative gene expression using realtime quantitative PCR and the 2-deltadeltaCT method. Methods 25, 402–408. 3. Pfaffl, M. W. (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45. 4. Thellin, O., Zorz,i W., Lakaye, B., De Borman, B., Coumans, B, Hennen, G., Grisar, T., Igout, A., and Heinen, E. (1999) Housekeeping genes as internal standards: use and limits. J. Biotechnol. 75, 291–295. 5. Dheda, K., Huggett, J. F., Bustin, S. A., Johnson, M. A., Rook, G., and Zumla, A. (2004) Validation of housekeeping genes for nomalizing RNA expression in real-time PCR. Biotechniques 37, 112–119. 6. Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., and Speleman, F. (2002) Accurate normalization of
7.
8.
9.
10.
11.
real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 3, 34. Gilsbach, R., Kouta, M., Bonisch, H., and Bruss, M. (2006) Comparison of in vitro and in vivo reference genes for internal standardization of real-time PCR data. Biotechniques 40, 173–177. Nolan, T., Hands, R. E., and Bustin, S. A. (2006) Quantification of mRNA using realtime RT-PCR. Nat. Protocols 1, 1559–1582. Rozen, S., and Skaletsky, H. J. (2000) Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S (eds) Bioinformatics Methods and Protocols: Methods in Molecular Biology. Humana Press, Totowa, NJ, pp 365–386. Bower, N. I., Moser, R. J., Hill, J. R., and Lehnert, S. A. (2007) Universal reference method for real-time PCR gene expression analysis of preimplantation embryos. Biotechniques 42, 199–206. Pfaffl, M. W., Hageleit, M. (2001) Validities of mRNA quantification using recombinant RNA and recombinant DNA external calibration
18
12.
13.
14.
15.
Analysis of Gene Expression in Bone by Quantitative RT/PCR
curves in real-time RT-PCR. Biotech. Letts. 23, 275–282. Pfaffl, M. W., Horgan, G. W., and Dempfle, L. (2002) Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative gene expression results in real-time PCR. Nucleic Acids Res. 30, e36. Karlen, Y., McNair, A., Perseguers, S., Mazza, C., and Mermod, N. (2007) Statistical analysis of quantitative PCR. BMC Bioinformatics 8, 131. Yuan, Y. S., Reed, A., Chen, F., and Stewart, C. N. Jr. (2006) Statistical analysis of real-time PCR data. BMC Bioinformatics 7, 85. Stahlberg, A., Hakansson, J., Xian, X., Semb, H., and Kubista, M. (2004) Properties of the
275
reverse transcription reaction in mRNA quantification. Clin. Chem. 50, 509–515. 16. Fronhoffs, S., Tozke, G., Stier, S., Wernert, N., Rothe, M., Bruning, T., Koch, B., Sachinidis, A., Vetter, H., and Ko, Y. (2002) A method for the rapid construction of cRNA standard curves in quantitative real-time reverse transcription polymerase chain reaction. Mol. Cell Probes 16, 99–110. 17. Bustin, S. A. (2000) Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 25, 169–193. 18. Whelan, J. A., Russel, N. B., and Whelan, M. A. (2003) A method for the absolute quantification of cDNA using real-time PCR. J. Immunol. Methods 278, 261–269.
sdfsdf
sdfsdf
Part IV Microscopical Techniques
Chapter 19 Histomorphometry in Rodents Reinhold G. Erben and Martin Glösmann Abstract Bone histomorphometry remains an important tool to study the pathophysiology of bone disease and the cellular mechanism by which treatments work. Here, we review the methods for embedding, sectioning, staining, and analysis of bone sections in rodents. Key words: Bone, Histomorphometry, Osteoblast, Bone remodeling
1. Introduction Bone histomorphometry is an indispensable tool for assessing the mechanisms by which bone diseases occur, the mechanisms by which therapeutic agents affect the skeleton, and the skeletal safety of therapeutic agents. While high-resolution imaging techniques such as mCT can provide excellent information about bone mass and bone structure, they cannot at present provide the researcher with insights into cellular activity in bone. When applied correctly, bone histomorphometry can yield a wealth of information about bone structure, bone formation, bone resorption, bone mineralization, as well as bone modeling and remodeling activity. This chapter focuses on histomorphometric analysis of rodent cancellous and cortical bone sites. The nomenclature for histomorphometric parameters in this chapter is based on the suggestions made by the ASBMR nomenclature committee (1). One of the “axioms” in histomorphometry is that “Your histomorphometry is only as good as your histology”. Because histological quality is a prerequisite for meaningful histomorphometric analysis, this chapter starts with a description of how mouse and rat bone specimens have to be embedded and stained to achieve high quality histological “raw” material.
Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_19, © Springer Science+Business Media, LLC 2012
279
280
R.G. Erben and M. Glösmann
We use two different methylmethacrylate (MMA) embedding protocols, a conventional method, and a modified embedding method suitable for histochemistry and immunohistochemistry. Conventional MMA embedding results in almost complete destruction of enzyme activity and antigenic determinants in the embedded tissue by covalent modification of biological molecules through radicals generated during the polymerization process. Therefore, bones embedded in conventional MMA cannot be used for histochemistry or immunohistochemistry in a reliable fashion. For partial preservation of enzyme activities and tissue reactivity to antibodies, we use a modified MMA embedding method developed in our laboratory (2). Because analysis of osteoclast numbers in mice is greatly facilitated by Tartrate Resistant Acid Phosphatase (TRAcP) histochemistry, we embed all our mouse bones using the modified method which involves performing the polymerization at low temperature. By contrast, we embed all our rat bones in conventional MMA, unless histochemical or immunohistochemical analyses are important end points. The histological quality is comparable for both methods of embedding. For sectioning we use both rotary (Microm HM 355S and HM 360) and sledge microtomes (Leica Polycut S2500). For optimal section quality, it is important to use a slide press for drying the sections. Standardization of sampling sites is also very important to achieve reproducible results and to reduce the interindividual variance between groups. We use midsagittal sectioning planes for both the rat tibia and the rat vertebra (Fig. 1). In mice, most labs prefer the distal femoral metaphysis for cancellous bone histomorphometry in the appendicular skeleton. A drawback of the distal femur is that the shape of the growth plate is more complex compared with the proximal tibia (Fig. 1). However, the strong curvature of the tibia in mice makes it more difficult to standardize the sectioning plane, outweighing the advantage of the simpler growth plate geometry. In contrast to rats, murine vertebrae need to be sectioned in a frontal plane. Otherwise, the amount of cancellous bone available for analysis is very limited (Fig. 1).
2. Materials 2.1. Sectioning, Fixation and Embedding
1. Rotary microtomes (Microm HM 355S and HM 360). 2. Sledge microtome (Leica Polycut S2500). 3. Water-cooled precision diamond band saw (Exakt, Norderstedt, Germany). 4. Slide press (Enno Vieth Mikrotome GmbH, Wiesmoor, Germany).
19
Histomorphometry in Rodents
281
Fig. 1. Sectioning planes in rat and mouse bones. (a–b) Midsagittal sectioning planes of a rat proximal tibia (a), a rat lumbar vertebral body (b), and a mouse lumbar vertebral body (c). (d–e) Exactly midsagittal (d) and slightly parasagittal (e) sectioning planes of a distal mouse femur show the complex geometry of the distal femoral growth plate in parasagittal sections. (f) Midsagittal section of a mouse tibia. (g) Frontal section of mouse lumbar vertebral body. (a) and (b) are von Kossastained 5-mm-thick sections without counterstain, (c)–(d) are 3-mm-thick von Kossa-stained sections counterstained with McNeal’s tetrachrome. Original magnifications ×12 in (a), ×20 in (b), ×25 in (c)–(g).
5. Binder environmental test chamber MK series (Binder GmbH, Tuttlingen, Germany). 6. Aminopropyltriethoxysilane. 7. Loctite 420 adhesive (Henkel, Düsseldorf, Germany). 8. Splicer (Exakt). 9. Microgrinding system (Exakt). 10. 30% H2O2. 11. Acetone–isopropanol: 50% acetone (v/v) in isopropanol. 12. Fluoromount (Serva). 13. PFA: 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. 14. 40% Ethanol, 70% ethanol, and 96% ethanol. 15. Propan-2-ol. 16. 0.1 M phosphate buffer, with 10% (w/v) sucrose, pH 7.4. 17. Xylene. 18. Dry benzoyl peroxide (see Note 1).
282
R.G. Erben and M. Glösmann
19. MMA Solution #1: Methylmethacrylate (e.g., Merck 800590) with 20% (v/v) dibutyl phthalate. 20. MMA Solution #2: Methylmethacrylate with 20% (v/v) dibutyl phthalate, and 1% (w/v) dry benzoyl peroxide. 21. MMA Solution #3: Methylmethacrylate with 20% (v/v) dibutyl phthalate, and 3% (w/v) dry benzoyl peroxide (see Note 2). 22. MMA solution #4: Methylmethacrylate with 35% (v/v) butyl methacrylate, 5% (v/v) methyl benzoate, and 1.2% polyethylene glycol 400. 23. MMA solution #5: Methylmethacrylate with 35% (v/v) butyl methacrylate, 5% (v/v) methyl benzoate, 1.2% polyethylene glycol 400, and 0.4% (w/v) dry benzoyl peroxide. 24. MMA solution #6: Methylmethacrylate with 35% (v/v) butyl methacrylate, 5% (v/v), methyl benzoate, 1.2% (v/v) polyethylene glycol 400, and 0.8% (w/v) dry benzoyl peroxide (see Note 2). 2.2. Von Kossa and McNeal Stain
1. 5% silver nitrate in distilled water (keep in dark). 2. Sodium carbonate/formaldehyde solution: 9.5% formaldehyde (v/v) in 0.138 M sodium carbonate (see Note 3). 3. Farmer’s reducer: 5% (w/v) potassium ferrocyanide in 10% sodium thiosulfate (see Note 4). 4. Tetrachrome stock solution: 0.1% (w/v) Methylene blue chloride, 0.16% Azure A eosinate, 0.02% Methylene violet (Bernthsen) in a solution of 50% methanol, and 50% glycerol (see Note 5). 5. Tetrachrome working solution: 5% tetrachrome stock solution in distilled water.
2.3. Toluidine Blue Stain
1. Buffer I: 8.22 mM Citric acid, 2.1 mM disodium hydrogen phosphate, pH 3.7. 2. Toluidine blue stain: 2% (w/v) Toluidine blue O in Buffer I, pH 3.7 (see Note 6).
2.4. Tartrate Resistant Acid Phosphatase Stain
1. Acetate buffer: 0.2 M Sodium acetate, 50 mM L(+)-tartaric acid, pH 5.0. 2. TRAcP reagent: 0.5% (w/v) Napthol AS-MX phosphate disodium salt and 1.1% Fast Red TR salt in distilled water (see Note 7). 3. Mayer’s Hematoxylin 0.1% (w/v) Hematoxylin, 0.02% (w/v) sodium iodate, 5% (w/v) aluminum potassium sulfate (12 H2O), 5% (w/v) chloral hydrate, and 0.1% (w/v) citric acid (see Note 8). 4. 0.2 M Tris–HCl buffer, pH 9.0.
19
Histomorphometry in Rodents
283
2.5. Cement Line Stain
1. Toluidine blue with tetraborate and formic acid: 1% (w/v) toluidine blue O, 1% (w/v) sodium tetraborate, and 0.1% (v/v) formic acid in distilled water (see Note 9).
2.6. Histomorphometric Analysis
1. Microscopes: Zeiss Axioskop microscope and Zeiss SV11 stereomicroscope. 2. Digital camera: Diagnostic Instruments Spot Insight CCD camera. 3. Osteomeasure interactive 3.0 interactive image analysis software (OsteoMetrics). 4. Zeiss AxioVision 4.7 software package.
3. Methods 3.1. Fixation, Dehydration and Infiltration of Bone Samples
The fixation and infiltration steps below should be carried out at 4°C using a magnetic stirrer. 1. Carefully remove soft tissues from the bones (see Note 10). 2. Fix the tissue samples as quickly as possible by immersing in 40% ethanol (see Note 11) for 48 h or in 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer, at pH 7.4, for 24 h. 3. When the fixation step is complete, wash the samples in 0.1 M phosphate buffer, pH 7.4, containing 10% (w/v) sucrose (see Note 12). 4. Dehydrate the samples by immersing in graded alcohols and xylene as detailed in steps 5–11 below, adjusting the duration of incubation depending on the bone characteristics (see Note 3). 5. Immerse in 70% ethanol for 1–4 days. 6. Immerse in 96% ethanol for 1–4 days. 7. Immerse in 100% propan-2-ol for 1–2 days and repeat twice in total. 8. Immerse in xylene for 1–4 days and repeat twice in total. 9. Immerse the samples in MMA Solution #1 (routine histology) or MMA Solution #4 (histochemistry and immunohistochemistry) for 2–4 days. 10. Immerse the samples in MMA Solution #2 (routine histology) or MMA Solution #5 (histochemistry and immunohistochemistry) for 2–4 days. 11. Immerse the samples in MMA Solution #3 (routine histology) or MMA Solution #6 (histochemistry and immunohistochemistry) for 2–4 days.
284
R.G. Erben and M. Glösmann
3.2. Preparation of Glass Vials for Tissue Embedding
3.2.1. Routine Embedding
In this section we describe how to prepare glass tubes containing polymerized MMA which are used as a receptacle for embedding the bone samples. The procedure described assumes that you are using 25-ml glass vials, but smaller vials can be used depending on the sample size (see Note 14). 1. Prepare fresh MMA #3 solution at RT. 2. Pour 5 ml of the polymerization mixture into each glass vial. 3. Place an airtight cap on the top. 4. Incubate for at least 24 h at 40°C. 5. Store the vials at room temperature until further use.
3.2.2. Histochemistry and Immunohistochemistry
1. Chill the 25 ml glass vials on ice. 2. Add 600 ml of N,N-dimethyl-p-toluidine to 100 ml of freshly prepared MMA solution which has been prechilled to 4°C and stir for a few minutes. 3. Pour 5 ml of the polymerization mixture into each glass vial. 4. Thoroughly gas the vial with N2 or CO2 for 20–30 s and place an airtight cap on the top. 5. Incubate for at least 24 h at 4°C. 6. Store the vials at room temperature until further use.
3.3. Embedding for Routine Histology
This polymerization and embedding protocol described below is based on that published previously by Schenk et al. (3) with some modifications. 1. Place the infiltrated bone samples from Subheading 3.1, step 11 into the prepared glass vials, described in Subheading 3.2.1, adding one bone sample per vial along with a label to identify the sample. 2. Fill the vials with the MMA #3 solution and place a plastic cap on the vial, ensuring that it is airtight. 3. Incubate in a water bath overnight at 26°C. 4. Continue the incubation at 28°C for a further 12 h and continue the incubation for a further 3 days, gradually increasing the temperature by 0.5°C to reach a final temperature of 31°C. 5. Store the embedded tissue samples at room temperature until further use.
3.4. Embedding for Histochemistry and Immunohistochemistry
Here, we describe an embedding technique for undecalcified bone samples suited for bone histomorphometry, histochemistry, and immunohistochemistry (2). The method can also be used for soft tissues. It is important that steps 1–4 are carried out on ice (see Note 15).
19
Histomorphometry in Rodents
285
1. Chill the prepared glass vials from Subheading 3.2.2 on ice. 2. Add 400 ml of N,N-dimethyl-p-toluidine to 100 ml of MMA III solution, which has been chilled to 4°C and stir for a few minutes. 3. Fill the vials with this solution. 4. Place the infiltrated bone samples from Subheading 3.1, step 11 into the prepared glass vials, described in Subheading 3.2.2, adding one bone sample per vial along with a label to identify the sample. 5. Place a plastic cap on the vial, ensuring that it is airtight. It is not necessary to gas the tubes, since the MMA is filled right to the top. 6. Transfer the vials to a cooling unit (see Note 16) and incubate at −23°C for 16 h. 7. Gradually increase the temperature from −23 to −22°C for over 1 h. 8. Gradually increase the temperature from −22 to −20°C for over 46 h. 9. Gradually increase the temperature from −20 to −18°C for over 24 h. 10. Gradually increase the temperature from −18°C to +2°C for over 12 h. 11. Store the tissue blocks at −20°C until further use (see Note 17). 3.5. Preparation of Micromilled Cross-Sections for Routine Histological Analysis
The usual sites for cortical bone histomorphometry in rats and mice are the femoral and tibial shaft. Because histochemical or immunohistochemical staining is rarely required for cross-sections, we embed all specimens routinely in conventional MMA as described in Subheading 3.2. In rats, we usually use the tibial shaft, sampled at 2 mm proximal to the tibiofibular junction. In mice, we use the femoral midshaft defined by equal distances from the proximal and distal end of the bone. The slides are then stained with toluidine blue after etching the surface with H2O2 (4) as described below or analyzed for fluorochrome labels without staining as described in Subheading 3.6: 1. Immerse acetone-cleaned glass slides in aminopropyltriethoxysilane for 5 min, rinse in distilled water, and allow them to dry. 2. Prepare 3–5 150 mm thick cross-sections of bone at the desired site using a water-cooled precision diamond band saw. 3. Glue the sections onto the 3-aminopropyltriethoxysilanecoated glass slides with Loctite 420 adhesive using a splicer (Exakt). 4. Grind the sections to a final thickness of 15–20 mm with the microgrinder.
286
R.G. Erben and M. Glösmann
5. Wipe the micromilled section with acetone–isopropanol. 6. Immerse the sections in 30% H2O2 and agitate for 5 min. 7. Thoroughly rinse in tap water. 8. Immerse the sections in toluidine blue solution for 60 min. 9. Rinse the sections in distilled water. 10. Allow the sections to air-dry for 120 min. 11. Wipe the sections with acetone–isopropanol. 12. Cover-slip sections with DePeX and proceed to histological analysis. 3.6. Preparation of Micromilled Cross-Sections for Analysis of Fluorochrome Labels 3.7. Von Kossa Stain
1. Follow steps 1–4 of Subheading 2.3. 2. Cover-slip sections with Fluoromount and proceed to histological analysis.
We use this stain for image analysis of bone structure, because it gives a very high contrast between bone which is stained black and bone marrow which is unstained. For optimal histological quality, it is advantageous to avoid dehydration at the end of the staining protocol and we therefore mount the sections using an aqueous mounting medium. 1. Immerse the sections in 2-Methoxyethyl acetate for 20 min and repeat three times in total. 2. Immerse the sections in 70% ethanol for 5 min. 3. Immerse the sections in 40% ethanol for 5 min. 4. Immerse the sections in distilled water for 5 min and repeat three times in total. 5. Immerse the sections in the dark with 5% silver nitrate solution for 5–10 min (see Note 18). 6. Wash the sections in distilled water and repeat three times in total. 7. Immerse the sections in sodium carbonate/formaldehyde solution for 2 min. 8. Rinse the sections in tap water. 9. Immerse the sections in Farmer’s reducer for 30 s. 10. Rinse the sections in running tap water for 20 min. 11. Cover-slip in Kaiser’s glycerol gelatine.
3.8. Von Kossa/McNeal Stain
This protocol describes a combination of von Kossa’s stain with McNeal’s tetrachrome stain as counterstain (3). It combines good cellular detail with a very clear distinction between mineralized and
19
Histomorphometry in Rodents
287
unmineralized bone. We use this stain for the assessment of cellular and osteoid parameters especially in mice. 1. Follow the protocol for von Kossa staining as described in Subheading 3.7, steps 1–10. 2. Immerse the slides in fresh tetrachrome working solution for 20–60 min. 3. Rinse the slides in distilled water. 4. Rinse the slides in propan-2-ol twice. 5. Rinse the slides in xylene for 5 min. 6. Cover-slip slides with DePeX mounting medium and proceed to histological analysis. 3.9. Toluidine Blue Stain
The toluidine blue stain at acid pH described previously by Baron et al. (5) gives very good cellular detail. If applied properly, it also gives a good distinction between mineralized and unmineralized bone. It is our favorite stain for the histomorphometric measurement of cellular parameters in rats. 1. Remove the MMA from the sections by follow steps 1–4 of protocol in Subheading 3.7. 2. Immerse the slides in toluidine blue stain for 10 min. 3. Immerse the slides in Buffer I for 1 min and drain the slide rack on blotting paper. 4. Repeat step 3. 5. Immerse the slides in n-butanol for 1 min and repeat three times in total. 6. Immerse the slides in n-butanol/xylene for 1.5 min. 7. Immerse the slides in xylene for 1 min and repeat twice in total. 8. Mount in DePeX, add a cover slip, and proceed to histological analysis.
3.10. Tartrate Resistant Acid Phosphatase Staining
This protocol is used for histochemical detection of TRAcP in undecalcified sections of bone which have been embedded using the modified MMA protocol described in Subheading 3.4. The stain identifies osteoclasts since they express very high levels of TRAcP (see Note 19). 1. Immerse the sections in 2-Methoxyethyl acetate for 20 min and repeat three times in total. 2. Immerse the slides in acetone for 5 min and repeat twice in total (see Note 20). 3. Immerse the slides in distilled water for 5 min and repeat twice in total.
288
R.G. Erben and M. Glösmann
4. Immerse the slides in 0.2 M acetate buffer, pH 5.0, for 20 min at room temperature. 5. Add approximately 100 ml TRAcP-reagent to each sections and incubate for 2–4 h at 37°C in a humidified chamber. 6. Rinse in distilled water. 7. Counterstain with Mayer’s hematoxylin for 2 min. 8. Rinse in distilled water. 9. Wash in running tap water for 5–10 min. 10. Mount in Kaiser’s glycerol gelatine. 3.11. Cement Line Stain
This protocol describes a modification of the surface-staining technique described by Schenk et al. (3) for demonstration of cement lines in undecalcified sections of rat and mouse bones. It is not necessary to remove the embedding material prior to this procedure. 1. Immerse the slides in 0.1% formic acid for 45 s. 2. Rinse the slides in distilled water. 3. Incubate the slides in 20% methanol for 60 min. 4. Rinse the slides in distilled water. 5. Immerse the slides in toluidine blue solution for 3 min. 6. Rinse the slides in distilled water. 7. Air-dry the slides for 120 min. 8. Cover-slip with DePeX and proceed to histological analysis.
3.12. Cancellous Bone Histomorphometry
Standard sites for cancellous bone histomorphometry in rats are the proximal tibial or femoral metaphyses and the lumbar vertebral bodies, but the choice of site depends on the age of the animal and whether or not the animal is osteopenic (see Note 21). Normally, cancellous bone histomorphometry is performed within the secondary spongiosa. To exclude the primary spongiosa, bone within a certain distance from the growth plate is excluded from the analyses (Fig. 2). There is no definitive rule for this, but suggested criteria are discussed below. In the rat proximal tibial metaphysis, 1 mm distance from the growth plate is appropriate in 2- to 3-month-old rats. Beyond about 5 months of age, 0.5 mm can be used. If necessary, this value can be reduced to 0.25 mm in rats beyond 9–12 months of age. In the murine distal femoral metaphysis and proximal tibial metaphysis, 0.25 mm can be used for all ages beyond 4 weeks of age. In lumbar vertebrae, 0.25 mm distance from the cranial and caudal growth plate each can be used for all ages in mice, and 0.5 mm for all ages in rats. Under some circumstances such as in experiments that involve the use of antiresorptive drugs, the area beneath the growth plate excluded from the analysis can be larger (see Note 22). To exclude endocortical bone remodeling activity, cancellous bone within 0.25 mm from the endocortical bone surface should be excluded from the analyses, regardless of the
19
Histomorphometry in Rodents
289
Fig. 2. Measuring areas for cancellous bone histomorphometry. (a–b) Large measuring areas for automatic image analysis encompass most of the secondary spongiosa in a sagittal section of a distal mouse femur (a), and a frontal section of a mouse lumbar vertebral body (b). The distance of the measuring field from the growth plates and the endocortical bone surfaces is approximately 0.25 mm in both bones. (c) Typical measuring fields for interactive measurements at ×200 magnification in a rat proximal tibia. The size of the individual measuring fields is 0.5 × 0.5 mm. A distance of 0.5 mm is kept from the growth plate. Von Kossa-stained sections of mouse and rat bones. Original magnifications ×25 in (a) and (b), ×12 in (c).
sampling site (Fig. 2). Unless there is an impairment in bone mineralization (see Note 23), we follow a two-step analysis strategy in our lab for almost all samples. In a first step, we measure bone structural parameters such as bone area or trabecular width by automatic image analysis in a large area encompassing more or less the whole secondary spongiosa in a specific site (Fig. 2). Because this is a very rapid analysis requiring only about 3 min per section, two sections can be analyzed to reduce the variance. We use a Diagnostic Instruments Spot Insight CCD camera in combination with a Zeiss Axioskop microscope with a × 2.5 objective or a Zeiss SV11 stereomicroscope for image acquisition. For image analysis, we use the Zeiss AxioVision 4.7 software package.
290
R.G. Erben and M. Glösmann
In a second step, we assess bone turnover by measurements done with an interactive image analysis system. We prefer to employ a microscope with a drawing attachment and a digitizing tablet equipped with a cursor with a LED light source for the interactive measurements. The measurement area is defined by a square grid in one of the oculars. Thus, with the help of the LED-illuminated cursor and the drawing attachment, features within the section can be traced by looking into the microscope. The advantage of this setup is that it is faster, more accurate, and also less strenuous for the eyes compared with measurements on the screen. We employ a Zeiss Axioskop microscope with a drawing attachment, and the OsteoMeasure interactive image analysis software for the latter setup. Typical measuring areas are shown in Fig. 2. 3.13. Assessment of Bone Structural Parameters
Bone structural parameters should be assessed using von Kossastained sections. The method described here is only applicable in samples with a low amount of osteoid (see Note 23). Depending on the sample size, we use a Zeiss Axioskop microscope with a ×2.5 objective or a Zeiss SV11 stereomicroscope for image acquisition. The images are processed and analyzed using Zeiss AxioVision 4.7 software. To reduce the variation, we measure two sections spaced at least 100 mm from each other. The mean value of both measurements is used for further calculations. Analysis of bone structural parameters involves making only four primary measurements (Table 1), but from these various other parameters in both two dimensions (2D) and three dimensions (3D) can be derived.
Table 1 Primary and derived structural parameters of bone Primary parameters Total area (T.Ar; the measuring area) Bone area (B.Ar) Bone perimeter (B.Pm), a The number of individual bone trabeculae (N.Tb) 2D derived parameters Bone area (B.Ar/T.Ar) = B.Ar/T.Ar × 100 (%) Number of trabeculae per tissue area (N.Tb/T.Ar) = Tb.N/T.Ar (no./mm²) Trabecular area (Tb.Ar) = B.Ar/N.Tb (mm²) Number of trabeculae per bone area (N.Tb/B.Ar) = N.Tb/B.Ar (no./mm²) Bone perimeter (B.Pm/T.Ar) = B.Pm/T.Ar (mm/mm²) Trabecular width (Tb.Wi) = B.Ar/B.Pm × 2,000 (mm) 3D derived parameters Bone volume (BV/TV) = B.Ar/T.Ar × 100 (%) Bone surface (BS/TV) = B.Pm/T.Ar × 4/p (mm²/mm³) Trabecular thickness (Tb.Th) = B.Ar/B.Pm × 2000 × p/4 (mm) Trabecular number (Tb.N) = 4/p × 0.5 × B.Pm/T.Ar (no./mm) Trabecular separation (Tb.Sp) = 1/Tb.N × 1000 − Tb.Th (mm)
19
Histomorphometry in Rodents
291
Two-dimensional parameters such as number of trabeculae per tissue area, trabecular area, and number of trabeculae per bone area indirectly reflect the connectivity of the trabecular network. The calculation of the 3D parameters bone surface, trabecular thickness, trabecular thickness, and trabecular separation from 2D data is based on the factor 4/p. This factor is based on the assumption that the structure is isotropic (1). This model assumption is obviously wrong for the standard sampling sites in mice and rats (Fig. 1). Therefore, one has to be aware that calculation of histomorphometric 3D parameters in rat and mouse cancellous bone is always associated with some error. Histomorphometry has largely been superseded by mCT analysis for analysis of 3D bone structure. Therefore, we usually express structural histomorphometric data in 2D only. In addition, we routinely calculate Tb.Th, Tb.N, and Tb.Sp for comparison with structural data obtained by mCT analysis. 3.14. Analysis of Dynamic Histomorphometry in Mice
Histomorphometry is an indispensable tool for the assessment of local turnover mechanisms within bone. For mouse studies, it is usually sufficient to analyze fluorochrome labeling as described in this section and osteoclast numbers as described in Subheading 3.15 because together these reflect bone remodeling activity. Osteoid and mineralization parameters are analyzed only when needed. Although older mice do have a bone remodeling activity, remodeling-based parameters are normally not assessed in mice. Dynamic bone histomorphometry is based on the analysis of fluorochromelabeled bone specimens and is used to assess the rate of osteoblastic bone formation and bone mineralization. We routinely use double calcein labeling for dynamic histomorphometry (Fig. 3). Other labs
Fig. 3. Calcein double labeling for measurement of bone formation. Unstained 3-mm-thick section viewed under blue excitation shows calcein double labels (arrows) in murine cancellous bone. Mineralized bone is marked by asterisks. Original magnification ×400.
292
R.G. Erben and M. Glösmann
use two different labels for double labeling. However, unless the information contained within the individual labels is used (6, 7), two different labels do not offer any advantage in our hands. It is very important to use appropriate marker intervals. In order to avoid large label escape and skewed sampling errors, the marker interval has to be as short as possible. For a detailed explanation of these errors, the reader is referred to other textbooks (6, 8). In 3to 4-week-old mice we use a marker interval of 1 day, in 6- to 12-week-old mice 2 days, and in older mice 2 or 3 days (6). In rats older than 3 months, we use a 5-day marker interval (6). The measurements are made on unstained sections, using a ×20 objective in most cases, together with an interactive image analysis system. Primary measurements are the bone perimeter, the mineralizing bone perimeter (M.Pm), and the mineral apposition rate (MAR). There are two possible definitions for M.Pm. M.Pm is either defined as the double-labeled perimeter (M.Pm = Db.Lb. Pm), or as Db.Lb.Pm + one half of the single-labeled perimeter (M.Pm = Db.Lb.Pm + 0.5 × S.Lb.Pm). The latter expression is the mathematically more correct term, and is the standard in humans (1). However, because nonspecific fluorochrome labeling is a problem in rats and mice, we only use the definition M.Pm = Db.Lb. Pm. This definition underestimates the true M.Pm, but reduces the likelihood of errors caused by nonspecific labeling. The MAR (mm/day) is defined by the mean distance between the labels, divided by the marker interval. The MAR can be measured indirectly by tracing along the individual labels, or directly by a twopoint distance measurement. When broader, “fuzzy” labels are present, the interlabel distance is best measured from mid-point to mid-point of the labels (8, 9). We mostly use the indirect method, because Db.Lb.Pm and MAR are measured at once, which saves time. The surface-based bone formation rate (BFR) is defined by multiplying M.Pm with MAR, BFR/B.Pm = BFR/BS = M. Pm/100 × MAR (mm²/mm/day or mm³/mm²/day). There are other ways to express BFR, using different referents such as the tissue volume or the time (1). However, we routinely use only BFR/B.Pm or BFR/BS, because it is the best reflection of the intensity of bone formation per unit of bone perimeter/surface. Dynamic histomorphometric parameters are a functional readout of matrix synthesis by the osteoblast and the subsequent mineralization of that matrix. Therefore, these parameters are clearly superior to any morphological assessments of osteoblastic activity such as osteoblast perimeter or osteoblast number. Special problems may arise in assessing dynamic histomorphometry when antiresorptive drugs are being used due to the inhibition of bone turnover which may result in the absence of double fluorochrome labels. How should BFR be reported in the case of a lack of double labeling? To exclude a technical problem due to missing labels, other sections and sites should be analyzed for the presence of
19
Histomorphometry in Rodents
293
double labels. The presence of a double label anywhere in the skeleton indicates that the animal was properly labeled. When the animal was properly labeled and double labels are absent within the sampling site, we report the M.Pm and the BFR as zero, whereas MAR is treated as missing value. 3.15. Assessment of Osteoclast Numbers and Bone Resorption in Mice
Osteoclasts are generally more difficult to recognize in mice compared with other species, because a large proportion of murine osteoclasts are mononuclear and because Howship’s lacunae are shallow. For reliable measurements of osteoclast numbers in mice, it is important to use TRAcP stained sections. We measure osteoclast parameters in mice on TRAcP-stained sections with a ×20 objective. Only TRAcP-positive nucleated cells in contact with bone are counted as osteoclasts, not osteoclast profiles lacking a nucleus or TRAcP-positive cells within bone marrow (Fig. 4). The most commonly used primary and derived measurements of osteoclast number and bone resorption are shown in Table 2. Osteoclasts can only occur on bone surfaces. Therefore, osteoclast numbers are best expressed per millimeter of bone perimeter (N.Oc/B.Pm). In fact, it can be very misleading to express osteoclast number per tissue area (N.Oc./T.Ar) in osteopenic animals. When there is a lot of osteoid, it can be useful to express osteoclast numbers per millimeter of mineralized bone perimeter, with Md. Pm = B.Pm − osteoid perimeter (O.Pm) since osteoclasts can only
Fig. 4. TRAcP staining of osteoclasts in murine bone sections. TRAcP-stained 3-mm-thick section of a mouse lumbar vertebra shows red-stained osteoclasts. Nuclei appear as lighter stained areas. Osteoclast profiles in contact with bone but without nucleus (arrow) or TRAcP-positive cells not in contact with bone (arrowheads) are not counted as osteoclasts. The section is counterstained with hematoxylin. Original magnification ×400.
294
R.G. Erben and M. Glösmann
Table 2 Measured and derived indices of bone resorption Primary parameters Bone perimeter (B.Pm) Number of osteoclasts (N.Oc) Osteoclast perimeter (Oc.Pm)a Derived parameters Osteoclast number (N.Oc/B.Pm) = N.Oc/B.Pm (no./mm) (surface referent) Osteoclast number (N.Oc/Md.Pm) = N.Oc/(B.Pm − O.Pm) (no./mm) Osteoclast number (N.Oc/T.Ar) = N.Oc/T.Ar (no./mm²) (tissue referent) Osteoclast perimeter (Oc.Pm/B.Pm) = osteoclast surface (Oc.S/BS) = Oc. Pm/B.Pm (%) a
The contact perimeter between the osteoclast and the bone surface
resorb mineralized bone. Therefore, N.Oc/Md.Pm (no./mm) is the best estimate of osteoclastic bone resorptive activity in situations where osteoid perimeter differs between different groups of animals. Because the TRACP stain does not permit reliable quantification of osteoid, Md.Pm has to be calculated as follows: Md. Pm = B.Pm − B.Pm × O.Pm/B.Pm. The proportion of osteoid-covered bone perimeter (O.Pm/B.Pm) has to be quantified separately. It is worthwhile expressing osteoclast number per mineralized perimeter only in the presence of pronounced differences in osteoid perimeter between the groups of animals. Additional parameters can be the number of nuclei per osteoclast, and mean osteoclast size. However, the latter parameters make sense only in the case that osteoclast morphology is altered. 3.16. Assessment of Bone Mineralization in Mice
We do not routinely assess osteoid or osteoblast parameters in murine bone samples. These measurements add useful information only when bone mineralization is impaired. We perform these measurements on sections stained with von Kossa and counterstained with McNeal’s tetrachrome, using a ×20 objective. This stain gives a very reliable and clear distinction between mineralized bone and unmineralized osteoid tissue (Fig. 5). Primary and derived measurements are summarized in Table 3. Increases in osteoid perimeter and osteoid area are not necessarily associated with impaired bone mineralization, but can also be caused by increases in bone formation in the absence of disturbed bone mineralization. Rather, increased osteoid width and, more specifically, increased OMT are indicative of impaired bone mineralization. However, many mouse models of impaired bone mineralization are characterized by severe impairments of bone mineralization (Fig. 5), resulting in the complete absence
19
Histomorphometry in Rodents
295
Fig. 5. Osteoid in murine bone sections. Von Kossa/McNeal staining provides the most reliable discrimination between black mineralized bone and pale-stained osteoid. (a) Thin osteoid seams (arrows) covered by osteoblasts in distal femoral cancellous bone of a wild-type mouse. An osteoclast showing one nucleus is marked by an arrowhead. (b) Severe osteoidosis (asterisks) in distal femoral cancellous bone of a Hyp mouse. Hyp mice are hypophosphatemic and are characterized by a loss-of-function mutation in the Phex gene (phosphate-regulating gene with homologies to endopeptidases on the X chromosome), which indirectly controls secretion of the phosphaturic fibroblast growth factor-23 in a negative fashion; 3-mm-thick sections. Original magnification ×400.
Table 3 Measured and derived indices of bone mineralisation Primary parameters Bone perimeter (B.Pm) Bone area (B.Ar) Osteoid perimeter (O.Pm) Osteoid area (O.Ar) Osteoblast perimeter (Ob.Pm) Osteoid width (O.Wi)a Derived parameters Osteoid perimeter (O.Pm/B.Pm) = Osteoid surface (OS/BS) = O.Pm/B.Pm × 100 (%) Osteoblast perimeter (Ob.Pm/B.Pm) = Osteoblast surface (Ob.S/BS) = Ob.Pm/B.Pm × 100 (%) Osteoid area (O.Ar/B.Ar) = Osteoid volume (OV/BV) = O.Ar/B.Ar × 100 (%) Osteoid width (O.Wi) = O.Ar/O.Pm × 1,000 (mm) Osteoid maturation time (OMT) = O.Wi/MAR (days) Osteoid thickness (O.Th) = O.Wi × p/4 (mm) a
Usually O.Wi is calculated from the osteoid area and perimeter, but it can be measured directly by a two-point distance measurement by sampling osteoid seams every 50 mm
of fluorochrome double labels and immeasurable values for MAR. Therefore, OMT cannot be determined in these mouse models. However, OMT is generally a very sensitive parameter to pick up subtle impairments in bone mineralization.
296
R.G. Erben and M. Glösmann
3.17. Assessment of Dynamic Histomorphometry in Rats
The procedures here are identical to mouse samples as described in Subheading 3.16.
3.18. Assessment of Static Histomorphometry in Rats
Static histomorphometric assessment of bone turnover in rats is different from mice because rat osteoclasts are easily recognized in bone sections due to their typical morphological and staining characteristics (Fig. 6) and because remodeling-based parameters can provide useful information about changes in activation frequency and remodeling periods in rats. In view of this, it is not necessary to analyze TRAcP-stained sections in rats but we routinely measure eroded perimeter in rats since this is necessary for the calculation of the resorption period. We use toluidine blue-stained sections and a ×20 objective for this type of measurement in rats. The advantage of toluidine blue over von Kossa/McNeal is that remodeling units within mineralized bone are still visible (Fig. 6). Although the von Kossa/McNeal stain is more reliable for distinguishing between osteoid and mineralized bone, information about the structural organization of mineralized bone is lost due to the deep black staining of mineralized bone. Therefore, we prefer the toluidine blue stain for analysis of structural parameters in rat bone. Primary parameters are bone perimeter, bone area, osteoid area, osteoid perimeter, osteoblast perimeter, osteoclast number, osteoclast perimeter, and eroded perimeter. Rat osteoblasts are generally more flattened compared with murine osteoblasts (Fig. 6). Therefore, a clear-cut morphological definition of rat osteoblasts is difficult. We exclude only very flat cells from the measurement of osteoblast perimeter (Fig. 6). Moreover, we count only nucleated cells as osteoclasts, not osteoclast profiles (Fig. 6). For the measurement of eroded perimeter, we use a minimum depth of 3 mm for resorption cavities as cutoff value to exclude very shallow
Fig. 6. Toluidine blue staining of rat cancellous bone sections. (a) Toluidine blue at acid pH stains mineralized bone light blue, so that structural details within bone are still visible (remodeling unit is marked by arrows ). (b) Osteoblasts sitting on a thin osteoid seam (arrows) in rat cancellous bone. Osteoclasts are labeled by arrowheads. Five-micron-thick sections of rat lumbar vertebrae stained with toluidine blue at acid pH. Original magnification ×400.
19
Histomorphometry in Rodents
297
resorption sites. Most derived parameters are identical to the ones listed in Table 1 for mice, with the addition or eroded perimeter (E.Pm/B.Pm) = Eroded surface (ES/BS) = E.Pm/B.Pm × 100 (%). 3.19. Assessment of Remodeling-Based Parameters in Rats
For the calculation of remodeling-based parameters it is necessary to determine wall width, which is the mean width of completed remodeling packages (Fig. 7). We use cement line-stained sections viewed under polarized light, and a ×20 objective for this measurement. Wall width can either be measured by tracing the bone surface and the reversal line of the remodeling package, or by two-point distance measurements. In the latter case, the standard is to make four evenly distributed distance measurements between the reversal line and the bone surface, perpendicular to the bone surface, for each remodeling unit (Fig. 7). To arrive at reliable values, we always measure the width of at least 15 remodeling units in one sample. Wall width can be converted to 3D wall thickness (W.Th) by multiplication with p/4. After determination of wall width, several derived parameters can be calculated (Table 4). The principle behind these calculations is that the surface extent of a certain activity is proportional to the time period occupied by this activity. In rodents, only the active formation period is used, not the formation period based on the adjusted apposition rate. The latter includes so-called “Off” periods (see Note 24). The relative proportion of cancellous bone remodeling compared
Fig. 7. Measurement of wall width for remodeling-based histomorphometric parameters. Wall width is defined as the mean distance between the bone surface and the scalloped reversal line in individual completed remodeling units. A smooth arrest line, indicating a temporary stop in osteoblastic bone formation within a remodeling unit, is marked by an arrowhead. Five-micron-thick section of a rat lumbar vertebra surface-stained with cement line stain. Original magnification × 400.
298
R.G. Erben and M. Glösmann
Table 4 Derived remodeling based parameters in rats Active formation period (FP) = W.Wi/MAR (days) Resorption period (Rs.P) = FP × E.Pm/O.Pm (days) Active resorption period (Rs.P act.) = FP × Oc.Pm/O.Pm (days) Reversal period (Rv.P) = FP × (E.Pm − Oc.Pm)/O.Pm (days) Remodeling period = FP + Rs.P (days) Total period = FP × B.Pm/O.Pm (days) Activation frequency (Ac.F) = 1/Tt.P (no./year)
Fig. 8. Morphology of cross-sections of murine cortical bone and direct measurement of cortical thickness. (a) Toluidine blue-stained microground cross-section of a mouse femoral midshaft. (b) Binary image of the same section showing the intercepts of 90 radii originating from the center of gravity of the bone section with the cortical bone ring. Original magnification × 25.
with modeling increases with age especially in the appendicular skeleton (10). Therefore, remodeling-based parameters are usually measured in rats >6 months of age. 3.20. Cortical Bone Histomorphometry
The usual sites for cortical bone histomorphometry in rats and mice are the femoral or tibial midshaft. In mice, we mostly use the femoral diaphysis, since mouse femurs are less fragile and less curved than the tibiae, and it is easier to define the femoral midshaft than the tibial midshaft. We measure structural parameters on 15- to 20-mm-thick microground sections stained with toluidine blue (Fig. 8). We quantify cross-sectional area (Tt.Ar), cortical area (Ct.Ar), marrow area (Ma.Ar), cortical thickness (Ct.Th), and
19
Histomorphometry in Rodents
299
number and area of intracortical pores (N.Po and Po.Ar) using Zeiss AxioVision 4.7 image analysis software. We perform image acquisition using a Zeiss Axioskop microscope with a ×2.5 objective for the mouse samples, or a Zeiss SV11 stereomicroscope for the rat samples, together with a Diagnostic Instruments Insight digital camera. We measure cortical thickness directly as a primary parameter, using 90 radii originating from the center of gravity of the bone section (Fig. 8). In addition to the absolute values for Ct.Ar, Ma.Ar, and Po.Ar, we always calculate the relative values for cortical and marrow areas (Ct.Ar/Tt.Ar and Ma.Ar/Tt.Ar, %), and intracortical pore area (Po.Ar/Ct.Ar, %). Relative values are helpful when samples of different size need to be compared. To evaluate the bone resorptive activity at endocortical bone surfaces, the endocortical eroded perimeter (Ec.E.Pm/B.Pm, %) can be measured (11). The percentage of endocortical eroded perimeter is traced with a ×10 objective, using an interactive image analysis system. Similar to cancellous bone, it is useful to use a cutoff value of at least 3 mm to exclude very shallow erosions. We use the Osteomeasure interactive system for this measurement. 3.21. Periosteal and Endocortical Bone Formation
In order to quantify periosteal and endocortical bone formation rates, it is necessary to measure the mineralizing perimeter and the mineral apposition rate at both surfaces. Similar to cancellous bone histomorphometry, we use only the double-labeled perimeter for the calculation of the mineralizing perimeter (M.Pm/B.Pm = Db. Lb.Pm/B.Pm). For most purposes, it is enough to measure one section. We measure the periosteal and endocortical mineralizing perimeter with the Osteomeasure interactive system, using ×10, ×20, or ×40 objectives, depending on the interlabel distance. Rats and mice lack true Haversian remodeling. However, intracortical remodeling can be induced in rats by drugs or microdamage accumulation (12–16). Therefore, in rare cases, the intracortical bone formation rate can be of interest. It is measured in analogy to the endocortical and periosteal envelopes by assessing MAR and M.Pm/B.Pm within cortical bone. When periosteal BFR is an important end point of a study employing aged mice and rats, the marker intervals used for cancellous bone double labeling may result in inseparable double labels at periosteal surfaces because MAR may be much lower there compared with cancellous and endocortical bone. To solve this problem, a second pair of markers with longer marker interval can be used, such as administration of alizarine complexone at Days 11 and 1 before necropsy for assessment of periosteal surfaces, and calcein at Days 5 and 2 before necropsy for assessment of cancellous bone BFR in a mouse study. In young mice and rats, this is usually not a problem due to the high periosteal MAR.
300
R.G. Erben and M. Glösmann
4. Notes 1. Dry the benzoyl peroxide using a desiccator or by incubating at 40°C using a drying oven. Dried benzoyl peroxide should be handled with caution, since it may explode! 2. Prepare the MMA solution freshly before use and stir for at least 1 h before adding N,N-dimethyl-p-toluidine. 3. Make up fresh before each use by adding 50 ml 38% formaldehyde to 150 ml 0.138 M sodium carbonate. 4. Make up fresh by adding 10 ml potassium ferrocyanide to 200 ml 10% thiosulphate; use within 1 h of preparation. 5. Combine the reagents and heat in water bath or oven for 12 h at 50°C. Incubate for a further three days at 37°C and filter into a brown flask. 6. Filter prior to use. The solution can be reused for staining multiple sections. 7. The TRAcP reagent needs to be made up fresh and used within 1 h of preparation. For negative controls, the sections can be stained with TRAcP reagent that has to be prepared without the addition of napthol AS-MX. 8. Filter before use. The solution can be reused for staining multiple sections. 9. Filter prior to use. The solution can be reused for staining multiple sections. 10. For larger bones such as the femurs and tibiae, it is advantageous to open the marrow cavity for better fixation and infiltration. We, therefore, suggest that these bones should be cut in half at the diaphysis to facilitate fixation. 11. Alkaline phosphatase enzyme activity is very sensitive to aldehyde-containing fixatives (16, 17). If histochemical analysis of alkaline phosphatase activity in bone is desired, we recommend that 40% ethanol fixation be used instead of PFA. 12. The wash step is only required if the samples have been fixed in PFA. 13. The incubation times for the dehydration and infiltration steps depend on sample size and age of the animals. Longer durations should be used for larger samples, samples from older animals or from animals treated with antiresorptives. Shorter durations can be used for bones from young animals or small bones. 14. Smaller glass vials can also be used for smaller bone samples. In this case, adjust the amounts of the MMA solution proportionately depending on the size of the vial.
19
Histomorphometry in Rodents
301
15. To prevent premature polymerization or the MMA, it is critical that all steps subsequent to addition of N,N-dimethyl-ptoluidine be carried out at 4°C (on water ice) and that the vials are prechilled on ice and kept on ice until they are transferred to a cooling unit for polymerization. If you have many samples to process, we recommend that you prepare fresh MMA/N,Ndimethyl-p-toluidine solution every 2 h. 16. Accurate temperature control during polymerization is critical. We use a Binder environmental test chamber for the complex temperature profiles that are required. 17. For many antigens it is possible to store the samples at room temperature, but this needs to be determined empirically on a case by case basis. 18. Older solutions of silver nitrate may require longer incubation times. 19. The TRAcP activity can be enhanced by incubating the sections in 0.2 M Tris–HCl buffer, pH 9.0, for 1 h at 37°C after the embedding material has been removed following completion of step 3 of the protocol. 20. It is important that you do not allow the sections to dry out. 21. Cancellous bone osteopenia in the appendicular skeleton is a typical feature of aging in mice. Accordingly, in aged mice or osteopenic rats, there may be only very little cancellous bone left in tibiae or femurs which precludes a meaningful analysis of cancellous bone turnover. To avoid this problem, the lumbar vertebrae should be harvested in aged mice or severely osteopenic rats. In osteopenic animals, the amount of cancellous bone available for analysis of bone turnover may be minimal. In order to arrive at meaningful results, we measure at least 20 mm of cancellous bone perimeter in rats, and 5 mm of cancellous bone perimeter in mice. If several sections need to be analyzed to arrive at these minimum requirements, it is important to always analyze the whole measuring area in individual sections (the same measuring area in all sections), and not just subregions. Preferential analysis of subregions may bias the measurement. 22. In experiments where growing animals are treated with potent antiresorptive drugs, the newly formed bone deposited during endochondral bone growth may form an area of densely packed bone spicules underneath the growth plate. This area of bone which is deposited under the influence of the drug is normally excluded from cancellous bone analyses. 23. Normally, the amount of unmineralized bone (osteoid) in rat and murine cancellous bone is very low, in the range of 1–2%. The method to measure structural histomorphometric data by image analysis of von Kossa-stained sections described in
302
R.G. Erben and M. Glösmann
Subheading 3.11 does not pick up osteoid. In the absence of increased amounts of osteoid, the error is very small and thus acceptable. However, image analysis of von Kossa-stained sections will yield erroneous values when bone mineralization is disturbed, resulting in increased amounts of osteoid. In the latter case, structural histomorphometric data need to be assessed by the interactive measurements described under Subheading 3.15 for mice and Subheading 3.17 for rats. 24. In humans, the adjusted apposition rate (Aj.AR) is often used to calculate the formation period. The Aj.AR is given by multiplying MAR with the M.Pm/O.Pm ratio, and includes so called OFF periods during the formation period, when osteoblasts temporarily stop synthesizing collagen. This is not applicable to mice and rats because M.Pm/O.Pm is ³1.0 in many cases (17). Thus, we use only the active formation period in rodents. References 1. Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., and Recker, R. R. (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2, 595–610. 2. Erben, R. G. (1997) Embedding of bone samples in methylmethacrylate: An improved method suitable for bone histomorphometry, histochemistry, and immunohistochemistry. J. Histochem. Cytochem. 45, 307–313. 3. Schenk, R. K., Olah, A. J., and Herrmann, W. (1984) Preparation of calcified tissues for light microscopy. In Methods of calcified tissue preparation (Dickson, G.R. Ed.), pp. 1–56. Elsevier, Amsterdam. 4. Reim, N. S., Breig, B., Stahr, K., Eberle, J., Hoeflich, A., Wolf, E., and Erben, R. G. (2008) Cortical bone loss in androgen-deficient aged male rats is mainly caused by increased endocortical bone remodeling. J. Bone Miner. Res. 23, 694–704. 5. Baron, R., Vignery, A., Neff, L., Silverglate, A., and Santa Maria, A. (1983) Processing of undecalcified bone specimens for bone histomorphometry. In Bone Histomorphometry: Techniques and Interpretation (Recker, R.R. Ed.), pp. 13–35. CRC Press, Boca Raton, FL. 6. Erben, R. G. (2003) Bone Labeling Techniques. In Handbook of Histology Methods for Bone and Cartilage (An, Y.H. and Martin, K.L. Eds.), pp. 99–117. Humana Press Inc, Totowa, NJ, USA. 7. Erben, R. G., Scutt, A. M., Miao, D. S., Kollenkirchen, U., and Haberey, M. (1997)
8.
9.
10.
11.
12.
13.
Short-term treatment of rats with high dose 1,25-dihydroxyvitamin D3 stimulates bone formation and increases the number of osteoblast precursor cells in bone marrow. Endocrinology 138, 4629–4635. Frost, H. M. (1983) Bone histomorphometry: choice of marking agent and labeling schedule. In Bone Histomorphometry: Techniques and Interpretation (Recker, R.R. Ed.), pp. 37–52. CRC Press, Boca Raton, FL. Frost, H. M. (1983) Bone histomorphometry: analysis of trabecular bone dynamics. In Bone Histomorphometry: Techniques and Interpretation (Recker, R.R. Ed.), pp. 109– 131. CRC Press, Boca Raton, FL. Erben, R. G. (1996) Trabecular and endocortical bone surfaces in the rat: Modeling or remodeling? Anat. Rec. 246, 39–46. Reim, N. S., Breig, B., Stahr, K., Eberle, J., Hoeflich, A., Wolf, E., and Erben, R. G. (2008) Cortical bone loss in androgen-deficient aged male rats is mainly caused by increased endocortical bone remodeling. J. Bone Miner. Res. 23, 694–704. Ibbotson, K. J., Orcutt, C. M., D’Souza, S. M., Paddock, C. L., Arthur, J. A., Jankowsky, M. L., and Boyce, R. W. (1992) Contrasting effects of parathyroid hormone and insulin-like growth factor I in an aged ovariectomized rat model of postmenopausal osteoporosis. J. Bone. Miner. Res., 7, 425–432. Lauritzen, D. B., Balena, R., Shea, M., Seedor, J. G., Markatos, A., Le, H. M., Toolan, B. C., Myers, E. R., Rodan, G. A., and Hayes, W. C. (1993) Effects of combined prostaglandin and alendronate treatment on the histomorphometry
19 and biomechanical properties of bone in ovariectomized rats. J. Bone Miner. Res. 8, 871–879. 14. Uzawa, T., Hori, M., Ejiri, S. and Ozawa, H. (1995) Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1–34) on rat bone. Bone 16, 477–484. 15. Bentolila, V., Boyce, T. M., Fyhrie, D. P., Drumb, R., Skerry, T. M., and Schaffler, M. B. (1998) Intracortical remodeling in adult rat long bones after fatigue loading. Bone 23, 275–281.
Histomorphometry in Rodents
303
16. Weber, K., Kaschig, C., and Erben, R. G. (2004) 1alpha-Hydroxyvitamin D2 and 1alphahydroxyvitamin D3 have anabolic effects on cortical bone, but induce intracortical remodeling at toxic doses in ovariectomized rats. Bone 35, 704–710. 17. Erben, R. G., Eberle, J., Stahr, K., and Goldberg, M. (2000) Androgen deficiency induces high turnover osteopenia in aged male rats: a sequential histomorphometric study. J. Bone Miner. Res. 15, 1085–1098.
sdfsdf
Chapter 20 Studying Gene Expression in Bone by In Situ Hybridization Ina Kramer, Rishard Salie, Mira Susa, and Michaela Kneissel Abstract Here, we described a method for carrying out nonradioactive in situ hybridization to detect mRNA transcripts in cryostat sections of mouse bone using the CryoJane® Tape-Transfer System and digoxigenin (DIG)-labeled riboprobes. Key words: In situ hybridization, ISH, Bone, Histology, Gene expression, mRNA, Transcript
1. Introduction The technique of in situ hybridization (ISH) (1) is a valuable method for assessing the temporal and spatial patterns of gene expression in various organs and tissues including bone (2, 3). It involves hybridizing a labeled nucleic acid probe to cells, tissue sections or whole mount tissues, and embryos. The difference between ISH and other methods of assessing gene expression such as quantitative real-time polymerase chain reaction (PCR) is that it allows the researcher to visualize expression of a particular gene of interest in tissue samples where the morphology has been preserved. Therefore, it is possible to determine which cell types express the gene of interest and to assess in a semiquantitative manner, if transcript abundance varies in different cell types. Moreover, ISH is frequently used for assessing temporal changes in gene expression by performing time course analyses of cellular differentiation and tissue maturation during embryonic and postnatal development (4). Disadvantages of ISH include the fact that it is relatively time-consuming and technically demanding and less suitable than real-time PCR for the detection of low abundance transcripts and quantitative gene expression analyses. Here, we
Miep H. Helfrich and Stuart H. Ralston (eds.), Bone Research Protocols, Methods in Molecular Biology, vol. 816, DOI 10.1007/978-1-61779-415-5_20, © Springer Science+Business Media, LLC 2012
305
306
I. Kramer et al.
described a method for ISH based on nonradioactive digoxigenin (DIG)-labeled riboprobes performed on cryo-sections of mouse bone generated with the CryoJane® Tape-Transfer System (5).
2. Materials 2.1. Tissue Collection, Fixation, Decalcification, and Embedding
1. 0.22-μm pore sized filter cups. 2. Plastic peel-away embedding molds. 3. Ketamine and xylazine. 4. Phosphate buffer: 1 M sodium phosphate in distilled water, pH 7.4. Autoclave and store at room temperature. 5. Fixative: 4% (w/v) paraformaldehyde (PFA) in 0.1 M sodium phosphate buffer, pH 7.4. Sterile filter and store at 4°C for a maximum of 2 days or freeze in aliquots at −20°C for longterm storage (see Note 1). 6. Decalcification solution (see Note 2). 0.48 M ethylenediaminetetraacetic acid (EDTA) in distilled diethylpyrocarbonate (DEPC) treated water, pH 7.4. Sterile filter and store at 4°C for up to 4 weeks. 7. 30% (w/v) sucrose in PBS without calcium and magnesium. Sterile filter and store at 4°C.
2.2. Tissue Sectioning
1. Cryostat for tissue sectioning equipped with the CryoJane® Tape-Transfer System (Instrumedics, St. Louis, MO). 2. Disposable or permanent metal knife for cryo-sectioning. 3. Razor blades to trim the frozen tissue block by hand prior to cryo-sectioning. 4. Small artist’s paintbrush for cleaning the knife. 5. Fine metal tweezers. 6. CryoJane® ultraviolet (UV) light-sensitive adhesive-coated slides (Instrumedics). 7. CryoJane® tissue tape and hand roller (Instrumedics). 8. Microscope Cover Slips, 24 × 60 mm.
2.3. Generation of DIG-Labeled Riboprobes
1. 5 μg template DNA (see Note 3). 2. Restriction enzymes (see Note 4). 3. DIG RNA labeling Mix (Roche). 4. T3, T7, and SP6 RNA polymerases (Roche). 5. RNAse inhibitor (40 U/μl). 6. DEPC-treated water.
20
Studying Gene Expression in Bone by In Situ Hybridization
307
7. RNase-free DNase I (Roche). 8. 8 M LiCl. 9. 0.2 M EDTA in DEPC water, pH 8.0. 10. DIG-labeled control RNA (Roche). 11. Agarose. 12. TBE buffer (50 mM Tris–HCl, pH 7.8, 50 mM orthoboric acid, 2 mM NaEDTA). 13. Ethidium bromide. 14. Petri dish. 15. 100% ethanol. 16. 70% ethanol. 17. 20% (w/v) Glycogen in distilled water. 2.4. Hybridization, Washes, Probe Detection, and Signal Development
1. Metal slide racks, glass slide troughs, and staining containers. 2. Small plastic slide box. 3. Hybridization oven. 4. 1 M Tris, pH 7.5 and pH 9.5. 5. Proteinase K stock: 10 mg/ml proteinase K in distilled water. Aliquot and freeze at −20°C. 6. Proteinase K buffer: 1 μg/ml proteinase K, 6.25 mM EDTA in 0.05 M Tris, pH 7.5. Add proteinase K fresh from the stock solution just before use. 7. Acetylation buffer: 1.16% (v/v) triethanolamine in distilled water. 8. 20× SSC buffer: 3 M NaCl and 0.3 M tri-sodium citrate (Na3C6H5O7) in DEPC water, pH 7.0. Autoclave to sterilize. 9. 50× Denhardt’s solution: 1% (w/v) Ficoll (Type 400), 1% (w/v) polyvinylpyrrolidone, and 1% (w/v) bovine serum albumin in distilled water. Filter sterilize and store at −20°C in 1–5 ml aliquots. 10. Baker’s yeast total RNA: 25 mg/ml in distilled water. Aliquot and freeze at −20°C. 11. Hybridization buffer: 50% (v/v) formamide, 5× SSC, 5× Denhardt’s solution, 0.25 mg/ml baker’s yeast RNA, 0.5 mg/ml single-stranded (ss) DNA from fish sperm in distilled water. Prepare 12-ml aliquots and store at −20°C. 12. 50% Formamide in distilled water. 13. B1 buffer: 0.1 M maleic acid, 0.15 M NaCl in distilled water, pH 7.5. Autoclave and store at RT. 14. Blocking reagent for nucleic acid hybridization and detection (Roche).
308
I. Kramer et al.
15. 10% (w/v) blocking reagent in B1 buffer (see Note 5). Autoclave and store in aliquots at −20°C. 16. B2 blocking buffer: 2% (v/v) blocking reagent in B1 buffer. Prepare fresh just before use from 10% stock. 17. Anti-DIG sheep IgG conjugated to alkaline phosphatase (antiDIG-AP antibody; Roche). Prepare 0.05% (v/v) working dilution in B2 buffer fresh and keep on ice until use. 18. B3 detection buffer: 0.1 M NaCl, 5 mM MgCl2 in 0.1 M Tris, pH 9.5. Sterile filter. 19. 10% (v/v) Tween-20 stock solution in distilled water. 20. 0.1% (v/v) Tween-20 in B3 detection buffer. Prepare fresh before use. 21. 5-Bromo-4-chloro-3-indolylphosphate/4-nitro blue tetrazolium chloride (BCIP/NBT) Alkaline Phosphatase substrate kit. 22. Levamisole. 23. B4 developing solution (see Note 6). 24. TE buffer: 0.01 M Tris, 1 mM EDTA in distilled water, pH 8.0.
3. Methods 3.1. Tissue Collection, Fixation, Decalcification, and Embedding
1. Anesthetize the animal by intraperitoneal injection of a cocktail of 120 mg ketamine per kg body weight and 25 mg xylazine per kg. 2. Verify that the animal is fully anesthetized, as reflected by absence of toe and eye blink reflexes. 3. Spray the animal’s skin and fur at the ventral abdomen with 70% ethanol. 4. Carefully cut the skin, abdominal muscle wall, and ribcage with sharp scissors from the midabdomen to about the throat level. 5. Remove the diaphragm and ventral ribs from the thoracic cavity, taking care not to rupture heart, lungs, or major blood vessels. 6. Puncture the right atrium of the heart with sharp scissors taking care not to damage the remainder of the heart. 7. Slowly inject 10 ml of ice-cold PBS, pH 7.4 into the left ventricle of the beating heart at a rate of approximately 3 ml/min to exsanguinate the animal (see Note 7). 8. When exsanguination is complete, perfuse the animal with icecold 4% paraformaldehyde fixative (see Note 8).
20
Studying Gene Expression in Bone by In Situ Hybridization
309
9. Carefully dissect out the bones and any other tissues that you wish to examine as quickly possible (see Note 9). 10. Immediately following dissection, fix the samples by immersing in ice-cold 4% paraformaldehyde and incubate on a shaking platform at 4°C. Fixation times vary from 6 h up to 3 days depending on the age of the animal and type of bone being analyzed (Table 1). 11. When fixation is complete, wash the tissue by immersing in PBS at 4°C for 30 min. 12. Transfer the samples to decalcification solution (see Note 10) and incubate on a shaking platform at 4°C with daily changes of decalcification solution for up to 5 days, depending on the age of the animal and type of bone being analyzed (Table 2). 13. Rinse the samples in ice-cold PBS for 5–10 min. 14. Transfer to 30% sucrose in PBS for 8–24 h at 4°C on a shaking platform. 15. When the sucrose infiltration is complete (see Note 11) remove excess sucrose solution with a paper towel.
Table 1 Suggested duration of fixation step at 4°C Mouse age (days)
Mouse calvaria
Mouse long bone, vertebrae
0–2.5
6h
8–12 h (overnight)
3–7.5
8–12 h (overnight)
1 day
8–14.5
1 day
1–2 days
15–21.5
1–2 days
3 days
Juvenile and adult (>21.5)
3 days
3 days
Table 2 Suggested duration of decalcification step at 4°C Mouse age (days)
Mouse calvaria
Mouse long bone, vertebrae
0–2.5
8–12 h (overnight)
1–2 days
3–7.5
1 day
3–5 days
8–14.5
3 days
3–5 days
Juvenile and adult (>14.5)
3–5 days
3–5 days
310
I. Kramer et al.
16. Carefully orientate the samples in plastic peel-away embedding molds filled with OCT compound and freeze on dry ice (see Note 12). 3.2. Cryo-Sectioning
1. Place the CryoJane® tissue tape, adhesive-coated slides, hand roller, and the frozen tissue block in the cryostat set at −24°C and leave for about 10 min (see Note 13). 2. If necessary, trim the sides of the block not containing any embedded tissue by hand with a razor blade. 3. Place the trimmed tissue block in the cryostat block holder in the desired position. 4. Section the tissue in increments of 10–20 μm thickness until just before the level of interest has been reached. 5. Adjust the section thickness to 5–7 μm and adhere a cold adhesive tape segment to the block surface by slowly peeling off the removable backing. 6. Place the adhesive side of the tape on the embedded frozen sample and ensure that it is firmly attached to the tissue block by applying pressure with the hand roller. 7. Raise the lower end of the tape above the level of the knifeedge and slowly cut a section in the usual manner. 8. Using fine tweezers, transfer the tape containing the freshly cut section to the adhesive-coated slide. 9. Using the hand roller, apply pressure on the tape to ensure that the section is firmly attached to the slide surface. 10. Remove the slide from the cryostat chamber, place it briefly on the back of your hand for 1–3 s, return to the cryostat chamber and apply pressure with the hand roller once again to ensure that the tissue is firmly attached to the slide (see Note 14). 11. Insert the slide into the CryoJane® flash tray and treat with a single UV flash to polymerize the adhesive coating of the slide. 12. Leave the slide in the coldest part of the cryostat for about 2–3 min. 13. With the slide remaining in the cryostat, carefully remove the adhesive backing of the tape from the slide using cold forceps, keeping the delaminated backing adhered to the slide to prevent the section from coming off with the tape. 14. Air dry the slides at room temperature for a minimum of 20 min and store the slides at −20°C until further use.
3.3. Linearization of the Plasmid Containing the Probe of Interest
1. Linearize 5 μg of plasmid DNA containing the probe of interest in a reaction volume of 100 μl in a sterile microcentrifuge tube using an appropriate restriction enzyme (see Notes 16 and 17).
20
Studying Gene Expression in Bone by In Situ Hybridization
311
2. Confirm that the plasmid is completely linearized by running about 5 μl of the digested plasmid on a 1% agarose gel alongside an uncut plasmid sample. 3. Purify the linearized DNA by adding 100 μl of phenol/chloroform/IAA to the plasmid and vortex to mix. 4. Place the tube in a microcentrifuge and spin at 10,000 × g for 3 min. 5. Carefully aspirate about 90 μl of the upper aqueous phase into a new sterile microcentrifuge tube. 6. Add 1 μl glycogen, 45 μl 7.5 M ammonium acetate, and 225 μl 100% ethanol and mix by vortexing. 7. Place the sample in a −70°C or −80°C freezer for 15–30 min. 8. Place the tube in a microcentrifuge and spin at 10,000 × g for 10 min at room temperature. 9. Carefully aspirate the supernatant taking care not to dislodge the DNA pellet. 10. Wash the pellet by adding 1 ml 70% ethanol to the tube, place in a microcentrifuge, and spin at 10,000 × g for 10 min at room temperature. 11. Air dry the DNA pellet at room temperature for about 5 min. 12. Resuspend the plasmid in 10 μl of RNAse-free 1× transcription buffer provided with the DIG RNA labeling mix kit. 13. Estimate the concentration of plasmid by running 1 μl of the resuspended DNA on a 1% agarose gel in TBE buffer alongside a DNA marker of known concentration. 14. Store the linearized plasmid at −20°C until further use. 3.4. Generation of DIG-Labeled Riboprobes
1. Add 1 μg of linearized plasmid (Subheading 3.3, step 14), 2 μl 10× transcription buffer, 2 μl DIG-NTP labeling mix, 0.5 μl RNAse inhibitor, 1.5 μl of the appropriate RNA polymerase (T7, T3 or SP6) to a sterile microcentrifuge tube, and bring the reaction volume up to 20 μl with DEPC water. 2. Collect the reaction mix at the bottom by pulsing in a microcentrifuge for 10 s. 3. Incubate the reaction mixture at 37°C for 2–3 h (see Note 18). 4. Add 1 μl of RNAse-free DNAse I to the reaction and incubate for 15 min at 37°C. 5. Stop the reaction by adding 2 μl RNAse-free 0.2 M EDTA. 6. Add 1.25 μl 8 M LiCl and 75 μl 100% ethanol. Mix the sample by vortexing gently and transfer to a −70°C or −80°C freezer for 15–30 min to precipitate the RNA. 7. Place the sample in a microcentrifuge and spin at 10,000 × g for 15 min.
312
I. Kramer et al.
8. Carefully remove the supernatant taking care not to lose the RNA pellet. 9. Add 1 ml 70% ethanol to the tube to wash the pellet. 10. Place the sample in a microcentrifuge and spin at 10,000 × g for 5 min. 11. Carefully aspirate the supernatant and discard. 12. Allow the RNA pellet to air dry for about 5 min at room temperature. 13. Dissolve the RNA in 50 μl distilled water containing 0.4 U/μl RNAse inhibitor. 14. Prepare a 1% agarose gel containing a few drops of ethidium bromide in a Petri dish and dot 1 μl of the riboprobe solution directly onto the gel surface alongside with serial dilutions of DIG-labeled control RNA at known concentrations. 15. Estimate the amount of DIG-labeled riboprobe present in the sample by comparing the intensity of the dot with the known amounts of DIG-labeled control RNA. 16. Store the probe frozen at −20°C until further use or for up to 12 months. 3.5. Hybridization
A summary of the sequential steps involving immersion of the slides in staining containers or horizontal incubation in humidified chambers is outlined schematically in Fig. 1. Unless otherwise indicated all steps are carried out at room temperature. Generally, both negative and positive controls should be included when performing ISH (see Note 19). 1. Take an aliquot of hybridization solution from the freezer and prewarm at 37°C. 2. Place the slides in a rack and fix the sections by immersing the slides in